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Abstract
An intense debate has occurred regarding research involving humans in developing
countries in recent years. Research in this area has focused mainly on examining the
ways in which the economic inequalities in healthcare between developing countries and
developed countries have affected the types of research conducted in developing
countries by external sponsors. Research has also focused on how these inequalities, and
the difficulties in applying the international ethical guidelines, give rise to ethical
concerns and controversies. Recent literature has therefore examined several ethical
concerns in health research in developing countries. What is missing in the literature on
research oversight in developing countries, however, is a broader analysis from a
governance and legal perspective which critically examines the structure and adequacy of
any existing governance systems and the potential effect of these systems on the
protection of human participants in these countries. The major argument that this thesis
makes and attempts to explore, therefore, is that there is need to take a more
comprehensive and systemic view of the regulation of research involving humans in
developing countries. This is particularly necessary given steps taken recently by several
developing countries to establish governance mechanisms for health research involving
humans. To undertake this analysis, the thesis adopts a hybrid framework of governance,
drawing from the understandings and strengths of "traditional" and "new" governance.
This framework acknowledges the important role of government but also takes into
account other components which may not always be dependent on government and law.
Further, in line with this framework, the thesis argues for the need to recognise, in
scholarship and operation, the interrelationships between the different components of
research governance - ethical, institutional, and legal. For more specific analysis, the
thesis focuses on Nigeria, a populous, influential, developing country in Africa, which
has taken steps in recent years to regulate health research involving humans. It examines
the historical and political context of these governance efforts, and analyses the adequacy
of current governance arrangements.
Based on the analyses, it makes several
recommendations to improve the emerging governance arrangements for health research
involving humans in Nigeria.

x

List of Abbreviations

AHEC

Australian Health Ethics Committee

AIDS

Acquired Immune Deficiency Virus

AJIL

American Journal of International Law

AJLM

American Journal of Law and Medicine

Am. J. Pub. Health

American Journal of Public Health

ANRS

France's Agence Nationale de
Recherches sur le Sida

AZT

Azidothymidine

BMJ

British Medical Journal

CAM

Complementary and Alternative
Medicine

CCLT

Canadian Cases on the Law of Torts

CDC

Center for Disease Control

CIDA

Canadian International Development

Agency
Chi. J. Int.' L.

Chicago Journal of International Law

CIHR

Canadian Institutes of Health Research

CIOMS

Council for International Organisation of
Medical Sciences

CMAJ

Canadian Medical Association Journal

Colum. J. Eur. L

Columbia Journal of European Law

Conn. J. Intl. L.

Connecticut Journal of International Law

XI

DfID

DRA

United Kingdom Department for
International Development
• Drug Regulatory Authority

EDCTP

European-Developing Countries Clinical
Trials Programme

EGE

European Group on Ethics in Science and
New Technologies

ENLR

Eastern Nigeria Law Reports

FDA

Food and Drug Administration

FLWA

Fletcher Forum of World Affairs

Fordham Urb. LJ.

Fordham Urban Law Journal

Geo. Wash. Int'l L. Rev.

George Washington International Law
Review

GCP

Good Clinical Practice

GDP

Gross Domestic Product

GNP

Gross National Product

HAART

Highly Active Antiretroviral Therapy

HapMap

Human Genome and the International
Haplotype Mapping Project

Health L. J.

Health Law Journal

HIV

Human Immune-Deficiency Virus

HRECs

Health Research Ethics Committees

Hum. Rts. Q

Human Rights Quarterly

ICCPCR

International Covenant on Civil and
Political Rights

ICG

International Crisis Group

xn

ICH-GCP

International Conference on
Harmonisation's Harmonised Tripartite
Guidelines for Good Clinical Practice

ICMR

Indian Council of Medical Research

IDRC

International Development Research
Centre

IMF

International Monetary Fund

Ind. Int'l & Comp. L. Rev.

Indiana International and Comparative
Law Review

JAMA

Journal of the American Medical
Association

JAMWA

Journal of the American Medical
Women's Association

JICA

Japan International Cooperation Agency

J.L. Med. & Ethics

Journal of Law, Medicine and Ethics

J. Gender, Race and Just.

Journal of Gender, Race and Justice

McGill L.J

McGill Law Journal

MDCN

Medical and Dental Council of Nigeria

MDG

Millennium Development Goals

MMV

Medicines for Malaria Venture

MRC

The United Kingdom Medical Research
Council

NAFDAC

National Administration for Food and
Drug Administration and Control

NBAC

National Bioethics Advisory
Commission

N. Eng. J. Med.

New England Journal of Medicine

NIH

National Institute of Health

NGOs

Non-Governmental Organisations

xin

National Health and Medical Research

NHMRC
Council
NHREC

National Health Research Ethics

Committee
NHS

National Health Service

NMA

Nigerian Medical Association

NWLR

Nigeria Weekly Law Reports

OHRP

Office for Human Research Protections

Que Sup Ct

Quebec Supreme Court

SCSN

Supreme Council of Sharia Nigeria

STDs

Sexually Transmitted Diseases

TAC

Treatment Action Campaign

TCPS

Tri-Council Policy Statement

TDR

Tropical Diseases Research

UCH

University College Hospital, Ibadan

UNAIDS

Joint United Nations Programme on
HIV/AIDS

UNESCO

United Nations Educational, Social and
Cultural Organisation

UNDP

United Nations Development Programme

UNICEF

United Nations Children's Fund

U. Pa. L. Rev

University of Pennsylvania Law Review

USAID

United States Agency for International
Development

WHO

World Health Organisation

xiv

WNLR

Western Nigeria Law Reports

WTO

World Trade Organisation

Vand. J. Transnat'l L.

Vanderbilt Journal of Transnational Law

Yale J. Health Pol'y L. & Ethics

Yale Journal of Health Policy, Law, and
Ethics

xv

Acknowledgements
I would like to acknowledge gratefully the financial support provided to me during the
course of my doctoral studies by the Canadian Institutes of Health Research Training
Programme in Health Law, Ethics, and Policy, the Schulich School of Law, and the
Faculty of Graduate Studies.
My academic journey has been enriched by meeting and working with Dr Jocelyn
Downie, my primary supervisor. Her thoughtful steering and incisive comments helped
inspire the ultimately interesting direction in which this work went. Her optimism,
encouragement, support and generosity, helped make the journey a positive experience.
It has been intellectually rewarding, an honour, and a pleasure to work with her.
I also thank Professor Bill Lahey, the Director of the Health Law Institute. Our
discussions exposed me to the rich and diverse field of regulation and governance, an
area in which I hope to do more work. The conversations we had, beginning with the
directed reading course, helped shape many of my arguments in this thesis. It was both
enlightening and a great pleasure to work with him.
I thank Dr. Chidi Oguamanam, the Director of the Technology Law Institute. His critical
insights, robust critiques of several of the arguments presented here, and his thorough
knowledge of the context brought a broader perspective than would otherwise have been
the case. Each member of my supervisory committee brought not only different areas of
expertise but a unique perspective and a deep interest in the subject of this thesis. I thank
them for their encouragement and their guidance. This thesis would have been a lesser
work without their input.
Apart from my supervisory committee, several people at the Schulich School of Law
provided assistance and encouragement in various ways. I thank Professor Richard
Devlin, the Associate Dean of Graduate Studies and Research, for his encouragement
throughout this process. I would also like to thank Sheila Wile, the former Secretary of
the Graduate Studies Committee, whose care and help with various administrative
matters ased several difficulties throughout this process. I thank Chrystal Gray, formerly
of the CIHR Training Programme, for listening to various concerns, academic and
otherwise, and always providing care and encouragement, as well as useful solutions.
My academic journey would have been a little thornier without her support. I thank
David Dzidzornu, for his encouragement and support, for reading the first proposal that
eventually became this thesis and giving useful comments, and for his friendship
throughout my years at the Law School. I thank the staff at the Law Library, in particular
Anne-Marie, for their assistance with materials at various stages of this project. I thank
Michelle Kirkwood, the Secretary of the Graduate Studies Committee, for her assistance
in the past year.
I am grateful to other persons who provided materials and helpful information throughout
the course of my work on the thesis, including Professors Femi Soyinka and Adeyinka
Falusi, both of the University of Ibadan, Professor Trudo Lemmens of the University of

xvi

Toronto, Professor Julia Black of the London School of Economics, Professor Richard
Ashcroft of the Queen Mary University of London, Professor Scott Burris of the Temple
University of Beasley School of Law, and Mrs Chioma Dozie-Nwana of NAFDAC.
I thank other friends that have contributed in diverse ways to this project. I am deeply
grateful to my family in Canada - Jane Craig and Angela Tibbo. Jane gave me and my
son a home in my first year in the doctoral programme. I cannot imagine how difficult
these past three and a half years would have been without her generous spirit, her comfort
in times of difficulty, and all the ways in which she made my life easier. Her love, her
prayers, and her many kindnesses to me and my children will never be forgotten. Angela
brought laughter and love into the lives of me and my children these past three years.
Both of them were an answer to prayer.
I thank my church family, Real Life Community Church, for their love and support
throughout this period. It would be difficult to name every single person in that church
who supported me during the completion of this projection, but they are much
appreciated.
I thank my parents, Dr. Obidinma Onyemelukwe and Dr. Rebecca Onyemelukwe for
their love, their support, and encouragement, and for their belief in my abilities. They
nurtured my educational ambitions from the beginning and inspired me to take this course
by their example. No one could have better parents.
I thank my siblings Akaoma, Ijendu and Soke for their love and encouragement.
I thank my husband, Fred Onuobia, for his support and encouragement, for help with
providing various materials for this project, and for the insightful discussions we had on
various points in the thesis. His love and faith in me have consistently made seemingly
impossible goals attainable, and dreams possible.
This project owes much to his
sacrifice and support. My life would be poorer without him in it and I am profoundly
grateful for his love and the gift that he has been to me.
The arrival of my children, Kelechi and Oluchi, right before and during the course of this
project brought a new and deeper meaning to my life.
I thank God, my Father, Jesus, my Saviour and Friend, and the Holy Spirit, my
Comforter, for many prayers answered and for dreams come true.

xvn

Chapter One
Introduction

1.1 Introduction

Over the past decade, an intense debate has occurred regarding research
involving humans in developing countries. Although there is concern about the
limited proportion of health research conducted in developing countries, the
most controversial part of these debates has focused on the ethics of research in
developing countries in the face of existing economic disparities between
developed and developing countries, important questions of global justice and
equity and the arguably greater vulnerability of research participants in
developing countries.
What naturally follows, then, is concern about how adequately research
participants in such countries are protected and the existence and sufficiency of
any governance mechanisms for that purpose. Past events in several countries,
including developed countries, underscore the need for regulation and oversight
of health research involving humans. These include the atrocities committed in
the name of medical research during World War II in Germany; the Tuskegee
Syphilis experiments on African-American men in the United States where the
research subjects were prevented from getting effective treatment while
participating in a study on syphilis long after a cure was discovered for the
disease; the Willowbrook studies where mentally ill children were injected with
hepatitis; the Jewish Chronic Hospital Disease Study in Brooklyn in which the

1

patients hospitalized with debilitating chronic diseases were injected with live
cancer cells without their consent; and the Cameron experiments where electric
shock experiments were tested on mentally ill patients in Canada.! The more
recent controversies surrounding the Zidovudine trials in several developing
countries in the late 1990s have once more brought to the fore fears about the
risks in research involving humans.
A number of developing countries have recently developed, or are in the
process of developing, new instruments for guiding and regulating research
involving humans. These instruments form the basis of governance of research
in these countries, and this seems an appropriate time, therefore, to consider the
governance of health research in developing countries. The aim of the thesis is
to examine analytically the system for governing health research involving
humans in a developing country, Nigeria.

1.2 Structure and Arrangement
The thesis consists of eight chapters. Apart from the introduction and the
structure and arrangement of the thesis, Chapter One describes the background
and a rationale for this study. It then engages in an identification of the need for,

1

See a detailed review of some historical cases in J. Katz, Experimentation with Human Beings
(New York, Russell Sage Foundation, 1972). Other experiments have also been described by
Henry K. Beecher, "Ethics and Clinical Research" (1966) 274: 24 N. Engl. J. Med. 1354.
2
Paquita De Zulueta, "Randomised Placebo-Controlled Trials and HIV-infected Pregnant
Women in Developing Countries: Ethical Imperialism or Unethical Exploitation?" 15: 4
Bioethics 290 at 293-296. See also, G. Annas "Human Rights and Maternal-Fetal HIV
Transmission Prevention Trials in Africa" (1998) 88 Am. J. Pub. Health 560, Marcia Angell,
"The Ethics of Clinical Research in the Third world (1997) N. Engl. J. Med. 847-849 and
Abdool Q. Karim, et al., "Informed Consent for HIV Testing in a South African Hospital: Is it
Truly Informed and Truly Voluntary?" (1998) 88 Am. J. Pub. Health 637.
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and the benefits of, health research involving humans, both generally and
specifically in developing countries. Further, this chapter discusses the need for
domestic governance systems in developing countries. Lastly, this chapter
introduces Nigeria, which is examined in the thesis as an example of a
developing country that has recently taken steps to establish a research
governance system.
Chapter Two examines governance as a useful analytical framework for
the work to be undertaken in thesis.

It attempts to clarify the concept of

governance, distinguishing it from the terms "regulation" and "law."

It

examines the applicability of governance to health research involving humans,
discussing the concept as a theoretical framework, identifying different forms of
governance, and providing a rationale for employing a hybrid framework of
governance.

It identifies the goals of the governance of health research

involving humans and the criteria by which a research governance system can be
assessed. It also discusses how the hybrid governance framework proposed will
be used in subsequent discussion in the thesis.
The third chapter attempts to identify and examine the components of
research

governance

frameworks.

systems, examining

the ethical and institutional

For this examination, it draws from the research governance

systems of various countries around the world.
The fourth chapter inquires into the role of law in research governance in
developing countries.

It argues that developing countries should consider

developing comprehensive legislation as part of their research governance

3

system. It identifies what should be the basic content of such legislation. It also
argues for greater recognition of the interrelationship between an ethical
framework, a legal framework and the institutional framework.
The fifth chapter provides specific context and background on Nigeria.
Nigeria is a developing country which provides a good case study for studying
research governance for several reasons.

These reasons include its high

population, its great need for health research, and the steps it has taken recently
to develop a research governance system. This chapter describes context for
research governance in Nigeria, including, the political organization of the
country, the legal environment for regulation and governance, and the operation
of the health system. It also describes the types of research that take place in
Nigeria. It examines the history of research governance in Nigeria, including
some allegations of unethical research. These allegations of unethical conduct
of research in Nigeria indicate the necessity for research governance, and the
findings from the history indicate issues that must be taken into consideration as
Nigeria develops a research governance system.
The sixth chapter analyses the current arrangements for research
governance in Nigeria. It discusses the components of the research governance
system in Nigeria, the ethical, legal and institutional frameworks. It analyses
these frameworks and identifies gaps, weaknesses, and potential problems.
Based on available evidence, it assesses Nigeria's research governance system in
line with the criteria identified in the second chapter.

4

The seventh chapter makes recommendations for improvement to the
Nigeria's system of research governance.
The eighth chapter concludes the thesis with a brief summary of the entire
work.

1.3 Research Background, Rationale, and Aims

In recent years, there has been, and there continues to be, considerable
interest in health research involving humans in developing countries. One part
of the discussion centers on the insufficient proportion of health research
conducted in developing countries. Many developing countries lack adequate
resources, expertise, and infrastructure for conducting health research, and
frequently depend on developed country sponsors, including international
organizations and government organizations in developed countries to conduct
research in required areas of healthcare.

Still, even with such dependence,

there is concern that many diseases that occur principally in developing
countries are not receiving sufficient attention in research.5
The increasing awareness of the difference in the circumstances of
developing countries and developed countries, the higher burden of disease, and
the higher level of vulnerability of persons in developing countries to
exploitation have, at the same time, prompted concerns about the ethical conduct

3

Nuffield Council on Bioethics, The Ethics of Research Related to Healthcare in Developing
Countries (London: Nuffield Council on Bioethics, 2002) at 6.
4
Sonia Shah, "Globalization of Clinical Research in the Pharmaceutical Industry" (2003) 33:1
International Journal of Health Services 29 at 30-31.
See Section 1.5

5

of research involving humans in these countries. The conduct of external
researchers in developing countries has been criticised for failing, in many cases,
to meet the ethical standards which such researchers would have been compelled
to adopt in developed countries. There have also been a number of claims that
multinational pharmaceutical companies have conducted unethical trials in
developing countries, endangering and sometimes damaging the lives of the
research participants involved in such trials.6 The other part of recent debate on
research in developing countries thus focuses on the regulation of research in
these countries. Although there are certain linkages between the two sides of
this debate - the proportion of research conducted and the regulation of such
research - the thesis is principally concerned with the latter, which is, the
governance and regulation of health research in developing countries.
Research in this area has focused mainly on examining the ways in which
the economic inequalities and disparity in access to healthcare between
developing countries and developed countries have affected the types of research
conducted in developing countries by external sponsors, and who dictates the
research agenda, including the types of research to be conducted. Research has
also focused on how these inequalities, and the difficulties in applying the
international ethical guidelines, give rise to ethical concerns and controversies.
Recent literature has therefore focused on several ethical concerns in research in
developing countries, including the adequacy of informed consent procedures in
developing countries, the standard of care to be offered to persons involved in
randomised clinical trials, access to the benefits of the research, and the
The case of Pfizer trials in Nigeria, discussed in detail in Chapter Five, is a good illustration.

6

inadequacy of ethics review in developing countries.7 To provide a context for
the discussion that follows in the thesis, these ethical concerns are laid out
briefly below. Although no attempt is made to address these concerns in great
detail or to answer the troubling questions which arise with respect thereto (this
not being the main focus of this thesis), these concerns, however, remain
relevant in the context of governance of research in developing countries
because the governance systems in these countries will have to grapple with
these issues which raise particular concerns in these settings.
Informed consent is now accepted as key in every research project
involving human participants. The requirement for informed consent is firmly
established in many international guidelines,

8

national guidelines and

regulations9 as well as international human rights law

as a fundamental

prerequisite in research involving humans. It is considered to be one of the most
important

safeguards

exploitation. n

required

to

protect

research

participants

from

While there is general agreement about the necessity for

informed consent in which research is conducted, obtaining informed consent in

7

See the Nuffield Council on Bioethics, 2002: The Ethics of Research Related to Healthcare in
Developing Countries (London: Nuffield Council on Bioethics, 2002) online:
<http://www.nuffieldbioethics.org/fileLibrary/pdf/errhdc_fullreport001.pdf> (October 17, 2007).
8
These include the Nuremberg Code 1947, World Medical Association (WMA) Declaration of
Helsinki: Ethical Principles for Research Involving Human Subjects, adopted by the 18 WMA
June 1964, latest amendment latest amendment made by the 59th WMA General Assembly,
Seoul, October 2008. Council of International Organisation of Medical Sciences, International.
Ethical Guidelines for Biomedical Research Involving Human Subjects adopted 1993 and revised
2002.
9
For instance Article 2.1 of the Tri-Council Policy Statement: Ethical Conduct for Research
Involving Humans applicable in Canada.
Article 7 of the International Covenant on Civil and Political Rights G.A. res. 2200A (XXI),
21 U.N. GAOR Supp. (No. 16) at 52, U.N. Doc. A/6316 (1966), 999 U.N.T.S. 171, entered into
force Mar. 23, 1976.
11
Ruth Macklin, Double Standards in Medical Research in Developing Countries (Cambridge:
Cambridge University Press, 2004) (hereinafter Macklin (2004) at 131.
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developing country settings may be especially challenging.

The challenges are

usually the result of such factors as low literacy rates, higher burden of diseases
and limited healthcare options, gender differences and inequalities, language
differences and translation difficulties, lack of familiarity with scientific research,
different understanding of the concepts of health and disease, high regard for
medical professionals, and conflict between cultures and accepted ethical
guidelines.12 The economic disparities between countries pose a particular
challenge to obtaining true informed consent. Many of the potential research
participants in many developing countries are poor, have little access to the poor
healthcare systems available and inadequate access to effective medicines in
many of these countries. In light of these challenges, people may be more
willing to participate in research with a belief that they may get free healthcare
services and medicines which would not otherwise be available. As such, there
appears to be a greater level of vulnerability, particularly when poverty and
other factors such as illiteracy, belief systems that are not necessarily compatible
Nuffield Council on Bioethics, supra note 7 at 39. In that report it is noted that"Sickness or
•death may be attributed to witchcraft or sorcery rather than biomedical explanations evoking
infectious agents, genetic predispositions, or weak immune systems—explanations central to the
western biomedical model of disease." See Patricia, A Marshall, Ethical Challenges in Study
Design and Informed Consent for Health Research in Resource-Poor Settings (Geneva: World
Health Organisation, 2007), online:
<http://www.who.int/tdr/publications/publications/pdf/ethical_challenges.pdf> (December 10,
2007) at 12. Language and translation difficulties also affect the comprehension of information, a
vital part of the informed consent process Terms like 'research" "placebo" and "randomization,"
may not easily be translated to local languages. See Patricia A Marshall, "Informed Consent in
International Health Research" (2006) 1 Journal of Empirical Research on Human Research
Ethics 25 at 26. V. Adams, et ah, "The Challenge of Cross-Cultural Clinical Trials Research:
Case Report from the Tibetan Autonomous Region, People's Republic of China" (2005) 19:3
Medical Anthropology Quarterly 267; N. Kass, S. Maman and J. Atkinson, "Motivations,
Understanding, and Voluntariness in International Randomized Trials" (2005) 27:6 IRB: Ethics
and Human Research 1.; R. R Love and N.C. Fost, "Ethical and Regulatory Challenges in a
Randomized Control Trial of Adjuvant Treatment for Breast Cancer in Vietnam" 45:8 Journal of
Investigative Medicine 423. NBAC, 2001; Nuffield Council on Bioethics, 2002.
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with western biomedicine, lack of political power and frequent human rights
violations in some developing countries are combined. A lack of options may
lead to undue inducement, arising from false expectations and inadequate
understanding of the risks of participation in research and may compromise the
informed consent process.13 The Pfizer trial which took place in Northern
Nigeria during a meningitis epidemic in 1996 was suggestive of inadequate
understanding of information because the poor parents of the children enrolled
in the trial may well have assumed that the children would receive treatment.
This case is discussed in detail in Chapter Five.
Although these challenges are well recognized and the need to balance
ethical requirements and socio-cultural differences is understood, there is little
consensus on precisely how they are to be addressed by researchers in practical
situations.

The literature continues to address very important issues which

underlie much of the research conducted by developed country sponsors in
developing countries. For instance, when, if ever, is it appropriate to deviate
from international ethical guidelines? Does cultural relativity justify ethical

13

Ibid. Undue inducement is prohibited by some guidelines including the CIOMS Guidelines.
Guideline 7 of CIOMS Guidelines deals with payment to research participants and in this context
prohibits payments which may be too large, or extensive medical services which would serve as
undue inducement. See also, Ezekiel Emmanuel, Xolani E. Currie and Allen Heman, "Undue
Inducement in Clinical Research in Developing Countries: Is It A Worry?" (2005) 366 Lancet
336. E. Tafesse, E. and Murphy, T. (1998) "Ethics of Placebo-Controlled Trials of Zidovudine to
Prevent the Perinatal Transmission of HIV in the Third World," New England Journal of
Medicine, 338: 838. See also, David B. Resnik, "Biomedical Research in the Developing World:
Ethical Issues and Dilemmas" in Ann Smith litis, Research Ethics (New York: Routledge, 2006).
14
See Macklin (2004) supra note 11 at 100.
15
Some commentators even argue that there is little data to show that the difficulties surrounding
informed consent are peculiar to developing countries. See, Christine Pace, Christine Grady &
Ezekiel J. Emanuel, "What We Don't Know About Informed Consent" (2003) SciDevnet,
online:
SciDevNet
<http://www.scidev.net/dossiers/index.cfm?fuseaction=dossierreaditem&dossier=5&type=3&ite
mid=189&language=l> (accessed September 19, 2009).
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relativism?

Is ethical relativism permissible in particular instances? Does it

constitute "ethical imperialism" to impose the requirements of the international
ethical guidelines regardless of differing circumstances, or is a universal
standard the only justifiable standard?

These questions also have great

relevance for concerns surrounding the standard of care issue, another ethical
concern that has received much attention in the literature.
The standard of care17 issue can rightly be stated to be the issue which
thrust ethical issues in research involving humans in developing countries into
the limelight in recent years. It is perhaps the most hotly debated issue in
internationally-sponsored research in developing countries.

This concern

revolves mostly around the nature of the care and treatment provided during
research, including all the preventive or therapeutic treatment that ought to be
provided to participants in the course of the research.

As Macklin succinctly

notes, the ethical issue focuses on "what is ethically acceptable to provide to a
control group in research with the standard of care in the developing country -

16

Macklin (2004), supra note 11 atl40. See generally, David B. Resnik, "Biomedical Research
in the Developing World: Ethical Issues and Dilemmas" in Ann Smith litis, Research Ethics
(New York: Routledge, 2006) at 141. D. Resnik, "Exploitation in Biomedical Research," (2003)
12 Theoretical Medicine and Bioethics, 197-224. See also, Ruth Macklin, Against Relativism:
Cultural Diversity and the Search for Universals in Medicine, New York: Oxford University
Press, 1999).
17
Although it is employed profusely in the literature, several different meanings may be
attributed to the phrase, "standard of care." Some of these include the ethical standards generally
that should apply in health research involving humans in different countries, "the types or level
of treatments provided to patients in the clinical setting, but it might not serve as a justification
for what ought to be provided to participants in research" See National Bioethics Advisory
Commission Ethical and Policy Issues in International Research: Clinical Trials in Developing
Countries Volumel- Report and Recommendations of the National Bioethics Advisory
Commission (Bethesda, Maryland: National Bioethics Advisory Commission, 2001), (hereafter
NBAC)at 13 (emphasis mine); See also, A.J. London. "The Ambiguity and the Exigency:
Clarifying 'Standard of Care' Arguments in International Research" (2000) 25 J Med Philos. 379;
"the nature of the care and treatment that will be provided to participants in research" (see the
Nuffield Council on Bioethics, supra note 6 at 86.); and the term might mean, what actually
obtains in a particular setting. See, NBAC, at 13.
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whatever is routinely provided to people in that country with that medical
condition? Or must a control group be provided with the best treatment available
elsewhere - the 'standard of care' in the sponsoring country?"18
The standard of care debate originates from the basic ethical requirement
that participants in research should not be exploited. But how this basic ethical
requirement is to be translated in actual practice, especially in developing
countries, which have more limited healthcare options, has created heated debate
in the literature. Several broad issues arise with regard to standard of care in
research. In view of the limited healthcare options available in many developing
countries, what standard of care should be offered participants in the control arm
of clinical research? Should this differ in any respect from the standard of care
offered within similar research elsewhere in the world, particularly in developed
countries? Should the same ethical standards apply across borders, irrespective
of the different context including, poverty and poor healthcare systems? Is a
different standard justifiable on the grounds that the results of the research will
ultimately benefit wider populations in developing countries? 9
Some argue that it is unethical to conduct trials in developing countries
which would never be conducted in developed countries for fear of harm to
participants and that doing so creates a double standard, one for the rich and
another for the poor, ° and creates room for exploitation. ' The opponents of

18

Macklin (2004), supra note 11 at 34.
Ibid at 36.
20
P. Lurie and S. M Wolfe, "Unethical Trials of Interventions to Reduce Perinatal Transmission
of the Human /Immunodeficiency Virus in Developing Countries" (1997) 337 New Eng. J. Med.
853.
21
See Marcia Angell, "Investigators' Responsibilities for Human Subjects in Developing
Countries" (2000) 342:13 New England Journal of Medicine 967.
19
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this argument counter that this would simply not be feasible in many cases due,
among other things, to the poor healthcare systems in many developing countries,
and the expensive prices of some of the interventions which, in any case, would
be unaffordable for many people in developing countries.

Further, they argue

that a strict interpretation of the requirement for the universal standard of care as
opposed to a local standard of care is unrealistic and may have the devastating
' effect of preventing research into certain diseases in these countries.22 It has
also been argued that providing effective treatment to participants in the control
arm of a clinical trial, where such treatment is not readily obtainable elsewhere
in the country, may compel prospective participants to enroll in the study, thus
serving as an undue inducement.23
The debates surrounding the issue of standard of care were ignited by the
1997 article of Lurie and Wolfe in the New England Journal of Medicine.,24 In it,
they objected to the unethical nature of clinical trials conducted by the US
National Institutes of Health (NIH) and the Centre for Disease Control (CDC)
for the prevention of perinatal transmission of HIV involving HIV positive
women in South Africa, Uganda, Thailand and other developing countries. The

For a summary of some of these arguments in relation to the HIV research in developing
countries, see generally Paquita De Zulueta, "Randomised Placebo-Controlled Trials and HIVinfected Pregnant Women in Developing Countries: Ethical Imperialism or Unethical
Exploitation?" 15: 4 Bioethics 290 at 293-296. See also, G. Annas "Human Rights and
Maternal-Fetal HIV Transmission Prevention Trials in Africa" (1998) 88 Am. J. Pub. Health 560,
Marcia Angell, "The Ethics of Clinical Research in the Third world (1997) N. Engl. J. Med. 847849 and Abdool Q. Karim, et al., "Informed Consent for HIV Testing in a South African
Hospital: Is it Truly Informed and Truly Voluntary?" (1998) 88 Am. J. Pub. Health 637.
23
See generally, Jack Killen et al, "Ethics of Clinical Research in the Developing World" (2002)
2 Nature 210. See also ibid. See NBAC, supra note 17 at 26.
See Lurie and Wolfe, supra note 20. There were responses to the article by Lurie and Wolfw,
in which others tried to show that these trials were not unethical. H. Varmus and D. Satcher,
"Ethical Complexities of Conducting Research in Developing Countries" (1997) 337 New Eng. J.
Med. 1003.
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women were not provided antiretroviral treatment, thereby arguably allowing
many infants to contract HIV unnecessarily. The trials were argued to be against
international ethical guidelines, notably the Helsinki Declaration, which at that
time required that "every patient, including those of a control group, if any ...
should be given the best proven diagnostic and therapeutic method."25 The
object of the trial was to discover a more affordable means of administering the
expensive drug zidovudine (AZT), which had proven effective in treating HIV in
developed countries, so that it could be more accessible in developing countries.
Commentators, like Angell, likewise insisted that since the use of a placebo
would have been unethical in the United States, the use of placebos in
zidovudine trials in these developing countries was also unethical.26 Critics
argued that the long-course treatment of AZT could have been used rather than
using no treatment at all, reducing the number of babies who became infected
77

with HIV in the trials while still achieving sound scientific results.

There were

countering responses to the article by Varmus and Satcher. They tried to show
that these trials were very much needed in developing countries to produce
affordable treatment for HIV. The placebo-controlled trials were necessary to
produce faster, clearer and more reliable results than would otherwise be
obtained through the use of active controls, which would be more expensive and
less efficient. The trials were not unethical, they argued, mainly because of the
Principle 30 of the 1996 Amendment.
Marcia Angell, "The Ethics of Clinical Research in the Third World (1997) N. Engl. J. Med.
847-849.
27
Lurie and Wolfe, supra note 22.
28
H. Varmus and D. Satcher, "Ethical Complexities of Conducting Research in Developing
Countries" (1997) 337 New Eng. J. Med. 1003.
26
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special context of the trial and the limited circumstances which obtained in the
countries in which the trials took place. Other commentators agreed, calling it
"ethical imperialism" to impose the standards obtaining in developed countries
on developing countries with very different circumstances.

These debates

drew attention to the problems relating to the use of placebos and the provision
of standard treatment to research subjects involved in randomized clinical
trials.

There have been other cases, for instance, the proposed Surfaxin trials

in several Latin American countries in which a placebo was to be used although
-5 1

effective treatment was available in the United States.
Thus, despite the provisions of the international ethical guidelines on these
issues, there continues to be controversy in this area and a diversity of thinking
on the issues. Is a global and universal standard of care the only acceptable
ethical standard? Does this amount to ethical imperialism? Is a local standard of
care (treatment based on the standard available in the local or regional context)
permissible in some cases, allowing local circumstances and existing conditions
to be taken into consideration? Or does this amount to exploitation? Is there a
midway between a universal standard of care and a local standard of care? What
Letter by Edward K. Mbidde (Chaiman of the AIDS Research Committee of the Uganda
Cancer Institute, to the director of the NH, 8 May 1997.
30
S, G. Annas, "Human Rights and Maternal-Fetal HIV Transmission Prevention Trials in
Africa" (1998) 88 Am. J. Pub. Health 560.
See James V. Lavery et al, (edj, Ethical Issues in International Biomedical Research: A
Casebook, (Oxford: Oxford University Press, 2007) at 151-159. See Macklin 2004, supra note
17 at 17-18; or the Hepatitis A vaccine trials conducted in Thailand in 1991 (see R Lie, "Justice
and International Research," in R. Levine, S. Gorovitz, and J. Gallagher, (eds.) Biomedical
Research Ethics: Updating International Guidelines (Geneva: CIOMS-WHO, 2000) at 27-40.).
For differing views on the exploitative nature of the Surfaxin trials, see Robert I. Temple,
"Benefit to the Trial Participants or Benefit to the Community? How Far Should the Surfaxin
Trial Investigators' and Sponsors' Obligations Extend? in Lavery, supra note 19 at 155- 159; and
Peter Lurie and Sidney Wolfe, "The Developing World as the Answer to the Dreams of
Pharmaceutical Companies: The Surfaxin Story" in Lavery, ibid, at 159- 168.
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is the role of the international ethical guidelines? Are they a descriptive standard
of what is to be done, or an aspirational ideal?

Even more broadly, the debates

address the disparity between the economic circumstances and healthcare
options in developed and developing countries and what justice, equity, and
equality mean in terms of health research involving humans in developing
countries. Different views on these issues are articulated in the still-growing
-jo

body of literature.
The other major ethical concern in the developing world context relates to
the benefits to be derived from the research to be conducted. This is also
directly linked to avoiding exploitation of research participants and research
communities. In developing countries where research is mainly sponsored by
external entities, research is often driven by economic or academic interests that
may not reflect the needs of these countries.
regard to benefits.

Two issues, therefore, arise with

First, is externally-sponsored research justifiable in

developing countries, that is, would the research benefit the participants and the
wider population? Secondly, what happens with regard to any potential benefit
derived from the research after it is over? The Helsinki Declaration

and the

International Ethical Guidelines for Biomedical Research Involving Human
51

Macklin (2004), supra note 11.
For more recent articles which deal with this issue, see for example: David Wendler et al, "The
Standard of Care Debate: Can Research in Developing Countries Be Both Ethical and
Responsive to Those Countries' Health Needs?" (2004) 94:6 American Journal of Public Health
923. A.A. Hyder and L. Dawson, "Defining Standard of Care in the Developing World: The
Intersection of International Research Ethics and Health Systems Analysis" (2005) 5 Developing
World Bioethics 142; Halley S. Faust, "Is a National Standard of Care Always the Right One?"
(2007) 7:1 Developing World Bioethics 45. Hans-Jorg Ehni and Urban Wiesing, International
Ethical Regulations on Placebo-Use in Clinical Trials: A Comparative Analysis" (2007)
Bioethics Online Early Article.
34
Nuffield Council on Bioethics, supra note 7.
35
Principle 17 of the Helsinki Declaration (2008).
33
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Subjects of the Council for International Organisation of Medical Sciences
(CIOMS Guidelines)

require that health research conducted in any country

must be beneficial to the participants in the research project and responsive or
relevant to the country's needs, respectively.
Like the standard of care issue, the issue of benefits is fraught with
divergent views, some of which have to do with defining exactly what "benefits"
consist of, others based on the broader issue of inequities between different
countries and how best to address them, and yet others based on different
conceptions of justice.37 Considerable attention has also been devoted in the
•20

literature to this issue.
These debates around these ethical concerns in the literature have drawn
attention to the wider problem of employing ethical standards in developing
countries that differ from the standards used in developed countries. Further,
these debates have highlighted the difficulty in the application of ethical
principles as may be contained in international ethical guidelines such as the
Helsinki Declaration.
Beyond the ethical concerns and the difficulties in applying the
international guidelines, however, a major concern is whether regulation or
^Guideline 10 of the CIOMS Guidelines.
37
Macklin (2004) supra note 11 at 94.
38
See for example, Shapiro and Meslin, ibid.;; Participants in the 2001 Conference on Ethical
Aspects of Research in Developing Countries, "Fair Benefits for Research in Developing
Countries". (2002) 298 Science 2133; C. Weijer and E.J. Emanuel, "Protecting Communities in
Biomedical Research" (2000) 289 Science 1142.
Segun Gbadegesin and David Wendler,
"Protecting Communities in Health Research from Exploitation" (2006) 20:5 Bioethics 248;
Leonard H. Glantz, George J. Annas, Michael Grodin and Wendy K. Mariner, "Research in
Developing Countries: Taking Benefits Seriously" (1998) 28 Hastings Center Report 38.
39
World Medical Association (WMA) Declaration of Helsinki: Ethical Principles for Research
Involving Human Subjects, adopted by the 18th WMA June 1964, latest amendment made by the
59th WMA General Assembly, Seoul, October 2008. Online:
<http://www.wma.net/e/policy/b3.htm>
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oversight is keeping pace with the increase in research in developing countries.
It would appear that insufficient attention has been paid to the regulation of
research involving humans in developing countries as evidenced, for instance,
by findings that some developing countries do not have research ethics review
boards.40

In 2001, the Regional Committee for Africa of the World Health

Organization (WHO) observed that studies involving humans in the Africa
Region were not subjected to ethics review.41 One study has found that among
members of ethics review committees in African countries, "knowledge of local
legal frameworks governing research was inconsistent and unclear."42 This may
be as attributable to a lack of comprehensive legal frameworks relating
specifically to research involving humans, as to a lack of adequate training about
them. Others have noted with specific regard to biomedical research that "many
developing countries lack regulatory mechanisms and a legal framework for
biomedical research."

3

Moreover, much of the literature relating to research involving humans in
developing countries focuses mainly on the ethics of externally-sponsored
research, that is, research sponsored by developed countries or international
organisations in developing countries. Much of the literature, while shedding
light on this important subject, thus fails to address the ethics and regulation of
40

Cheryl Cox Macpherson, "Ethics Committees Research Ethics: Beyond the Guidelines" (2001)
Developing World Bioethics 57.
41
J. Kiriga, C. Wambebe and A. Baba-Mousa, "Status of National Bioethics Committees in the
WHO African Region" (2005) 6 BMC Med Ethics E10, online: BMC <
http://www.biomedcentral.eom/1472-6939/6/10> (April 3, 2007).
42
See Cecilia Milford, Douglas Wassenaar, and Catherine Slack, "Resources and Needs of
Research Ethics Committees in Africa: Preparations for HIV Vaccine Trials" (2006) 28: 2 IRB:
Ethics & Human Research 1 at 9.
43
Alimuddin Zumla and Anthony Costello, "Ethics of Healthcare Research in Developing
Countries" (2002) 95 (6) J R Soc Med. 275
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indigenous research.

For instance, the National Advisory Bioethics Council

set up by President Clinton in 2000, produced an important and wide-ranging
report on the ethics of research in developing countries in 2001: Ethical and
Policy Issues in International Research: Clinical Trials in Developing Countries
(Volumes 1 and 2).45 While this report draws attention to the problems of ethics
review in developing countries, it focuses mainly on how American researchers
and researchers sponsored by institutions in the United States can conduct
research ethically in developing countries.
Another report

emanating

from

the United States titled:

"The

Globalization of Clinical Trials: A Growing Challenge in Protecting Human
Subjects"46 focused on assessing the capacity of the United States Food and
Drug Administration (FDA) to protect research participants in foreign clinical
trials from which data is generated for the purpose of obtaining FDA approval.
It provided a summary of current oversight available in the United States
regarding protections for research participants in countries outside the United
States, particularly developing countries.
Other insightful texts have been produced on the subject of health research
in developing countries in recent years. The Nuffield Council on Bioethics, an
independent organization created in 1991 to consider ethical issues in medicine,

44

See Zulfiqar Ahmed Bhutta, "Ethics in International Health Research: A Perspective from the
Developing World" (2002) 80:2 Bulletin of the World Health Organisation 114 at 115.
National Bioethics Advisory Commission Ethical and Policy Issues in International Research:
Clinical Trials in Developing Countries Volume 1- Report and Recommendations of the National
Bioethics Advisory Commission (Bethesda, Maryland: National Bioethics Advisory Commission,
2001), (hereafter NBAC).
Department of Health and Human Services, Office of the Inspector General, "The
Globalization of Clinical Trials: A Growing Challenge in Protecting Human Subjects" (2001),
available online at: <oig.hhs.gov/oei/reports/oei-01-00-00190.pdf> ( September 22, 2007)
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based in the United Kingdom and funded partly by the United Kingdom Medical
Research Council,

also produced an in-depth report on health research in

developing countries in 2002: The Ethics of Research Related to Healthcare in
Developing Countries. The stated purpose of the report was to "examine the
ethical issues raised when research related to healthcare is carried out in
developing countries and funded by sponsors from developed countries."

In

this light, it discussed extensively the major ethical concerns of informed
consent, standard of care, and post-trial obligations. It went further to examine
the problems of ethics review in developing countries and how to deal with these
problems in practical ways. It recommended, amongst other things, that all
countries should establish an effective system for the ethical review of research,
which includes the establishment and maintenance of research ethics committees
independent of governments and sponsors. It did not, however, engage in a
detailed examination of research governance within developing countries.
A book by Ruth Macklin titled: Double Standards in Medical Research in
Developing Countries,49 possibly the first book wholly devoted to the subject of
research involving humans in developing countries, discusses issues relating to
the ethical concerns in internationally-sponsored research in developing
countries. This timely book discusses in detail the reasons why employing
double ethical standards in medical research in developing countries does not

47

See Nuffield Council on Bioethics <www.nuffield bioethics.org> (November 9, 2008).
Nuffield Council on Bioethics, 2002: The Ethics of Research Related to Healthcare in
Developing Countries (2002), online: <
http://www.nuffieldbioethics.org/fileLibrary/pdf/errhdc_fullreport001.pdf> (October 17, 2008),
at xv.
49
Ruth Macklin, Double Standards in Medical Research in Developing Countries (Cambridge:
Cambridge University Press, 2004).
48
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stand up to scrutiny.

It focuses on "the ethical controversies that have

surrounded the design and conduct of international medical research sponsored
by industrialized countries or industry, and carried out in developing
countries."50

There are several illuminating illustrations of allegations of

exploitative research in developing countries and a detailed analysis of the
international ethical guidelines and their interpretation and application in
developing countries and the difficulties associated with them.

However, the

book's objective did not include analysis of the governance of research
involving humans in developing countries - which this thesis directly engages.
A more recent book on research involving humans in developing countries
is Ethical Issues in International Biomedical Research: A Casebook.

It

contains articles and commentaries from several authors who have written
extensively about health research in developing countries. It self-describes as
"the definitive book on the ethics of research involving human subjects in
developing countries."52 The book's special strength and contribution is the use
of several actual case studies to explore and address the thorny ethical issues that
arise in conducting research in developing countries. It also attempts to broaden
the scope of ethical concerns that arise in the context of research in these
countries.

Two of the case studies deal with ethics review and regulations.

Although arguably implicated in its discussions, there is little discussion of legal
frameworks in developing countries.

James V. Lavery et al, (ed.), Ethical Issues in International Biomedical Research: A Casebook,
(Oxford: Oxford University Press, 2007).
See Preface.
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Several articles have, however, examined emerging ethics review systems
in developing countries, including countries in Africa and Latin America.53
These articles have put forth information about the establishment and the
challenges facing ethics review systems in developing countries. Many of them
have called for more attention and more studies on ethics review committees in
developing countries.

While they are certainly a welcome addition to the

burgeoning literature in this area, there is still room for further examination.
It is important to note that academic discourse, with its main focus on
ethical issues in conducting research in developing countries has, understandably,
taken place mainly within a bioethics context. Thus, there has been relatively
little analysis from a legal perspective. There is much discussion of ethical
principles, and the interpretation, application, and the inadequacies of the
international ethical guidelines which contain provisions on these issues.

The

international ethical guidelines have thus been the subject of a great deal of
debate about the principles behind the guidelines, as well as the application of
these principles in practice. While this is a good place to start, much remains
See Nancy Kass et al, "The Structure and Function of Research Ethics Committees in Africa:
A Case Study" PLoS Med 4:1 :e3 See also, R R Love and N Fost, "A Pilot Seminar on Ethical
Issues in Clinical Trials for Cancer Researchers in Vietnam" (2003) 25 IRB 8-10; A Hyder, S.
Wali, A Khan, N Teoh , N Kass, et al. "Ethical Review of Health Research: A Perspective from
Developing Country Researchers" (2004) 30 J Med Ethics 68-72; B. Arda, "Evaluation of
Research Ethics Committees in Turkey" (2000) 26 J Med Ethics 26: 459- 461; Jonathan Camp
et al, "Challenges Faced by Research Ethics Committees in El Salvador: Results from A Focus
Group Study" (2009) 9:1 Developing World Bioethics 11; C C Macpherson, "Ethics Committees,
Research Ethics: Beyond the Guidelines" (2001) 1 Developing World Bioethics 57-68; D.
Elsayed, "The Current Situation of Health Research and Ethics in Sudan" (2004) 4 Developing
World Bioethics 154-159; R Rivera and E Ezcurra, "Composition and Operation of Selected
Research Ethics Review Committees in Latin America" (2000) 23 IRB 9-12; R. Coker and M
McKee, "Ethical Approval for Health Research in Central and Eastern Europe: An International
Survey" (200) 1 Clinical Medicine 197-199; WHO South East Asian Regional Office, Ethics in
Health Research, (New Delhi: World Health Organization, 2001); J.M Kirigia, C Wambebe,
and A Baba-Mousa, "Status of National Research Bioethics Committees in the WHO African
Region" (2005) BMC Medical Ethics 6.
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unexplored in terms of the regulation of health research within developing
countries.
What is missing in the literature on research oversight in developing
countries, then, is a broader analysis from a governance and legal perspective
which critically examines the structure and adequacy of any existing governance
systems and the potential effect of these systems on the protection of human
participants in these countries. In this respect, assemblages of research
participants' protections such as contained in the International Compilation of
Human Research Protections compiled by the Office for Human Research
Protections (OHRP) in the United States Department of Health and Human
Services,54 and the Global Research Ethics Map,55 a resource prepared by the
Harvard School of Public Health, provide important information.

However,

these resources do not provide, and indeed are not intended to provide, in-depth
analysis of research participants' protections in developing countries.
The major argument that this thesis makes and attempts to explore,
therefore, is that there is need to take a more comprehensive and systemic view
of the regulation of research involving humans in developing countries. There is
a need to expand the focus on research involving humans in developing
countries to include a consideration of not only the ethical issues, but also fuller
examinations of the existing and emerging governance structures and
arrangements in developing countries.
54

OHRP, International Compilation of Human Research Protections, 2010 online:
<http://www.hhs.gov/ohrp/international/HSPCompilation.pdf> (May 30, 2010).
55
Harvard School of Public Health, Global Research Ethics Map online:
<https://webapps.sph.harvard.edu/live/gremap/index_main.cfm?CFID=2273289&CFTOKEN=3
5907300> (May 30, 2010).
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The importance of the governance and regulation of research cannot be
overemphasized.

Health research involving humans poses physical, social,

economic and psychological risks, some of which are amply illustrated in the
early historical cases.56 These risks emphasise the need to ensure that research is
ethical and as safe as possible. There is therefore need for oversight of such
research.

Moreover, researchers require a secure regulatory environment in

which to conduct research with the knowledge of what the rules and standards
are and, perhaps, the greater possibility of producing research which is socially
beneficial to the wider community.

Balancing these sometimes competing

priorities (ensuring the safety of research participants on one hand, and
providing a stable environment for research on the other) requires a governance
system.

The central objectives of research governance therefore include the

promotion of socially beneficial research and improving the quality of any
research and any outcome, protecting and safeguarding the interests of persons
on whom research is conducted and building, and maintaining public trust.57
Governance of research involving humans has thus been defined as "a
framework through which institutions are accountable for the scientific quality,
ethical acceptability and safety of the research they sponsor or permit."58

A detailed review of some historical cases is contained in J. Katz, Experimentation with
Human Beings (New York, Russell Sage Foundation, 1972). See also Introduction for some
examples.
57
See A. Samanta and J. Samanta, "Research Governance: Panacea or Problem?" Clin Med.
2005 May-Jun;5(3):235; M. McDonald (ed.), The Governance of Health Research Involving
Human Subjects (Ottawa: Law Commission of Canada, 2000) at 4; Marie Hirtle, "The
Governance of Research Involving Human Participants in Canada" (2003) 11 Health L. J. 137 at
144; Jocelyn Downie and Fiona McDonald, "Revisioning the Oversight of Research Involving
Humans in Canada" (2004) 12 Health Law Journal 159 at 160.
58
M H Walsh, J J McNeil, K J Breen, "Improving the Governance of Health Research" Med J
Aust 2005; 182: 468-471. Others define it as: the system of administration and supervision

23

Further, according to the United Kingdom Research Governance Framework for
Health and Social Care, research governance: "sets out principles, requirements
and standards; defines mechanisms to deliver them; describes monitoring and
assessment arrangements; improves research and safeguards the public by
enhancing ethical awareness and scientific quality, promoting good practice
reducing adverse incidents and ensuring lessons and forestalling poor
performance and misconduct."59

To summarise in a definition that brings

together the process of governance and its objectives in relation to research
involving humans, research governance refers to, "the systems in place for
ensuring that ... research on human beings is safe [or as safe as possible],
conforms to ethical standards and is likely to contribute to scientific
understanding."60

Thus, a research governance system is comprised of

mechanisms based on ethical standards, employed to protect research
participants and the public, and to ensure that research is potentially beneficial.
Governance issues, as Michael McDonald rightly observes, arise with
respect to the proper division of responsibilities for the protection of research
participants amongst the agencies and organizations that conduct, sponsor, and
regulate research.61 Extrapolating from this, research governance requires an

through which research is managed, participants and staff are protected, and accountability is
assured. This definition however deemphasizes, wrongly in my view, the ethical foundation for
research governance. Sara Shaw, Petra M Boynton and Trisha Greenhalgh, "Research
Governance: Where Did it Come From, What Does it Mean?" (2005) 98 Journal of the Royal
Society of Medicine 496.
United Kingdom, Department of Health, Research Governance Framework for Health and
Social Care (Second Edition) (United Kingdom, 2005) at 1.
0
Victoria Armstrong et al, Public Perspectives on the Governance of Biomedical Research: A
Qualitative Study in a Deliberative Context (United Kingdom: Wellcome Trust, 2007) at 4.
61
Michael McDonald, "Canadian Governance of Health Research Involving Human Subjects: Is
Anybody Minding the Store?" (2001) 9 Health L. J. 1 at 4, online:
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examination of the scope and structure of the system, the responsibilities and
composition of the institutions within the system, accountability and compliance
mechanisms within the system, all of which have implications for ensuring the
protection of participants and promoting beneficial research.

Research

governance systems (which may be formal or informal), may include
overarching legislative/regulatory frameworks and policy framework. Thus, in
discussing research governance, one may perhaps choose to focus on a legal
perspective examining, for instance, the legal framework for the protection of
research participants in developing countries.

However, an examination of

governance systems in the particular context of research involving humans, as
this thesis intends to engage in, appears more encompassing than a strictly legal
perspective.

This more comprehensive perspective allows a broader, less

reductionist analysis of the linkages that come together to form the research
governance system, including law.
Research governance is a broad concept focusing on interactions
between different actors, state and non-state actors, and encompassing principles
and standards on the one hand, and systems defined by accountability
mechanisms on the other. The standards straddle different disciplines. As has
been rightly noted, "standards that underpin effective research governance exist
in the domains of ethics and law, science, information protection, health and
safety, intellectual property and commercialisation, financial management, and
public relations."62 An analysis of research governance thus seems necessarily
to entail a discourse on a broad range of subjects and even separate disciplines.
62

Walsh et al, supra note 58 at 469.
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However, my focus is mainly on analysing regulatory systems and structures,
rather than on inquiring deeply into the ethics of research or into scientific
methodologies and outcomes, although these clearly present some of the reasons
for the existence of the governance systems. In this thesis, I propose to examine
the different components of governance system, including an ethical framework,
a legal framework, and institutional mechanisms, using a hybrid framework of
governance.
There is increasing interest in the area of health research involving
humans and in its governance in developing countries, with many recent
publications considering ethics review systems in developing countries.

But

there are comparatively few publications that examine the governance of
research in these countries in a comprehensive way, including the specific role
of government or the legal system in regulating research. For instance, with
specific respect to law relating to research participants' protection, a recent
article observes in relation to such law in West Africa that:
One difficulty in researching human research
subjects laws in West Africa when using law
reviews, research journals, and similar sources
is that the majority of the articles focus less on
actual laws, and more on the need for laws and
ethical issues in this area.
In another instance, with specific regard to ethics review committees, an
acknowledged component of research governance, Kass et al, note that:
Most literature examining RECs [Research
Ethics Committees] comes from wealthier
63

See note 53.
Laszlo M. Szabo and Tamara J. Britt, "Guide to Researching Human Research Subjects Laws
in West Africa" (2007) 2:4 Journal of Empirical Research on Human Research Ethics 93 at 100.
64
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countries... However, there has been little
research examining procedures, strengths, and
challenges of RECs in developing countries.65

Macklin adds that:
Among the countries known to have
regulations or guidelines requiring prior
ethical review of research by an independent
committee are Uganda, India, Nepal, Thailand,
Zimbabwe, Zambia, and South Africa. Less is
known about the actual operation of these
committees—their membership requirements,
terms of reference, and operating procedures.
This vacuum has also been noted by others, including Bhutta, who also observes
the relative lack of input by researchers from the developing world. He notes
that:
Recently, there has been considerable debate
about the ethical conduct and reviewing of
health research, but this debate has largely
taken place among ethicists and researchers in
They further note that: "Additional information on how African RECs function, including their
staffing, operating procedures, strengths, and challenges would be useful for African and
international researchers working within Africa, and for growing efforts to enhance ethics
capacity on this vast continent." See Nancy Kass et al, "The Structure and Function of Research
Ethics Committees in Africa: A Case Study" PLoS Med 4:l:e3, online:
<http://medicine.plosjournals.Org/archive/1549-1676/4/l/pdf/10.1371 Journal.pmed.0040003S.pdf> (June 9, 2007). The authors list a number of articles describing issues relating to ethics
review committees in developing countries: R R Love and N Fost, "A Pilot Seminar on Ethical
Issues in Clinical Trials for Cancer Researchers in Vietnam" (2003) 25 IRB 8-10; A Hyder, S.
Wali, A Khan, N Teoh , N Kass, et al. "Ethical Review of Health Research: A Perspective from
Developing Country Researchers" (2004) 30 J Med Ethics 68-72; B. Arda, "Evaluation of
Research Ethics Committees in Turkey" (2000) 26 J Med Ethics 26: 459- 461; C C
Macpherson, "Ethics Committees, Research Ethics: Beyond the Guidelines" (2001) 1
Developing World Bioethics 57-68; D. Elsayed, 'The Current Situation of Health Research and
Ethics in Sudan" (2004) 4 Developing World Bioethics 154-159; R Rivera and E Ezcurra,
"Composition and Operation of Selected Research Ethics Review Committees in Latin America"
(2000) 23 IRB 9-12; R. Coker and M McKee, "Ethical Approval for Health Research in
Central and Eastern Europe: An International Survey" (200) 1 Clinical Medicine 197-199;
WHO South East Asian Regional Office, Ethics in Health Research, (New Delhi: World Health
Organization, 2001); J.M Kirigia, C Wambebe, and A Baba-Mousa, "Status of National
Research Bioethics Committees in the WHO African Region" (2005) BMC Medical Ethics 6.
66
Ruth Macklin, "After Helsinki: Unresolved Issues in International Research" (2001) 11
Kennedy Institute of Ethics Journal 17 at 25.
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industrialized countries. The views of public
health practitioners and researchers from
developing
countries
have
been
67
underrepresented.
With increasing publications on research ethics and governance by developing
country researchers,68 this may be changing. However, there is certainly room,
and need, for greater representation.
As for regulatory agencies that approve new drugs in developing
countries, these have been largely overlooked in the literature. It is not clear how
effective they are in protecting any research participants who participate in trials
for drugs. Luna points out that this may be because, in fact, they rely on already
completed studies in developed countries.69 However, trials are currently being
undertaken in several developing countries for various new drugs and vaccines
not yet approved in developing countries, including vaccines for HIV/AIDS.
The Pfizer incident which generated much controversy and allegations of harm,
If)

discussed later in the thesis, was a trial of a drug in a hospital in Nigeria.
Further, although ethics and ethical issues are at the core of the need for
the governance of research, and one can therefore not realistically divorce
completely the ethical concerns from the governance of research, there is a
vacuum with regard to governance and regulation in the literature that needs to
be more fully explored. This gap in the literature is understandable given that
Bhutta supra note 45 at 114.
A significant number of articles were published within the period that this doctoral thesis was
written between 2007 and 2010. See for example, Wen Kilama and Aceme Nyika (ed.), Health
Research in Africa: Ethical and Practical Challenges Volume 112, Supplement 1, Pages SI-SI 02
(November 2009).
69
Florencia Luna, "Research in Developing Countries" in Bonnie Steinbock, The Oxford
Handbook ofBioethics (Oxford: Oxford University Press, 2007) at 329-330.
0
This case is discussed in more detail in Chapter Four.
68
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many developing countries have, until recently, lacked mechanisms for the
protection of research participants, including ethics review committees. For
instance, in a study commissioned by the United States National Bioethics
Advisory Committee, some researchers expressed frustration over the failure of
"national governments to regulate research and to enforce ethical guidelines for
all research projects implemented within national boundaries."71 Bhutta further
notes that,
While the tradition of ethical review committees
is well established in developed countries, and
the selection and training of members is
relatively well organised, this is not the case in
developing countries. Indeed, until recently, the
concept of local ethics committees - especially
established 'standing' committees - was
unfamiliar.
Increasingly, however, many developing countries, including African countries,
are taking steps to address gaps in the oversight of research and to provide
protection for participants in research by establishing or formalizing domestic
regulatory regimes and governance structures. These steps include establishing
national ethics review boards, and enacting, or amending previously existing
guidelines, and even legislation governing research involving humans.

Nigeria

is one example. At the end of 2006, it produced a national code for ethics in
health research.

Other developing countries have taken steps to develop new

or update old guidelines, revive old ethics review committees or establish ethics

See also, Nancy Kass and Adnan Hyder, "Attitudes and Experiences of US and Developing
Country Investigators Regarding US Human Subjects Regulations" in NBAC volume 2, supra
note 17atB-105.
72
NHREC, National Code for Health Research Ethics (2006), online:
<http://www.nhrec.net/nhrec/index.html> (February 7, 2008).
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review systems to address existing vacuums in this area. They include Brazil
(1996)73 Uganda, (1997)74 India (2000)75 Nepal (2001),76 Malawi (2002),77
South Africa (2004)78 Tanzania (2002)79 and Kenya (2004).80 Others like
Bangladesh are in the process of developing national guidelines.

Still others

have taken steps to develop regional associations of ethics committees such as
the Forum for Ethical Review Committees in Asia and the Western Pacific
(FERCAP),82 the Latin American Forum of Ethics Committees in Health,
Research (FLACTES),83 and the Pan-African Bioethics Initiative (PABIN).84 A
Pan-African registry is currently being developed for clinical trials conducted in
Africa.85 These are exciting and important developments. Some commentators

73

The National Ethics of Research Committee (CONEP) was established by the Brazilian
National Health Council (CNS) in 1996 (Resolution 196/96).
74
Uganda, Guidelines for the Conduct of Health Research Involving Human Subjects in Uganda
(National Consensus Conference 1997). See S. Loue and D. Okello "Research Bioethics in the
Ugandan Context II: Procedural and Substantive Reform" (2002) 28 Journal of law, Medicine
and Ethics 165-173.
75
Indian Council of Medical Research (ICMR), "Ethical Guidelines for Biomedical Research on
Human Subjects" (2000), online: <http://www.icmr.nic.in/ethical.pdf> (March 29, 2007).
Nepal Health Research Council, National Ethical Guidelines For Health Research in Nepal
(2001), online: < http://www.nhrc.org.np/guidelines/nhrc_ethicalguidelines_2001.pdf>
(February 7, 2008).
National Research Council of Malawi, Procedures and Guidelines for the Conduct of
Research in Malawi (2002).
78
National Health Research Ethics Council, Ethics in Health Research: Principles, Structures and
Processes Guidelines. (Pretoria: Department of Health, 2004).
79
Tanzania set up a national ethics review committee in 2002. See J.K.B. Ikingura, M. Kruger
and W. Zeleke, "Health Research Ethics Review and Needs of Institutional Ethics Committees in
Tanzania" (2007) 9: 3 Tanzania Health Research Bulletin 154.
National Council for Science and Technology, Guidelines for Ethical Conduct of Biomedical
Research Involving Human Subjects in Kenya (2004); Ministry of Health: Kenya National
Guidelines for Research and Development of HIV/AIDS Vaccines (2005) Science and
Technology Act (2001).
Harun-Ar-Rashid, "Regional Perspectives in Research Ethics: A Report from Bangladesh"
(2006) 12: 1 East Mediterranean Health Journal S66.
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http://www.fercap-sidcer.org/
Foro Latino Americano de Comites de Etica en Investigacion en Salud, online:
<http://www.flaceis.org>
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See online: <http://www.pabin.net/>
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The Pan African Clinical Trials Registry, online: <http://www.atmregistry.org/> (September
17, 2009).
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have suggested that the emerging policies are comparable, in theory if not
practice, to the older systems in developed countries.

This is not surprising,

given that while these more recent guidelines may be more wide-ranging and
may operate more broadly than the older systems found in some developed
countries, they have probably drawn on experiences in those countries while also
drawing on local context.
Understanding the governance arrangements currently in place in
developing countries seems particularly important at this time because of these
recent steps taken by many developing countries, including African countries.
This need is not lessened by the fact these systems are relatively recent and, it
may thus be argued, allowing insufficient time to analyse in any great detail their
adequacy and effectiveness in protecting research participants. The potential of
these emerging systems and their possible strengths and weaknesses are, in fact,
perhaps best analysed at this point when the arrangements are fluid enough to
allow for amendments, improvements, and developments in different directions.
Certainly some weaknesses may present after a long period of operation.
However, instead of choosing to repair a broken system many years from now,
this may be the best time to point out possible and early identifiable mistakes
and gaps in these new arrangements which could then be corrected from the
outset. Such evaluation is also especially crucial because developing countries
without governance systems or in the process of establishing governance
86

See S B Bhat and T T Hegde, "Ethical International Research on Human Subjects Research in
the Absence of Local Institutional Review Boards" (2006) 32 J. Med. Ethics 535 at 535 referring
to India's guidelines note that, "Indian policy on biomedical clinical trials originating outside the
country, although not necessarily effective in practice, is fairly well defined, and in theory
comparable with the systems in developed nations."
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systems may want to adopt the procedures and systems now in use in developing
countries that have taken early steps in this respect.87
Examining these systems from a governance perspective is also
important not only because such examination provides much-needed descriptive
information on the emerging governance systems in developing countries, but
because it moves the discourse from identification of issues to proffering of
solutions.

The discussion about ethical concerns is important because it

addresses the ways in which the conduct of research affects participants. To put
these concerns into a context in which action can be taken, however, there is a
need for domestic governance structures and systems, including policy
guidelines, legislation and ethics review mechanisms.
As earlier pointed out, much of the literature on research involving
humans in developing countries focuses on internationally-sponsored research in
developing countries. Discussions on the ethics of international research or
research supported by developed country sponsors in developing countries and
particular ethical concerns remain important, not least because they address
important issues of global equity and the practical application of ethical
principles. However, the literature fails to address the ethics and regulation of
indigenous or domestic research,88 that is, research sponsored by entities within
developing countries. The current emphasis on global economic, health and
knowledge disparities is not misplaced, and this has undoubtedly had a positive
For instance, Nigeria appears to be borrowing some of South Africa's concepts, including
enacting legislation similar to South African legislation and establishing a national ethics review
committee.
88
See Zulfiqar Ahmed Bhutta, "Ethics in International Health Research: A Perspective from the
Developing World" (2002) 80:2 Bulletin of the World Health Organisation 114 at 115.
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impact on recent regulatory developments in developing countries. But there is
little consideration of how indigenous research is governed or regulated in
developing countries or how research participants in this type of research (no
matter how little) are protected. An understanding of domestic governance
systems is especially important therefore because such systems govern all
research involving humans, not only internationally-sponsored research but also
indigenous or domestically-sponsored research.
In a similar vein, there is some focus in the literature on the provision of
equivalent protections by developed countries when their citizens or companies
sponsor or conduct research in developing countries. These are undoubtedly
important and even morally desirable. But discussion of domestic governance
systems allows room for consideration of developing countries' ownership in the
protection of their citizens who become research participants. This shift in focus
could also allow for more participation of researchers from the developing world
in these important debates.
Examining research involving humans from a governance perspective is
also helpful because it allows one to ask the crucial question: What regulatory
tools and institutions are required to effectively govern research involving
humans? The first tool that typically comes to mind is ethics review. Ethics
review is a process by which research projects and protocols are evaluated by a
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See for example, United States, Department of Health and Human Services, 'Report of the
Equivalent Protections' (2003), available at:
_http://www.hhs.gov/ohrp/international/EPWGReport2003.pdf (5 April, 2007). See also,
"Biomedical Research Projects in Developing Countries" (Denmark) (2006), online:
<http://www.cvk.im.dk/cvkEverest/Publications/cvkx2Eimx2Edk%20x2D%20dokumenter/Engli
sh/20061130095326/CurrentVersion/ulandssagerENG.pdf> (April 3, 2007).
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committee of persons independent of the researchers to assess the ethical
acceptability of the projects.90 These committees are required to safeguard the
rights, safety, and well-being of the research participants. J Ethics review is now
a central part of the research governance systems of many countries and the
ethics review system may therefore be mistakenly considered the governance
system.
The literature tends, therefore, to examine mainly the work of ethics
review committees, particularly in developed countries where they have been
established for a longer period. However, a broader and more inclusive view of
research governance systems may include other components apart from the
ethics review system, such as a legal framework, including formal legislation
and other forms of law; national and international ethics guidelines; professional
associations and codes of conduct; national regulatory bodies such as the ones
which regulate pharmaceutical production and the use of human participants,
departments of health (of which the drug regulatory agency may be a part); civil

An ethics committee has been defined as: " An independent body ... consisting of healthcare
professionals and non-medical members, whose responsibilities it is to protect the rights, safety,
and wellbeing of human subjects involved in a trial and provide public assurance of that
protection by, among other things, expressing an opinion on the trial protocol, the suitability of
the investigator and the adequacy of the facilities, and on methods and documents to be used to
inform trial subjects and obtain their informed consent." See Directive 2001/20/EC of the
European Parliament and of the Council of 4 April 2001. Official Journal of the European
Communities 1 May 2001. L121/34. <http://eudract.emea.eu.int/docs/Dir2001-20_en.pdf> (8
Mar 2007). The independence of ethics review committees has been questioned in the literature,
especially where they operate within an institutional context and there is a possibility of conflicts
of interest as in Nigeria and South Africa and many other countries. See for example, Ezekiel J
Emmanuel et al, "Oversight of Human Participants Research: Identifying Problems to Evaluate
Reform Proposals" (2004) 141: 1 Annals of Internal Medicine 282, online:
<http://www.annals.Org/cgi/reprint/141/4/282.pdf> (May 24, 2007) at 283. See also, Carl H.
Coleman and Marie Bousseau, "Strengthening Local Review of Research in Africa: Is the IRB
Model Relevant?" (2006), online: <http://www.bioethicsforum.org/ethics-review-of-medicalresearch-in-Africa.asp> (June 22, 2007).
91
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society, including non-governmental organizations which promote patients'
rights; the general public, the research participants themselves, and the
interactions between these entities.

An examination of different jurisdictions

will show that these tools and institutions are employed in the governance of
research in varying degrees.
There is need, therefore, to expand the focus on health research
involving humans in developing countries to include a consideration of not only
the ethical issues, but also more detailed examinations of the emerging
governance structures in developing countries. An analysis of these emerging
domestic regulatory and governance regimes is necessary to understand the
context for the local application of ethical principles, to provide information on
these recent developments, and as mentioned earlier, to proactively identify and
draw attention to national systems and practices, and the potential issues,
weaknesses and problems that may arise in these new regimes. And, in so doing,
one could indicate concerns that developing countries may want to take into
consideration in establishing or building on their domestic governance
mechanisms.

Hence, the main aim of this thesis is to set forth a more

comprehensive and systemic view of the governance and regulation of research
involving humans in developing countries. For this purpose, my thesis will
focus on a case study of a developing country: Nigeria.
A word is perhaps necessary here on the use of the term "developing
countries." Although the main focus of the thesis is on an analysis of the
92

See Ann Strode, Catherine Slack, Muriel Mushariwa, "HIV Vaccine Research - South
Africa's Ethical-Legal Framework and Its Ability to Promote the Welfare of Trial Participants"
(2005) 95: 8 South African Medical Journal 598.
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Nigerian system of research participants' protection, I make reference to
'developing countries' as part of the contextual framework which provides the
rationale for the thesis and within which I pursue my analysis. With particular
regard to research involving humans, understanding the context within which
such research takes place is important for a proper appreciation of some of the
peculiar issues that may arise in analysing the need for oversight and the
obstacles that may beset the governance systems. I also address the issues from
the perspective of a scholar originating from one of such countries. Further, this
research targets developing countries as some of its main audience, for whom I
hope this work may serve a useful purpose.
So, what are 'developing countries'? The term 'developing countries,'
although a widely-used term does not have a strict definition, is frequently used
rather loosely,93 and "lacks precision and explanatory power."94 However, it
refers principally to an economic level which is lower than that of some other
countries. 5 Other features include widespread poverty in both rural and urban

Mitsuo Matsushita et al., The World Trade Organization (Oxford: Oxford University Press,
2003) at 374. Even within important international agreements, such as the World Trade
Organisation agreements which sometimes require differential treatment of developing countries,
the term is not defined.
94
Robert J. Griffiths (ed.), Developing World 95/96 (Sixth Edition) (Connecticut: The Dushkin
Publishing Group, 1995) at 4.
95
The World Bank which categorises countries using gross national income (GNI) per capita as
the main criterion, classifies developing countries into low-income economies (that is, countries
with an income per capita of $735 or less). These include countries like India, Nigeria,
Afghanistan, Bangladesh, Uganda, Zambia, and Zimbabwe, lower middle-income economies
(countries with an income per capita of $736 to $2,935). These include countries like South
Africa, China, Egypt, Thailand, Philippines. The countries which fall into these income
brackets are generally referred to as developing countries. The UN also designates forty-nine
countries as "least developed countries (LDCs)." This designation is based on such indices as
low income, weak human assets, a high level of economic vulnerability and a population of less
than 75 million The low income per capita criterion employed by the World Bank places all
developing countries in one category in spite of the wide diversity that exists between these
countries including socio-cultural and political dissimilarities as well as differences in population,
size, ownership of natural resources, wealth distribution, and ethnic diversity among other things.
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areas, massive migration from rural to urban areas, uneven distribution of wealth
and unequal opportunities for education, employment and access to health
care.96 Although they are not a homogenous group, and important differences
exist between developing countries, even in terms of economic development and
health research capacity,

there are important similarities which make a group

analysis possible and appropriate. These include the inadequacy of resources to
meet the needs of their citizens, widespread poverty, low standards of living,
high rates of population growth, and general economic and technological
dependence on developed countries, relatively poor health care systems, high
birth and death rates and low life expectancy, as well as the relative lack of
access to knowledge and information about research.98 Macklin notes that it
may be appropriate to address developing countries together especially with
respect to analysis on the subject of research involving humans. According to
her:

See World Bank, "Country Classification" online: World Bank
<http://www.worldbank.org/data/countryclass/countryclass.html> (December 8, 2007). United
Nations Conference on Trade and Development (UNCTAD), The Least Developed Countries
Report 2002: Escaping the Poverty Trap (Geneva, UNCTAD, 2002) at ii. Online:
<http://www.unctad.org/en/docs/Adc2002_en.pdf> (December 8, 2007).
96
Griffiths, supra note 94.
97
Macklin notes accurately that: "there is a continuum along which countries typically called
"developing" fall with regard to the above characteristics. Most of the countries in sub-Saharan
Africa are desperately poor, have little or no manufacturing capability, and have few highly
trained and experienced biomedical researchers. South Africa is the key exception, with Uganda,
Kenya and Nigeria ranking somewhat above most other countries in these respects. A look at
South America reveals that Brazil and Argentian boast many highly trained and experienced
biomedical researchers. These countries have had an industrial infrastructure for many years.
Yet Brazil is the country with the widest gap between the richest and poorest members of the
population, and Argentina has slid from being a First World country (at the beginning of the
twentieth century) to occupying the financial status of a Third World country (at the beginning of
the twenty-first century). Among Asian countries, Thailand, India, and China all have highly
trained and experienced biomedical researchers and all also have the capability to manufacture
drugs." See Macklin (2004), supra note 11 at 10-11.
98
Martin Bulmer and Donald P Warwick, Social Science Research in Developing Countries:
Surveys and Censuses in the Third World (London: UCL Press, 1993) at 1- 2.
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It depends on the specific features of a country
that bear on the research enterprise. It is
appropriate to lump together countries that are
resource-poor, since neither the government
nor the majority of citizens can afford medical
treatments that become largely available to
residents of wealthier countries once research
is concluded.
It is appropriate to lump
together countries that have few trained
scientists and little experience of conducting
biomedical research. And it is appropriate to
lump together countries that lack ethical
guidelines for research and have little or no
capacity for conducting ethical review of
research conducted there by industry or by
scientists from industrialised countries."
The regulatory capacity of many developing countries in many areas including,
as Macklin points out, health research involving humans, is weak.100 This is
evident in the paucity of ethics review committees and limited capacity for
effective ethics review. Apart from limited financial resources, the expertise
needed for ethics review is frequently inadequate and the need for training in
research ethics, which is currently lacking in many developing countries, has
been noted elsewhere. 101

Further, generally speaking, regulation and

governance take place against a backdrop of, in many cases, relatively new
democracies in which regulatory institutions are still in the process of
development. "

The analysis undertaken in the thesis discusses governance

99

See Macklin (2004), supra note 11 at 10.
J Stern, "Electricity and Telecommunications Regulatory Institutions in Small and
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within this context. The group analysis that creates the background for the thesis
is, however, nuanced and made more specific by a focus on Nigeria.
The thesis is descriptive, analytic, and prescriptive. Part of the aim in
conducting this analysis is to describe and set out in detail the emerging
governance systems in developing countries, specifically, Nigeria.

The

descriptions are then employed in assessing and evaluating the adequacy of the
systems in place in Nigeria and to make suggestions for further improvement.
Several questions are raised and an attempt is made to answer them in this thesis.
Such questions include: Why are research governance systems needed in
developing countries? How is research involving humans currently governed in
the country under analysis, Nigeria? What are/ought to be the values underlying
these emerging systems of governance? What is the role of law, if any, in these
systems, and what are the implications of this role or lack thereof on the
protection of research participants? What ought to be the role of law? What are
the strengths and weaknesses of the governance system currently under
development in Nigeria? How can the system be improved to ensure better
protection of research participants in Nigeria?
In conducting the analysis, reference is made to the existing oversight
systems of other countries. Such references are not in-depth discussions but are
necessarily limited to particular contexts in order to ensure proper focus on
Nigeria and to keep the thesis within manageable limits. The aim of such
reference will not only be to draw useful contrasts and comparisons, but to draw
lessons from these countries in terms of what governance and regulatory
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arrangements truly work and what arrangements would be unworkable for
Nigeria and other developing countries.
It is anticipated that this work will to some extent address the existing
vacuum in the literature, namely an exposition and analysis of the governance
arrangements for health research involving humans in developing countries. It
is also hoped that it would contribute to the burgeoning literature on health
research involving humans in developing countries. It would hopefully be of
value to scholars, research sponsors, researchers and regulators in developed and
developing countries who need to understand research governance and
regulation in different jurisdictions, particularly the emergent governance
regimes of developing countries.

1.4 The Need for Health Research
While it is important to ensure that research is governed in such a way
as to ensure the safety of research participants, it is reasonable to ask the
questions: What is health research? Why is it needed in developing countries?
Below I consider briefly what health research means, the need for health
research generally, and then examine in the next subsection the need for health
research specifically in developing countries.
Health research involving humans may be described as research that
seeks by systematic investigation to produce generalisable knowledge about the
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health of human beings.

In effect, it is a process in which social and scientific

investigations are undertaken with human beings as subjects, and which has as
its goal generalisable knowledge with the potential to improve human health.
Different types of health research are carried out in all countries (on different
levels and scales) for the purposes of, among others, preventing and treating new
diseases, including through the development of new and better means of
diagnosis, therapeutic and preventive medicines and delivery systems. In
addition to aiding the discovery of new treatments, health research also helps to
determine the actual effectiveness of already accepted treatments.104 It also
involves research seeking to answer medical questions regarding the history,
causes (including socio-economic roots) and progression of diseases. Testing
new treatments, in particular, may require the conducting of clinical trials to
determine the merits of different treatments and interventions. Such clinical
trials often entail research on human beings and materials drawn from human
beings105 and is usually aimed at providing generalisable knowledge for the
health benefits of a wide group of people. In this sense, clinical research is
different from therapy, which may also be carried out concurrently with such

This extrapolates the definitions of 'research' found in the Tri-Council Policy Statement:
Ethical Conduct for Research Involving Humans (1998) available online at Interagency Advisory
Panel
on
Research
Ethics
<http://www.pre.ethics.gc.ca/english/policystatement/policystatement.cfm> (August 11, 2007);
in the United States Department of Health and Human Services regulations: 42 CFR 52.5.
104
See Jocelyn Downie, "Contemporary Health Research: A Cautionary Tale" (2003) Health
Law Journal (Special Edition) at 1.
105
Baruch A. Brody, The Ethics of Biomedical Research: The Ethics of Biomedical Research: An
International Perspective (New York, Oxford University Press) 1998 at 2.
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research.

Other types of health research investigate social determinants of

disease and the effect of behavioural patterns on health.
Health research thus includes clinical research, social and behavioural
research, basic research, laboratory and operational research as well as
feasibility studies, epidemiological research, and health systems research.! 7 But
not all these types of research require participation by human subjects.
Feasibility studies, for instance, may be carried out to evaluate the practicability
of integrating certain methods of inspection into existing health care facilities.
Health systems research may be carried out to assess the suitability of health
care facilities in delivering care to patients.

These may, however, not

necessarily require participation by human subjects.
An important caveat to mention at this juncture is research involving
complementary and alternative medicine (CAM) and traditional medicine.
While this may involve human participants, and while this may raise issues
particularly relevant to many developing countries in which CAM and
traditional medicine are employed widely, this thesis focuses on research on
conventional or orthodox medical practices and social investigations related
therewith. References to drugs are as understood in orthodox biomedicine.
There are several reasons for excluding this type of research, the most important
of which is that much of the emerging regulatory guidelines in developing
countries do not specifically refer to the governance of CAM. And, while it
See Kathleen Cranley Glass and Trudo Lemmens, "Research Involving Humans" in Jocelyn
Downie et al, (eds.), Canadian Health Law and Policy, 2nd ed. (Ontario, Butterworths, 2002) at
460.
107
See Nuffield Council on Bioethics, The Ethics of Research Related to Healthcare in
Developing Countries (London: Nuffield Council on Bioethics, 2002) at 25-26.
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would be a worthwhile venture to explore the governance of CAM involving
humans, in order to limit the scope of this thesis to manageable proportions
within the limited timeframe, I do not focus specifically on the governance of
research involving humans in CAM and traditional medicine.
It is important to note that, although there tends to be a focus in the
literature, and even in research governance systems, on biomedical or clinical
research (perhaps because of the more obvious physical risk involved in such
research), health research involving humans is not restricted to such research.
Health research involving humans also extends to social science or behavioural
research and research in the humanities in which humans are the subjects and
which may have health implications. For instance, the example of the Tudor
study in which it was sought to determine if children could be induced to stutter
by being labeled stutterers may, strictly speaking, not be considered clinical
research and yet it caused harm to children.10 Other examples may include a
study of the effect of sexual violence on women during genocide, or a study of
stigmatization as a result of infection with leprosy, mental illness or HIV, or
studies on sexual behaviours of persons who have undergone HIV testing and
counseling,

aimed at reducing high risk sexual behaviour, or studies of the

health effects of domestic violence and emotional abuse against women.

no

Such research also includes studies involving children with learning disabilities
or cognitive impairments or studies involving access to records of personal or

108

Nicoline Grinager Ambrose & Ehud Yairi, "The Tudor Study: Data and Ethics" (2002) 11:2
Am. J. Speech-Language Pathology 190.
109
Nuffield Council on Bioethics, supra note 7 at 25.
110
See La very, supra note 33 at 347-358.
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confidential information, including genetic or other biological information,
concerning identifiable persons. n i

These scenarios can all, in a broad

understanding of "health," be considered health research involving humans. In
these kinds of research, there is also the possibility of harm. For instance,
failure to obtain informed consent or disclosure of private information obtained
in the course of the research may cause harm to research participants. Other
harms may also include psychological stress, or an experiencing of anxiety or
humiliation.
As Downie points out, and as the examples above show, research risks
11")

are not so neatly identified with disciplines.

The discipline, by itself, does not

determine the presence or absence of ethical considerations, but rather whether
or not the methodology employed (which is not determined by the discipline)
results in the research having a direct impact on human beings.113 Moreover,
with the increasingly interdisciplinary nature of investigations of health
accompanying the recognition that the determinants of health come not only
from health therapies and technologies but are also dependent on social and
economic factors, focusing governance only on biomedical research seems

111

Economic and Social Research Council, "Research Ethics Framework" at 8, online:
<http://www.esrc.ac.uk/ESRCInfoCentre/Images/ESRC_Re_Ethics_Frame_tcm6-11291.pdf>
(March 3, 2010).
112
Jocelyn Downie, "The Canadian Agency for the Oversight of Research Involving Humans: A
Reform Proposal" (2006) 13 Accountability in Research 75 at 83. Social Science Research
Ethics in Developing Countries and Contexts" (2004) ESRC Research Ethics Framework,
<http://www.york.ac.uk/res/ref/docs/REFpaper3_v2.pdf> (April 26, 2007). See also, Brenda
Louw and Rina Delport, "Contextual Challenges in South Africa: The Role of a Research Ethics
Committee" (2006) 4:4 Journal of Academic Ethics 39-60. See Kevin D. Haggerty, "Ethics
Creep: Governing Social Science Research in the Name of Ethics" (2004) 27: 4 Qualitative
Sociology at 399.
113
Michael Owens, "Engaging the Humanities? Research Ethics in Canada" (2002) 33:3 Journal
of Research Administration 5 at 6.
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faulty.

In any event, many institutions and countries have adopted the

gradation of risk, including the concept of "minimal risk"115 in an attempt to
provide a system where research is reviewed according to the intensity of the
risk.
With respect to risks, Waring and Lemmens classify the risks
accompanying health research involving humans into two broad categories: risks
to persons and risks to social values. Risks to the person might be physical, such
as death or injury resulting from interventions or unexpected responses to
environmental, genetic, pharmacological, or environmental factors. Risks to the
person might also be psychological harms including psychological stress, or an
experiencing of anxiety or humiliation. Risks to social values include risks to
the objectivity and scientific integrity of research that are posed by conflicts of
interest and to public trust in the ethical conduct of research. Research risks
may also be collective in the sense that research may potentially harm a
community instead of an individual.

114

The results of research may cause

Increasingly, therefore, oversight is being extended to social science research involving
humans. In Australia and Canada, for example, major guidance covers biological sciences,
social sciences and the humanities. See Canadian Institutes of Health Research, Natural Sciences
and Engineering Research Council of Canada, Social Sciences and Humanities Research Council
of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans 1998
(with 2000, 2002 and 2005 amendments). See NHMRC, National Statement on Ethical
Conduct in Human Research 2007, online:
<http://www.nhmrc.gov.au/publications/synopses/_files/e72.pdf> (June 20, 2007). See generally,
"Purpose, Scope and Limits of this Document" at p.7.This is not always viewed favorably. See
for example, Haggerty, supra note 114. See, C. Kristina Gunsalus, "Human Subject Protections:
Some Thoughts on Costs and Benefits in the Humanistic Disciplines" in Arthur Galston, and
Christiana Peppard (eds.) Expanding Horizons in Bioethics (Dordrecht: Kluwer Academic
Publishers, 2005). See also, Giving Voice to the Spectrum: Report of the Social Sciences and
Humanities Research Ethics Special Working Committee to the Interagency Advisory Panel on
Research Ethics (June 2004), online:
<http://www.pre.ethics.gc.ca/english/workgroups/sshwc/SSHWCVoiceReportJune2004.pdf>
(October 19, 2007).
115
These include countries like the United States and Canada.
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significant harm in the community, for instance, where the results are used to
justify discrimination against or within a community, or support harmful
stereotypes or social perceptions. Such harm is of particular issue in already
vulnerable and disadvantaged communities in various countries, including
developing countries.116 These risks are the main reason why health research
involving humans requires regulation by effective governance mechanisms.
They can also occur in different types of health research. All told therefore, it
may not be wise to draw a strict line between the types of research, biomedical
research or social science research which has health implications, particularly
since there are risks in these types, (although the risks are perhaps more
conspicuous in biomedical research and less easy to assess in social and
behavioural research117), and this strict demarcation is avoided in this thesis.
Even with the risks, health research involving human participants has
many benefits, including the promotion of health and understanding of human
behaviour. Steady progress in biomedical research in particular has, in recent
years, yielded a larger store of effective medicines and sophisticated

116

Duff R Waring and Trudo Lemmens, "Integrating Values in Risk Analysis of Biomedical
Research: The Case for Regulatory and Law Reform (2004) 54:3 University of Toronto Law
Journal 249 at 251. See also Baruch A. Brody, Laurence B. McCullough, Richard R. Sharp,
"Consensus and Controversy in Clinical Research Ethics" (2005) 294: 11 Journal of the
American Medical Association 1411 at 1412. See also, Sherry I. Brandt-Rauf et al, "Ashkenazi
Jews and Breast Cancer: The Consequences
of Linking Ethnic Identity to Genetic Disease" (2006) 96:11 American Journal of Public Health
1979.
With respect to conflict of interest, Waring and Lemmens note that: "Conflicts of interest, for
example, may have a conscious or unconscious impact on the way researchers represent risks or
on other behaviour of research staff during the recruitment process or during the research itself.
In areas where there are problems with the understanding and transmission of risk information to
participants, there is greater concern about the impact of conflicts of interest and more reason to
develop a fully independent review of risks." See p. 251
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Susan M. Labott and Timothy P. Johnson, "Psychological and Social Risks of Behavioral
Research" (2004) 26:3 IRB: Ethics and Human Research 11.
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technologies for curing diseases and improving health outcomes than has ever
been

available.

Moreover,

the

clear linkages between

health

and

development,118 and health and human rights,119 mean that research into factors,
including socio-economic factors, which promote good health remains vital,
particularly in developing countries. Consequently, health research involving
humans is carried out in all countries (on different levels and scales) for the
purposes of, among other things, preventing and treating new diseases, exploring
social behaviours, attitudes, and values which may have practical benefits,
including providing information for policy-making as well as promoting health.

1.5 The Need for Health Research in Developing Countries
In developing countries where eighty percent of the world's population
live, there is a high burden of disease and high levels of poverty, including
communicable diseases and very low levels of life expectancy. 120 In these
countries, health research is particularly important to find ways of reducing that
burden and, where possible, by the least expensive means. Research into the
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See Global Forum for Health Research, 10/90 Report on Health Research 2003-2004, online:
<http://www.globalforumhealth.org/Site/002_What%20we%20do/005_Publications/001_10
%2090%20reports.php> (November 3, 2008) at pp.3-6, for an exposition of the linkages, with
several examples in different countries. See also, See for example, World Bank, World
Development Report 1993: Investing in Health (Geneva: World Bank, 1993), online: World
Bank
<http://wwwwds.worldbank.org/servlet/WDS_IBank_Servlet?pcont=details&eid=000009265_397071614231
9> (September 15, 2008) at 17-19, discussing the impact of health on economic growth and
development in developing countries.
119
See for example, Paul Hunt, Rebecca Steward, Judith Bueno de Mesquita and Lisa Oldring,
"Neglected diseases: A Human Rights Analysis" Social, Economic and Behavioural Research.
Special Topics No.6, TDR Research Publications (2007), online: <
http://www.who.int/tdr/svc/publications/tdr-research-publications/neglected-diseases-humanright-analysis> (November 12, 2008), examining the linkages between neglected diseases and
human rights in developing countries.
120
Nuffield Council on Bioethics, supra note 7 at 6.
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factors that determine good health is also important. Although many of the
diseases in developing countries require simple interventions that do not perhaps
necessitate extensive health research, such as improved sanitation, adequate
nutrition arid clean water, the high incidence of diseases such as HIV/AIDS and
191

malaria means that continued health research remains crucial.

Also, therapies

that have already proven effective elsewhere may need to be tested specifically
1 99

in developing countries because of genetic and environmental differences. "
Research undertaken in the past in many developing countries into
diseases such as malaria, yellow fever, and trypanosomiasis has contributed
immensely to knowledge about the prevention and treatment of these diseases.123
Clinical trials in developing countries conducted in developing countries have
contributed to public health knowledge and practice in both developing and
developed countries.124 The HIV/AIDS epidemic in particular — with an
estimated 33 million people infected worldwide, the majority of these people
1 9S

living in developing countries, especially sub-Saharan Africa " — emphasizes
the need for research. HIV/AIDS research has made it possible to discover the
cause of the disease and interventions such as antiretroviral drugs that have
Nuffield Council on Bioethics, The Ethics of Clinical Research in Developing Countries
(London: Nuffield Council on Bioethics 1999) at 2.
122
Nuffield Council on Bioethics, supra note 7 at 15.
123
Nuffield Council on Bioethics, supra note 7 at 6. For instance, the Rockfeller Foundation
Yellow Fever Commission undertook research on yellow-fever in 1920s in West Africa. See
Olajide Ajayi, "Health Research in Nigeria." Online: Oxford Research Forum
<http://www.oxfordresearchforum.il2.com/editorials/nigeria.htm> (March 3, 2004).
124
See David Mabey, "Importance of Clinical Trials in Developing Countries" (1996) 348
Lancet 1113 for examples of trials in developing countries that have influenced clinical and
public health practice in the developed world.
125
Joint United Nations Programme on HIV/AIDS (UNAIDS), 2008 Report on the Global AIDS
Epidemic (Geneva: UNAIDS, 2008), online:
<http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.
asp> (November 5, 2008) at 32.
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made the disease a manageable condition rather than a death sentence.
Continued research in developing countries is necessary to discover better
preventive methods, a cure, or preventive vaccine.
Despite the obvious need for health research in developing countries,
resources for undertaking such research are sadly lacking. Developing countries
lack trained researchers, infrastructure, and sufficient resources to allocate to
health research. They may also lack the political will to devote the resources
available to them to health research.

There is a high level of dependence,

therefore, on foreign sponsors in the developed world.

Governmental

organizations such as the National Institutes of Health (NIH), and the Centers
for Disease Control (CDC) in the United States, the Canadian International
Development Agency (CIDA), the International Development Research Centre
(IDRC), the Canadian Institutes of Health Research (CIHR), the United
Kingdom Medical Research Council (MRC) and the UK Department for
International Development (DfTD), France's Agence Nationale de Recherches
sur le Sida (ANRS) and the European-Developing Countries Clinical Trials
Programme (EDCTP); international organizations such as the World Health
Organisation (WHO) and United Nations Development Programme/World
The Commission on Health recommended a programme of essential national health research,
a concept for identifying research priorities for each developing country to address problems
specific to each country as well as global problems. It also recommended that at least 2 per cent
of national health expenditure should be invested in the programme and that at least 5 per cent of
all grants should go to research. Not many developing countries have heeded these
recommendations. At present, some developing countries, including South Africa, Thailand,
Pakistan and Tanzania, have adopted the Essential National Health Research (ENHR) strategy.
However, progress in implementing the ENHR strategies has been "slow and uneven." See
Nuffield Council on Bioethics, supra note 72 at 27. See Global Forum on Health, Equitable
Access: Research Challenges for Health in Developing Countries (Geneva: Global Forum on
Health,
2008),
online:
<http://www.globalforumhealth.org/Site/002_What%20we%20do/005_Publications/009_For
um%20Reports.php> (November 7, 2008) at 17.
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Bank/WHO 'Special Programme for Research and Training in Tropical
Diseases' (TDR); or non-profit organisations originating in developed countries
such as the Wellcome Trust and the Bill and Melinda Gates Foundation, sponsor
research on areas such as HIV/AIDS, tuberculosis, malaria, diabetes,
hypertension, cardio-vascular disease, and sexual and reproductive health in
1 97

many developing countries.
Pharmaceutical companies also sponsor research into new drugs in
developing countries. The development of new drugs may be targeted for the
needs of developing countries or may simply be undertaken for the development
of new interventions for diseases which may not necessarily be prevalent in
developing countries.

The dependence on foreign sponsors creates its own

problems, raising questions about the motives of such sponsors,128 research
priorities and how responsive research projects are to the health needs of the
1 90

population, who sets the agenda for research in the developing world,

as well

See generally the Nuffield Council on Bioethics, supra note 72; see also Global Forum on
Health, The 10/90 Report on Health Research 2003-2004 (Geneva: Global Forum on Health,
2004), particularly Chapter 9.
The motives of foreign sponsors are arguably varied, ranging from altruistic to self-interested
reasons. As the NB AC notes: 'The studies in question might simply be one way of helping the
host country address a public health problem, or they might reflect a research sponsor's
assessment that the foreign location is a more convenient, efficient, or less troublesome site for
conducting a particular clinical trial. They might also represent a joint effort to address an
important health concern faced by both parties." See NBAC, supra note 17 at i. Some authors
have questioned the motives of multinational pharmaceutical companies in conducting drug
research in developing countries, especially when the resulting drugs may be unaffordable for
people in these countries. See Macklin (2004), supra note 11 at 6-9. Reduced costs, legislative
and regulatory vacuum resulting in fewer delays and requirements, the availability of more
willing and treatment naive participants, foreign market development have been identified as
possible motivations for multinational pharmaceutical companies' interest. See David M. Carr,
"Pfizer's Epidemic: A Need for International Regulation of Human Experimentation in
Developing Countries" (2002) 35 Case W. Res. J. Int. L. See also Shamoo, supra note 9 and
Shah, supra note 8, Globalization of Clinical Trials, ibid.
129
Nuffield Council on Bioethics, supra note 7.
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as whether or not developing countries benefit adequately from such research
efforts.
However, even with the resources provided by sponsors in the
developed world, there is still a wide gap in the resources for, and therefore the
level of, health research conducted in developing countries. Previous studies,
particularly the study published by the Commission on Health Research for
Development in 1990,13° had shown that only ten percent of the resources
available globally are devoted to diseases that account for ninety percent of
global diseases, principally affecting poor people in developing countries - the
"10/90 gap."131 In recent years, there has been an increase in the volume of
research in these countries, a trend frequently referred to as the "globalization of
research."132 For example, a report by the Office of the Inspector General in the
United States Department of Health in 2001 noted a sharp 16-fold increase in

Commission on Health Research for Development, Health Research: Essential Link to Equity
in Development (New York: Oxford University Press, 1990) reporting the great disparity
between the amounts spent on research in developed and developing countries and noting that
only 5 percent of monies available were devoted to research in developing countries which bear
over 90 percent of the burden of diseases. See generally also, Global Forum for Health Research,
The 10/90 Report on Health Research, 2001-2002 (Geneva: The Forum, 2002), online: Global
Forum
<http://www.globalforumhealth.org/Site/002_What%20we%20do/005_Publications/001_10
%2090%20reports.php> (September 15, 2007). As well, health issues in the developing world
appear to be under-represented in medical literature around the world. See for example, A
Langer, Diaz-Olavarieta, C K Berdichevsky and J Villar "Why is Research from Developing
Countries Underrepresented in International Health Literature, and What Can Be Done about It?"
(2004) 82:10 Bulletin of the World Health Organisation. Bernard Lown and Amitava Banerjee,
"The Developing World in The New England Journal of Medicine" (2007) Globalization and
Health, online: <http://www.globalizationandhealth.eom/content/2/l/3> (October 10, 2007).
World Health Organization, Investing in Health Research and Development: Report of the Ad
Hoc Committee on Health Research Relating to Future Intervention Options (Geneva, WHO,
1996).
132
"Social Science Research Ethics in Developing Countries and Contexts" (2004) ESRC
Research Ethics Framework, <http://www.york.ac.uk/res/ref/docs/REFpaper3_v2.pdf> (April 26,
2007), describes this as research becoming a broadly distributed process, with many different
actors across the globe. See also, Seth W Glickman et al, "Ethical and Scientific Implications of
the Globalization of Clinical Research" (2009) 360:8 New England Journal of Medicine 816.
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foreign research conducted for the approval of drugs in the United States.
Much of this increase has been reported in countries in Eastern Europe, Latin
America, and Asia. m

This increase in global research, particularly in

developing countries, is attributable to several factors, including the interest of
non-profit organizations like the Bill and Melinda Gates Foundation in these
countries, the increase in international collaboration and public-private
partnerships such as the Medicines for Malaria Venture (MMV). 135 The
pharmaceutical industry's interest in the availability of treatment naive
participants and in foreign market development, as well as the prevalence of
HIV/AIDS and other diseases in some developing countries and the ensuing
search for vaccines, are also possible reasons for the increase in global health

Office of the Inspector General, 'The Globalization of Clinical Trials: A Growing Challenge
in Protecting Human Subjects" (2001), available online at: <oig.hhs.gov/oei/reports/oei-01-0000190.pdf> (September 22, 2007) at 6. (Hereafter, Globalisation of Clinical Trials.) Others cite
an increase in the volume of research from personal experience with research or researchers: See
Godfrey B. Tangwa, "Research with Vulnerable Human Beings" (2009) 112 (Suppl. 1) Acta
Tropica S16 at S17.
134
Mary Jo Lamberti, Susanna Space and Sara Gambrill, "Going Global" (2004) 13 Applied
Clinical Trials 84., online: Applied Clinical Trials
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=98387>
(September 26, 2005). See also, Globalization of Clinical Trials, supra note 8 at 8.
135
See Jill Wechsler, "New Research Models Spur Third-World Efforts" (September 1, 2006)
Applied Clinical Trials, online:
<http://www.actmagazine.com/appliedclinical trials/article/articleDetail.jsp?id=370343&&pageI
D=2> noting that the private-public partnership (PPP) model promoted by the Bill and Melinda
Gates Foundation has brought about an increase in interest in research into drugs for neglected
diseases in developing countries. See, Andres de Francisco and Stephen Matlin (eds.),
Monitoring Financial Flows for Health Research 2006: The Changing Landscape of Health
Research for Development (2006), online:
http://www.globalforumhealth.org/Site/002_What%20we%20do/005_Publications/004_Reso
urce%20flows.php> (April 21, 2007). See also, Global Forum for Health Research, 10/90
Report on Health Research 2003-2004, online:
<http://www.globalforumhealth.org/Site/002_What%20we%20do/005_Publications/001_10
%2090%20reports.php> (October 16, 2007).
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research. HIV vaccine research is currently taking place in countries like Uganda,
Kenya, South Africa, Botswana, and Nigeria.
But the amount of research in developing countries trails behind
research in developed countries and is still very much below optimal levels.
The Global Forum on Health Research in its 2004 report notes that, "Many
diseases and risk factors accounting for a high level of burden in terms of
morbidity and mortality suffer from very low levels of funding for research.
These include, in particular, acute respiratory infections, diarrhoeal diseases, TB,
tropical diseases, perinatal conditions and HIV/AIDS."138 International efforts
such as the Tropical Diseases Research (TDR)

have been hampered by a lack

See Cecilia Milford, Douglas Wassenaar, and Catherine Slack, "Resources and Needs of
Research Ethics Committees in Africa: Preparations for HIV Vaccine Trials" (2006) 28: 2IRB:
Ethics & Human Research 1 at 2, David P. Fidler, ""Geographical Morality" Revisited:
International Relations, International Law, and the Controversy over Placebo-Controlled HIV
Clinical Trials in Developing Countries" (2001) 42 Harv. Int'l. J. 299 at 301-302, noting that one
of the strategies for addressing the HIV/AIDS problem in developing countries is to develop
cheap HIV vaccines and therapy regimes that are easy to implement and that this requires ' *
clinical trial research in developing countries which will remain an attractive venue for such
research. Shamoo summarises the reasons behind the growth of clinical research in developing
countries, noting that: "The increase in clinical trials in developing countries is fueled by the
recent push for global commerce. Trends include the pharmaceutical industry's interest in new
drugs; new emerging markets; emerging infrastructure from investigators in developing
countries in the newly found, home-grown pharmaceutical services corporations; inability to
conduct such research in developed countries; and the less costly and less restrictive regulatory
environments found in developing countries." See Adil E. Shamoo, "Debating Moral Issues in
Developing Countries" (Jun 1, 2005) Applied Clinical Trials, online: Applied Clinical Trials
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=165484>
(September 26, 2007).
137
See Global Forum for Health Research, 70/90 Report on Health Research 2003-2004 (Geneva:
Global Forum for Health Research, 2004), online: <
http://www.globalforumhealth.org/Site/002_What%20we%20do/005_Publications/001_10%
2090%20reports.php> (December 8, 2007) at 122.
138
Ibid.
139
TDR is a joint effort of the WHO, World Bank and the United National Development
Programme (UNDP), which seeks to "promote public-private partnerships, and to assist
pharmaceutical companies in the late stage of product development. Acting as a broker linking
academia, governments, industry, health professionals and affected communities, TDR has been
involved in the implementation of field trials and the licensing out of new products, or new uses
for existing products." Nuffield Council on Bioethics, supra note 72 at 27.
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of funds and support.

Expenditures on diseases such as malaria, which affects

mainly people in the developing world and which has claimed even more lives
than HIV/AIDS,141 remain paltry in comparison to expenditures on diseases that
affect people in the developed world.142

New drugs are needed to reduce

morbidity and mortality from malaria and to deal with the increasing incidence
of resistance to older drugs, but many developing countries lack the necessary
resources for the needed research, (an estimated US$ 2 billion per year in Africa
and US$ 1 billion per year for other malaria-endemic areas)143 and the resources
provided by the public and private sectors in developed countries remain
insufficient.
With respect to new drugs, there is an inadequacy of effective, safe and
affordable medicines to control infectious diseases that cause high morbidity and
mortality in developing countries.

Where treatments exist, they are often old,

toxic and difficult to administer and unsuitable for the challenging conditions in
developing countries.14

Although there appears to be, in recent years, an

increase in drug development in developing countries, pharmaceutical
James Orbinski and Solomon Benatar, "Drug Development for Visceral Leishmaniasis: A
Failure of Market and Public Policy" in Lavery, supra note 20 at 92.
141
According to the Global Forum on Health Research, "Malaria kills over 1 million people a
year, mainly children under five and pregnant women. It is estimated that there are between 300
and 500 million cases of malaria every year in sub-Saharan Africa, Asia and South America."
See the Global Forum on Health Research, The 10/90 Report on Health Research 2003-2004,
supra note 103 at 215. R W Snow et al, "Estimating Morbidity, Mortality and Disability Due to
Malaria among Africa's Non-pregnant Population" (1999) 77 Bulletin of the World Health
Organisation 624^10.
142
Ibid at 123 and 215. See Nuffield Council on Bioethics, supra note 7 at 23.
143
Global Forum on Health, supra note 103 at 247, (these are 2004 figures).
144
Recent initiatives include the WHO, UNICEF and UNDP's, Roll Back Malaria Partnership,
and the Medicines for Malaria Venture (MMV). However,
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P. Trouiller et al, "Drug Development for Neglected Diseases: A Deficient Market and A
Public Policy Failure" (2002) 359: 9324 Lancet 2188.
146
See Beatrice Stirner, "Stimulating Research and Development of Pharmaceutical
Products for Neglected Diseases" (2008) 15 European Journal of Health Law 391 at 394.
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companies have largely ignored diseases that occur in these countries because
investment in research and development in these countries would yield only
poor, if any, returns. One study pointed out that of 1393 new chemical entities
marketed between 1975 and 1999, only 16 were for tropical diseases and
tuberculosis, and observed that there is a 13-fold greater possibility of bringing a
drug for central-nervous-system disorders or cancer to the market than for a
neglected disease.147

The state of drug development in developing countries

arguably shows both a failure of public policy (governments in both developing
and developed countries have paid insufficient attention to this issue, including
providing the necessary support and funding) and a shirking of ethical
responsibility (pharmaceutical companies have consistently placed profit ahead
of the lives of the poor).148
Further, health research in developing countries is particularly
important with the realization that dependence on health research conducted in
developed countries may not be sufficient for the purposes of developing
countries in some instances. For example, research findings in developed
countries, where more resources are expended on research, may not easily be
transferable to developing country settings for various reasons, including the fact
that communicable diseases which are prevalent in developing countries are not
typically prevalent and thus are not the focus of research in the developed world,
socio-cultural and economic circumstances differ, and interventions developed
in the developed world do not always work as effectively in the developing
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world.

Genetics, cost factors, and climatic conditions may require different

interventions to be developed for developing countries.
Although some increase in resources and in the volume of health
research has been noted, as the discussion above indicates, the disequilibrium in
resources devoted to health research in developing countries persists. In the
discussion that follows regarding the governance of research in developing
countries, one cannot lose sight of the fact that there is need for more health
research in developing countries. More research remains necessary to address
public health needs, improve health outcomes, increase life expectancy and
promote human rights and economic development.

Hopefully, the growing

trend in health research in developing countries will continue, and will extend to
African countries and to neglected diseases.
It is hoped, however, that the need for more research in developing
countries will not hinder adequate oversight in developing countries.150 One is
also hopeful that as more resources become available and more research projects
are undertaken, there will be adequate oversight of such research. This will help
to ensure the safety, and preserve the trust of research participants in developing
countries, which might in turn facilitate greatly needed health research in those
countries.

Global Forum on Health Research, supra note 103 at 124-125.
There have been speculations that some developing countries have, in the past, willfully
neglected to address the regulation of research because of concerns that this may limit resources
for research from rich countries. See R. N. Nwabueze, 'Ethical Review of Research Involving
Human Subjects in Nigeria: Legal
and Policy Issues' (2003-3004) 14 Ind. Int'l & Comp. L. Rev. 87 at 89.
150
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1.6 The Need for Research Governance Systems in Developing Countries
Much of the discussion of health research involving humans in
developing countries has focused on ethical principles, standards, and the
discussions and dissensions that have occurred with respect to these, particularly
in the context of research conducted in developing countries by external
sponsors. But several important questions may occur in the consideration of
these issues. What are the domestic contexts of these discussions? What are,
and what should developing countries be doing in terms of protecting their
citizens who may participate in research? Should all the discussion about the
ethical conduct of research in developing countries be conducted at the
international level, especially in view of the great impact of externallysponsored research in developing countries? This particular question can be
answered firmly in the negative. For one thing, the domestic context for the
governance of health research in developing countries is important not least
because it effectively engages the parties that need to be involved in any serious
discussion of the protection of participants in health research in developing
countries. For another, governance of health research in developing countries
would encompass all research conducted in developing countries - externallysponsored research and domestically-sponsored research.
Further, addressing some of the thorny ethical issues in a domestic
context, with domestic policies and guidelines may be useful in resolving these
issues to some extent in a practical way, and in a manner which engages
developing countries more effectively in the debates surrounding the ethics of
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health research. These domestic policies and guidelines would, of course, be
part of the steps that developing countries will be taking to address issues
relating to human participants' protection, and be part of a domestic governance
system. In this regard, Johnson and others succinctly argue that:
[A]s the current controversies in ethics
predominantly involve research in developing
countries, it is vital that these countries are
partners in decisions and consensus building in
bioethics, and that discussion of key
contemporary ethics problems are not
predominantly taking place in medical journals
and by Western researchers but are actively
considered by national bodies in all countries
which sponsor or host health research.

In addition, the debates emphasise the necessity of establishing or further
developing domestic governance systems to prevent unethical conduct in
research in developing countries.

As well, the development of domestic

research governance systems can also curb total dependence on ethics review
carried out externally by sponsor agencies or countries that are unfamiliar with
the social, health, and economic realities of developing countries.
Even apart from the controversies surrounding some of the provisions
of the international ethical guidelines, as has been rightly pointed out elsewhere,
1 S^

they operate under a voluntary adoption model.

The domestic governance

Sonali Johnson et al, "Ethics, Justice and Public Trust: Promoting Research Ethics
Governance at National Level" (2008), online: <
http://www.tropika.net/specials/bamako2008/background-documents/tuesday/EthicsBackground-paper-for-circulation.pdf> (/December 12, 2008).

J5^ Ibid.
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James Lavery, "The Challenge of Regulating International Research with Human Subjects"
(June, 2004) Science and Development Network, online:
<http://www.scidev.net/dossiers/index.cfm?fuseaction=policybrief&policy=52&section=265&d
ossier=5> (December 9, 2008). Some have therefore argued that this model fails to protect
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system thus becomes even more relevant when one considers the voluntary
nature of the major guidelines, which are typically not directly enforceable in
domestic law and, which cannot, strictly speaking, be considered as part of
international law. The Helsinki Declaration and the CIOMS Guidelines, while
widely accepted, are not binding international law, and contain no provisions for
legal enforcement. This means that countries are not under any legal obligation
to comply with, or implement the requirements of the international ethical
guidelines. Moreover, there are hardly any rules in international law which
regulate the activities of multinational pharmaceutical companies or even
generally provide for research ethics.154 The ethical standards set out in the
international and national guidelines, though important because they underpin
the governance system, are not the same as, and should not be conflated with the
governance system - which include legal regulation and other non-legal
guidance and the role of institutions - and its functioning.
Further, the international guidelines and the new national guidelines
will be ineffective without the appropriate mechanisms for their implementation
in a domestic setting.155 Issues of implementation and enforcement necessitate

research participants in developing countries and that persons from these countries be excluded
from biomedical research on the basis of inadequacies of the international ethical guidelines. See
for instance, R. R. Kishore, "Biomedical Research and Mining of the Poor: The Need for their
Exclusion" (2006) 12:1 Science and Engineering Ethics 175.
154
See generally Kevin M King, "A Proposal for the Effective International Regulation of
Biomedical Research Involving Human Subjects" (1994) 34 Stan. J. Int'l L. 163, for a discussion
of the different international law rules which apply to research, including international
humanitarian law against torture, and the ICCPR which contains the requirement for informed
consent (Article 7), International Covenant on Economic, Social and Cultural Rights 16
December 1966, 993 U.N.T.S 3, (entered into force 3 January 1976) which contains a right to
benefits of scientific research.
155
See Susan Bull, "Introduction: Ethics of Research" (2002) SciDev, online: <
http://www.scidev.net/dossiers/index.cfm?fuseaction=dossierfulltext&Dossier=5> (November 7,
2007).
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that developing countries set up governance systems that can operate effectively
in a local context to protect research participants while allowing socially
desirable health research to take place.

In other words, even where countries

choose to comply with the requirements of the international guidelines
domestically, ethical principles, rules and guidelines require domestic structures,
mechanisms and agents for their implementation. Ethics review, an important
mechanism of research governance, typically operates within particular domestic
systems. Thus, as some commentators have rightly noted, the international
guidelines are by themselves "no substitute for a substantive system of research
governance entrenched at the national level."156 The international guidelines
require localisation, application, and enforcement in the context of developing
countries' domestic policies, laws and regulations. Developing countries can
therefore not simply rely completely on the international guidelines to provide
oversight of health research but need to develop domestic governance systems.
The point also has to be made that many developed countries have
domestic systems of research governance to provide oversight of health research.
This may be in addition to the international ethical guidelines or even despite the
international guidelines. These governance systems are designed primarily to
allow health research to be undertaken within safe parameters.

Several

developed countries have attempted to address protections for research
156

J Ford and G Tomossy, 'Clinical Trials in Developing Countries: The Plaintiffs Challenge',
Law, Social Justice & Global Development Journal, online:
<http://www2.warwick.ac.uk/fac/soc/law/elj/lgd/2004_l/ford/> (April 4, 2007). See also,
George F. Tomossy and Jolyon Ford, "Globalisation and Clinical Trials: Compensating Subjects
from Developing Countries" in B. Bennett and G.F Tommossy (eds.), Globalization and Health:
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participants in developing countries where research is sponsored by such
developed countries.157 These domestic systems are, however, aimed primarily
at the protection of the citizens of these.countries and there may be competing
motives.

For instance, political developments in a developed country, as

Dickens observes, might create a possibility that populations in developing
countries may find their interests compromised by policies in the developed
country.
Also, as Dickens and Cook note with specific respect to submissions of
research projects to be conducted in developing countries for review in
developed countries, and the need for ethics review committees in developing
countries:
The claim that a committee will not approve
greater risks to members of another country's
population than it will approve to its own is
usually well-intentioned and honorable, but
may deny members of the other country's
population choice and autonomy, be
insensitive to the other country's own view of
its priorities, and be paternalistic. It is not
submission to an irresponsible 'anything goes'
type of ethical relativity to recognize that
ethical principles and priorities can differ
between countries, and that what is

See, for example, "Biomedical Research Projects in Developing Countries" (Denmark)
(2006), online:
<http://www.cvk.im.dk/cvkEverest/Publications/cvkx2Eimx2Edk%20x2D%20dokumenter/Engli
sh/20061130095326/CurrentVersion/ulandssagerENG.pdf> (April 3, 2007). For an insightful
exposition of the concept of equivalent protections in relation to the United States, see Bernard
Dickens, "The Challenge of Equivalent Protection" in NBAC volume 2, supra note 16. See §
46.101(h) of Title 45 Code of Federal Regulations. See also, United States, Department of
Health and Human Services, 'Report of the Equivalent Protections' (2003), available at:
_http://www.hhs.gov/ohrp/international/EPWGReport2003.pdf ( 5 April, 2007).
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unacceptable in one country may be acceptable
in another, and vice versa.159
They note also that:
Despite the many challenges and occasional
doubts, with training and appropriate
resources, committees can be brought to a
level of reliable structure and effective
functioning, in developing and developed
countries alike.160
Developing countries need domestic systems that put their needs, priorities and
the safety of their citizens first. For instance, in 2008 the United States FDA
decided to allow using data from foreign clinical trials in new drug applications
even if the trials only compare new products to placebos instead of best
available treatments, thus ceasing to apply the 1989 version of the Helsinki
Declaration, previously the standard, in foreign clinical trials.

While some

commentators have expressed concern about how this might affect participants
in developing countries, " where a developing country has a standard similar to
the latest version of the Helsinki Declaration or even stricter, and takes steps to
enforce these standards, researchers from other countries will nevertheless have
to maintain these standards when they come to do research in such country.
The major argument which could be raised against the establishment of
domestic governance systems in developing countries is that of cost and
priorities.

The point can perhaps realistically be made that regulatory and
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governance

structures,

including

appropriate

training

for

regulators,

infrastructure and technology, and adequate remuneration for those employed in
this area, amongst other things, cost money. Developing countries have many
challenges, including pressing health problems such as those relating to reducing
maternal and infant mortality, tackling malaria and HIV/AIDS, building new and
maintaining old and dilapidated health infrastructure, dealing with brain drain of
health workers, and addressing poverty and poverty-related diseases, with only
limited resources to meet them. It may be argued therefore that the regulation of
health research may not be an area to which many developing countries should
choose to devote resources given other pressing needs. This line of argument
assumes that since developing countries lack capacity, they can do little to
prevent unethical conduct of research and to create governance structures which
protect research participants. This assumption may be based on practical realities,
including limited resources in developing countries. Indeed, a close look at the
attitude of developing countries in the past regarding the governance of health
research reflects this perspective.
Nonetheless, while developing countries may be handicapped in terms
of available resources to monitor research, there are certainly steps that they can
reasonably take to ensure the safety of their citizens who participate in it.
Moreover, given the urgent need for increased health research in developing
countries, the lacuna in the regulation of health research that currently exists
both domestically and internationally and what this means in terms of the
protection of research participants, research risks, and the allegations of abuses
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that have occurred in several developing countries in recent years, a more urgent
issue arises: Can developing countries afford not to put in place effective
governance systems? Examples such as the Pfizer incident in Nigeria, where
basic procedures such as the requirement for ethics approval for the clinical trial
were not clear, met, or enforced, indicate the need for effective regulatory and
governance systems in developing countries. Governance of health research is
clearly a priority in developing countries, alongside the need for increased
research on neglected diseases in developing countries. External help from
developed countries and international organisations may be necessary to address
issues of costs and gaining increased understanding of regulatory and
governance systems from countries which have had them longer. Such external
help recognises the fact that developed countries have an interest in disease
eradication in developing countries because many diseases do not respect
geographic boundaries. Diseases such as HIV/AIDS require research, which
should realistically occur in many developing countries as there is a greater
burden of that disease in such countries.

Yet such research would benefit

developed countries too as they seek to provide treatments and cures to their
own citizens. Effective regulation of such research in developing countries
would therefore benefit developed countries. As will become clear in the
discussions that follow, some external assistance from foreign countries has
been forthcoming and is increasingly a key component of the steps that some
developing countries have taken in regards to the domestic governance of
research.
163

All told, however, the issue of costs and priorities does not negate

These include research ethics capacity-building programs developed by the Fogarty
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the need for domestic governance systems. In addition, some of the critical
health problems which developing countries face require research, and such
research would occur more safely within a regulated environment which takes
into consideration the peculiarities of the developing world context already
discussed.
It would of course be naive to ignore or gloss over global inequalities
and how these may affect the steps that developing countries are willing to take
to protect their citizens while encouraging beneficial health research to be
undertaken. Thus, the need for increased health research in developing countries,
in an increasingly competitive global research environment may prompt some
countries to refrain from putting in governance structures or may cause them to
merely adopt, without due consideration, governance arrangements approved in
developed countries. In this regard, although there is little empirical data in
support, some commentators have observed that developing countries may, in
fact, avoid putting in place governance mechanisms in place to regulate research,
since this might limit necessary research by external sponsors, which these
countries have limited resources to undertake.

However, even if this is true

and, even apart from the negative implications of expediently putting the lives,
safety and welfare of citizens at risk in order to achieve certain (perhaps even
laudable) objectives, one could counter that argument as not well-founded.
Implicit in such an argument is a lack of understanding of the relationship
between the two sides of the debate, that is, that there is conceivably a
International Center of the United States National Institutes of Health, and the European-based
European and Developing Countries Clinical Trials Partnership (EDCTP).
164
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relationship between the need for increased resources for beneficial research in
developing countries and the regulation of such research. It can be argued that
appropriate governance structures may create more room to undertake, and
manage, such research. To explain further, there is the possibility that such
structures may ensure that such research operates within safe, clearly established
parameters. This, in turn, may help create trust between researchers and research
participants and the wider community, thus potentially making increased room
for research that is more likely to be beneficial to the target population.

This

way, everyone stands to gain - researchers, research participants and the wider
community. As rightly observed by Johnson and others, "Research governance
regulations and mechanisms at national level, are necessary not only for
maintaining credibility and a high quality of research but also for maintaining
public trust in the purpose and conduct of health research."1

5

Trust is a particularly important factor to consider in the developing
world context. This is because the erosion of trust affects not only the potential
participation in health research; it may also affect participation by the general
population in important and beneficial health programmes. For instance, the
rejection in 2004 of the polio vaccine in Northern Nigeria (a disease that has
largely been eradicated in many countries around the world) has been attributed,
in part, to the fears engendered by the Pfizer incident.166 The unanticipated costs

Johnson et al, supra note 147.
See A. S. Jegede, 'What Led to the Nigerian Boycott of the Polio Vaccination Campaign?'
4(3) PLoS Med (2007): e73 available at: _doi:10.1371/journal.pmed.0040073_ (3 April 2007).
See also, Ebenezer Obadare, A Crisis of Trust: History, Politics, Religion and the Polio
Controversy in Northern Nigeria" (2005) 39:3 Patterns of Prejudice 265 at 278-279.
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of failure to establish effective governance structures may therefore exceed the
costs of proper governance.
As for merely adopting governance arrangements approved in
developed countries, in a process that has been termed "bioethical colonialism"
or "ethical imperialism," this is a major concern, especially if one accepts like I
do, that external assistance may be necessary to help developing countries. To
counter this problem at the international level, some commentators like Dickens
have suggested that not only should research sponsors in developed countries
invest in developing research capacity in poorer countries, but that they engage
in developing research ethics capacity. Such research ethics capacity would be
helpful

in allowing more authentic international collaboration in the
1 f\l

development process of the international guidelines.

Such research ethics

capacity would also be helpful in developing national systems of governance.
Attention must, of course, be paid to the potential for "bioethical
colonialism" and that external sponsors who choose to promote research ethics
capacity in developing countries must constantly reevaluate their programs in
this respect. But it does not negate the need for, and in fact emphasises, the need
for greater participation by developing countries in the regulation of health
research involving participants from these countries. Such involvement does not,
in my opinion, include re-inventing the wheel. In other words, mechanisms that
may be helpful in the governance of research, such as ethics review, cannot be
167
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discarded on the basis of avoiding "bioethical colonialism."
attention to domestic contexts is necessary.

But paying

Thus, there may be other

mechanisms that may not necessarily apply in some developed countries that
may be necessary. This may include addressing controversial ethical issues in
domestic ethical guidelines.

It may also include the use of comprehensive

legislation as I suggest in the following chapters.
In sum, there are strong arguments for domestic systems in developing
countries and that these systems would be beneficial for health research in
developing countries as well as for the safety of research participants. The steps
that several developing countries are taking in this respect are therefore a
welcome development.1

8

Descriptions and analyses of these developments as

this thesis and the growing literature on research governance in developing
countries provide are also welcome to identify ways to improve these emerging
systems.

1.7 Research Governance in Nigeria: An Introduction
Although the thesis addresses the governance of research involving
humans in developing countries, it focuses specifically on Nigeria as a case
study. Below I give a brief background on the Nigeria.
Nigeria is Africa's most populous nation, with a population estimated at
about 150 million people and accounting for about 47 percent of the population

See section 1.3 for some examples of these steps.
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of West Africa.169 It is an influential player in African affairs.170 It has recently
established a peaceful transition to a democratic government, adopting a new
constitution in 1999. Prior to 2006 when it established a national code for
research ethics, the research oversight mechanisms in Nigeria consisted of a
spectrum of formal and informal mechanisms including regulation by the federal
government through agencies created for that purpose, review by ethics review
bodies in research institutions and self-regulation by medical practitioners.
There were no policy guidelines or law relating specifically to research
involving humans, or requiring the existence of ethics review committees in
research institutions, setting down their structure or composition and functions
or even requiring that research protocols must pass through ethics review. In
late 2006, Nigeria established a National Health Research Ethics Committee as
well as a National Code for Health Research Ethics designed to provide
171

oversight for research.
There are several reasons for focusing on Nigeria. First, I have chosen
Nigeria because of my personal connection to that country (I am Nigerian), and
my personal interest in research governance in that country which arose initially
from allegations of unethical conduct of research in that country (like the Pfizer
incident which made headlines around the world). But I have also opted to
study Nigeria, an African country, because developing countries in Africa have
169
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<http://web.worldbank.orgAVBSITE/EXTERNAL/COUNTRIES/AFRICAEXT/NIGERIAEXT
N/0„menuPK:368906~pagePK:141132~piPK:141107~theSitePK:368896,OO.html> (February 8,
2008).
170
Ibid.
171
National Health Research Ethics Committee: <http://www.nhrec.net/nhrec/> (January 14,
2010).

69

some of the most pressing problems of poverty and health challenges, such as
malaria and HIV/AIDS and other neglected diseases which require much
research. Many of them also, until recently, lacked governance mechanisms for
research involving humans. Others still do not have any organized mechanisms
for regulating research involving humans. In focusing on Nigeria I am focusing
on an African country which has considerable influence in the region, politically
and economically.
Nigeria, a major oil exporting country, also plays an influential role in
1 79

African affairs. It is the eighth largest oil exporter in the world. " The BBC
notes that "Nigeria is the economic powerhouse of West Africa, contributing
nearly 50% of regional GDP.173 The Economist, in an even broader statement,
observes that, "Nigeria remains crucial to the future of Africa: the continent's
most populous country and its largest economy after South Africa, with which it
jostles for continental leadership."174 It has acted as a mediator in many African
conflicts and provided military assistance to many peacekeeping efforts in the
17S

continent, including in Liberia, Eritrea and Sierra Leone.

It is currently a non-

permanent member of the United Nations Security Council.
With its multi-ethnic and multi-cultural population, past history of
colonization, military rule, recent transition to democratic rule, many squandered
opportunities to raise the standard of living of its citizens, and rural/urban
172
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disparities, it shares the challenges that many developing countries face,
including leadership and democratic challenges as well as poverty and healthrelated problems. In addition, Nigeria is also an interesting context to look at
research governance because of its great burden of disease, vast population, and
high human resource potential in terms of potential high numbers of researchers,
all of which present great need and opportunities for health research.

Past

allegations of unethical conduct of research further cement this great need. Also,
from an economic standpoint, Nigeria has economic challenges but also the
economic potential to provide a workable, if not perfect, governance system for
health research.
It has taken steps recently towards improving the governance of health
research, and it is hoped that many developing countries in the African continent
can learn from its governance experience.

Detailed analysis of Nigeria's

context and research governance efforts are undertaken in Chapters Five and Six,
and recommendations for improvements are made in Chapter Seven.
It is hoped that the analysis of the research governance regime in
Nigeria will prove helpful in identifying ideas that may be helpful to the country
as its governance system evolves. It is also anticipated that these ideas will
prove more easily transferable to other developing countries with similar socioeconomic and political contexts and challenges which are in the process of
establishing research governance systems.
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Chapter Two
Governance as an Analytical Framework for Health Research Involving
Humans

2.1 Introduction
Health research involving humans in developing countries has
been the subject of much ethical analysis, particularly in the area of biomedical
research. But Chapter One identified a vacuum in our understanding and
analysis of this important area - not much work has been done with respect to
taking a broad look at the emerging regulatory systems in these countries and
linking the various parts of the governance of research into a comprehensive
whole. This chapter explores one way to address this vacuum by taking an indepth look at governance.
Governance and regulation have become very relevant and interesting
areas of consideration for scholars in recent years.

Concerns about

overregulation, inefficiency of regulating institutions, legalism, inflexibility and
costs of regulation, and arguments in favour of deregulation gained ground in
recent years. Much has thus been made of the concept of 'new" governance
which allows greater participation of private actors in social regulation. The
idea of regulation as the state's top-down control of behaviour through certain
means, including the enactment and enforcement of legal rules, had increasingly
given way to a growing reliance on private actors and non-legal rules. But
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recent events

have once more brought to the fore questions about regulation

and governance, and the appropriate role of government in not only economic
regulation but also in social regulation.
Health research involving humans is one area of human endeavour in
which the areas of governance and regulation have particular relevance. As
explained briefly in Chapter One, formal and informal mechanisms are
employed in the regulation of research involving humans, to ensure, among
other things that research is conducted within ethically acceptable and safe
parameters.

This chapter seeks then to analyse health research involving

humans using a governance analytical framework.
The focus on governance raises several interrelated questions:
First, what specifically is governance? This is necessary because the term
"governance" is applied liberally with respect to research involving humans.
Sometimes it is used interchangeably with the related term "regulation." Do they
mean the same thing? Can they mean the same thing in the particular context of
regulating the conduct of research involving humans? Second, what is a
governance analytical framework?

Third, are there other possible alternative

analytical frameworks? If there are, why use a governance framework? Fourth,
how will the governance framework be used?
I answer these questions in different sections below. In the second
section, I define the term 'governance' and examine its relationship to regulation

Such as the recent global economic crisis which caused frantic state interventions in several
Western countries to minimize the impact of the crisis on the world's troubled financial markets,
or the recent oil spill in the United States, billed as the most catastrophic environmental disaster
since the Exxon Valdez incident.
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and to law. In the third section, I discuss governance as a valuable and functional
analytical framework for research involving humans, considering its theoretical
aspects, its current manifestations in the literature and the hybrid framework
which I am adopting. I explain the rationale for choosing to apply a governance
lens to the subject of research involving humans in developing countries
generally and in particular, Nigeria. I also describe briefly how this framework
will be employed.

2.2. What is Governance?
'Governance' is a term now used liberally not only in relation to
regulation or organisational management, but in political administration
internationally and domestically, as well as in the field of development. As a
concept, it appears to be subject to many interpretations. And the increasing
recognition of 'new' governance arrangements has added to confusion as to the
meaning of the term. In particular, these "new" governance arrangements have
spurred whole schools of thought devoted to understanding the concept of
governance within political and social science.177
The concept of governance has been used in academic and other
literature in various ways. In discussions about states in general, and developing
countries in particular, governance is frequently employed in discussions
relating to democracy and the rule of law and the challenges that developing
177
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countries face in these areas.

The reference to democracy and rule of law may

allow us to view this idea of governance as "democratic governance." It is
therefore not surprising that some define governance as including: "the
processes by which governments are chosen, monitored, and changed; the
systems of interaction between the administration, the legislature, and the
judiciary; the ability of government to create and to implement public policy;
and the mechanisms by which citizens and groups define their interests and
interact with institutions of authority and with each other."
Apart from the democratic nature of any specific government,
governance is also used in reference to the responsibilities of governments. The
World Bank thus defined governance in 1997 as: "the manner in which power is
exercised

in

development"

the

management

of

a country's

economic

and

social

and more recently in 2006 as: "the manner in which the state

acquires and exercises its authority to provide public goods and services."

The

United Nations Development Programme (UNDP) similarly defines governance
as: "the exercise of political, economic and administrative authority to manage a
nation's affairs. It is the complex mechanisms, processes and institutions through

See for instance, USAID, "Sub-Saharan Africa: Democracy and Governance," online:
<http://www.usaid.gov/locations/sub-saharan_africa/sectors/dg/> (February 5, 2009).
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which citizens and groups articulate their interests, exercise their legal rights and
obligations, and mediate their differences."
These descriptions of governance have prompted the term "good"
governance, used especially by international financial and development agencies
such as the World Bank and the UNDP in relation to developing countries, that
is, the extent to which the government uses its power to produce and sustain
development for its citizens. In promoting the idea of good governance, these
institutions have taken steps to encourage democracy, free-market reforms,
promote institutional and regulatory reforms, shifting power from the public
sector or government to the private sector, and engaging civil society in the
process of achieving public goals in an efficient manner. This usage of
governance draws together strands from the political, administrative, and
economic values of legitimacy and efficiency.183 In short, with the concept of
"good governance," these organisations, as Rhodes points out, have combined
the principles of new public management and liberal democracy.

UNDP, Reconceptualising Governance (New York: UNDP, 1997), online:
<http://www.pogar.org/publications/other/undp/governance/reconceptualizing.pdf> at 9.
183
See Cynthia Hewitt de Alcantra, "Uses and Abuses of the Concept of Governance" (1998) 50:
155 International Social Science Journal 105 at 106. de Alcantra notes that the increasing
reliance of international development agencies on the concept of governance signifies an
intellectual shift from complete reliance on free market policies to a more social and
development-oriented approach. She points out that: "By talking about 'governance' - rather
than 'state reform' or 'social and political change - multilateral banks and agencies within the
development establishment were able to address sensitive questions that could be lumped
together under a relatively offensive heading and usually couched in technical terms, thus
avoiding any implications that these institutions were exceeding their statutory authority by
intervening in the internal political affairs of sovereign affairs." See also, George Philip, "The
Dilemmas of Good Governance: A Latin American Perspective," (1999) 34:2 Opposition and
Government 226.
184
R A W Rhodes, "The New Governance: Governance without Government" (1996) 44
Political Studies 652 at 656.
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More recently, the term "governance" has also been used particularly in
academic literature in referring to the changes associated with transformations in
the regulatory landscape, the different roles now adopted by governments (or the
state), and private and non-state actors. In .this sense, governance, also described
as "new" governance, refers to: "a basically nonhierarchical mode of governing,
where non-state, private corporate actors (formal organizations) participate in
the formulation and implementation of public policy,"185 "the investigation of a
plurality of sites of non-state regulatory activity"186 or as concerning "activities
related to public purposes that are undertaken jointly by multiple actors,
including those 'beyond government,' or at the very least beyond the
organizational boundaries of a single government,"1 7 It has also been employed
to describe implementation of public policy by self-organising networks and
sometimes as synonymous with the "new public management."
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This

conception of governance involves several core ingredients including: the
accomplishing of public goals through collaboration with other organizations,
including private-sector and nonprofit organizations and employing nonhierarchical, informal, and extra-constitutional means.189 This understanding is

Renate Maynzt, "From Government to Governance: Political Steering in Modern Societies,"
Paper presented at the Summer Academy on IPP: Wuerzburg, September 7-11, 2003, online:
<http://www.ioew.de/govemance/english/veranstaltungen/Summer_Academies/SuA2Mayntz.pdf
> (February 26, 2008). See also,
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in Michael Mac Neil, Neil Sargent, and Peter Swan, Law, Regulation, and Governance (Ontario:
Oxford University Press, 2002) at 10.
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different from what may be referred to as the "old" or traditional governance
which denotes a process of steering and controlling activities in the economy
and the society in which the state plays a central role.190
The concept of governance is thus a loose one - ranging from
how power is acquired (democratic governance) to what actors exercise control
over public policy (old and new governance) -

to which several specific

meanings can be attached, and of which there may be different types and which
may be connected to different potential theories, and different empirical and
normative concerns.

Theoretically, as subsequent discussion in this chapter

will show, many authors currently employ the term "governance" only in the
new governance sense (discussed in more detail later in the chapter), and fail to
distinguish between it and governance as a generic term.
Beyond any specific understanding of the concept, however,
governance has a generic meaning which underlies the different understandings
held in particular fields of thought. In this sense, according to Mossenberger, it
is simply the process of governing.192 de Alcantra points out that:
In the English speaking world, 'governance' is
a word routinely used over the course of many
centuries to refer to the exercise of authority
within a given sphere. It has often been
employed as a synonym for the efficient
management of a broad range of organisations
and activities, from the modern corporation
(corporate governance) or university (the

Jon Pierre, "Introduction: Understanding Governance ," in Jon Pierre (ed.) Debating
Governance (Houndmills, Basingstoke, Hampshire: Palgrave Macmillan, 2000) at 3.
191
Ibid, at 3.
192
Mossenberger, supra note 14 at 13.
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governance of Vassar College) to the ocean
depths.193
Thus, the term "governance," is used widely and is applicable to regulation and
management activities in a variety of institutions and organisations, including
governments, companies (hence, corporate governance), and in discourse
relating to world affairs (hence, global governance). For the purpose of the
analysis undertaken in this thesis, it is important to go back to this generic
understanding of governance.
In this respect, according the University of Ottawa Centre on
Governance, governance is broadly speaking, "about the processes by which
human organizations, whether private, public or civic, steer themselves."194
Governance also generally refers to the "processes and structures that an
organization uses to direct and manage its general operations and program
activities."195 Similarly, Rosenau defines governance as "systems of rule, as the
purposive activities of any collectivity that sustain mechanisms designed to.
ensure its safety, prosperity, coherence, stability, and continuance."196 In a
description that presents a holistic conception of governance, a Law
Commission of Canada study explains the concept of governance as pertaining
not only to organizations, but also to the
complex ways in which private, public and
social organizations interact and learn from
one another, the manner in which citizens
193
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contribute to the governance system, directly
and indirectly, through their collective
participation in civil, public and corporate
institutions; and the instruments, regulations
and processes that define the 'rules of the
game.'"197
The study of governance therefore involves an examination of the distribution of
rights, obligations and power that support the organisational system, the patterns
of coordination that support its activities and sustain coherence, and establishing
benchmarks, and sharing knowledge to ensure restoration when there are signs
that the system requires repair.
These generic descriptions of governance, which are applicable to
any activity that requires some control, perhaps explain the liberal use of the
term with particular regard to research involving humans, and are helpful for the
purpose of analysis in this thesis. It also explains in part why the concept may
be seen by some as allowing some form of control over activities, without
necessarily requiring governmental input or intervention. On the other hand, as
exemplified by its usage in the context of democratic governance or even the
idea of good governance, the role of the state in the process of governance
cannot simply be ignored. It is important to state that the generic understanding
of governance is pivotal to the analysis conducted in the thesis, even though I
draw also from specific understandings of governance in trying to develop a
suitable and useful framework for analyzing the systems that regulate research
involving humans in developing countries.
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2.2.1 Governance and Regulation: An Examination of Relationship
The terms "governance" and regulation are frequently used
interchangeably, and sometimes together. Do they mean the same thing? A
review of the literature on regulation and governance does not present a clear
answer as many authors writing in this area assume an understanding of the
terms and do not set out to define them or describe specifically how they choose
to use the terms.

Having described governance above, I now consider the

related term "regulation."
Regulation is, broadly speaking, a process of imposing order and
prescribing acceptable conduct.199 The term, like governance, is also used in a
variety of situations, but is more often than not understood as the command and - control techniques by which the state, typically through the use of legallybacked sanctions, prescribes acceptable conduct. Regulation is conceived, by
traditionalists, as a product of the state or government.

This concept of

regulation locates its basis in the theory of legal positivism.200 Thus one could,
as Majone does, define regulation as: ". . . sustained and focused control
exercised by a public agency, on the basis of a legislative mandate, over
activities that are generally regarded as desirable to society" or as Hood and
others do, "the use of public authority to set and apply rules and standards." 201

199

See Christine Parker, Colin Scott, Nicola Lacey, John Braithwaite (eds.), "Introdduction" in
Regulating Law (Oxford Oxford University Press, 2004) at 4. See also, Anthony Ogus,
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200
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Governance, (Montreal & Kingston: McGill-Queens University Press, 2005), hereafter
Designing Government.
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G. Majone, Regulating Europe, (London: Routledge, 1996) at 9. C. Hood, et al, Regulation
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This understanding of regulation is associated with, and mostly, limited to law in
the form of formal legislation or legal regulations or a set of authoritative rules,
often administered by a governmental agency, for monitoring and enforcing
compliance.
Regulation as rulemaking and rule-enforcement by governments,
according to King, has its roots in the early stages of modern statehood and is a
function undertaken by all states.202 However, although this view of regulation
has been predominant (especially in legal circles), it is becoming increasingly
outdated as many begin to accept the notion of regulation as a wider activity
encompassing more than command-and-control. Indeed, regulation is widely
acknowledged as including different types of regulation, including regulation by
law, economic or fiscal regulation (for example, through the use of taxes or
licensing or the manner in which private firms are restrained from
anticompetitive behaviour), market regulation (or regulation by market forces)
or self-regulation within a particular industry or profession (which may be
acknowledged by law). Further, different disciplines have different conceptions
of regulation. For instance, for economists, regulation may be the means by
which private firms are compelled to adopt anti-competitive behaviour. Some
therefore view economics, law and politics as intertwined, while some
distinguish between economic regulation and social regulation.203

University Press, 1999) at 3. See also, Julia Black, "Critical Reflections on Regulation" (2002)
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202
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A more modernist and arguably more comprehensive and appropriate view of
regulation includes both state and non-state actors, legislation and other nonformal forms of law and social rules. 2

This understanding of regulation

identifies more closely with the understanding of the "new governance,"
described in detail in sections below. One definition of regulation thus views it
as "all mechanisms of social control or influence affecting behaviour from
whatever source, whether they are intentional or not."205 This definition is
broader than those stated above, but as Black rightly observes, it is rather diffuse,
having little or no definitional boundaries and consequently leaving little room
for analysis.

It may therefore be more fruitful to consider regulation as an
907

intentional attempt to control, order, or influence the behaviour of others.
Indeed, some consider regulation as always intentional, even though its results
90S

and outcomes may be unintended.

In this sense, regulation is not limited to

state intervention in the economy or society or targeted rules, and it includes the
basic prerequisites for a regulatory regime, namely, the setting of standards;
processes for monitoring compliance with the standards; and mechanisms for
enforcing standards.209

Analysis of Regulation" (2003) Annals of Public and Cooperative Economics 649. See generally,
R Baldwin, C Scott and C Hood, A Reader on Regulation (Oxford University Press, 1998).
204
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The view of regulation as controlling of conduct or imposing
order leads to thinking that regulation may only be an aspect of governance
which emphasises a wide variety of actors and coordination of different
mechanisms in managing a policy sphere.

This is particularly true if one

considers regulation as a product of the state. For instance, Swan observes that:
"governance defined as any strategy, process, procedure, or program for
controlling, regulating, or exercising authority over animate or inanimate objects
or populations, is regarded as being much broader than the conception of state710

centred regulation."

A review of the literature shows that although some may

still regard regulation as 'what states do,' increasingly, governance is used to
indicate the fact that non-state bodies do something similar (particularly in the
context of the 'new' governance). Many authors then extrapolate from this to
employ governance as the overarching term and 'regulation' as a sub-set of
governance.211
As only an aspect of governance, regulation may not completely
capture all the activities or all the actors which a governance framework
anticipates, including, for instance, citizens and their participation in the process.
Governance may therefore be a higher order or more encompassing activity that
includes regulation (involving the setting of standards; processes for monitoring
compliance with the standards; and mechanisms for enforcing standards.), but
71 7

also many other kinds of actions, policy options and approaches.
210

Indeed,

Swan, supra note 11 at 11.
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some describe governance broadly as "the regulation of social activities utilizing
91 ^

a variety of modes and mechanisms of societal regulation,"

and as, "all the

forms of regulation that are neither market nor state: it is civil society minus the
market ... plus local political society."21 The governance of research involving
humans could thus be argued to include all regulatory activities affecting such
research. Conceived in this way, then, regulation is subsumed in, and is only, a
component of governance.

Agreeing with this view, Braithwaite, Coglianese,

and Levi-Faur describe 'governance' as a broader term than 'regulation.' To
them: "Governments and governance are about providing, distributing, and
regulating. Regulation can be conceived as that large subset of governance that
is about steering the flow of events and behavior, as opposed to providing and
distributing. Of course, when regulators regulate, they often steer the providing
91 S

and distributing that regulated actors undertake as well."

Lobel adds that

regulation as a concept carries with it the problematic issues of boundaries and
predetermined solutions, but that the concept of governance is "open, dynamic,
91 f\

and diverse with a built-in temporal dimension.""

Braithwaite and Parker

further point out that, "Governance is a more general theoretical domain than
regulation in that governance is also about allocating resources in ways that are
213
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not intended to steer the flow of events," and that "regulatory theory is becoming
an increasingly central part of the theory of governance."

However, others,

particularly those who view governance only from the perspective of "new"
governance, see governance as being narrower than regulation.

In this vein,

Vincent-Jones notes that:

Thus, there is sufficient common ground in
regulation and governance theories to suggest
that a synthesis is possible and may be useful
in the analysis of central-local relations.
However, while the approaches share a
concern with processes of social control,
direction and influence, there are fundamental
differences in the form of inquiry and scope of
explanation. In the regulation approach, the
motivating force is the state as a 'purposeful
actor.' Governance theorists studying the
exercise
of political power
through
governmentality, on the other hand, address
the narrower issue of what authorities of
various sorts want to happen, in relation to
problems defined how, in pursuit of what
objectives, and through what strategies and
techniques.
However, even if one does not assume that regulation is an activity engaged in
only by the state in a top-down, command-and- control fashion, but an activity
which involves a controlling of conduct by other actors, governance could still
be argued to be a broader domain. This is because, perhaps more than regulation,
it allows for a wide range of actors and institutions, permits the examination of
the distribution of rights, obligations and power that support the organisational
217
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system, the patterns of coordination that support its activities and sustain
coherence, and establishing benchmarks, and sharing knowledge to ensure
71 Q

restoration when there are signs that the system requires repair.
In any event, whatever views one holds, there is certainly a
significant correlation between governance and regulation. To make the
distinction between governance and regulation thus seems difficult, and to some,
may even appear to be a matter of mere semantics or simply unnecessary given
that, fundamentally speaking, the two concepts refer to controlling or directing
behaviour, persons and organisations. That difficulty persists given that in some
understandings or approaches, both governance and regulation do not
necessarily emanate from the state, and both draw on such important criteria as
effectiveness. And yet to others such an argument would amount to drawing "a
simple-minded equation of regulation and governance."220 What, then, is the
significance of attempting to define these terms? A basic understanding of the
terms, governance and regulation, as attempted here is important because, as the
above discussion clearly shows, these are terms that may be used differently,

2,9
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depending frequently on the context or the discipline."

It is therefore essential

to consider basic definitions of these terms generally and also specifically with
respect to how they are employed in this thesis.
I understand and employ the term 'governance' in this thesis as
involving regulation (with the ingredients of standard-setting, compliancemonitoring, and standards enforcement) as a core element. Regulatory theory is
therefore drawn on significantly in the analysis undertaken in this thesis. It is,
however, convenient to employ primarily the term (and framework of)
governance, especially given that the term 'governance' is used quite frequently
in the literature dealing with research involving humans.

But beyond this

convenience, the generic understanding of governance, the different meanings
which one can attach to the term, as well as the literature on the 'new
governance,' which I employ in my analysis below, affords broad room for
understanding, analysing, and making recommendations on, the emerging
research governance systems in developing countries.

2.2.2 Governance and Law
It may also be necessary to distinguish law from governance
(which in this thesis includes regulation as a core element) because law,
however conceived, also deals with controlling of behaviour, both in a
normative and positivist sense. Considered in the positivist sense advocated by
Hart, law represents rules articulated and enforced by an institutionalized

221

For a lawyer, for instance, regulation and governance may mean legislation or other types of
legal regulation.
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authority which regulate conduct or behaviour."

In this sense, law, as an

official product of the state and as a set of rules articulated by the state and
usually backed by sanctions (hard law) is a critical part of the much-maligned
command-and-control regulation. The state, then, is clearly an actor (perhaps
the most important actor) in regulation and governance. As I will argue in the
following

subsections, in

some circumstances, despite the increasing

acknowledgement of the role of other actors in regulation and governance, the
state (with its function of developing formal law) remains a very important actor.
Whether or not one views regulation as broader than the positivist view of the
top-down use of state authority to control conduct, law performs some
regulatory and instrumental functions (which Black refers to as "regulatory
99^

law"'").
governance.

It is a mechanism or one of the policy options envisaged by
Law, then, is a lever of action with the object or purpose of
994.

changing or controlling behaviour with prescriptions. " The concerns attached
to seeing law as a tool of governance in the form of legislation and legal
regulations would thus relate to how the state seeks to achieve compliance and
may also include creating mechanisms in legislation or legal regulations for
allowing self-regulation by the persons or organisations which need to be
regulated.
In a normative sense, law is clearly broader than the positivist
view of law "as made and judged by the legislative and judicial branches of
222
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state-government then enforced by the policing agencies of the executive."
Scott's definition of regulation identifies the relationship between law in a
normative sense and regulation. Regulation, as he defines it, may be "any
process or set of processes by which norms are established, the behaviour of
those subject to the norms monitored or fed back into the regime, and for which
there are mechanisms for holding the behaviour of regulated actors within the
acceptable limits of the regime (whether by enforcement action or by some other
mechanism)."226 These norms may be in this case legal norms operating within
a legal framework with legal enforcement mechanisms, such as penal sanctions.
Lange further argues that from a postmodernist point of view, law could be
considered as operating progressively more through norms, and that it is no
longer inevitably connected to the powers of a central sovereign state.227 As the
work on the new governance indicates, non-state normative orders are also
components of regulation and governance in the present day. In a normative
sense, law acts not only in a positivist fashion as one of the mechanisms of
regulation and governance, but also provides the context in which governance
and regulation take place. Further, because of its standard-setting potential, law
can also influence the course of governance.

It can also mediate between

other actors involved in governance.

Kelvin Walby, "Contributions to a Post-Sovereigntist Understanding of Law: Foucault, Law
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Since it regulates conduct, it is obvious that there is a close relationship between
law, governance, and regulation. This relationship is perhaps clearer to sociolegal scholars, who consider law in social contexts, than legal scholars who take
an internal view of law and focus on doctrine.

For socio-legal scholars, then,

the linkages between law, governance, and regulation are not limited to the
objective of controlling conduct in order to achieve certain social goals. In this
regard, looking at law through a regulatory lens may also involve understanding
the interactions between hard law and soft law, doctrines and legislation, public
and private law, as well as the effect that common law doctrines may have on
the operation of statutory law intended to regulate conduct and vice versa.

It

would also involve looking at the ways in which legal norms affect the
regulatory environment.
At any rate, it is arguable that whether understood in a positivist
sense or in a normative sense, law by no means covers all the terrain that
governance does, given that governance involves different
mechanisms.

actors and

Law entails "complex, reciprocal, multiple, and overlapping

modes of regulations" and provides only some, but not all, of the major
mechanisms through which governance is implemented.231

However, law,

understood broadly, particularly in a normative context, as providing the
background and support for governance (for example, in the context of the rule
of law) and may also be argued by some to be broader than regulation and
governance.
229
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What is clear is that even though there may be areas of overlap, it
is easier not only to see law and governance as distinct from each other (than
perhaps it is to distinguish regulation from governance), but to view law as one
of the options that governance utilizes, and which may play a central role in
governance. Indeed, scholars who favour the "law as governance" approach (or
the law as a constitutive mode of regulation approach) see a symbiotic
relationship between law and governance.

They suggest a "modest role for

law where law is conceived as connectively situated among a multiplicity of
other constitutive modes of regulation."233 Further, focusing on law in a
normative or positivist sense addresses mainly legal regulation and legal
institutions but does not necessarily allow proper focus on other institutions or
policy mechanisms or the interactions between these mechanisms. A governance
approach offers a broader analysis. In subsequent sections of this chapter and in
the following chapter, I consider the role of law in the governance of research
involving humans in developing countries.

2.3 Governance as an Analytical Framework for Research Involving
Humans
Health research involving humans, given its nature and the issues
connected therewith, has been the subject of much ethical analysis. There is
certainly a preoccupation in the literature with research ethics and institutional
and research practice.

Although this is not out of place, understanding the

subject of health research involving humans not only in terms of the ethical
232
233
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standards or even the work of ethics review committees requires a broader
perspective. Analysing this subject comprehensively from the perspective of
controlling and managing it requires a broader framework of analysis than a
strictly ethical framework, or even a legal framework, or one that considers only
an organisational framework.

It requires a framework that is able to marry

these different angles effectively to provide a broad and wide-ranging analysis
and offer an encompassing account of the regulation of health research in
developing countries. For the purposes of this thesis, governance (specifically a
hybrid form of governance discussed in subsequent pages) seems more useful
for understanding and making recommendations on the research governance
systems emerging in developing countries.
It may seem somewhat circular to consider the governance and
regulation of research involving humans by employing a governance framework.
One could, however, ask what would be a better way to look at governance
systems than by adopting a framework of governance, especially when one
considers that governance, aside from being an activity, has also increasingly
begun to be regarded as a theoretical field worth studying in the social sciences.
In essence, then, I am applying a theoretical framework of governance to the
activity of governance.

The reasoning behind this position is discussed in

greater detail below.
Below I consider governance as a theoretical field. I explain why
I consider governance to be a useful framework of analysis. I discuss the
application of governance as a framework for analysing health research
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involving humans and, the goals of governance in the context of health research
involving humans.

2.3.1 Governance as Theory
I have described above the various meanings that can be ascribed
to governance but can governance be viewed as a theory capable of providing a
lens through which to examine fruitfully a policy field such as health research
involving humans? The different meanings assigned to governance indicate that
viewing governance as a coherent theoretical field able to generate hypotheses
may be problematic. In this respect, Mossenberger argues that: "Any general
theory of governance is likely to be so abstract that it has little explanatory value
in specific instances."234

Frederickson and Smith also argue that, "Lacking a

universal definition, governance is currently more an acknowledgement of the
empirical reality of changing times than it is a body of coherent theory."
They, however, admit that there is an emerging field of governance theory.23
Others go so far as to question if it should count even as a concept, noting its
notorious slipperiness,237 and arguing that it is merely another rhetorical device
which adds nothing of substance to the object of study.238
While recognising the validity of the concerns surrounding
governance as a theoretical concept, it is not inconceivable that the different
234
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definitions of the term may mean, not that there is not "a theory" of governance,
but that there are varying theoretical understandings of, or approaches to
governance. Moreover, going by the different definitions discussed above,
governance is clearly a concept describing certain processes, even though it may
lack some precision. As Bevir and Rhodes point out, however, most concepts
are vague when taken on their own; they require determination of their
compositional ingredients.239

Conceptual frameworks, such as governance,

"provide a language and frame of reference through which reality can be
examined and lead theorists to ask questions that might not otherwise occur. The
result, if successful, is new and fresh insights that other frameworks or
perspectives might not have yielded. Conceptual frameworks can constitute an
attempt to establish a paradigm shift."24

Thus, even if there is not as yet a

cohesive theory of governance (and this is, of course, debatable), as a concept it
is valuable as a means of understanding the processes that come within its
confines, and affords a valuable lens through which to consider certain types of
activities and regulatory arrangements.
Some authors therefore describe theories of governance in different
contexts.241 Maynzt states that governance theory "began by being concerned

M Bevir and R Rhodes,A Decentered Theory of Governance: Rational Choice,
Institutionalism, and Interpretation" Working Paper 2001-10 (Institute of Governmental Studies,
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240
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Communication (Manchester: Manchester University Press, 2003) at 27. Vasudha Chhotray and
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with the steering actions of political authorities as they deliberately attempt to
shape socio-economic structures and processes."-

Governance theory has now

extended from concern with steering in the political sphere to being, at its
broadest perhaps, about "the practice of collective decision-making."243 Jessop
provides a general description of governance theories and what they offer as an
analytical framework. He states that:
One could define the general field of
governance studies as concerned with the
resolution of (para-)political problems (in the
sense of problems of collective goalattainment or the realization of collective
purposes)
in
and
through
specific
configurations of governmental (hierarchical)
and extra-governmental (non-hierarchical)
1

•

244

institutions, organizations, and practices.
These commentators consider governance theories not only as organising
frameworks or frameworks that merely identify the changes now occurring in
the ways in which public goals are achieved (as much of recent literature on
governance does), but also as theories offering propositions regarding modes for
achieving public goals with public and private actors. These theories have
different expressions in, and implications for, different disciplines, including law,
public administration, political science, development studies, international
relations, and environmental studies. The theories extend analytical frames as
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242
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deficiencies are identified,245 and also offer advice as to "what might be" (how
the functioning and operation of governance arrangements may be made better)
as opposed to merely stating "what is" 2 4 6 (for example, how governance
arrangements are chosen (intentionally or unintentionally), how they are
maintained or how they are changed).247

Such theories, it is argued, offer "a

valuable and challenging dimension to our understanding of our contemporary
social, economic, and political world."248
The theoretical understandings of, or the approaches to,
governance that have been discussed extensively in the literature include those
relating to governance by command-and-control, governance by networks,249 the
neo-liberal theory of governance which is related to rational choice theory,250
collaborative governance,251 as well as sustainable governance.252

Others

include global governance theory,253 the multi-level theory of governance
observed particularly in the European Union system of governance,

25
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245

See generally Maynzt, ibid.
Vasudha Chhotray and Gerry Stoker, supra note 66 at 4-5.
247
Ibid, at 6.
248
Chotray and Stoker, supra note 66 at 1.
Rhodes, R.A.W., Understanding Governance: Policy Networks, Governance, Reflexivity and
Accountability (Buckingham/Philadelphia: Open University Press, 1997).
250
Bevir and Rhodes, supra note 64.
~5 Chris Ansell and Alison Gash, "Collaborative Governance in Theory and Practice" (2008)
18:4 Public Adm Res Theory 543. See alsojohn Donahue, "On Collaborative Governance,"
(2004) Corporate Social Responsibility Initiative Working Paper No. 2, John F. Kennedy School
of Government, Cambridge: Harvard University), online: <http://www.hks.harvard.edu/mrcbg/CSRI/publications/workingpaper_2_donahue.pdf> (May 16, 2009).
5
Kernaghan Webb, "Sustainable Governance in the Twenty-First Century: Moving beyond
Instrument Choice" in Pearl Eliadis et al, Designing Government: From Instruments to
Governance (McGill-Queen's University Press, 2001) (hereafter Designing Government).
253
Martin Hewson and Timothy J. Sinclair, "The Emergence of Global Governance Theory," in
Martin Hewson and Timothy J. Sinclair, Approaches to Global Governance Theory (Albany, NY:
State University of New York Press, 1999).
254
Ian Bache and Matthew Flinders (eds.) Multi-level Governance (Oxford: University Press,
2004).
246

97

governance employed by international organisations.

It is beyond the scope

of this thesis to delve into each of these approaches to governance. I discuss
instead the common bases which these understandings have and, in the next
section, the broad understandings of the traditional and the new governance,
which encompass generally, and in different combinations, the ingredients of the
different understandings of governance now explored in the literature.
The contents of these theoretical understandings have certain
commonalities and overlap to a large extent. For one thing, they relate to the
achievement of public objectives and policy goals, through regulation, the
provision of fiscal incentives, and other means of social control. For another,
they tend to be actor-centred and instrument-centred, identifying the actors that
are, and that should be, involved in the achievement of these goals and the
instruments or tools that should be utilised in reaching these objectives.
Traditional approaches to governance, as I discuss in fuller detail below, clearly
acknowledge the role of the state as an actor in governance, while other
approaches may view the state as only one of the actors in the activity of
governance.

Traditional or "old" governance clearly acknowledges the

government as the central actor, such that governance is simply what
government does, and is in many ways synonymous with government.
But the understanding of the state as only one actor (sometimes a
minimal actor) is captured particularly in the new governance (discussed below)
and its variants, including good governance, collaborative governance,
sustainable governance and, governance by networks. Mossenberger notes that
255
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recent usage (in the new governance understanding) has emphasized "the need
to coordinate the actions of multiple actors to realize public purposes." 256 This
approach unpacks the state in terms of sundry processes of governing requiring
the active participation of different groups in civil society."
participatory, pericentric

or collective

It emphasises a

approach in which different actors

and institutions play important roles. The UNDP's conceptualisation of good
governance, for instance, includes certain characteristics: freedom of association
and participation and freedom of the media. It also includes application of the
rule of law, transparency, sustainability, and accountability in the functioning of
bureaucracies, promotion of equity and equality and diverse perspectives,
efficient and effective in the use of resources. In addition it involves the ability
to define and take ownership of national solutions, freely available and valid
information, effective and efficient public sector management, and cooperation
between governments and civil society organisations, and is enabling and
facilitative, regulatory rather than controlling.260 Good governance systems,
according to the UNDP, are participatory, involving all members of governance
institutions or actors - the state, the private sector and civil society - in
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259
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influencing decision-making.261 Sustainable governance, an offshoot of the new
governance, with its emphasis on the value of harnessing the energies,
experience, expertise, and advantages of multiple actors (including state and
private actors), instruments, institutions, and processes," also underscores the
participatory nature of these understandings of governance and the state as only
one of the actors in the activity of governance and regulation."

So, too, does

collaborative governance, with its emphasis on collaboration between private
and public sectors.264 Network governance, in addition to its other features
(such as the asymmetric interdependencies and self-referentiality of the
actors)-

also stresses this participatory nature of governance, allowing that

public goals are met by networks of government or the state, private actors,
including business entities and voluntary or non-profit actors, although there
may also be times when the networks consist only of non-state actors.2
The descriptions of the part these actors play in many of the
approaches are empirical in the sense that they describe present realities. They
are also considered in a prescriptive sense, recommending an ideal with different
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analyses as to what part they could play in the governance process.

The actors

involved in governance typically act and interact within an institutional
framework.268 In this respect, governance has been described as a theoretical
perspective which attempts to address systems and emphasise the actors (with
their own rationales and motivations) who perform within an institutional setting
which shapes, but does not necessarily determine, every option.269

As a

theoretical domain, therefore, governance draws broadly from institutional
theory and systems theory. 270
Institutional theory has been depicted as attending to:
the deeper and more resilient aspects of social
structure. It considers the processes by which
structures, including schemas, rules, norms,
and routines, become established as
authoritative guidelines for social behavior. It
inquires into how these elements are created,
diffused, adopted, and adapted over space and
time; and how they fall into decline and
disuse.271
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Some commentators describing this theory observe that social reality is a human
construction

created

through

interactions

which

eventually

become

institutions. 272 Institutions are therefore seen as "collections of standard
operating procedures and structures that define and defend interest."

In this

way, institutions explain the political actions of individuals and constitute
political actors in their own right. More succinctly, institutions have been
described as "formal rules, compliance procedures, and standard operating
practices that structure relationships between individuals in various units of the
polity and the economy."

The process by which behaviours are replicated and

conferred with the same meaning by human beings (who interact to create social
reality) is referred to as institutionalisation and institutionalised rules "provide a
framework for the creation and elaboration of formal organizations," or
institutions.275 Institutional theory is employed in examining systems, and is
therefore closely related to systems theory. 7
Systems, according to Parsons, refer to "a whole consisting of
interrelated parts that perform specific functions in relation to each other and
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contribute to the maintenance of the whole."" Modern society, according to
him, consists of autonomous systems: the economy, the political system, the
societal community and the fiduciary or values system, each of which performs
special functions but which interact with each other, with law (and the legal
system) playing an integrative role.

A system, according to Stewart and

Ayres, consists of interrelated parts, specified relations between the parts and
specified boundaries.

They add that: "The word 'system' is often used to

describe the assembly of organisations to be found in a given policy field, and to
suggest the interconnections between them as in 'health system' or 'research
system.'"

They observe further that: "As a methodology for the social

sciences, systems approaches build on an understanding of the phenomena of
interest to the investigator as a sub-set of more general processes and
relationships," with the investigator treating the subject of investigation as a
whole which has interrelated parts.280
As an analytical framework, then, governance (particularly the
new governance perspective and its variants) takes a systems approach,
permitting the discussion of steering of activities in terms of the interrelated
parts of that activity, that is, the institutions and organisations involved in a
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1977) at 177-203. See Mathieu Deflem, 'The Boundaries of Abortion Law: Systems Theory
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particular policy field. It recognises the institutions within a system and all the
actors in the policy field, including those being regulated, as potentially active
actors in the governance process.281

Thus it allows for the study of the

configuration of particular institutions, organizations and agencies, involved in
various ways in a system (such as the research governance system) and the
interactions of, and relationships between these bodies.282
The commonalities in the different approaches to governance are
captured effectively in the generic definition which I have adopted for this
thesis: "the processes by which human organizations, whether private, public or
civic, steer themselves," 283 with a core element of regulation and control to
achieve certain goals. Similarly, according to Chotray and Stoker, "Governance,
within the socio-legal frame, is an overarching concept to describe the complex
and multi-faceted social processes - official and unofficial, intended and
unintended, visible and invisible - that together mediate social behaviour and
conduct."284 Thus, governance as a theoretical construct has been described as "a
system of rules in action (i.e. applied by social actors) by which desired societal
states of affairs are approached (positive control), and undesired states avoided
(negative control)." " Further, from that generic perspective, governance is not
only about achieving goals and objectives through positive and negative control,
it also includes the provision of policies, facilities, processes, instruments (such
281
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as statutes and policy mandates) available resources, institutions, and
institutionalised rules and norms by which these goals are to be realised.2
The contribution of the governance perspective to theory, argues
Stoker, is not at the level of causal analysis, nor does it offer a new normative
theory. Instead, its significance lies in serving as an organising framework, and
providing a framework for understanding changing processes of governing.
As a theoretical framework, it is rather broad, and thus may be considered too
wide as an analytical framework.288 However, this breadth might be seen as a
weakness in terms of depth. But it is also its strength, especially as a framework
for investigating a system such as that of health research involving humans
which consists of different actors, systems and institutions. As Schneider and
Bauer assert, the major advantage of governance is "that it provides a rather
abstract frame in order to cover a broad array of institutional arrangements and
mechanisms by which the coordination, regulation and control of social systems
and subsystems can be conceptualized."Further, as a concept, governance focuses on the tools or
instruments employed in achieving public objectives.

Thus beyond the

perspective taken on governance - whether traditional or new - many theories of
governance focus on the tools or instruments of governance.

Each theoretical

understanding may favour or emphasise a different set of tools for achieving
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public objectives.

Several tools are generally used in the governance of

research involving humans, including ethics review committees, a legal
framework that may include legislation, and a policy framework that may
include ethics guidelines and guidelines for the operation of ethics review
committees. For my purposes, the question would be: What tools or instruments
are required to effectively govern research involving humans in developing
countries? If one accepts certain actors and tools in governance as necessary,
the question arises: Against what criteria can the actors and tools be measured?
The different understandings of the forms of governance and
recent ideas about them, which I describe below, are useful in this examination. I
will employ the literature on the new governance to raise and attempt to answer
questions on the role of government and other actors, as well as the role of
formal legislation and national guidelines in the governance of research
involving humans in Nigeria.

Below I consider the different forms of

governance - traditional and new - and where the focus should rest in an
examination of research involving humans in developing countries.

2.3.2 Governance - 'Old,' 'New,' and 'Hybrid'
Discourse on governance has gained currency within recent
conceptualizations of the "new governance." Governance, in particular 'new
governance,' reflects recent ideas of implementing public policies not only
through government bureaucracies but also through private actors and public" See generally Salomon, supra note 90.
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private partnerships.

Prior to this, the focus was on governance as done in a

top-down, hierarchical fashion, which I describe here as traditional or "old"
291

governance.
9Q9

Traditional governance or "old" governance"

involved the

government at the centre directing all other actors, playing the role of main
regulator, but also acting as a service provider, job creator, property owner and
employer.293 The state was viewed as essential to achieve public objectives.
Indeed, "The traditional use of 'governance' and its dictionary entry define it as
a synonym for government."294 Traditional governance involved a hierarchical
or legislator's perspective to policy development and implementation, with a
90S

firm bias for a vertical command-and-control regulatory model."

The state set

rules or standards through the legislature (creating legislation), or agencies
delegated power by the legislature (creating regulations), and private actors had
to comply with those rules. These rules were enforced through the mechanisms
of inspection, judicial enforcement296 and other means, sometimes with the
assistance of private attorneys general.297 The state remained the central actor in
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governance and regulation even if it met with resistance from regulated
groups,

operating in an adversarial manner instead of collaboratively.
Research in this area, however, revealed policy and regulatory

failures arising from this governance perspective. Strong arguments against
state control, focusing on issues of inefficiency, ineffectiveness, overregulation,
legalism, and inflexibility have led to an increasing shift to governance which
involves all the stakeholders in the governance process. 9 Scholars in different
fields, including economics, international relations, and political science,
became disenchanted, and expressed growing dissatisfaction, with what Jessop
describes as "the conventional realist distinction between the domestic political
hierarchy organized under the dominance of a sovereign state and the
international anarchy formed through inter-state relations in international
relations, and in political science, a rigid public-private distinction in statecentred analyses of politics and its associated top-down account of the exercise
of state power."300
"New" governance is understood, in recent literature in political
science and public administration, as pushing conventional arrangements in the
traditional governance towards delegated self-regulation, through persuasion,
informal networks and norms, benchmarking and experimental deliberation.301
Government or the state has been observed to be overburdened and therefore
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unable to cope effectively and adequately with the myriad societal problems
facing it. The need arises, therefore, to engage other actors in dealing with some
of these problems. In the new governance, areas that were previously taken to
be the sole province of the state, the regulation of which were considered the
exclusive prerogative of government, are now increasingly viewed as general
problems that can be undertaken and solved by other actors and institutions,
sometimes in conjunction with the state. This understanding took root as a
reaction to past events, including the fiscal crises in western democracies in the
1980s and the move from earlier ideas of nationalization, public corporations
and central planning toward privatization, deregulation and globalization, all of
which were considered to be more effective in stimulating economic growth,
productivity and innovation.302 The appeal of governance thus derives largely
from the reforms of the public sector promoted by neoliberal governments in
Britain and the United States in the 1980s, with an understanding of governance
as more likely to bring about increased efficiency in the public sector than state
bureaucracy.303 (As the recent recession, and even the recent oil spill in the Gulf
of Mexico have shown,304 however, leaving much power in private hands has its
own problems). In any event, these movements have, it is argued, eroded the
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traditional authority of the state, and caused the limitations of that authority,
with regard to governance and regulation, to become more evident.
Much of the literature dealing with the new governance, in
attempting to define this concept, thus identifies and elaborates an increasing deemphasis on hierarchical regulation by the state through strictly command-andcontrol methods, to governance through partnerships between the government
and private entities, with the aim of achieving public goals. It describes the
increasingly networked nature of the actors in governance, the proliferation of
different tools in governance, and governments acting more indirectly, shifting
lawmaking and other regulatory processes from a command-and-control
framework to a more responsive approach tailored to local circumstances. It
also describes the use of less traditional regulatory instruments and more
creative means to achieve public objectives, including robust public participation,
one

benchmarking

and information

sharing to solve public problems.

Partnerships between the state, industry, and civil society, are thus one of the
main hallmarks of the new governance.30
Within the "new governance" concept, traditional ways of
achieving regulatory goals yield not only to participative approaches but also to
innovative approaches. These include voluntary approaches under which
regulators work with industry associations to develop practice codes,
information sharing practices, sharing of best practices, self-auditing that
involves evaluation of compliance by regulated entities or third parties,
305

Solomon supra note 121 at 822. (This project was being written at the time of the BP 2010
Gulf of Mexico Oil Spill said to be the biggest environmental crisis in American history.
306
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management-based systems that entail firm responsibility for adhering to plans
that limit regulated harms, and performance-based approaches that put emphasis
on regulation for results.307

In terms of regulation in the new governance, "the

scope of regulation as command shrinks while the parameters of regulation as
self-governance unfold."308 New governance systems may therefore include, in
certain respects, systems of self-regulation, that is, systems where private actors,
such as professional associations, regulate their members on issues delegated to
them directly or indirectly by government.309 Such self governance typically
takes place in the "shadow of hierarchy" (the state).

New governance tools or

instruments also include soft law, that is, guidelines, benchmarks and standards
that have no formal sanctions, rather than hard law, such as legislation (which in
T i l

a positivist sense can be regarded as a top-down projection of state authority)
as key components of governance.
Law (both in a broad sociological and normative sense, as well as
in the positivist, functional and formal sense) in the new governance context
could be described as operating as a facilitating vehicle, recognising, permitting
and ratifying the implementation of voluntary and other approaches and forms of
ordering employed in the new governance. In the new governance, law becomes
' Peter J. May, "Regulatory Regimes and Accountability" (2007) 1 Regulation & Governance 8
at 8.
308
Swan, supra note 11 at 14.
In such cases, state involvement is indirect if self-regulation takes place as a response to
threats by government that if nothing is done, state action will follow. See Robert Baldwin and
Martin Cave, Understanding Regulation: Theory, Strategy, and Practice (New York: Oxford
University Press, 1999) at 126. See also Maynzt, supra note 126 at 4.
310
Maynzt, supra note 66.
311
Macdonald, supra note 26 at 209.
312
See Louise G. Trubek, "New Governance and Soft Law in Health Care Reform" (2006) 3
Indiana Health Law Review 139 at 158.
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"softer, less coercive, less hierarchical, more revisable, more flexible, more
experimental, more inclusive of nontraditional actors, less reliant on courts and
formal legislation."313 The use of sanctions and coercive methods are attenuated,
and attempts are made instead to "maintain incentives and opportunities to
elaborate robust norms in context."314 In this regard, it has been observed that
some approaches to the new governance retreat from the idea of specific rights
established by formal legal bodies and enforced by judicially imposed sanctions.
Less coercive sanctions, with the potential for flexibility in implementation and
compliance (such as a reporting requirement) are preferred to hard legal rules
TIC

(with penalties such as fines or imprisonment).
Further, with its preference for soft law (that is, open-ended
guidance as opposed to rules, and no formal sanctions) new governance places
responsibility for law-making in deliberative processes which are to be
continually revised by participants taking experience into account. Lawmaking
thus moves from a top-down, command-and-control structure, (which has been
criticized as being sometimes underinclusive and undereffective, other times
overeffective and leading to overregulation and overlegalisation, or becoming
captured by powerful interests)

to a cooperative, reflexive approach tailored to

local circumstances.317 Accountability is provided mainly through transparency

Neil Walker and Grainne De Burca, "Reconceiving Law and New Governance," (2007)13
Columbia Journal of European Law 519 at 525.
314
Scott and Sturm, supra note 121 at 568.
315
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316
Lobel supra note 41 at 363.
317
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and peer review rather than democratic institutions of state and formal legal
processes.
As Salomon points out, these systems are not necessarily new as
the term implies, but recognition of the concept and interest in the ways in which
government works to achieve public goals may be more recent.

Likewise,

Trubek notes that the word "new" refers to the "widespread and explicit use of
nonconventional forms of governing," rather than its novelty32 and in the sense
of being different from traditional mode of governing. Lobel, for her part,
considers the "newness" of the new governance approach to be an essential
feature of this emerging approach, a dynamic innovation that allows the regime
to constantly renew itself.321
In any event, such governance aspires to being more opentextured, flexible, and participatory, involving all stakeholders in the regulatory
process and responsive to contribution from those being regulated.

Thus

Salomon notes that "the upshot is an elaborate system of third party government
in which crucial elements of public authority are shared by a host of nongovernmental or other-governmental actors, frequently in complex collaborative
systems...." 322 Lobel adds that, "The adoption of governance-based policies
redefines state-society interactions and encourages multiple stakeholders to
share traditional roles of governance."323 At the centre of the concept of new
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governance, therefore, is the recognition that government is not the sole actor in
the policy sphere and that there is a spectrum of public and private actors,
domestically and internationally, that make significant contributions to the
governance process, creating relationships between governments and private
IS) A

organizations which Salomon has described as "collaborative."

The new

governance has been applied, in its different approaches, to diverse areas such as
' Salamon supra note 129. The "new regulatory state" which also comes up frequently in the
literature on the new governance shares a similarity with the new governance (and also with the
new public management) but is not the same. The new regulatory state denotes "a shift by
governments away from command and control regulation to a reliance on new institutions that
set and enforce market rules at arm's length.... Institutionally, the regulatory state is
characterized by a set of agencies, commissions, and special courts that governments have
created to define, monitor, and enforce market rules." See David Bach and Abraham L.
Newman, "The European Regulatory State and Global Public Policy: Micro-institutions, Macroinfluence" (2007) 14: 6 Journal of European Public Policy 827 at 828 and 830. Like the new
governance, the regulatory state, (the growth of which in many accounts is linked to the rise of
marketization) is dependent upon, an array of civil and non-governmental groups and networks.
However, the new governance is broader than market-supporting rules as envisaged under the
new regulatory state, which is arguably only a form of governance. New governance is also less
about what the increasingly regulatory state does (which is act by regulation instead of through
providing as in the welfare state), and more about what other actors do. For instance, the new
regulatory state, having ceased to be the all-round provider, allows companies in through
privatization and then sets up regulatory agencies to regulate the privatization process and the
companies' performance. The use of hierarchy (albeit not in a bureaucracy) is a central
characteristic of the regulatory state. See Colin Scott, "Regulation in the Age of Governance:
The Rise of the Post Regulatory State in Jacint Jordana, and David Levi-Faur, (eds.) The Politics
of Regulation: Institutions and Regulatory Reforms for the Age of Governance. (Cheltenham, UK:
Edward Elgar Publishing, 2004) 145-174. The new governance does share some of the
challenges of the new regulatory state, including those of legitimacy and accountability. The
broader definition of the regulatory state given by King is perhaps more helpful: "In one sense,
the notion of 'the regulatory state' may refer fairly straightforwardly to the changing
administrative form of the state, such as increased reliance by governments on standards-setting
and enforcement agencies, or on the shedding of operational responsibilities for the delivery of
public services by government departments to executive bodies that are controlled by Ministers
through broad framework agreements. It may also, in these meanings, include reference to the
rise of 'regulation inside government' - the sleaze-busters and wastewatchers ... - or to the
increasing interpenetration of the national state by supranational regulatory bodies, such as the
EU and the European Court of Justice (ECJ). However, 'the regulatory state' as a mode of
governance is characterized as much by its relationships with non-state actors and by an
increasing variety of regulatory norms, instruments and controllers, as it is by changes in its
administrative architecture." See Roger King, The Regulatory State in an Age of Governance:
Soft Words and Big Sticks (Houndmills, Basingstoke, Hampshire: Palgrave Macmillan, 2007) at
5. Michael Moran, "Understanding the Regulatory State" (2002) 32 Brit. J. Pol. Sci. 391; J.
Braithwaite, "Accountability and Governance under the New Regulatory State" (1999) 58:1 Aus.
J. Pub. Admin. 90; Michael Moran, "The Rise of the Regulatory State in Britain" (2001) 54 : 1
Parliamentary Affairs 19; and John Braithwaite, "The New Regulatory State and the
Transformation of Criminology" (2000) 40: 2 British Journal of Criminology 222.

114

environmental law,

policing, information technology, occupational health "

and medical error. "
For

some,

the

new

governance

may

represent

an

acknowledgement of the failure of the state.328 But, as Pierre observes, this may
be an overstatement.329

The emergence of the new governance, Pierre points

out, should not be taken merely as proof of the decline of the state, but should be
understood as the state's ability to adapt to external changes.

Moreover, as

Swan points out, some of the new approaches to governance do not necessarily
assume that state power is in decline but instead suggest that contemporary
QO 1

governance and regulation is more complex and is being transformed.
Government is adopting a different role, from a more hands-on-approach to a
more indirect approach.
Still much has been made of the seemingly diminishing role of
government as the provider of regulation and control in a lot of the literature on
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the new governance.

" While such a framework recognises clearly the

limitations of the state or government, and the deficiencies of a strictly
command-and-control type of governance (such as legalism and rigidity), one of
the issues a new governance framework raises is the apparent minimisation of
the role of government and the usefulness of the command-and-control approach,
which is necessarily one of the most important regulatory instruments of
government. There appears to be a "tendency" to expel the state and "ignore
consideration of state power." 333

Indeed the term "governance" appears

employed increasingly in place of, and at the expense of, the concept of
government334 and has been described as "governance without government."
This is true particularly where governance is seen as a fundamentally nonhierarchical, interactive process in which no one actor enjoys more effective
authority than the others.

Thus it has been pointed out that:
The language of governance rather than
government in itself signals a shift away from
the monopoly of traditional politico-legal
institutions, and implies either the involvement
of actors other than classically governmental
actors, or indeed the absence of any traditional

Jordan, supra note 151.Rhodes, supra note 9 at 652-653, pointing out the frequent usage of
governance in place of government. See generally Swan, supra note 10 at 1-3. See also, Alan
Hunt, Explorations in Law and Society: Toward a Constitutive Theory of Law (New York:
Routledge, 1993) at 312. Governance, "is supposed to permit collective projects to be carried
through without the formal authority and concrete sanction of governments." Pierre de
Senarclens, Governance and the Crisis in the International Mechanisms of Regulation (1998) 50:
155 International Journal of Social Science 91 at 94.
333
Ibid.
334
Ibid, at 13.
335
This comes from the title of a prominent book: See J. N. Rosenau and E.- O. Czempel,
Governance without Government Governance without Government: Order and Change in World
Politics supra note 129.
336
See generally, Jan Kooiman, in Pierre, supra note 15 at 8.
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framework of government, as is the case in the
EU and in any trans-national context.
While this approach to governance may resonate well in a system like that of the
European Union, it may not apply more generally. Pierre thus observes that
many approaches to the new governance appear to have very little to say with
T.T.Q

respect to government's role in society more generally. '

In this regard also,

Jachtenfuchs has suggested that, "the governance approach . . . has a strong bias
towards effective and efficient problemsolving and almost completely ignores
questions of political power."
It is useful, then, to question what government brings to the
governance table, and where and how law, often considered a product of state,
fits in. Does the new governance mean a replacement of law by non-legal
normative orders? Further, is the new governance approach necessarily
transformative of law or does it create a hybrid approach?

Should law only

operate as a legal framework or background for new governance and an
encourager of the regulatory facilities of organisations or should there remain a
more extensive role for law? These are very broad questions which cannot be
answered completely within the scope of this thesis. In any event, according to
Salomon:
The new governance acknowledges that
command and control are not the appropriate
. administrative approach in the world of
' Grainne de Burca and Joanne Scott, "New Governance, Law and Constitutionalism," online:
<http://www.ucl.ac.uk/laws/clge/docs/govlawconst.pdf> (June 9, 2009) at 3.
338
Pierre, supra note 15.
339
M. Jachtenfuchs, 'The Governance Approach to European Integration," (2001) 39:2 Journal
of Common Market Studies 245 at 258.
340
Jason M Solomon, "Law and Governance in the 21st Century Regulatory State," (2008) 86
Texas Law Review 819.
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network relationships that increasingly exists.
Given the pervasive interdependence that
characterizes such networks, no entity,
including the state, is in a position to enforce
its will on the others in the long run. In these
circumstances, negotiation and persuasion
replace command and control as the preferred
management approach, not only in the setting
of policy but in carrying it out.341
It is important to ask whether this view applies equally in all contexts. There are
arguably contexts in which the command-and-control function of government
remains useful and even necessary as a means of coercing other parties involved
in the governance process and therefore ensuring that public objectives are met
and that public values are protected. Should law then continue to operate with
sanctions, while specifically detailing and protecting the rights of those unable to
do so for reasons including their relative powerlessness? As further discussion
will show, I answer this question in the affirmative.
With the potential, if not actual, displacement of the state comes
also the problematic issues of accountability. While new governance promises
greater effectiveness as well as increased efficiency in meeting regulatory goals,
a number of concerns arise such as: how can private actors who are not elected
by the general public be held accountable for actions taken in the interest of the
public? Also, there is sometimes an implicit assumption of equality of power
between all the actors in the governance sphere,342 which is emphasised by
frequent references to horizontal and hierarchical actions in describing the new
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governance. As I discuss below, this is one the reasons why a hybrid form of
governance would be more effective than a strict new governance framework.
Aside from these issues, the other matter that rears its head with
regards to the application of the new governance, and is of particular interest in
this thesis, is its workability in the context of developing countries.

In this

respect, one of the major criticisms of the new governance approach, is that it
appears essentially technocratic and somewhat apolitical (or perhaps more
accurately, as Hirst calls it, post political).

Peters accurately captures this

concern when he states that:
These various versions of governance also
appear to present something of a travelling
problem .... This hazard appears primarily as
we think about the 'new governance' approach
as it functions in different societies. On the
one hand in those societies in which civil
society has not been seen to be sufficiently
developed to sustain effective governance, the
question appears to be how to build a strong
society and to do so for reasons of building the
capacity of government to govern. On the
other hand, in more developed societies, the
existence of a strong civil society appears to
become a barrier to effective governance.344
Although it is difficult to see how a strong civil society could be an obstacle to
effective governance, (indeed a strong civil society appears essential to effective
governance), Peters identifies the issue that arises with applying the new
governance in certain developing countries where the civil society may not be
strong, the bureaucracies may not be functional or accountable and many
Paul Hirst, "Democracy and Governance," in Pierre, supra note 15 at 24.
B. Guy Peters, "Governance and Comparative Politics" in Pierre, supra note 14 at 42. See
also, Maynzt supra note 115 at 5 6. See also King summarizing the different ways in which the
regulatory state functions in different countries. King, supra note 149 at 9- 10.
344
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consider the governments to be captured by commercial or ethnic interests.
Moreover, in terms of application, the concept of new governance and
decentralization is more established in developed countries than in developing
countries, where a dependency on government support and reliance on
centralized government still exists.345 However, this is gradually changing,
allowing for the consideration of the new governance in developing countries.346
Also, instances in which developing country governments allow the use of
vigilante groups to combat crime in place of ineffective police forces,3 7 or the
contributions made by private companies to health management through
workplace policies and programmes348 and the adoption of public-private
partnerships in different policy areas, and the active participation of new
governance actors such as non-governmental organisations in different policy
areas also point toward the fact that strategies similar to new governance
strategies are not alien to developing countries.
Still, many approaches to the new governance as now detailed in
the literature have little room for dealing with the sorts of issues that may arise
See Klaas Schwartz, "The New Public Management: The Future for Reforms in the African
Water Supply and Sanitation Sector?" (2008) 16 Utilities Policy 49 at 56, noting the new public
management reforms implemented in three African countries but observing that there is still a
significant level of dependency on government and donor support so that it becomes difficult to
measure the actual impact of the new management reforms.
See Dele Olowu, "Governance in Developing Countries: The Challenge of Multi-Level
Governance" paper presented at the Seventh International Seminar on Geo-Information Science
(GIS) in developing countries, 15-18 May, Enschede, the Netherlands, 2002, online:
<http://www.gisdevelopment.net/proceedings/gisdeco/sessions/key_olowu.htm> (January 19,
2008).
347
Johannes Harnischfeger, "The Bakassi Boys: Fighting Crime in Nigeria" (2003) 41: 1 The
Journal of Modern African Studies 23. Questions of legitimacy and accountability have,
however, arisen in the face of extra-judicial killings and allegations of human rights abuses.
348
Such as those relating to HIV/AIDS in South Africa. See for example, Gavin George and Tim
Quinlan, "Health Management' in the Private Sector in the Context of HIV/AIDS: Progress and
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Development 19.
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in developing countries, since they make the assumption that these approaches
will take place in a liberal democracy, with a strong civil society, and
functioning bureaucratic institutions. In developed countries, these assumptions
may arguably be overstretched,349 but they are even more so in the context of
many developing countries with considerably different

democratic and

regulatory narratives. However, as I pointed out in the previous subsection, the
concept of governance can also be identify what ought to be rather than only
what is. But even beyond addressing normatively governance in a developing
country environment, any approach taken with respect to governance in any
particular field in developing countries must also take into consideration the
context. In other words, one must tread the line between the practical and the
ideal, the descriptive and the normative, and using what is to achieve what ought
to be.
In my view, therefore, a hybrid form that takes into account the
specific context of developing countries as well as the strengths of the various
approaches to governance is necessary. In this regard, I agree with Maynzt's
view that, "In modern governance, hierarchical control and civic selfdetermination should not be opposed to, but combined with each other.
Theoretically, this combination can be more effective than either of the "pure"
forms."

In fact, as Schneider and Bauer point out, it is difficult to imagine a

scenario where either one or the other is in exclusive operation. They observe
that:

349
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In many areas of inquiry, where the
governance concept is used to analyse the
functioning of political systems or the
performance
of
public
policies
by
governmental and nongovernmental actors,
there is currently this danger of oversimplification. For instance, it is sometimes
argued that modern societies are in a transition
from hierarchical to network governance.
Although there is a grain of truth in this
statement, it would not make much sense to
assume that societies are only governed by
hierarchies, or networks, or markets. Concrete
societies are based on combinations of these
generic and many other mechanisms, which
we perhaps do not fully understand at the
moment.351
Or, as Sinclair insightfully states with respect to environmental regulation:
If conventional wisdom is rejected, and
absolute distinctions between self-regulation
and command and control regulation are
viewed as being essentially arbitrary and
misleading, then, in many instances, regulatory
differences will merely be a question of
emphasis. It may be more accurate and
productive, therefore, to envisage the range of
environmental policy instruments as being on
a regulatory continuum, with idealized forms
of "pure" self-regulation and "strict" command
and control regulation at opposing ends... In
the vast majority of circumstances, neither
pure self-regulation nor strict command and
control regulation will be appropriate; rather,
some combination of the two will provide the
optimal regulatory solution. By recognizing
this truth, policymakers will be in a much
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stronger position to adapt regulation to suit a
range of circumstances.
Although new governance does not wholly reject the application of traditional
governance methods and tools like formal legislation, certain approaches within
the new governance do deemphasise them, favouring instead voluntary
agreements, soft law, and self regulation, operating in the distant shadow of
hierarchy.

The state, as Lobel describes it, becomes a facilitator, rather than a

regulator and controller, while the law becomes a shared problem solving
OCT

process rather than an ordering activity.

The preference for soft law in the

new governance (such as guidelines), according to Lobel, signifies not that law
is unnecessary but that law can operate in different normative ways.
As practical as this may appear, these new roles for government
and law may not be sufficient in all situations, particularly in areas where certain
populations are vulnerable and direct government input may be necessary. Law,
then, cannot only be a facilitator, or a coordinator, or a harmonizing influence
between different subsystems,355 it should also act as prospective protector of
rights and enforcer of responsibilities. In my view, government and formal law
(understood not only normatively as a background support but also as a
command-and-control technique) can still operate in a productive way to address
important public policy issues, while utilizing other creative approaches which
involve the private sector and the citizenry more fully in regulation and decision352
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making.

In this regard, Webb observes in a discussion of the concept of

sustainable governance that:
To recognize some of the limits of the state and
the importance of nonstate actors is not to
suggest that state institutions will not remain the
central actor in public policy or that
conventional instruments of governing will not
remain of central importance. But it is to
suggest that governments can and should work
more systematically with others to develop and
implement sustainable approaches to governing
- that is, governance approaches that, because
they integrally involve other actors have the
potential to be more robust, responsive, efficient,
effective, and flexible than conventional, stateimposed regulatory approaches.
The sustainable governance concept, an offshoot of the new governance,357 is
characterized by an acknowledged place for government action and law, but
which extends beyond the command-and-control methods of traditional
regulation to recognise the role of other actors and institutions outside of
government. Similarly, May notes that the reforms of new governance have not
"wholly or even widely supplanted traditional regulation that emphasizes
enforcement of rules by governmental agencies and penalties for noncompliance
with the rules."

Moreover, as King rightly notes, certain notions of

"governance without government," in which states create little more than legal

Kemaghan Webb, "Sustainable Governance in the Twenty-First Century: Moving Beyond
Instrument Choice" in Pearl Eliadis et al, Designing Government: From Instruments to
Governance (McGill-Queen's University Press, 2001) (hereafter Designing Government) at 242243. The concept of sustainable governance is therefore particularly helpful in that the role of the
government is not completely minimized or even altogether discarded, but I go even further in
giving the government an enhanced role in my hybrid framework.
Webb describes the concept of sustainable governance as "attempts to recognize and draw on
the largely untapped potential of the private sector, the third (voluntary) sector, and individual
citizens to assist in governing in the public interest." See Webb, ibid, at 243.
358
May, supra note 130.
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frameworks within which networks function, fail to take into account four key
state governance functions, (or, at any rate, the function which states ought to
exercise) namely: "articulating a common set of priorities for society; having
consistent and coordinated goals that provide coherence across a large range of
policy sectors; steering, including new instruments such as the use of the private
sector; and accountability, which is especially important for democratic
governance, and which is a particular weakness for non-governmental actors in
•ICQ

the governance process."
Understanding the role of different actors is perhaps more critical
in developing countries where the state's regulatory capacity is typically weak,
and governments and public institutions may be weak or corrupt. Yet in a still
centralized atmosphere, the state may remain the major regulatory body usually
having the most resources at its disposal. As Minogue and Carino assert, "many
factors in developing country political and economic systems demonstrate a
propensity for regulation inside government."360
However, some would argue that while these arguments in favour
of a broader role for the state and the law than may otherwise currently exist
may sound strong, in practice they may not stand at all.

It could therefore be

argued in relation to other policy issues that devising stricter rules and more
elaborate laws do little in the face of high levels of corruption, non-compliance
and non-enforcement of these rules and laws. In fact these rules may even
359
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contribute to more corruption. Yet, as Polidano discusses in the context of new
public management, (which is akin to, but not the same as, the new
governance)

there are also contexts in which an active government role and

increased rules alongside public reforms have worked effectively and yielded
beneficial outcomes. He concludes that political and administrative leadership
make a huge difference in the implementation of certain reforms.362

A

generalisation as to the situation in developing countries may therefore not be
appropriate. As I argue in greater detail in the next chapter, a broad role for law
is important, especially in the interest of research participants and the general
public in developing countries.
In other words, it needs to be recognised that government, with all
the challenges that may be attached to that institution in developing countries,
remains an actor in the governance and regulation of different policy spheres.
This recognition allows for a pragmatic approach that takes practical realities
into account, and around which more realistic possibilities in improving
governance can be built. Thus, we can argue for the active involvement of the
state but also for complementary in-put from other sectors such as civil society
and non-governmental organizations, as well as arms-length processes, which
would be necessary for adequate oversight. It may not be wise to minimise the
essential role of the state to that of simply facilitating other forms of regulation,
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particularly in a developing country context, but other actors and tools are
needed for greater effectiveness.
The aim, then, is not to return to an era of complete command and
control (if it ever truly existed in that manner), nor to employ the state and the
law only as facilitative instruments for the work of other actors and institutions.
The intention is instead to point out that a framework that emphasises and
utilises the strengths of all actors and institutions, (especially in the specific
context of health research), is likely to be more helpful. A hybrid approach
between the all-powerful state and autonomous, hierarchical, self-organising
private and societal actors is thus necessary.363
With specific regard to a sensitive area such as research involving
humans, the subject under consideration, agendas may differ in terms of what
counts as beneficial research and how to facilitate it. Also, the vulnerability of

In the helpful analysis of Trubek and Trubek, hybrids consisting of traditional governance
(which they call legal regulation), consisting of fixed statutes and detailed rules and judicial
enforcement on the one hand, and new governance approaches, consisting of other flexible
approaches such as policy guidelines, may operate in different ways with different outcomes.
They could be complementary, existing side by side. They could be competing such that the two
approaches are utilised and in the end only one form survives, and Trubek and Trubek call this
rivalry. They could also be transformational of each other where the two become fused or
integrated such that none can function without the other. See Trubek and Trubek, supra note 152
at 543- 544 and 560. de Burca and Scott also identify different type of hybrid approach namely:
'baseline or fundamental normative hybridity', 'functional/developmental hybridity', and
'default hybridity (or 'governance in the shadow of law). They note that "Of the three variants
of hybridity, baseline hybridity is arguably the most restrained or even cautious in its insistence
on a robust role for a traditional legally grounded framework.... The rise of experimental
governance and new problem-solving approaches has generated profound scepticism and
unbridled enthusiasm alike, and an insistence on the co-existence of the familiar (traditional,
legally and constitutionally grounded regulation) with the new (experimental governance) sets a
limit to the risks posed by an excessive faith in new governance... A more positive version of
fundamental or baseline hybridity claims not merely a continuing parallel role for traditional law
and regulation, but also that new governance mechanisms may even serve to enhance the
effectiveness of law's traditional role." See de Burca and Scott supra note 136 at 12 and 13. As
the discussion shows, I favour both these approaches. See also, Jordan et al, supra note 151 at
481, describing the different ways in which the traditional governance interacts with the new
governance - coexistence, fusion, competition, and replacement.
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research participants, particularly in the developing world context to potential
exploitation is palpable.

Self-regulation by professional organisations of

physicians and medical researchers may be helpful in determining the manner in
which research should be conducted.

However, professional organizations

regulate members who may have other interests that conflict fundamentally with
the interests of those who subject themselves to such research.

Funding

agencies' requirements may also be helpful. But since these requirements could
vary from one funding agency to the next, and from one funded organisation to
another, these requirements will not only be non-comprehensive in facilitating
research and setting appropriate parameters, they can only offer at best patchy
and incomplete protection to research participants.
Thus, in an area such as I describe below which had previously
been dominated by non-state actors, the mediating role of the government as a
protector of its citizens remains essential still. Given that governments should
ideally work for the citizens' best interests, they may, if they actively exercise
appropriately the powers at their disposal, be a more effective negotiator on
behalf of the citizens. This does not suggest that the government itself is not an
interested party - it may, for instance, be interested in attracting foreign research
and the accompanying jobs and monies, an interest that may conflict with the
paramount objective of ensuring the safety of participants in research. Indeed,
although there have been no empirical studies to support this, some have
accused developing world governments of refusing to adopt legal regulations in
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order to retain the interest of research sponsors.

And it is not unusual in a

developing country context that the state may be run by a corrupt government.
As I mentioned in the Chapter One, economic constraints may mean that the
scarce resources are devoted to myriad problems. Leadership challenges, where
the state fails to lead in providing basic amenities, may abound,

such that

other actors, such as non-governmental organisations are becoming more
relevant in providing basic services, including healthcare.

The relevant

capacity for reviewing and monitoring research, important aspects of research
governance, may not be found within developing country bureaucracies. As I
discuss in subsequent chapters, Nigeria has many of these issues. For some,
therefore, the weaknesses of the state, especially in a developing country context,
may mean that a system without the active input of the government, except
perhaps in some kind of facilitative role may be best.
However, other actors that may be involved in the research
governance systems are not necessarily free from some of these concerns.
More importantly, my arguments in Chapter One regarding the importance of a
domestic context and the need to create national governance systems also feed

See for example R. N. Nwabueze, "Ethical Review of Research Involving Human Subjects in
Nigeria: Legal and Policy Issues" (2003-2004) 14 Ind. Int'l & Comp. L. Rev. 87
365
Kenneth L. Leonard, "When Both States and Markets Fail: Asymmetric Information and the
Role of NGOs in African Health Care" (2002) 22 International Review of Law and Economics
61 at 62, noting the various challenges associated with governments in Africa.
366
Ibid.
367
See for example, with respect to non-governmental organisations, Raymond C. Offenheiser,
"Enhancing NGO Effectiveness in Africa: Re-Evaluating the Potential for Genuine Partnerships
7 Oxfam America, Working Paper No. 4, 1999), noting that African NGOs are viewed as lacking
amongst other things, legitimacy, and may be prone to cronyism. See also, Henry Zakumumpa,
"Are NGOs the New Colonial Power in Africa?" Daily Monitor, June 3, 2009, online:
<http://www.monitor.co.ug/artman/publish/opinions/Are_NGOs_the_new_colonial_power_in_A
frica_85863.shtml> (June 19, 2009). Yet others argue in relation to the delivery of health care
services in Africa that NGOs offer better services. See Leonard, ibid.
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into my arguments here about the importance of the state in an area such as that
of health research involving humans. The active involvement of the state in the
governance of health research would, in my view, result in a more organised,
less fragmentary system. Reliance only on funding requirements or conditions
in employment contracts or institutional ethics review committees which are not
coordinated in any fashion and which face inherent conflict of interest issues, or
on drug regulatory authorities which are typically government agencies, will not
be comprehensive and may be inadequate. In any event, to dismiss an actor with
perhaps the most resources, however imperfect, especially in a developing
country is, in my view, unhelpful and counterproductive. Instead of dismissing
the state, it is necessary to seek ways to clearly delimit the authority of the state
and to encourage its active and effective input, if only to add legitimacy to the
system (for instance, through the creation of a national ethics review system, set
up by government but not a part of government bureaucracy).

Also necessary

are ways to build the necessary expertise and capacity in specific areas such as
ethics review and encouraging advocacy by interested groups.
Further, mechanisms for providing inducement, checks, and
balances, are needed. Creating relevant arms-length processes, addressing issues
relating appointments into, and the composition of the relevant bodies created by
the state, are all avenues through which the independence, integrity, and

Some have therefore argued, for instance, with respect to national research ethics review
committees in the developing world, that an attachment to the ministry of health would be more
effective and legitimate. See Carl H. Coleman and Marie Bousseau, "Strengthening Local
Review of Research in Africa: Is the IRB Model Relevant?" (2006), online:
<http://www.bioethicsforum.org/ethics-review-of-medical-research-in-Africa.asp> (June 22,
2007).
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ultimately the effectiveness of the system can be ensured. To these would be
added the active participation of other actors such as civil society, including
research participants, patients' rights organisations and even institutions such as
the media, which may not have a formal or explicit role in research governance.
They should complement and act as a check on government, boosting the
effectiveness of the governance process. Indeed, they may actively induce the
state or government to perform and utilise the appropriate resources. These steps
emphasise that a strictly top-down framework will not suffice (and, as I discuss
further in this chapter, is increasingly not the case even in developing countries),
and that other actors are necessary, but in addition to the state.
Additionally, a formal legal framework is an instrument which the
government should ideally bring to the governance table. The legal framework
should establish a system of governance (facilitative) that details the obligations
of all parties involved in the process. But it should go further, even beyond the
protections that could be provided through the retrospective decisions of courts,
and the possible administrative law applications to the work of ethics review
committees, to offer prospective and specific safeguards for participants and
sanctions for noncompliance (protective and regulative). In addition, allowing
for guidelines (soft law) in areas where specificity could be elusive, potentially
offers not only more legitimacy but a greater level of accountability than would
otherwise be the case. One could reasonably argue that law is an important
underpinning for the governance of research involving humans, not least
because law, more often than not, implies a role for government, is wide-
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ranging, thus potentially regulating and imposing accountability on all the actors
in the governance systems, including the government.

It confers a certain

legitimacy on public actions, including governance systems and choice of
governing instruments.

This legitimacy arises when law operates in a

democratic context such that resulting legislation and or regulations have
indirect input from the citizens who place representatives in government.369
Further, the threat of sanctions in this context may serve as an incentive for
complying not only with the legislation but also with the guidelines. 70
Consequently, rather than seeing the governance context in these
countries as simply a command-and-control condition or a situation in which the
government has minimal role, it is perhaps more useful to draw on both
traditional governance (by which I mean state control) and the new governance
(the newer recognition of a partnership between all the stakeholders). This
relates to the sustainable governance concept or the good governance approach
mentioned above: governance would be carried out with an explicit role for
government as well as a space in which private actors could contribute to
governance.

One could then reasonably ask such important questions as how

the characteristics of traditional governance (including formal or hard law) can
be fruitfully blended with, or be complementary to, less traditional forms of
governance, (such as soft law or increased civil society participation), for greater
effect where necessary. One could also ask what benefits the different actors 369

See generally Pierre Issalys, "Choosing Among Forms of Public Action: a Question of
Legitimacy" in Designing Government, supra note 180 particularly at 169-171.
370
Trubek and Trubek, supra note 152 at 8.
371
The good governance approach recognizes the important role of the state and the rule of law,
while emphasizing the importance of the private sector and the civil society.
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government, research sponsors, researchers, professional bodies, and research
participants - bring to the table and how these can be more effectively managed
to ensure better governance of research.
In this way, new governance, with its emphasis on utilising all the
actors and institutions along with taking cognisance of multiple sites of
regulation and addressing the relationship between state intervention and
societal autonomy, in combination with traditional approaches by the state,
becomes helpful in creating an effective framework in the context of health
research involving humans in developing countries. While this may obviously
not have the same purchase in all settings, or be suitable for all situations
requiring governance, a hybrid framework that adopts a generic understanding to
which both traditional and new governance contribute their strengths, harnesses
the synergies of different actors and institutions, and takes into account the
political and socioeconomic contexts and also the best interests of developing
countries is needed in such countries as Nigeria.
In employing this hybrid, it is important to admit that I am
making some assumptions, the most important of which is that governance will
take place within a democracy, no matter how imperfect, such that any resulting
legislation is the product (however indirectly) of the people's wishes.
Fortunately, this is the case in Nigeria. But it may limit the applicability of such
a framework in other contexts where this may not be so. Thus, there would, of
course, be more difficulties in an undemocratic setting. It is also not possible
within the scope of this thesis to examine big questions relating to the challenges
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that law presents in the sense that, as described by Hunt, it can be both a
mechanism that contributes to social domination (as in, for instance, law enacted
in a military regime), and as a mechanism that contributes to the potential of
human emancipation.372 I am clearly dwelling more on the positive aspects of
law, but I address in more particular detail the role of law and any possible
objections in the context of research governance in the Chapter Four. Again, the
political context1 in terms of the division of authorities and the organisation of
the legal system also matter. I will dwell on the political and constitutional
context of Nigeria in Chapter Five and Chapter Six. As these chapters will show,
the hybrid presented here, in my view, is likely to be feasible in the legal and
political contexts of this country.
In the following subsections, I employ this hybrid version as the
analytical framework for the subject of regulation of health research involving
humans. I also argue for its potential effectiveness when used appropriately.
This is not difficult to do since, even though this is hardly articulated in the
literature,373 some systems of health research governance, as a subsequent
section shows, currently operate certain versions of this hybrid. The liberal use
of "governance" in describing the management of structures and mechanisms in
research involving humans may also, although not always clearly articulated in
the literature, arise from this recognition of the different instruments and actors
involved in such management.
372

Hunt, supra note 33 at 327.
An important exception is the Canadian report The Governance of Health Research Involving
Human Subjects, which dwells on the concept of governance). See M. MacDonald (ed.), The
Governance of Health Research Involving Human Subjects (Ottawa: Law Commission of
Canada, 2000).
373
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This framework would be incomplete, however, without a
consideration of what the goals of governance for research should be, and the
criteria by which to measure the attainment of those goals. I consider this in the
following subsection.

2.3.3 Goals and Criteria for Governance of Health Research Involving
Humans
In the application of any kind of framework to the subject of
research governance in developing countries, it is important to question: What
are the goals of the governance of research involving humans? Although this is
"in A

addressed summarily in Chapter One, it bears reiteration here.

Downie and

Mcdonald carefully list the main objectives of the governance of health research
involving humans.

In their insightful review, the goals of governance

arrangements are to:
•Respect the dignity and rights of research
participants
• Protect the safety of all research participants,
as much as it is possible to do so
•Build and maintain trust between the
researchers, research institutions, research
participants, and society as a whole
•Promote potentially beneficial research
•Promote safe and effective research
•Analyse, balance and distribute harms and
benefits
•Pursue all of the above in a way that is
administratively and financially efficient and
fair.375
374

See page 14 of Chapter One.
Jocelyn Downie and Fiona McDonald, "Revisioning the Oversight of Research Involving
Humans in Canada" (2004) 12 Health Law Journal 159 at 160.
375
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These can be summarised as yielding three main goals, namely: first, the goal of
ensuring that research is potentially beneficial and, second, that while inherent
risks exist in the process, efforts are made to minimise them and to protect the
safety, dignity and wellbeing of research participants. A third important goal is
the maintenance of trust between the research community and society as a whole,
which flows from the first two goals. 7
Thus, the major reason for conducting research is that it has the
potential to provide benefits, whether in terms of providing effective (or more
effective) therapeutic interventions for diseases or information which influences
health policies. In the developing world, as I discussed in Chapter One, the need
for health research and the potential benefits attached therewith cannot be
overstated.
In the process of obtaining these benefits, the safety of research
participants must be actively ensured.

Research participants who volunteer

themselves for research for the purpose of potentially obtaining benefits for the
society deserve to have their safety, rights and welfare protected to the greatest
extent possible. Research ethics as articulated in the international guidelines
makes this abundantly clear. Where there are conflicts between these goals, the
goal of ensuring the safety of the participants and minimizing any risk to them
clearly takes precedence.

The Helsinki Declaration clearly states that: "In

medical research involving human subjects, the well-being of the individual
^77

research subject must take precedence over all other interests."
376
377

McDonald, Governance of Health Research Involving Humans in Canada, at 51.
Article 6 of the Helsinki Declaration, 2008.
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The

precedence of research participants in the scale of priorities represents an
important value. The normative goals for research governance can then be
framed thus: There is value in ensuring that the health of people in general is
improved. The protection of the rights, safety, dignity and welfare of research
participants is, however, of greater value. In ensuring the rights of research
participants, the trust of the community is preserved, and in turn more the
potential for more beneficial research is made possible.
All the governance arrangements and structures put in place
therefore have to achieve these goals and reflect these values, respecting the
paramount importance of not jeopardizing the health and well-being of research
volunteers.

Furthermore, the governance arrangements, as Downie and

McDonald rightly note, need to be operated in an efficient manner, which in the
final analysis, will affect the effectiveness of the arrangements.
If the goals of research governance are clear, what about the
criteria by which the attainment of these goals are measured?

Governance

literature is also very helpful in this regard. Salomon discusses several criteria,
some of which are particularly helpful in my analysis, namely, effectiveness,
efficiency, equity, manageability, and legitimacy and political feasibility.
Others

have proposed

such

criteria

as clear mission;

responsibility;

accountability; transparency; stewardship; flexibility; succession; representation;
and simplicity.

From the good governance approach, which fundamentally

links democracy, development and health promotion, we have such criteria as
378

Salomon, supra note 142 at 1647-1649.
MacDonald, supra note 19 at citing The Canadian Institutes for Health Research (CIHR)
Public Report on Governance.
379
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participation,

consensus

orientation,

accountability,

transparency,

responsiveness, effectiveness, equity and respect for the rule of law.380

Hirtle

links the good governance criteria to health research involving humans,
observing that: "To address research ethics issues from the perspective of public
governance is to focus on elements of good governance. These include
accountability, oversight and transparency, clear government roles and
responsibilities, clear relationships, structures and standards, and public
processes, mechanisms and participation."
From these various discussions, I derive eight criteria, which
encapsulate the above prescriptions. The criteria are: effectiveness, legitimacy,
clarity, comprehensiveness, efficiency, adequacy, uniformity, and simplicity. I
discuss the criteria against which the actors, instruments and mechanisms
applied in attaining the goals of health research involving humans can be
assessed respectively below.
Effectiveness, as Salomon points out, is the most fundamental and
basic measure for assessing the success of public action. "It essentially measures
the extent to which an activity achieves its objectives."382 The criterion of
effectiveness in the context of the governance of health research thus raises the
question of whether the objectives of the system are being met - promoting
beneficial research and protecting research participants.
380

Questions of

Helmut Brand, "Good Governance for the Public's Health" (2007) 17:6 European Journal of
Public Health 561, citing the United Nations Economic and Social Commission for Asia and the
Pacific (UNESCAP) at 1.
381
Marie Hirtle, 'The Governance of Research Involving Human Participants in Canada" (2003)
11 Health L. J. 137 at 138-139. See Stephanie J Poustie et al, "Implementing a Research
Governance Framework for Clinical and Public Health Research" (2006) 185 The Medical
Journal of Australia 623.
382
Salomon, supra note 144 at 1647.
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compliance also fall under the criterion of effectiveness. This criterion therefore
applies to all the tools or instruments and institutions employed in governance of
health research involving humans. All the other criteria are important only to the
extent that they contribute to meeting this criterion. Thus, while I engage in an
examination of each of the other criteria in examining specific mechanisms of
research governance, the criterion of effectiveness runs through all the
examination and will be an intrinsic part of the analysis of each of the tools. In
other words, I will be asking if the degree of uniformity or clarity or
comprehensiveness of standards, actors, tools and institutions involved in
research governance is effective in meeting the goals of promoting socially
beneficial research and protecting research participants in developing countries,
specifically in Nigeria.
Working within a governance framework, therefore, the thesis
will consider what tools ought to be employed in the research governance
system and examine their potential effectiveness in achieving the goals of
research governance in Chapter Three.

The assessment of effectiveness is

certainly not easy, even in this case where the goals are fairly clear.

Systems

are usually shown to be ineffective when an incident occurs, (in the case of
research governance, research participants die or are harmed). It is perhaps
more accurate to state that what we are concerned with here is both actual and
potential effectiveness.

In other words, what potential does the system in

Nigeria have to work effectively?
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Within the criterion of effectiveness also comes the related
criterion of legitimacy which is also a criterion that runs through each of the rest
of the criteria. Legitimacy raises issues of rights, obligation and power, and of
acceptance of authority. In a general sense, legitimacy has been described as
being about:
the moral grounding of power and therefore
involves social and cultural norms and
expectations concerning proper behaviour of
those that govern, the social relationship
between rulers and ruled, the role of trust,
reputation and force, and the balance between
authority and obeisance. Such norms and
expectations vary across time and space. They
can refer to the output or input of
policymaking, to the procedures or legality of
decision making or to its content, to the
performance or to the status of rulers, and to
limited or ultimate criteria of justice.383
Thus legitimacy refers not only to power and authority but also to
the internal and external processes of exercising that authority in a policy sphere.
Legitimacy is crucial to garner wide support for the measures taken to govern a
particular activity, in this ease health research involving humans, and thus
ensure its effectiveness. A legitimate tool is more likely to be accepted and to be
effective in achieving its ends. Thus Issalys frames the issue of the choice of
governance tools in terms of legitimacy. He observes that legitimacy "resides in
the acceptance both of an authority and of the rules laid out by this authority, it
has obvious repercussions for the effectiveness and even for the efficiency of

' NWO Research Programme, "Shifts in Governance: Problems of Legitimacy and
Accountability" (The Hague: Netherlands Organisation for Scientific Research, 2004).
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any mechanism of public intervention."

Effectiveness and efficiency of

governance actions are therefore closely linked to legitimacy, as are public
•3QC

participation, accountability and transparency.
Questions about the independence, transparency, and credibility
or conflicts of interest in ethics review committees thus provoke questions about
legitimacy. Several issues addressed in this thesis are by implication questions
of legitimacy. For instance, questions about the origins of research governance
in developing countries such as whether recent research governance systems are
being established for the principal purpose of receiving research funding from
developed countries, involve an examination of legitimacy. Questions about the
sufficiency of public participation in research governance, or questions about the
role of law in research governance or the role of government generally or even
in the context of national ethics review committees, necessarily engender an
examination of legitimacy. Thus, like effectiveness, questions of legitimacy
implicitly undergird much of the discussion that follows in analysing the
mechanisms of research governance in Nigeria.
The other criteria raise specific issues as to the organisation and
operation of the research governance system. Clarity in the context of research
governance requires that the roles, responsibilities, rights of all the stakeholders
in the research governance system, including research sponsors, research funders,

Pierre Issalys, "Choosing Among Forms of Public Action: a Question of Legitimacy" in
Designing Government, describing the various perspectives adopted in discourse relating to the
criteria for choosing the tools for public action, particularly with respect to legitimacy at 154.
385
Baldwin and Cave also referring to legitimacy point out the benchmarks for regulation
namely: legislative mandate, accountability, due process, expertise, and efficiency. Baldwin and
Cave, supra note 128 at 77-84. These criteria are similar to those laid out by Issalys, ibid, at 171.
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research institutions, professional bodies, research regulators and research
participants, and lines of accountabilities be clear and unambiguous to ensure
greater effectiveness.
Related to this is the need for uniformity or consistency and
adequacy.

The legal and ethical standards applied within the research

governance system must be both adequate and consistent, and not dependent, for
instance, on the institution in which research is taking place or the organisation
which is funding the research. Adequacy is also important in the consideration
of the authority of the different institutions.

They must have adequate

independence, adequate resources, and adequate authority to operate and carry
out tasks within the research governance system, including standard setting, and
standards implementation.
The system also needs to be comprehensive, including the whole
spectrum of actors and different types of health research involving humans,
provide protections for a wide scope of research participants, and should be
encompassing in terms of the relevant issues. It should include not only ethical
standards and legal regulations, but prescriptions relating to other factors (for
instance, the training of researchers or the creation of clinical trial registries),
which may affect the conduct of health research. These should be addressed
comprehensively within the various legal and policy instruments which govern
research.

As Downie and McDonald note, non-comprehensive systems (for

instance, in terms of what kinds of health research are covered, or what receives
ethics review) pose threats to research participants, may impose increased costs
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on society, increase adherence or compliance problems and put public trust in
the research process at risk.38
The system needs to be efficient. Efficiency is a criterion that
00-7

considers the balance of results against costs.

It questions how best to achieve

results with minimum financial, human, and time resources. Particularly in the
context

of

a developing

country,

the

available resources,

financial,

infrastructural and human resources must be utilised efficiently. These should
permit seamless relationships between different actors and instruments and
proper coordination between structures, and allow no duplication and waste of
scarce resources.

Efficiency, however, can only be contributory to the

effectiveness of the system; it cannot be a goal in itself, otherwise the protection
of research participants may be jeopardised.
Despite the wide range of actors involved in what is increasingly
a complex activity, the organisation of the governance system and the processes
employed therewith, although there are underlying complexities, should aim to
permit a relative ease of operation and the clarity of roles and lines of
accountability earlier mentioned. In subsequent chapters of the thesis, and in the
specific context of the research governance systems of Nigeria, I will be making
assessments using these criteria.

Downie and McDonald, supra note 199 at 8.
Salomon, supra notel42 at 1648.
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2.3.4 Rationale for a Governance Framework
The term "governance" has been used, in recent times, quite
liberally in relation to health research involving humans and other ethics-related
issues. Much of the usage occurs without specificity and with an assumption
that the meaning and the reason for such use is clear.

This has caused a

commentator like Ruth Chadwick, a bioethicist, to speculate as to the reason for
this profusion in use:
The controversies about ethics and Bioethics
in particular, however, surely constitute one
factor in the increasing popularity of talking
about 'governance' in addition to or even in
preference to ethical oversight. The hope and
promise of good governance is reassuring, and
might be thought to be stripped of the
suggestion of 'moralising' that could be
associated with 'ethics' for some, on the one
hand, while it might also appear to imply more
critical distance, on the other.388

Although I disagree that governance eliminates "moralising," (indeed, as I
argued in Chapter One, and as I point out in the application of the framework in
section 2.6 below, ethics is an important building block of the governance
framework applied here), it may be, as Chadwick suggests, that governance as a
concept allows some distance and measured or deliberate judgment in
addressing the subject of health research involving humans. However, beyond
the presumed objectivity which governance might offer or its current fashionable
usage, my main argument is that it offers a comprehensive frame within which
to consider the regulation of what is a beneficial, yet potentially risky, activity.

Ruth Chadwick, "Bioethics and Governance" (2007) 21:4 Bioethics (Editorial).
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I examine this argument in more detail below and discuss the reasons why a
governance framework is not only helpful but necessary.
Governance of research involving humans in developing
countries is, as I have previously pointed out, an area not yet sufficiently
researched. Governance, as is clear from discussions above, can also be used as
an analytical framework. Using governance as an analytical framework seems
to flow, then, as a natural consequence of my consideration of this topic. My
specific framework, a generic understanding of governance, includes all the
actors, including the government, research sponsors and citizens as active
participants in the process, and finds merit in a hybrid form that includes the
strengths of both traditional and new governance.
To begin with, the problems arising from research involving
humans in the developing world are problems of governance. The fundamental
questions that this thesis attempts to answer in the specific context of Nigeria are
clearly questions of governance, namely: How ought health research involving
humans, a clearly beneficial and public activity which also has risks, to be
managed? By what criteria ought the current systems to be assessed? In what
ways can the systems be improved? The preceding discussion shows the clear
value of governance as a means for understanding the controlling of activities in
order to achieve public goals and objectives. The issues that arise in the context
of these questions, for instance, the consistency of ethical and legal standards,
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the comprehensiveness of any regulatory standards, compliance with those
standards, and effectiveness of any regulations, are all issues of governance.389
Furthermore,

as

observed

elsewhere,

the importance

of

governance as an analytical framework is that it is "more comprehensive and
encompassing than traditional approaches to political analysis, because it refers
to more actors and levels of authority than national governments and includes
informal and non-institutionalized as well as formal and institutionalized
procedures and processes."390 It will also be recalled that governance as an
analytical framework "covers a broad array of institutional arrangements and
mechanisms by which the coordination, regulation and control of social systems
TQ1

and subsystems can be conceptualized."

One could certainly focus on a

specific actor such as the state or the government, or the impact of the judicial
system or medical institutions or ethics review committees. But health research
involving humans is an activity managed by different institutions and
mechanisms, and which has effects beyond the specific group managed by a
specific medical institution or a specific research sponsor.
Further, as McDonald observes, "governance issues arise with
respect to the appropriate division of responsibilities for the protection of human
subjects amongst the agencies and organizations that conduct, sponsor, and
regulate research."

Extrapolating from this, research governance requires an

389

See Jocelyn Downie, "Contemporary Health Research: A Cautionary Tale" (2003) Health
Law Journal (Special Edition) 1 at 5, describing several governance issues.
390
Leisink and Hyman, supra note 63 at 280.
391
Schneider and Bauer, supra note 109 at 3-4.
392
Michael McDonald, "Canadian Governance of Health Research Involving Human Subjects: Is
Anybody Minding the Store?" (2001) 9 Health L. J. 1 at 4.
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examination of the scope and structure of the system, the responsibilities and
composition of the institutions within the system, accountability and compliance
mechanisms within the system, all of which have implications for ensuring the
protection of participants and promoting beneficial research, and all of which
come clearly under the umbrella of governance.
Additionally, a consideration of national systems as engaged in
here requires a comprehensive systemic approach. Moreover, in my view, there
is value in considering the processes as well as the desired outcomes and goals
or objectives of ensuring that health research involving humans is conducted in a
particular manner, that is, in the safest way possible and with the greatest
possibility of achieving beneficial results. If considered in this way, a holistic
and systemic approach which considers all the actors and institutions involved in
the processes and in achieving these outcomes and reaching these objectives will
prove not only useful but necessary.393
As an analytical framework, then, governance has descriptive,
explanatory, organising and normative value that allows us, in my view, to
examine not only the policy response to any particular field of activity, in this
case, health research involving humans. It also compels us to think more broadly
in terms of the systems governing that field, the constellation of actors and
institutions that come together to make up the systems, and to question what the
appropriate relationships and interactions between them should be. Governance
is thus a very useful analytical framework for health research involving humans
because of the importance of the comprehensive systems perspective. It offers a
393

Chotray and Stoker, supra note 66 at 6.

147

macro perspective (or what Mcdonald calls a 'second-order' perspective)

on

the actors, institutions, mechanisms, rules and processes that are involved in, and
manage, health research involving humans. It helps to analyse broadly and in a
less reductionist fashion the linkages that come together to form the research
governance system, including law.

A hybrid governance framework, as

employed here, acknowledges that the oversight of research includes not only
the active role of formal government but also takes account of other components
which may not always be dependent on government and law.
Taking
governance framework

the

comprehensive

perspective

afforded

by

the

also allows an evaluation of what these instruments

convey about the nature of the relationships between all the policy actors and
institutions, including such actors and institutions as the government and the
legal system, civil society and patients rights' organisations, researchers and
ethics review committees, and research participants.

It thus affords, for

example, freedom to examine law in the context of different disciplines that bear
on research involving humans, such as biomedicine and social science.

It

permits an inquiry into not only the role and place of law in the system (for
instance, is it facilitative?), but also its relationship with other components and
key institutions frequently employed in the oversight of research involving
humans, such as ethics review committees (for instance, does it create legal
obligations for these institutions) in achieving the public policy objectives of
enabling beneficial research while ensuring the safety and dignity of research
participants. It is necessary also to locate and evaluate the place of ethics review
394

Mcdonald supra note 19 at 23.
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alongside other components and instruments, including the ethical framework,
the legal framework and institutional mechanisms such as drug approval
agencies, departments of health, professional organisations and also civil society,
including non-governmental organizations which promote patients' rights.
Thus, within the perspective of a hybrid framework of governance
one could fruitfully ask whether, based on available evidence, these institutions,
and actors work separately or together and if so how harmoniously. In many
countries, developed and developing, the systems of research participants'
protection (with respect to standards, structures, regulations and policies) are not
necessarily ordered as a coherent, cohesive and organized structure and consist
of fragmented institutions and policies involved in the governance process.
To explain this point further, the different actors in research governance may
employ different forms of governance. For example, funding agencies may have
separate criteria for funding eligibility different from those utilized in research
institutes which may themselves have no coercive control over researchers. The
universities may also have different guidelines and ways for ensuring
compliance, including clauses in researchers' employment contracts, which may
be different from those employed by self-regulating professional bodies which
may exercise significant influence and control over their members, which may
also differ from the powers exercised by departments of health.

395

See Ann Strode, Catherine Slack, Muriel Mushariwa, "HIV Vaccine Research - South
Africa's Ethical-Legal Framework and Its Ability to Promote the Welfare of Trial Participants"
(2005) 95: 8 South African Medical Journal 598.
See Jocelyn Downie, The Canadian Agency for the Oversight of Research Involving Humans:
A Reform Proposal" (2006) Accountability in Research 75 where she points out that in Canada
"Numerous bodies are tasked with various aspects of what can really only loosely be called a
"system."
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The normative weight of international organizations such as the
World Medical Association and the guidance they provide, as well as how these
have influenced the development of the governance systems in developing
countries also provide a source of governance.397 What are the contributions of
these different bodies to the research governance system? And how do these
different sources of regulation affect how adequately research participants are
protected? Do they work cohesively or not and how does this affect the
effectiveness and adequacy of the system? A governance framework helps to
identify and analyse these sources and determine how the interplay between the
different players and the forms of governance and how harnessing these
subsystems could provide greater effectiveness in research governance. One
could then reasonably attempt to answer such important questions as how the
characteristics of traditional governance (including formal or hard law) can be
fruitfully blended with, or be complementary to, less traditional forms of
governance, (such as soft law or increased civil society participation), for greater
effect where necessary. One could also try to determine what benefits the
different actors - government, research sponsors, researchers, professional
bodies, and research participants - bring to the table and how these can be more
effectively managed to ensure better governance of research.
Further, I am of the view that employed appropriately, and
without overstretching what might be considered an already diffuse concept,
governance does not only have an explanatory and organising value, it also has

397

See Adele Langlois, "The UNESCO Universal Declaration on Bioethics and Human Rights:
Perspectives from Kenya and South Africa," (2008) 16:1 Health Care Analysis 39.
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prescriptive value. In this regard, one can consider simply the organisation of
the system and the actors within that system, or how the system is changing to
accommodate different types of actors, instruments and processes (as much of
the recent literature in governance does). But one can also go beyond that to
question whether the system is working effectively, which then requires us to
question what the system, (whether organised coherently or cohesively or not) is
set up to achieve, and even further what the system should achieve. One can also
ask whether the right interests are involved in decision-making in research
governance. One can also question if the right instruments or tools are being
utilised, a central concern in governance literature. We could also question if the
current governance arrangements in any country help the delivery of better
outcomes. In other words, governance as an analytical framework also allows us
to inquire normatively as to what the goals of regulation and governance should
or ought to be, the necessary actors and instruments or tools, and the criteria by
which to evaluate governance.
Just as importantly, the actors, institutions, instruments and
processes involved in research governance work within a socio-political context
which may affect their effectiveness. A hybrid governance framework allows
not only the evaluation of these contexts, but also permits one to address
normatively the ideal context for the institutions, actors and processes to
function effectively.

A governance framework is also helpful in raising

important questions relating to legitimacy of governance actions within any
given socio-political context, for example, in determining the source(s) of

151

authority for relevant matters such as law-making and production of national
guidelines.
Although I am adopting a framework of governance, there are
several other possible analytical frameworks that could be fruitfully employed in
investigating health research involving humans in developing countries. These
include a strictly bioethical framework, international relations theory, tort law,
criminal law, or a human rights framework. A strictly bioethical framework
would be useful in examining and making recommendations about the relevant
ethical concerns that arise in the context of health research in developing
countries.

International relations theory (including regime theory)398 may

provide an understanding of the complex relationships that exist at the
international level and their impact on the international organisations which
regulate research internationally and which provide the guidelines that are
applied in some domestic contexts. It may even address the global inequalities
that exist internationally, the part that different states may play in fostering such
inequalities, and how these may affect domestic governance regimes. A tort law
framework may provide answers to questions about the judicial role in research
governance in developing countries and the legal obligations of researchers and
research sponsors to research participants.

So, too, could a criminal law

framework, which may also analyse the impact of legal sanctions on prohibited
Regime theory aims at explaining the political forces which drive international co-operation
between states and how the distribution of global public goods is affected. According to Abbott,
the theory "incorporates information and ideas as well as power and interests, and acknowledges
significant roles for private and supranational actors and domestic politics." See Kenneth W
Abbott, "International Relations Theory, International Law, and the Regime Governing
Atrocities in Internal Conflicts" (1999) 93:2 The American Journal of International Law 361 at
367. See Andreas Hasenclever, Peter Mayer and Volker Rittberger (eds.), Theories of
International Regimes, (Cambridge University Press, 1997).
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behaviours arising from health research involving humans. A human rights
framework could address the rights of research participants and the obligations
arising therewith - a discourse focused on rights, duties and related institutional
arrangements. None of these frameworks, however, has the comprehensive reach
of a governance framework which, by description, encompasses elements of
these theories. In addition, given the stated vacuum in this area, the stated goals
of this thesis, and the importance of a systems perspective already pointed out, a
governance framework seems most suitable.

2.4 Application of Governance as an Analytical Framework for Health
Research Involving Humans

To undertake a systemic analysis as anticipated in this thesis, one
has to consider broadly the actors and institutions involved in the research
governance system. To do this, an examination of the value bases for the system
(which are principally located within research ethics) as well as the instruments
(the guidelines, legal regulations) and the regulating institutions which attempt
to accomplish these value-based objectives is necessary.

The analytical

framework of the thesis therefore takes a three-pronged approach, consisting of
ethical, legal and performance approaches, to the investigation of research
governance arrangements and mechanisms in Nigeria.

These are discussed

respectively below, and then applied in the rest of the thesis.
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2.4.1 Research Governance: Ethics and Values
Research governance and ethics are inextricably linked. The
international ethical guidelines, including the Helsinki Declaration, the CIOMS
Guidelines and the Good Clinical Practice: Consolidated Guideline, ICH
Harmonized Tripartite Guideline, International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for Human Use and,
more recently, the UNESCO Declaration on Bioethics and Human Rights, have
therefore been primary instruments for regulating research involving humans.
While they have no formal legal character and cannot, by themselves, be
considered law, these guidelines may be incorporated into domestic law.399 But,
even where they are not so incorporated, they contain some provisions that may
bind researchers and research institutions requiring them to adopt certain
standards. While these international guidelines have provided a form of
governance, national guidelines, mostly recent, play a crucial role in research
governance in many countries, including Australia,

the United Kingdom,

Canada,402 and developing countries such as Uganda,403 India,404 Nepal,405 South

399

See, A.C Campbell and K.C Glass, "The Legal Status of Clinical and Ethics Policies, Codes,
and Guidelines in Medical Practice and Research" (2001) 46 McGill L.J. 473 at 478.
400
Australia: NHMRC, National Statement on Ethical Conduct in Human Research 2007, online:
<http://www.nhmrc.gov.au/publications/synopses/_files/e72.pdf> (June 20, 2007).
401
Department of Health, Research Governance Framework for Health and Social Care (Second
Edition) (United Kingdom, 2005), online:
<http://www.dh.gov.Uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalas
set/dh_4122427.pdf> (June 19, 2007).
402
Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council
of Canada, Social Sciences and Humanities Research Council of Canada, Tri-Council Policy
Statement: Ethical Conduct for Research Involving Humans 1998 (with 2000, 2002 and 2005
amendments) online:
<<http://www.pre.ethics.gc.ca/english/policystatement/policystatement.cfm> (August 11, 2007).
403
Uganda, Guidelines for the Conduct of Health Research Involving Human Subjects in Uganda
(National Consensus Conference 1997).
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Africa,

and Nigeria.

Some of these more recent national guidelines appear,

in varying degrees, to be more exhaustive than the international guidelines. This
is not surprising given that they are inspired by, and are building on, the
foundations already established by these guidelines.

The thesis therefore

discusses also the ethical framework provided by the guidelines and the role they
play in the governance of research in Nigeria.
To analyse these guidelines and their impact on the research
governance system, one must be able to situate them in context and understand
their origins. The analysis of paradigm shifts in the understanding of ethical
protections for research participants and research oversight by Emmanuel and
Grady in a recent article is helpful in this regard. They note that research
oversight has undergone four major paradigm shifts.408 These paradigm shifts
have occurred as a result of different events signifying the risks of research and
embody different perspectives on the value of research and its potential hazards
and different conceptualizations of the objectives of oversight. According to
them, "Each period also advances a different underlying ethical principle
guiding the protections of research participants, empowers different institutions
to implement the protections, and has its own way of balancing protection of

Indian Council of Medical Research (ICMR), "Ethical Guidelines for Biomedical Research
on Human Subjects" (2000), online: <http://www.icmr.nic.in/ethical.pdf> (March 29, 2007).
Nepal Health Research Council, National Ethical Guidelines For Health Research in Nepal
(2001), online: < http://www.nhrc.org.np/guidelines/nhrc_ethicalguidelines_2001.pdf>
(February 7, 2008).
National Health Research Ethics Council, Ethics in Health Research: Principles, Structures
and Processes Guidelines. Pretoria: Department of Health, 2004 online:
<http://www.doh.gov.za/docs/factsheets/guidelines/ethnics/> (June 19, 2007).
407
NHREC, National Code for Health Research Ethics (2006), revised 2007.
4
Ezekiel J. Emmanuel and Christine C. Grady, "Four Paradigms of Clinical Research and
Research Oversight" (2006) 16 Cambridge Quarterly of Healthcare Ethics 82 at 82.
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research participants against other important values in biomedical research."
Thus they categorise these four periods, which though distinct may sometimes
overlap, as: researcher paternalism, regulatory protectionism, participant access
and community partnerships. These different periods could also be linked to the
changes in governance from the old to the new, as discussed above.
Researcher paternalism, the paradigm operating during and
immediately after World War II, 410 denotes a period in which a utilitarian
approach, an ethical approach which justifies individual sacrifice for the greater
good of society, was adopted.

In that milieu, the ethical principle guiding

research and research oversight was social value: "Individual sacrifice was
necessary for research and justified by the tremendous good it would produce for
all of society."411 Emphasis was therefore placed more on the value of research
rather than on the safety of participants. It is not surprising, then, that the major
mode of research oversight was through self-regulation by researchers, who took
on the paternalistic role of determining what was ethical and useful, "weighing
social value over individual risk-benefit assessments when they were in
tension."

Such paternalism corresponded with the prevailing medical ethics

Jonathan D. Moreno, "Goodbye to All That: The End of Moderate Protectionism in Human
Subjects Research" (2001) 31: 3 Hastings Center Report 9 at 10.
411
Emmanuel and Grady, supra note 233 at 84.
412
Ibid, at 85. Louis Lasagne's statement quoted in Emmanuel (ibid), summarises this position
succinctly:
Society frequently tramples on the rights of individuals in the "greater interest." . . . [T]he good
of the individual and the good of society are often not identical and sometimes mutually
exclusive. I submit that the successful development of such an ethical conscience, combined with
professional skill, will protect the patient or experimental subject much more effectively than
any laws or regulations. . . . I believe it is inevitable that the many will continue to benefit on
occasion from the contributions—sometimes involuntary—of the few. The problem is to know
when to say "Halt!" Louis Lasagne, "Some Ethical Problems in Clinical Research" in E
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at that time - the doctor-knows-best mind-set.413 Professional ethics, codes, and
oaths established by physicians, such as the Hippocrates Oath, served as
normative standards. Although peer review of research took place in several
institutions, it was by no means mandatory.414 As was made clear by the
scandals exposed in articles and books, researcher paternalism far from
protecting research participants, in fact, exposed participants to harm. There
was with little regard for informed consent and the deception of participants was
justified on the basis of the good of society.
The scandals, including the Tuskegee Syphilis trial on AfricanAmerican men, led to a paradigm shift to a model of regulatory protectionism or
what Moreno refers to as "strong protectionism,"416 which was essentially a
minimisation of the discretion of researchers in governing their conduct of
research involving humans,

7

and formal introduction of the state into research

governance. This paradigm shift led to such regulatory steps as the enactment in
the United States of the National Research Act in 1974 and the creation of the
National Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research which drew up the Belmont Report which states the ethical
principles which should provide the basis for all research involving humans, as

Mendelsoh, J P Swazey, and I Taviss, (eds.) Human Aspects of Biomedical Innovation
(Cambridge, Mass: Harvard University Press, 1971), 98-110, at 108, 110.
413
Ibid.
414
Moreno, supra note 235 at 11.
The misconduct of researchers became open with such incidents as the publication of Henry
Beecher's landmark article in 1966 in which he detailed some of the unethical practices taking
place in the name of research and such incidents as the Tuskegee Syphilis Study in the United
States and Jewish Chronic Disease Hospital.
416
Moreno, supra note 235.
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previously mentioned.

Further, independent ethics review committees and

government regulators such as the Federal Drug Agency (FDA) in the United
States became important mechanisms for governing the conduct of research on
the basis of the principles elaborated in the Belmont Report. The utilitarian
approach thus gave way to an approach of principlism.

Principlism avoids

comprehensive ethical theories but adopts midlevel principles that are common
to, and can be justified and agreed upon by, multiple ethical theories, especially
utilitarianism and deontology or virtue theory. The ethical principles of respect
for persons/autonomy, beneficence/non-maleficience, and justice, stipulated in
the Belmont Report, originated from this approach. This approach has gained
wide approval and is much employed within bioethical circles.

This may be

classified as the period which most relates to the era of traditional governance
with strong government intervention.
According to Ezekiel and Grady, there has been another paradigm
shift from regulatory protectionism to participant access mainly as a result of the
HIV/AIDS epidemic, beginning in the early eighties.

Participants now see

regulatory protectionism as somewhat paternalistic and demand the right to be
involved in the decision-making process, most particularly with regards to the
right to participate in research which they think will be useful in finding cures to

418

These ethical principles originated from principlism, subsequently formalised by Childress
and Beauchamp in their seminal work Principles of Biomedical Ethics. It has however been
criticised for being somewhat paternalistic and for its restrictive approach to research involving
certain populations, including prisoners and women. Tom L. Beauchamp and James F. Childress,
Principles of Biomedical Ethics (Oxford: Oxford University Press, 2001) (Fifth Edition). See
Ezekiel, supra note 233.
1
See for example, Aurora Plomer, The Law and Ethics of Medical Research: International
Bioethics and Human Rights (Oxford: Cavendish Publishing, 2005) at 8-10, describing the role
of principlism in the work of national bioethics committees.
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diseases such as HIV/AIDS which as yet have no cure. McDonald
acknowledged this paradigm observing that:

In some cases, articulate interest groups with
strong agendas have formed to lobby for
research in areas affecting their health, e.g.,
people with AIDS or those with or at risk of
hereditary forms of breast cancer. This has
also complicated the picture we currently have
of the ethics of research involving humans, so
that it is no longer just a question of protecting
research subjects from the potential harms of
research (as would have been seen to be a
principal task of research ethics processes in
the 1970's and 1980's).420
Hence, as summarised by Ezekiel and Grady, "Individuals did not need to be
protected by regulation; rather they should be entrusted to know their own good
and interests and be free to pursue them."421 The core ethical principle during
this period was, then, the right to autonomy.

Scholars of governance may see

this as part of the move to the new governance era described above.
This move is emphasised even more with the shift which Ezekiel
and Grady conclude with, a shift from the participant access paradigm to a
paradigm of collaborative partnership (reminiscent of Salomon's description of
collaborative governance). Involvement of communities is now argued to be a
necessary part of the research approval process.

Collaborative partnership

recognizes the importance of the social framework in determining both research
agendas and priorities, and in negotiating better protections for research

M McDonald, "The Current Context of the HRIHS in The Governance of Health Research
Involving Human Subjects (HRIHS), in McDonald, supra note 19 online:
<http://www.ethics.ubc.ca/people/mcdonald/lccmacdonald.pdf> (November 24, 2007) at 89.
421
Ezekiel and Grady, supra note 233.
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participants. Interestingly, this is a trend clearly observed in obtaining approval
for biomedical research in developing countries currently.

Only recently, a

microbicide clinical trial being conducted in Thailand had to stop, partly due to
protests by community activists that the communities were not sufficiently
involved in the process of approving the research.422 As Ezekiel and Grady note:
"One frequently recommended response to the need to protect developing
country communities from exploitation was to develop partnerships with the
community in which the research was being conducted."423

In developing

countries, ethics review committees now frequently have the role of ensuring
that benefits are made available to the communities as well as protecting the
individual participants of research. Arguments for the research participants'
representation on ethics review committees, which are increasingly made in the
literature,

can clearly be categorised as falling into this paradigm.

It is

important to note that these paradigm shifts overlap to a certain extent and two
paradigms may exist at the same time.

A. Chua, N. Ford, D. Wilson and P. Cawthorne, "The Tenofovir Pre-Exposure Prophylaxis
Trial in Thailand" (2005) 2: 10 PloS Medicine 346.
4
Ezekiel and Grady, supra note 228. See for example, E Emanuel, D Wendler, J Killen, C
Grady, "What Makes Clinical Research in Developing Countries Ethical? The Benchmarks of
Ethical Research" (2004) 189 Journal of Infectious Diseases 930; C Weijer, G Goldsand, E J
Emanuel, "Protecting Communities in Research: Current Guidelines and Limits of
Extrapolation" (1999) 23 Nature Genetics 275-80; C Weijer, E J Emanuel, "Protecting
Communities in Biomedical Research" (2000) 289 Science 1142-4; P E Cleaton-Jones "An
Ethical Dilemma: Availability of Antiretroviral Therapy after Clinical Trials with HIV Infected
Patients Are Ended" (1997)314 British Medical Journal 887-8; P. Wilmshurst, "Scientific
Imperialism: If They Won't Benefit from the Findings, Poor People in the Developing World
Shouldn't Be Used in Research" (1997) 314 British Medical Journal 840-1; L H Glantz and G J,
Annas, M A Grodin and W K Mariner, "Research in Developing Countries: Taking 'Benefit'
Seriously (1998) 28:6 Hastings Center Report 38^12.
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The descriptions of these paradigm shifts focus on biomedical
research and on western countries, in particular the United States. However,
Ezekiel and Grady's characterisation of these paradigm shifts in research
oversight illustrates regulatory movements in research governance from selfregulation to increased government role and the use of command-and-control
techniques to a collaborative partnership increasingly involving all stakeholders
in the research process, including ordinary citizens and research participants.
These shifts appear to show a movement towards the new governance paradigm
described above, still including the regulatory presence of the United States
government in publicly funded research. As I have argued, a strong government
presence in addition to increased participant involvement in governance
processes, amongst other steps, may yield more effective results in developing
countries.
Ezekiel and Grady's characterization of these movements is also
useful for the purposes of identifying relevant issues that need to be addressed in
the governance systems that currently exist in developing countries.

For

instance, what are the origins of research governance in developing countries?
Have they developed in reaction to adverse events or external funding
requirements or to replicate developments in other jurisdictions? And how have
these origins affected the path their development has taken - the route of
voluntary guidelines or a more regulated approach, including the enactment of
relevant legislation? In the United States, for instance, the legislative approach
was adopted with respect to federally funded research in response to reports of
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unethical conduct. Has this been the case in developing countries? Answers to
such questions are examined in the specific context of Nigeria in Chapter Four.
Other questions also arise such as: What are the values at stake in research
governance generally, and in developing countries particularly? And how are
these reflected in the types of research governance systems and the mechanisms
currently emerging in developing countries? Finally, the categorisation also
raises the question: What implications do these systems have for the protection
of the rights and safety of research participants? These are examined in detail in
subsequent chapters.

2.4.2 Research Governance: Legal Context
Apart from the ethical foundations of the governance of research
involving humans, law and legal analysis have not been absent from the area of
research involving humans. Much current analysis in the legal context focuses
on risk and on determining the legal responsibilities of stakeholders in the
research enterprise.

Such analysis considers from that perspective, liability

under the law of torts, including what actions by researchers, such as failure to
obtain informed consent leading to injury, may constitute or be actionable as
trespass, (that is, assault, battery) or negligence. Law thus regulates researchers'
conduct. Legal analysis may also focus on the duty of care owed to research
participants by others in the governance arena, including the researchers, the
government, and the ethics review committees may also be reflected upon within
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a legal framework of analysis. "

Such matters as the legal status of the

emerging guidelines and the legal protections available to research participants,
may also be determined within this framework.
Given the history of regulating research involving humans in
many countries, law may not be the centrally dominant regulatory institution,
but yet it is not insignificant to research governance. Law appears to be a
purposive instrument, a regulatory tool of oversight, but this is by no means
generally applicable. Indeed, law appears in many countries not to have direct
application in the research governance systems and, in the apt words of Bernard
Dickens in relation to the Canadian system of governance, law frequently
"applies almost inadvertently" to the research enterprise.426
With respect to the governance perspective adopted in this thesis,
the main question that arises is: What is the appropriate role for law in the
research governance system? Can it go beyond the rules of tort to a more
specific, extensive role such as direct legislation?

Accordingly, one of the

central issues which the thesis examines broadly is the role of law as a social
control, the place of law in governance arrangements, and the limits of law in an
evolving, dynamic and special area such as the area of health research involving
humans.

In other words, the jurisprudential significance of the analysis of

research governance systems which the thesis proposes to undertake is, to
determine the role that law should play in the particular governance systems of
425

See Susan V Zimmerman, "Translating Ethics into Law: Duties of Care in Health Research
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developing countries.

Indeed, this is the main rationale for adopting a

governance framework - that is, to examine the role of law alongside other
governance mechanisms or instruments.

Generally speaking, law can establish,

authorize, and legitimate decision-making and oversight processes. Law may
thus regulate research involving humans and, normatively, through its standardsetting aspects, contribute to the promotion of ethics standards.

In my view,

therefore, research governance or oversight should have a legal context, and law,
as I argue in Chapter Four must go beyond a facilitative role and extend to a
protective one.
In the rest of the thesis I ask such questions as: What role ought
law to play in the governance of health research in developing countries? What
types of legal instruments are currently employed in research governance and,
497

what are the reasons behind this choice of instruments?

What is, and what

ought to be, the role of law in research governance in Nigeria? Does this role
relate to only specific issues (for example, facilitation of research through the
creation of research institutes, or protection of research participants via
provisions on confidentiality or privacy issues or informed consent)? Or does it
affect governance arrangements more generally?428 What role do private actions
in tort play and to what extent do such actions, and arising case law, currently
govern research in developing countries and specifically in Nigeria? More
427

These questions were raised in a more specific way in a study focusing on research
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importantly, how should the role of law expressed - through legislation, case
law, common law concepts or contractual arrangements - and what should such
law cover? The thesis thus examines the existing legal arrangements which may
form part of the governance framework and whether or not these arrangements
have the potential to promote socially beneficial research and provide better
protection of research participants in these countries. In doing this, it examines
also the political and social contexts of law in these countries, and more
specifically in Nigeria.

2.4.3 Research Governance: Institutional Context
Good governance requires that collective moral intentions (or
values) be translated into effective and accountable institutional actions.

It is

important, then, to examine the institutions that actually implement the rules and
guidelines contained in legal and non-legal instruments. What form does the
institutional framework take and what is the organisational structure of research
governance in Nigeria?
One of the key institutions in the governance of research in all
countries is the ethics review committee which may be established by
institutions like universities or research institutes or by governments.
Government departments of health are also another institution involved in
research participants' protection. Legal institutions such as judicial institutions
(discussed in the legal context) also play a role in research governance. Another
429

McDonald, supra note 19 at 149.
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is the drug regulatory agency which gives approval for new drugs and regulates
the use of human participants in the testing of those drugs.
I examine these different institutions but illustrate here the issues
that may arise in the context of ethics review committees. Ethics review is
central to most research governance systems, including that of Nigeria. Several
questions arise within the context of a governance framework with specific
regard to ethics review and include: What form does the ethics review
committee structure take? Is the ethics review committee an arm's length review
body that is independent and objective in terms of membership, processes, and
reporting relationships? Who does the ethics review committee report to? Who
appoints its membership? Are the interests of prospective research participants
adequately represented on the committee and how? Are there lay or community
representatives? Are there transparent and effective accountability relationships
to those who set standards? Who, if anyone, addresses gaps and inconsistencies
in standards and processes and how?

Is there any requirement for any specific

expertise, (for instance, ethics expert, legal expert, statistics or clinical research
expert) and for lay representation? Do the committees provide approval before,
during and after research commences?

In other words, is there ongoing

monitoring and oversight?
While these questions specifically relate to ethics review
committees, the same questions can be raised in relation to other institutional
structures involved in research involving humans, such as drug approval
430

Mcdonald, supra note 19 at 63.
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agencies - the institutions that bear responsibility for the drug approval
processes in these countries - and departments of health and professional
organisations such as medical associations.

I investigate whether, based on

available evidence, these governance issues are adequately addressed or have the
potential to be so addressed.

An investigation of these institutions is also

required to determine if they work together in a systematic, co-ordinated fashion
to effectively protect research participants while creating a stable environment
for research.

2.4.4 Performance of the System
Beyond gaining an understanding of the ethical framework of the
governance system, the legal context and the institutional instruments of
governance, another important issue that requires consideration is the current
and potential functioning of the systems for research governance in Nigeria.
How well is the system working in practice and what potential does it have to
work well?
Based on available evidence, the thesis considers in the chapters
that follow issues relating to legitimacy, effectiveness, comprehensiveness,
clarity, efficiency, simplicity, consistency and adequacy. Questions that will be
asked in this section with respect to the different actors and instruments include:
How comprehensive is the system? What aspects of research does it cover?
How much public participation is there in the processes? What provisions are
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made within the system for important matters such as standards, compliance,
and education? Does the system make for simplicity or is it a convoluted process
in which there is no certainty of what the standards are, or clarity of structures?
Are the rights and responsibilities of actors in the governance system clear? How
is the system financed? How efficient is it? Are the conduct and enforcement of
oversight adequate and effective?

Is there an adequacy of resources and

expertise for effective governance?

The answers to these questions will go

beyond the descriptive to the normative, from what currently is, to what ought to
be.

2.5 Conclusion
The governance of health research involving humans in
developing countries requires a more comprehensive analysis than has hitherto
been undertaken. The aim of this chapter has been to discuss the analytical
framework within which a detailed examination of this subject can be
undertaken. In the foregoing pages, I have attempted to set out a governance
framework which, in my view, will allow the comprehensive and wide-ranging
analysis required here. The framework draws considerably from work already
done by scholars of regulation and governance, but attempts to set out a hybrid
framework which I consider to be more suitable for the purposes of the thesis. I
have addressed the rationale for adopting this framework. I have also, in the
foregoing pages, indicated how this framework will be applied in the rest of the
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thesis.

The subsequent chapters will provide more details and put this

framework further in the specific context of Nigeria.
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Chapter Three
Components of Research Governance Systems: Ethical and Institutional
Frameworks
3.1 Introduction
The governance of health research involving humans is a wideranging subject.

In many countries, research governance typically operates

through different institutions, instruments, and processes, all of which I term
"components of research governance."

As will become obvious in the

discussion that follows, the number and diversity of actors and instruments
which come together to form the components of governance requires a hybrid
framework of analysis such as I suggested in Chapter Two. These components
may include drug regulatory authorities; funding agencies; a legal framework;
the ethics review system; and policy guidelines that detail the ways in which
research should be conducted.
Three main questions may arise in examining the components and
tools of research governance, namely: What are the components of research
governance currently in use in countries around the world, and how do they
operate to govern health research? What should be the components of
governance of health research in developing countries? Do these components
act, and should they act in a coordinated fashion?
In this chapter, I answer the first question, namely, what are the
components of research governance systems currently in use around the world?
The objectives of this chapter are therefore to identify and describe two
components of research governance systems widely accepted both in the
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literature and in actual operation, namely: the ethical framework and the
institutional framework. In my view, these are important components and there
is no need to re-invent the wheel in developing countries. In essence, these
components are also essential in developing countries.
However, while there is clear understanding in the literature and in
the actual operation of governance systems that these are necessary components
for the governance of health research, there may be some debate about their
content. Thus, for instance, there is broad acceptance of the need for an ethical
framework but there may be disagreement about the content of domestic or
international ethical guidelines or how they should be implemented in
developing countries.
Another example of a widely accepted component, both in the
literature and in the actual operation of governance systems, is the central role of
ethics review committees. Even though widely accepted, there are systemic
issues that may limit their functionality and effectiveness in protecting research
participants. I identify these systemic issues and the specific issues that have
been of concern in developing countries.
Less articulated in the literature is the inclusion of non-governmental
organisations or research participant advocacy groups in the institutional
framework. Non-governmental organisations are omitted in most accounts of
the components of research governance. This is understandable because these
organisations may be argued not to be, strictly speaking, part of the formal
research governance system. But in light of the hybrid framework proposed in
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Chapter Two, the balancing purpose that such organisations can serve, and the
need to provide a more complete picture of research governance components, as
this thesis proposes, I argue here that such organisations are a necessary
component of the institutional framework.
In providing a description of the institutional framework, I identify
systemic issues that may limit the effectiveness of the different organisations
involved in research governance in different countries, many of which are
articulated in the literature on research governance. It is necessary to identify
these concerns because they are matters that need to be addressed in research
governance systems, including the emerging governance systems of developing
countries.

These systemic issues are then considered in more detail in the

specific context of Nigeria in subsequent chapters. Descriptions undertaken in
this chapter are drawn from various jurisdictions around the world, particularly,
Australia, Canada, Denmark, Nigeria, South Africa, the United Kingdom, and
the United States.
The discussion is undertaken with the macro perspective discussed
in Chapter Two in mind, allowing for breadth of analysis rather than specificity.
Thus, although some specific issues are identified, it is not intended to be a
detailed description of all the specific issues and concerns that arise in the
context of an ethical framework or an institutional framework.
one country has a perfect system.

In essence, no

The problematic issues identified in the

discussion undertaken here indicate some of the issues that need to be addressed
in the contexts of developing countries like Nigeria.
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The chapter commences with this introduction as the first section.
The second section comprises three subsections. The first considers the ethical
framework, examining the role of national and international guidelines in
creating an ethical framework for the governance of health research involving
humans. It notes that establishing domestic guidelines in developing countries
may be one way to address issues that have been controversial in the
international ethical guidelines. The second subsection considers the role of
different institutions and organisations involved in the governance of research
involving humans, particularly ethics review committees. It identifies some of
the systemic issues that have been problematic in developed countries, and also
issues that may pose difficulties in developing countries. The third subsection
concludes the chapter.

3.2 Ethical Framework
Research governance and bioethics are inextricably linked. The
ethical framework of the governance of research involving humans is a vital and
foundational component of research governance system.

Indeed, an ethical

framework should be a core part of the governance of research involving
humans. It is within the ethical framework that the true goals and objectives of
research governance are located - the goals of ensuring beneficial research and
protecting the safety of research participants. Thus governance involves not
only procedures and processes but the underlying values that require the
adoption of these procedures. And although governance and regulatory
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structures are important active aspects of protecting research participants, their
procedural aspects and institutional mechanisms must be built on an ethical
foundation.

This ensures that there are not merely governance mechanisms

operating formalistically without any ethical directions, or compliance with
procedural requirements divorced completely from the ethical principles which
necessitate the governance structures to begin with. As Slowther and others
acknowledge:

Recognizing and responding to the ethical
dimension of research is a fundamental part of
the research governance process. Ethical codes
of practice and regulatory frameworks reflect
concern about actual or potential examples of
unethical research.1
Hence, ethical standards and principles have been an important underpinning for
research governance both internationally and locally. Any serious discussion of
the governance of research must therefore consider ethical foundations and
values and begin with the discussion of the ethical framework.
The ethical framework, as discussed here, consists of the research
ethics principles which may be located in the international ethical guidelines and
in the national ethical guidelines. Many of these guidelines are amended at
intervals in light of evolving understanding of ethical issues.

The ethical

framework may also derive from values articulated in other important national
sources, such as constitutions of countries. For the purposes of this chapter, I
will consider international ethical guidelines and research ethics principles

Anne Slowther, Petra Boynton, and Sara Shaw, "Research Governance: Ethical Issues" (2006) 99
J R Soc Med 65 at 65.
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which are specifically dedicated to the ethics of research involving humans
around the world. I will consider any national sources in the specific context of
Nigeria in Chapters Five and Six.
This section undertakes, therefore, a brief description of some
research ethics principles and then an overview of the international ethical
guidelines.

As discussed below, although commonly recognised as the ethical

framework, there is nonetheless disagreement as to their universality. One way
to address that thorny issue would be for developing countries to adopt national
ethical frameworks which are cognizant of general ethical issues and local
contexts.

3.2.1 Research Ethics: Ethical Principles
There is a clear understanding that research has to be conducted in
an ethical manner, even though there may be disagreement in certain situations
as to what is ethical or not. Much of the debate relating to ethical concerns
surrounding research involving humans in developing countries assumes an
understanding of research ethics, ethical principles, and the international ethical
guidelines. Ethical principles have been adopted in several countries, including
the United States, to provide a general framework for analysis, which can
subsequently be applied to a specific ethical problem to arrive at a resolution.
These principles provide guidance as to what may be ethical, and can be used in
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evaluating appropriate behaviour in the conduct of research.2 They therefore
make a valuable contribution to the ethical framework which applies in the
research governance systems of countries around the world. A consideration of
these ethical principles may be a good starting point for the examination of the
ethical framework underpinning research governance systems.

Given the

considerable attention that these principles have received (and continue to
receive) in research ethics literature, as well as the scope of this thesis, only a
brief examination is undertaken here.
Below, I describe briefly the ethical principles which have been
considered by some to be foundational in the governance of health research,
namely: respect for persons, beneficence, and justice. I then consider briefly the
arguments against the general applicability of these principles and arguments
against their application as an adequate underpinning for research governance
systems in all contexts, especially in the developing world context. I point out
that, given that these principles are not necessarily uncontested, there needs to be
a local contextual adaptation of these and, possibly, the inclusion of other
principles.

I also conclude that national guidelines and policies, (already

adopted in a few developing countries) which take into consideration the
contexts and the values of different countries may be one way of resolving
dilemmas around determining what the appropriate ethical underpinnings of
research governance systems in these countries ought to be.

2

As is noted in the Canadian Tri-Council Policy Statement (Article G): "In their best uses,
principles serve as short-hand reminders of more complex and context-specific moral reflection."
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The most prominent of these ethical principles can be located in the
Belmont Report.

The Belmont Report was produced by the US National

Commission for the Protection of Human Subjects of Biomedical and
Behavioural Research created under the 1974 National Research Act to address
the ethical concerns arising from the revelations of the Tuskegee Syphilis Study,
the Willowbrook studies, and the Jewish Chronic Hospital Disease Study,
among others.3 The report enunciated three guiding principles for research
involving humans namely, respect for persons, beneficence, and justice.
Below, I describe the understanding of these guiding principles in major
research ethics literature.
The first principle, respect for persons, is associated in much of the
literature on research ethics with the concept of autonomy.

The principle of

respect for persons requires that everyone is regarded with respect, with interests
that have to be taken into account, and not merely the means to an end. In other
words, people are not to be used as objects, without interests, feelings or dignity,
in a research study. Further, there is a presumption that persons are the best
guardians of their own interest and must therefore be involved in any decision
which may affect them.5 According to Beauchamp and Childress, "personal
autonomy is an extension of political self-rule to self-governance by the
individual: personal rule of the self while remaining free from both controlling

3

National Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research, The Belmont Report: Ethical Principles and Guidelines for the Protection of Human
Subjects of Research (Bethesda, Md.: The Commission, 1978) at 1-8 [Belmont Report].
4
Ibid.
5
Nuffield Council on Bioethics, The Ethics of Research Related to Healthcare in Developing
Countries Nuffield Council of Bioethics (2002) at 51.
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interferences

by others

and personal

limitations, such as inadequate

understanding, that prevent meaningful choice."6 The requirement for informed
consent in research involving humans is derived from this principle. The other
part of the principle of respect of persons, according to the Belmont Report,
requires that persons with diminished autonomy (by reason of mental
incapacitation, or incarceration) require protection.
The second principle, beneficence, according to most understandings
of the term in literature, requires not only that persons are respected but that
efforts are made to secure their safety and welfare. "Beneficence ensures that the
risks of the act of research are kept within the essential context of the
commitment to do the good for the benefit of others."7 Given that there is always
the possibility of risk in research involving humans, it requires investigators to
give thought to the maximization of benefit and the reduction of risk to
participants in research. In the Belmont Report, beneficence requires not only
the positive obligation to ensure the good of participants in research, but also the
negative obligation to refrain from harming participants.

This negative

obligation, known as non-maleficience, is sometimes dealt with separately by
bioethicists.8
The last principle, justice, requires the just distribution of the
benefits of research and the avoidance of undue imposition of burdens.
6

The

Tom L. Beauchamp and James Childress, Principles of Biomedical Ethics, (New York: Oxford
University Press, 2001) (5th Edition) at 68. See also, Robert J. Levine, Ethics and Regulation of
Clinical Research (Second Edition) (Baltimore: Urban and Schwarzenberg, 1986) at 11-18. It
must, however, be noted that while the above-stated view of autonomy predominates in research
ethics, there are other understandings of autonomy, such as, relational autonomy.
7
Edward F. Gabriele, 'The Belmont Ethos: The Meaning of the Belmont Principles for Human
Subjects Protection" (2003) 34: 2 Journal of Research Administration 19 at 21.
8
See Beauchamp and Childress, supra note 11.
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principle requires that the risks of research cannot be allowed to sit unfairly and
unevenly on a specific population. Like beneficence and respect for persons, it
requires that persons who are disadvantaged and vulnerable are protected from
carrying the burdens and risks of research. The other side of this principle
requires that the benefits are distributed fairly and that these benefits do not
become the sole province of the advantaged.
These principles, subsequently discussed more extensively by
Beauchamp and Childress in their pioneering work Principles of Biomedical
Ethics,10 were the attempt of the Commission to summarise the basic ethical
precepts that it identified during its deliberations. Certainly, the Nuremberg
Code and the Helsinki Declaration which preceded the Belmont Report provided
a statement of several ethical principles to guide researchers. However, the
Belmont Report engaged in a more detailed exploration of the ethical
foundations of research involving humans.11

The adoption of principles, as

found in the Belmont Report, in defining guidance for the ethical conduct of
research involving humans, (often

referred

to as principlism) avoids

comprehensive ethical theories. Instead this approach adopts midlevel principles
that are common to, and can be justified and agreed upon by, multiple ethical

9

See the Belmont Report.
Tom L. Beacuchamp and James F. Childress, Principles of Biomedical Ethics (5th Edition)
(New York: Oxford University Press, 2001). The first edition was published in 1978. See also,
Robert J. Levine, Ethics and Regulation of Clinical Research (Second Edition) (Baltimore:
Urban and Schwarzenberg, 1986 at 11-18.
11
Albert R. Jonsen, "On the Origins and Future of the Belmont Report" in James F. Childress,
Eric M. Meslin and Harold T. Shapiro, Belmont Revisited: Ethical Principles for Research with
Human Subjects (Washington DC: Georgetown University Press, 2005) at 3.
10
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theories, especially utilitarianism and deontology or virtue theory. " The ethical
principles therefore draw from different ethical theories, but discussion of these
ethical theories is beyond the scope of this work.
Many of the challenges that arise in health research involving
humans are usually dealt with by reference to the principlism approach. These
include, but are by no means limited to, issues such as: What is the right balance
between the benefits of research and the risks to the individual? (concerns about
beneficence and maleficience) Can a research participant truly understand the
risks and benefits to participation in research? (that is, concerns about
autonomy) How should the burdens of research be fairly distributed? (that is,
concerns about justice).13 Thus, issues of informed and voluntary consent,
minimization of risk and ensuring a favourable risk/benefit ratio, equitable nonexploitative selection of participants, and privacy and confidentiality of
participants, are dealt with by reference to the principles described above.14
This approach has gained wide approval and is much employed
within bioethical circles and is entrenched in various guidelines and regulations
for research involving humans.15 Further, the principles inform and are reflected
in the work of many international agencies that have great influence
internationally with regards to the regulation of research involving humans, such
12

See Beauchamp and Childress, supra note 10 at 51. See also, Eric M. Meslin et al,
"Principlism and the Ethical Appraisal of Clinical Trials" in George F. Tomossy and David N.
Weisstub, Human Experimentation and Research (Hants: Ashgate Publishing Company, 2003) at
77.-78.
13
Janet L. Dolgin and Lois L. Shepherd, "Law, Medicine, and Philosophy" in Janet L. Dolgin
and Lois L. Shepherd, Bioethics and the Law (New York: Aspen Publishers, 2009) at 402.
Baruch A Brody, The Ethics of Biomedical Research: An International Perspective (New
York: Oxford University Press, 1998) at 36.
5
Meslin, supra note 17 at 77.
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as the World Health Organisation (WHO), the Council for International
Organisations of Medical Sciences (CIOMS) and the United Nations.16 What is
more, the inclusion of the concept of informed consent, derived from the
principle of respect of persons, in the International Convention on Civil and
Political Rights also allows the consideration of such concepts not only as
ethical values but also as fundamental human rights. Moreover, as Meslin and
others point out, "the advantage offered by the principles is that they do, in fact,
provide a generally accepted framework of values within which individual
contextual considerations may be evaluated."17 These guiding ethical principles
- respect for persons, beneficence, and justice - serve as the basis for the US
1R

federal regulations for research involving humans.
The principlism approach, though widely adopted, has faced several
criticisms. These include that reliance on principlism limits more robust moral
discourse and appears to suggest that ethical matters can be quantified in a more
or less mathematical manner.19

It is also argued by some that principlism

obscures and confuses moral reasoning by its random and varied use of moral
theory.

Other arguments are even more critical of the way in which the

principles have developed. For commentators like Rhodes, the derivation of the
Monica Konrad, "Norms, Values and Transcultural Medical Ethics," in European Group on
Ethics in Science and New Technologies to the European Commission, The Ethical Aspects of
Biomedical Research in Developing Countries: Proceedings of the Round Table Debate (2003),
online: <http://ec.europa.eu/european_group_ethics/publications/docs/tb 1 oc_en.pdf> (December
2, 2008) at 14.
17
Meslin, supra note 17 at 81.
18
Office for the Protection of Research Subjects, "History of Research Ethics" online:
<http://research.unlv.edu/OPRS/history-ethics.htm> (November 24, 2008).
19
See John H. Evan, "Max Weber Meets the Belmont Report: Toward a Sociological
Interpretation of Principlism" in Childress et al, supra note 122 at 229.
20
K. Danner Clouser and Bernard Gert, "A Critique of Principlism" (1990) 15: 2 The Journal of
Medicine and Philosophy 219.
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principles from the Nazi trials of prisoners in World War II not only presented a
backward way of developing principles for regulating health research involving
humans, but also created an essentially paternalistic model for the governance of
research involving humans.

Other critical arguments address the limited scope

of the principles, including that the principles focus on individuals and thus do
not adequately address communities participating in research.22 The emphasis on
individualism, it also argued, obscures "the importance of a nexus of human
relationships indispensable to traditional decision-making in much of the
world."23

Feminist critiques make similar arguments against principlism's

elevation of so-called rational principles over relational values such as relational
autonomy, care, empathy and mutuality.

4

Moreover, the principles, while

possibly offering clarity with respect to the values that they represent, do not
9S

offer a precise or even usable guide for action in difficult situations

and they

may require broader interpretation than given in the Belmont Report context to
21

Rosamonde Rhodes, "Rethinking Research Ethics" (2005) 5: 1 American Journal of Bioethics
7. Others argue, however, that this paternalism is justifiable for the purposes of protecting
research participants. See Franklin G. Miller and Allan Wertheimer, "Facing Up to Paternalism
in Research Ethics" (2007) 37 Hastings Center Report 24.
See Aurora Plomer, The Law and Ethics of Medical Research: International Bioethics and
Human Rights (Oxford: Cavendish Publishing, 2005) at 8-10, describing the role of principlism in
the work of national bioethics committees and in major reports such as the Nuffield Council on
Bioethics report, supra note 5. However, Meslin and others note that many criticisms against
principlism are especially relevant to principlism if considered as a substitute for moral theory.
See Meslin, supra note 17 at 81.
23
Norio Fujiki and Darryl R. J. Macer (ed.), Bioethics in Asia (Bangkok: Eubois Ethics Institute,
2000) at 77-80.
24
Ibid. See also, Sue Sherwin, "Whither Bioethics? How Feminism Can Help Reorient
Bioethics" (2009) 1:1 International Journal of Feminist Approaches to Bioethics 7, discussing
relational autonomy and global bioethics.
25
See for example, K. Danner Clouser and Bernard Gert, "A Critique of Principlism," (1990) 15
Journal of Medicine and Philosophy 219 at 220. Among their criticisms of the principlism
approach is the argument that the principles do not necessarily provide a specific directive or
guidance for action. See also, R B Davis, "The Principlism Debate: A Critical Overview" (1995)
20: 1 Journal of Medicine and Philosophy 85, arguing that there is no conclusive evidence in
favour of, or against, principlism in academic debate because most scholarly research is biased in
favour of its adopted position based on prior epistemological commitments.
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deal with complex concerns, such as those arising in the context of developing
countries.
Arguments against the applicability of the ethical principles in the
developing world context point out that the conceptual framework underlying
the ethical principles are of Western origins and orientation (or even more
specifically American origins). As such, even when de-contextualised, they are
not necessarily accommodating of other non-Western cultures with different
values. For instance, the principle of respect of persons, it is argued, arises from
the individualist values of Western cultures and may not work in precisely the
same way in some developing country contexts.2

Konrad summarises this

concern succinctly when she states:

Principlism and the '4-principles approach'
developed by Beauchamp and Childress
(1994) with its stress on the respect for persons
through (1) autonomy (2) beneficence (3)
nonmaleficence and (4) justice, including
equity, was not originally formulated with the
explicit remit of tackling the socio-political
effects of multiculturalism - either within the
USA or elsewhere. Nor, in its founding
conceptualisation, was it particularly sensitive
to the challenges facing cross-cultural field
research in international health. Nonetheless, it
is these very principles that have provided
general guidance for many regulatory bodies
involved in formulating ethical guidelines for
97

biomedical research.

26

N. Yasemin Oguz, "Research Ethics Committees in Developing Countries and Informed
Consent: With Special Reference to Turkey" (2003) 141:5 Journal of Laboratory Clinical
Medicine 292. Lukas Kaelin, "Contextualizing Bioethics: The UNESCO Declaration on
Bioethics and Human Rights and Observations about Filipino Bioethics" (2009) Eubios Journal
of Asian and International Bioethics 42.
27
Konrad supra note 21 at 13.
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Plomer further

argues that recourse to fundamental

ethical

principles "can create an illusion of consensus and at its worst act as a poor
substitute for democratic procedures and processes to find agreement and
practical compromises between different moral cultures in pluralist societies."28
But others disagree with these views, arguing that beyond the differences in
context and circumstances, the ethical principles affirm the value of every
human being and that certain ethical principles are applicable across cultures.
Beauchamp notes, for instance, that "Belmont's principles are so woven into the
fabric of morality in morally sensitive cultures that no responsible research
investigator could conduct research without reference to them."29 Yet others
argue, for instance, that the principle of respect of persons as revealed in the
requirement for informed consent is individualist and therefore Western in
orientation.
These arguments indicate that the general applicability of these
principles is by no means uncontested. It is obvious that there are no easy
answers on issues regarding the universality or otherwise of the ethical
principles, not least because these issues reflect a broader controversy about how
to deal with global differences, inequalities, and disparities that go beyond the
ethics of health research. It is also apparent that while on the surface there

28

Plomer, supra note 27 at 2.
Tom L. Beauchamp, "The Origins and Evolution of the Belmont Report" in Childress et al,
supra note 124 at 15.
30
Lisa Newton, "Ethical Imperialism and Informed Consent" (1990) 12:3 IRB: A Review of
Human Subjects Research 11. However, others have pointed out that appeals to cultural
sensitivity frequently rely on "limited and often dated anthropologic literature that does not
reflect the rapid cultural changes brought about by colonialism and independence, warfare, and
urbanization." C. Ijsselmuiden, C. and R. Faden, "Images in Clinical Medicine" (1990) 326 New
England Journal of Medicine 833 at 833.
29
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appears to be some consensus on ethical principles there are troubling issues that
suggest that this might not be an entirely accurate picture.
In my view, looking at ethics and governance in a local context
may prove helpful in addressing these conflicting views. In this respect, instead
of accepting wholesale and without reflection the ethical principles used
elsewhere, developing countries can acknowledge that there are divergent views
and begin to address these issues thoughtfully in their national policies and
guidelines. Thus, instead of adopting a strictly "local" ethic built only on local
values, a "universal" ethic which may be considered imperialist, a "mid-way"
which recognises local values, local needs, and circumstances but which also
adopts the protections offered by the ethical principles underlying the
international ethical guidelines, may be more helpful.

This may mean

addressing problematic issues in national policies, bearing in mind the need to
minimize the possibility of exploitation, a particular concern in resourcechallenged countries.

Also, since cultural challenges cannot be generalized to

all developing countries,31 addressing such issues in a way that defines what the
national position on these challenges is may be useful.

As well, legal

requirements vary from one country to the next. Addressing some of the ethical
issues in a local context may allow the different legal and ethical requirements to
be brought into harmony, where appropriate.
31

See for instance, Emmanuel R. Ezeome and Patricia A. Marshall, "Informed Consent Practices
in Nigeria," (2008) Developing World Bioethics, Early View Article at 2. Patricia A Marshall,
"The Individual and the Community in International Genetic Research" (2004) 15: IThe Journal
of Clinical Ethics 76. See Anant Bhan, Mina Majd, Adebayo Adejumo, "Informed Consent in
International Research:
Perspectives from India, Iran and Nigeria" (2006) 3 Medical Ethics 36; See Ruth Macklin,
"Informed Consent for Research: International Perspectives" (2000) 55 JAMWA 290 at 291,
describing cultural divergences in informed consent issues in developing countries.
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Additionally, if one sees the three principles of respect for persons,
beneficence/maleficience, and justice as only starting points, one can move to
expanding the borders of ethical values as some commentators have done.
Several countries have adopted this approach also. The Australian National
Statement on Ethical Conduct in Human Research, for example, notes that
research has to be conducted according to certain values and principles, the
major ones being, respect for human beings, research merit and integrity, justice,
and beneficence.

The current edition of Canada's Tri- Council Policy

Statement on Ethics takes a more detailed approach, including such ethical
principles as respect for human dignity, respect for free and informed consent,
respect for vulnerable persons, respect for justice and inclusiveness, balancing
harms and benefits and maximizing benefits.34 Other organisations that deal
with bioethics have adopted similar, but not identical, principles. For instance,
in its report on the ethics of healthcare in developing countries, the Nuffield
Council on Bioethics identified four applicable principles: alleviation of
suffering, respect for persons, and sensitivity to cultural differences, and the duty

Emmanuel and others, for example, have proposed several principles and benchmarks for the
ethical conduct of clinical trials (which could conceivably be extended to other types of health
research), including such principles as solidarity. Ezekiel J. Emanuel, David Wendler, Jack
Killen, and Christine Grady, "What Makes Clinical Research in Developing Countries Ethical?
The Benchmarks of Ethical Research," (2004) 189 The Journal of Infectious Diseases 930.
Australia: NHMRC, National Statement on Ethical Conduct in Human Research 2007, online:
<http://www.nhmrc.gov.au/publications/synopses/_files/e72.pdf> (June 20, 2007) at 10.
34
Section C: "Guiding Ethical Principles," Canadian Institutes of Health Research, Natural
Sciences and Engineering Research Council of Canada, Social Sciences and Humanities
Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research
Involving Humans 1998 (with 2000, 2002 and 2005 amendments) online:
<<http://www.pre.ethics.gc.ca/english/policystatement/policystatement.cfm> (August 11, 2007).
These have been distilled in the latest draft forthcoming edition into three principles, - respect for
dignity, moral worth of every person, and minimisation of harm.
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not to exploit the vulnerable.

The European Group on Ethics in Science and

New Technologies (EGE) has also identified ethical principles to which it
adheres, including: the principle of respect for human dignity, individual
autonomy, justice, beneficence and non-maleficience and proportionality.
Apart from the inadequacies of the international ethical guidelines,
(some of which are considered necessary partly because many developing
countries lack domestic ethics policies)37 determining the ethical principles that
form the bedrock of the governance of research requires an understanding of the
domestic context. Others have suggested the addition of new ethical values
which have particular significance in the context of internationally-sponsored
research, such as solidarity, and communitarianism, to other widely accepted
values. 38 And some argue that the ethical principles underlying international
projects, for instance in population genomics research, include respect for
on

persons, but also center on the values of solidarity and equity.

These values

can be built into the national guidelines and the domestic governance systems of

Nuffield Council on Bioethics, supra note 5 at 49.
The European Group on Ethics in Science and New Technologies (EGE): "Opinion Number
17 on the Ethical Aspects of Clinical Research in Developing Countries," (2003), online:
<http://ec.europa.eu/european_group_ethics/docs/avisl7_en.pdf> (November 18, 2008) at 12.
37
Howard Wolinsky, "Bioethics for the World" (2006) 7:4 European Molecular Biology
Organization Reports 354-358.
38
See for instance, Shawn H. E. Harmon, "Solidarity: A (New) Ethic for Global Health Policy"
(2006) 14 Health Care Analysis 215.
Bartha Maria Knoppers, "Challenges to Ethics Review in Health Research," (2009) 17:2 and
3 Health Law Review Bartha Maria Knoppers and Ruth Chadwick, "Human Genetic Research:
Emerging Trends in Ethics" (2005) 6 Nature Reviews Genetics 75; Human Genome
Organization (HUGO) Ethics Committee, "Statement on Human Genomic Databases" (2003)
Eubios Journal of Asian and International Bioethics 99. "Asian Experts Want Bioethics
Incorporate Asian Values" online:
<http://www.unescobkk.org/fileadmin/user_upload/library/OPI/Documents/UNESCO_in_the_ne
ws/0808Augl2AsianExperts.pdf> (February 23, 2010).
6
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developing countries. What is called for, therefore, is careful reflection on the
issues arising, the values of the country in question, and the context.
I have described generally the main ethical principles adopted as part
of ethical frameworks.

As described above, this is not necessarily an

uncontested area, and the principles may vary between countries and
organisations. I have pointed out that national ethical guidelines and policies
may be necessary to address problematic areas. The inadequacies of the
principles adopted in the United States and elsewhere require that developing
countries make a concerted effort to develop national guidelines that address
ethics and values in addition to developing procedural guidelines. In essence,
then, in developing countries there must be continued reflection in light of their
specific contexts on what ethical principles work best to protect research
participants. These must then be addressed in national ethical guidelines. In the
Chapter Five, I consider the ethical principles which inform, and provide the
ethical framework of, the domestic governance system of Nigeria.

3.2.2 Research Ethics: Ethical Guidelines
Beyond the underlying principles and values discussed above,
international ethical guidelines have specific requirements for the ethical
conduct of research.

Moreover, the international ethical guidelines play an

important role in the domestic governance systems of many countries, operating
as soft law in the regulation and governance of health research. The governance
approach of these guidelines fits well into the new governance approach because
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these international ethical guidelines provide, to a large extent, open-ended
guidance as opposed to rules, and very little formal sanctions.40 Further, the
origin, development, and effect of these guidelines are prototypical examples of
the new governance approach.
Many countries either employ these guidelines directly, or
indirectly, drawing upon them in national regulations, policies and guidelines.
A brief overview of the international ethical guidelines is therefore necessary.
More importantly, I argue that developing countries should consider developing
national guidelines to address any areas of weakness in the international ethical
guidelines and to provide the national position on issues in the international
ethical guidelines that may be controversial.
The overview of current international ethical guidelines begins
with the Nuremberg Code. Although, the principles enunciated in the Code
were part of the judgment at the Nuremberg Trials

and were therefore not

intended to be a code of medical research ethics, the Code is of major historical

O. Lobel, "The Renew Deal: The Fall of Regulation and the Rise of Governance in
Contemporary Legal Thought" (2004) 89 Minnesota Law Review 342 at 363.
41
See Delon Human and Sev S. Fluss, 'The World Medical Association's Declaration of
Helsinki: Historical and Contemporary Perspectives" (2001) World Medical Association, online:
<http://www.wma.net/e/ethicsunit/pdf/draft_historical_contemporary_perspectives.pdf> (April
4, 2007).
42
The origins of modern international bioethics can be traced to the abuse of research
participants in concentration camps in the Second World War and the subsequent enunciation of
the Nuremberg Code, the first international declaration of ethical standards for research outlined
by the judges at the Nuremberg trials of Nazi doctors in 1947 at the Nuremberg 'Doctors Trials'
in 1947. See generally G.J. Annas and M. A. Grodin, The Nazi Doctors and the Nuremberg
Code.- Human Rights in Experimentation (New York, Oxford University Press, 1992). Evelyne
Shuster, "Fifty Years Later: The Significance of the Nuremberg Code" (1997) 337 N Engl. J.
Med 1436; Jochen Vollman, "Informed Consent in Human Experimentation before the
Nuremberg Code" (1996) 313 BMJ 1445; Pascal Arnold and Dominique Sprumont, "The
'Nuremberg Code': Rules of Public International Law" in Ulrich Trohler and Stella Reiter-Theil
(eds.), Ethics Codes in Medicine: Foundations and Achievements of Codification Since 1947
(Aldershot: Ashgate Publishing Ltd., 1998).
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importance. It codified the ethical tenets governing scientific research on human
beings43 and marked the beginning of a larger consciousness of the need to
establish standards for the ethical conduct of human research. It brought the
issue of the ethical conduct of research involving humans to wider awareness.44
The Nuremberg Code has therefore been described by some
commentators as the most important document in the history of medical research
ethics.45 It is widely cited as influential in the development of international and
national guidelines for research involving humans, including the Helsinki
Declaration.46 It was largely responsible for the inclusion of a provision on the
need for informed consent in human experimentation in the International
Covenant on Civil and Political Rights.

Some have even argued, perhaps due

to its origins as part of a court judgment, and also the moral force of its
principles, that the Nuremberg Code is part of customary international law
binding on states.48

But, as has been pointed out by some authors, the

requirements of customary international law include evidence of general state
practice and opinio juris, (that is evidence that the practice of states is informed
by a sense of legal obligation,) which may arguably not be present in regard to

Annas and Grodin, ibid.
See Sharon Perley et al., 'The Nuremberg Code: An International Overview" in Annas and
Grodin ibid at 152- 155.
45
Evelyne Shuster, "Fifty Years Later: The Significance of the Nuremberg Code" (1997) 337 N
Engl. J. Med 1436.
46
See for example, Hans-Martin Sass, "Reischrundschreiben 1931: Pre-Nuremberg Germany
Regulations Concerning New Therapy and Human Experimentation," (1983) 8 Journal of
Medicine and Philosophy 99. Perley et al, supra note 44 at 154.
47
G.A. res. 2200A (XXI), 21 U.N. GAOR Supp. (No. 16) at 52, U.N. Doc. A/6316 (1966), 999
U.N.T.S. 171, entered into force Mar. 23, 1976. See Perley et al, ibid at 153.
48
See Pascal Arnold and Dominique Sprumont, "The 'Nuremberg Code': Rules of Public
International Law" in Ulrich Trohler and Stella Reiter-Theil (eds.), Ethics Codes in Medicine:
Foundations and Achievements of Codification Since 1947 (Aldershot: Ashgate Publishing Ltd.,
1998).
44
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the application of the international ethical guidelines discussed here. But some
of their requirements may be considered part of international law. For instance,
a United States court decided in 2009 that violation of the requirement for
informed consent in human experimentation was a violation of customary
international law.49
The Nuremberg Code's major contribution to contemporary
research ethics is its requirement for informed consent, now widely accepted as
a core requirement for research involving humans.50

Its requirements are

evidently concerned with respect of persons, and beneficence/maleficience, (not
as much with justice), although this is not specifically stated.
Despite its contributions to the development of research ethics,
the Nuremberg Code has been criticised for its absolutist informed consent
requirements and failure to make any exceptions in this regard, the narrow
context in which it was drawn up which limited the scope of the code, and for
the responsibilities it places on investigators or researchers, without any
safeguards to ensure that those responsibilities are carried out.
Although it remains an influential document, the Nuremberg
Code has, however, largely been superseded in practical application by the

See Markus Schott, "Medical Research on Humans: Regulation in Switzerland, the European
Union, and the United States" (2005) 60 Food and Drug L. J. 45. See Rabi Abdullahi v. Pfizer,
Inc Docket Nos. 05-4863-cv (L), 05-6768-cv (CON), 2009 WL 214649 (2d Cir January 20,
2009).
See Jay Katz, "The Consent Principle of the Nuremberg Code: Its Significance Then and
Now" in Annas and Grodin, supra note 40 at 227-238. Pascal Arnold and Dominique Sprumont,
"The 'Nuremberg Code': Rules of Public International Law" in Ulrich Trohler and Stella ReiterTheil (eds.), Ethics Codes in Medicine: Foundations and Achievements of Codification Since
1947 (Aldershot: Ashgate Publishing Ltd., 1998).
51
Perley, supra note 42 at 157.
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Helsinki Declaration:* Since 1964 when it was adopted, the severally revised
Helsinki Declaration has provided the primary guiding principles for regulating
medical research involving human participants for the purpose of guiding
physicians and others conducting biomedical research involving humans.

It

contains a number of requirements for the ethical conduct of research, such as
provisions requiring informed consent from participants in medical research,
which reflects the value of respect of persons. 4 It has modified the principle of
informed consent as found in the Nuremberg Code in allowing for, and requiring
proxy consent where the potential research subject is incapable of consenting.55
One of the most controversial requirements in the Declaration in recent years in
the context of research involving humans in developing countries has been the
requirement relating to the standard of care to be provided to participants in
randomized clinical trials. It currently provides that the effectiveness of a new
method should be tested against those of the best current prophylactic,
diagnostic, and therapeutic methods.56 Another requirement which has raised
concerns in the developing world context is the requirement that medical
research can only ethically be justified where there is a reasonable likelihood
that the populations in which the research is conducted stand to benefit from the
results.57

" Ibid at 150.
53
See Introduction, para. A of the Helsinki Declaration.
54
Principle 22 and 24.
55
This has been criticised by several authors who allege that this has watered down the effect of
the principle. See for Jay Katz, Experimentation with Human Beings (New York, Russell Sage
Foundation, 1972)..
56
Principle 32.
57
Principle 19.
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The Helsinki Declaration is widely applied and referenced in
different national and international guidelines.58

It has not only been

instrumental to the governance and regulation of biomedical research by
providing guiding principles, it has also been influential in the establishment of
ethical review committees, a key component of research governance.59

In

establishing a requirement for independent ethical review committees in the
1975 amendment and requiring that reports of experimentation violating the
Declaration's ethical principles not be accepted for publication, it gave teeth to
substantive standards through procedural mechanisms.60 But, as Dickens notes,
it remains procedurally undeveloped.
The issues that have arisen with the Helsinki Declaration,
particularly in the context of the developing world, have been issues of
interpretation and application in the special circumstances that may arise in that
context. Charges of ethical imperialism leveled against the ethical standards set
in the Helsinki Declaration, and opposing arguments about ethical relativism,
have raised questions about the universality of the principles contained in the
Declaration and whether or not the Declaration can truly represent a broad and
international spectrum of opinion on ethical standards such as would be

See Snezana Bosnjak, "The Declaration of Helsinki- The Cornerstone of Research Ethics"
(2001) 9:3 Archive of Oncology 179.
59
World Medical Association, "WMA History: Declaration of Helsinki" online:
<http://www.wma.net/e/history/helsinki.htm> (November 24, 2008). See Principle 13.
60
James F. Childress, "Nuremberg's Legacy: Some Ethical Reflections" 43:3 Perspectives in
Biology and Medicine 347 at 351.
61
Bernard Dickens, "The Challenge of Equivalent Protection" in National Bioethics Advisory
Commission Ethical and Policy Issues in International Research: Clinical Trials in Developing
Countries Volume II- Report and Recommendations of the National Bioethics Advisory
Commission (Bethesda, Maryland: National Bioethics Advisory Commission, 2001 at A-3.
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necessary to guarantee its legitimacy. " The clarifications which have been
added to the Declaration in recent years as a result of these concerns have,
according to some commentators, threatened to weaken the authority of the
principles contained therein.

3

Further, although it has set procedural and substantive standards
for the ethical conduct of biomedical research and carries great moral and
normative authority, the scope of the Declaration is limited by the fact that it is
binding only on medical researchers. Its legal status in many countries is also
uncertain.64 However, where guidelines, such as the Helsinki Declaration, are
adopted by legislation, they become legally binding. Moreover, courts may also
consider it in examining the standard of conduct which may be expected from
researchers. For instance, the Quebec Supreme Court in Canada referred to the
Helsinki Declaration in Weiss v. Solomon, in trying to determine the standard of
care required of a researcher and a hospital through the approval of the protocol
by the hospital's ethics review committees65 The Helsinki Declaration has also
informed legislation, and has been incorporated in the regulations and guidelines
of some countries.6

See Plomer, supra note 27 at 4.
See for example, "Dismantling the Helsinki Declaration" (2003) 169:10 CMAJ Editorial.
64
See the Nuffield Council on Bioethics, supra note 5 at 64. Plomer, supra note 27 at 5.
65
Weiss v. Solomon (1989) 48 CCLT 280 (Que Sup Ct). The researcher was found liable for not
adequately disclosing the risks of involvement in a biomedical research project, in which the
research participant subsequently died.
65
See, Fluss and Human, supra note 45. See S Gevers, "Medical Research Involving Human
Subjects: Towards an International Legal Framework?" (2001) European Journal of Health Law
293 at 294, noting the indirect legal significance of the Helsinki Declaration. See Angela
Campbell & Kathleen Cranley Glass, "The Legal Status of Clinical and Ethics Policies, Codes,
and Guidelines in Medical Practice and Research" (2001) 46 McGill L.J. 473.
63

194

Despite being influential in the development of national and
international ethical guidelines and legal regulations, Plomer notes that "the
legal force of the Helsinki Declaration is severely limited by local, procedural
and substantive rules."67

An uncertain legal status in various countries

notwithstanding, the Helsinki Declaration, as previously stated, is a primary
reference document with regards to ethical standards in health research. This
uncertainty, however, indicates that a national ethics policy may be more useful
as a guidance document in developing countries, especially when supported
directly or indirectly by domestic law.
The Council for International Organisation of Medical Sciences
(CIOMS)68 in conjunction with the World Health Organisation has also adopted
guidelines for ethical research, the International Ethical Guidelines for
Biomedical Research Involving Human Subjects

(CIOMS Guidelines). They

were first drafted in 1982 to propose ways in which the principles set out in the
Helsinki Declaration could be effectively applied in developing countries.70 The
guidelines have historical foundations in the Helsinki Declaration.71 They were
most recently revised in 2002, following the intense debates about the standard

See Plomer, supra note 27 at 5.
The Council for International Organizations of Medical Sciences (CIOMS) is an international,
non-governmental, non-profit organization established jointly by WHO and United Nations
Scientific and Cultural Organization (UNESCO) in 1949. See online: <www.cioms.ch> (March
8, 2008).
69
The Council for International Organizations of Medical Sciences, International Ethical
Guidelines for Biomedical Research Involving Human Subjects adopted 1993 and revised 2002.
3
3 The "Background Note" of the 1993 edition of the CIOMS Guidelines stated as their main
purpose was: "...to indicate how the ethical principles...as set forth in the Declaration of
Helsinki, could be effectively applied, particularly in developing countries, given their
socioeconomic circumstances, laws and regulations, and executive and administrative
arrangements."
71
Ibid.
68
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of care issue (briefly discussed in Chapter One).

They are designed to be

useful to countries in defining national policies on the ethics of biomedical
research involving human subjects.

They contain ethical guidelines and

standards which apply specifically to the circumstances of developing countries.
For instance, the guidelines state that the ethical justification of biomedical
research is the prospect of discovering new ways of benefiting people's health,
and can only be ethically justifiable if it is carried out in ways that respect,
protect, are fair to, and morally acceptable within the communities in which the
research is conducted.73 It also requires that all research be submitted to an
ethics review committee which must be independent of the research team.74 It
contains specific provisions relating to establishing or improving ethical review
mechanisms, particularly within developing countries, taking into consideration
the lack of resources and other peculiar conditions.75
Other ethical guidelines deal with specific issues in research. They
draw from, and build on, the major guidelines described briefly above, primarily
the Helsinki Declaration. These include the Operational Guidelines for Ethics
Committees that Review Biomedical Research drawn up by the WHO and the
Ethical Considerations in HIV Preventive Vaccine Research drawn up by
UNAIDS, which applies to HIV vaccine research, (most of which is currently
taking place in developing countries), and the more recent UNESCO Declaration

See Trudo Lemmens et al, "CIOMS' Placebo Rule and the Promotion of Negligent Medical
Practice" (2004) 11 European Journal of Health Law 153.
"Guideline 1.
74
Guideline 2.
75
See
the
CIOMS
Guidelines
Preamble,
online:
<http://www.cioms.ch/frame_guidelines_nov_2002.htm> (March 4, 2004).
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on Bioethics and Human Rights.

They also include the International

Conference on Harmonisation's Harmonised Tripartite Guidelines for Good
Clinical Practice (GCP)77 which aims to "provide a unified standard for the
European Union, Japan and the United States to facilitate the acceptance of
clinical data by the regulatory authorities in these jurisdictions."

The GCP

establishes scientific and ethical quality for drug trials internationally.79 The
existence of the GCP reflects increasing recognition of the need for a
harmonization of rules between countries to ensure easier facilitation of ethical
review of research, as well as increased foreign market access for
pharmaceuticals.80

The GCP contains mainly regulatory and administrative

procedures, but also addresses such ethical issues as informed consent. Many
countries, including developing countries, now require compliance with the GCP
as part of their drug approval processes.81
These international ethical guidelines aim to provide general
guidance for ethical conduct of research in countries around the world. They

Tropical Disease Research and World Health Organisation, Operational Guidelines for Ethics
Committees that Review Biomedical Research, online: WHO
<http://www.who.int/tdr/publications/publications/ethics.htm> (September 19, 2008). James
La very, "The Challenge of Regulating International Research with Human Subjects" (June,
2004) Science and Development Network, online:
<http://www.scidev.net/dossiers/index.cfm?fuseaction=policybrief&policy=52&section=265&d
ossier=5> (December 19, 2008).
77
International Conference on Harmonisation of Technical Requirements for Registration of
Pharamceuticals for Human Use, ICH Harmonised Tripartite Guideline - Guideline for the Good
Clinical Practice (ICH-GCP Guideline) (Geneva: 1996).
78
Ibid.
79
Paragraph 3.
80
Adriana Petryna, "Ethical Variability: Drug Development and Globalizing Clinical Trials"
(2005) 32: 2 American Ethnologist 183 at 185.
81
See Marie Hirtle et al, "A Comparative Analysis of Research Ethics Review Mechanisms and
the ICH Good Clinical Practice Guideline" (2001) 7 European Journal of Health Law 265 at
265-266. It has been argued that the WHO is the more appropriate international organization to
set international standards related to pharmaceuticals, rather than the ICH.
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provide a new governance approach to the regulation and governance of health
research, with the attendant benefits of a voluntary model of adoption, and of
flexibility. As guidelines, they are flexible and so can address a wide variety of
issues in a broad manner. They provide soft law guidance rather than hard law
regulation. Instead of penal sanctions, there are other methods of enforcement,
including, for instance, non-publication by journals where a research project
clearly violates a requirement of the guidelines.82 As discussed in Chapter Two,
such flexibility, voluntariness, and lack of penal sanctions would appeal to
proponents of the new governance. In a complex enterprise, comprising diverse
perspectives held by different stakeholders, with often conflicting interests, the
guidelines may be argued to provide a basic standard. In my view, their moral
authority, particularly the Helsinki Declaration, provides a form of governance
and regulation which may go beyond obedience to black-letter laws.
However, views on their practical application are divergent. Their
provisions can sometimes conflict.83 Moreover, since compliance with the
guidelines is mainly voluntary, uniformity in practice is not guaranteed, which
may lead to less protections for research participants in some countries.
Further, the same flexibility which allows room for addressing issues broadly
means that there is little precision in the guidance that they give and application
in practice may sometimes prove difficult.

See for instance, Article 30 of the Helsinki Declaration which requires researchers to report
research results, including sources of funding, conflicts of interest, and institutional affiliations.
See Human and Fluss, supra note 45.
83
Lemmens et al, supra note 72. See also Howard Wolinsky "The Battle of Helsinki" (2006) 7:7
European Molecular Biology Organization Reports 670.
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As Plomer observes, the increasing globalisation of medical research
brings to light the tension between the aspiration to universality of the ethical
principles in the international guidelines and the reality of the plurality of
cultures.84 As the ethical concerns in developing countries described briefly in
Chapter One clearly show, even though the international guidelines, particularly
the Helsinki Declaration, carry great normative weight and have informed
national policies and guidelines for research involving humans around the world,
it is not always clear what is required to satisfy the rules in these guidelines. It
has also been argued that they provide insufficient consideration of issues of
global inequality, social justice, and inclusion of all groups in the benefits and
burdens of research,85 thus limiting their legitimacy. In this respect, Lavery
observes that:
The process by which international guidelines
are developed is critical to their legitimacy and
authority, particularly since the main
guidelines function under a voluntary adoption
model. During recent revisions of the
Declaration of Helsinki and the CIOMS
Guidelines, the issue of whose perspectives
were taken into account emerged as a critical
challenge. In particular, questions were raised
over whether there was sufficient developingcountry representation during the drafting
process, and also whether there was sufficient
transparency with respect to the influence of
powerful research interests to ensure an
appropriate balance between protecting
research participants and facilitating important
scientific research.86
84

Plomer, supra note 22 at 13.
See Lisa Eckenweiler et al, "The Declaration of Helsinki through a Feminist Lens," (2008) 1:1
International Journal of Feminist Approaches to Bioethics 162.
86
Lavery, supra note 81 at 204. See Jonathan Kimmel, Charles Weijer, Eric Meslin, "Helsinki
Discords: FDA, Ethics, and International Drug Trials" (2009) 373: 9657 Lancet 13.
85
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Also, Lemmens and others point out the contradictions in the guidelines (with
specific respect to the use of placebo in biomedical research) and note that it
may affect the weight that might be accorded them by domestic courts.
According to them:
These contradictions are sufficient to warn
researchers and research ethics committees
against a mere reliance on these documents as
setting binding research standards. Although
such incompatibility could be viewed as
undermining their moral authority and
jeopardizing their usefulness, we rather
suggest that it indicates the limitations of these
guidelines. They are the reflection of an ongoing ethical debate and political struggle
within their respective organizations. The
contradictions between the different rules and
the process by which they were established
indicate why these ethics guidelines cannot be
considered as creating binding norms. They
also make it hard to claim that national courts
could look to these documents for guidance to
determine what constitutes appropriate and
widely accepted research practice.87
In addition, as noted in Chapter One, the United States, in 2008, decided to cease
applying the Helsinki Declaration in foreign clinical trials if used to support
applications for registration of products in the United States, relying instead on
the ICH-GCP. This effectively permits the greater use of placebos in foreign
oo

clinical trials.

The decision raises questions about general applicability of the

87

Lemmens, supra note 72 at 156.
"FDA Scraps Helsinki Declaration on Protecting Human Subjects," online:
<http://www.cspinet.Org/integrity/watch/200805051.html#2> (December 19, 2008). See also,
Jonathan Kimmel, Charles Weijer, Eric Meslin, "Helsinki Discords: FDA, Ethics, and
International Drug Trials" (2009) 373: 9657 Lancet 13. Michael E Goodyear, Trudo Lemmens,
Dominique Sprumont and Godfrey Tangwa, "Does the FDA have the Authority to Trump the
Declaration of Helsinki?" (2009) 338 BMJ 1559.
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international ethical guidelines, but even more so, about what developing
countries should do to take ownership of the protection of research participants
in those countries.
One way to address the complex concerns about ethical principles,
and the contents and legitimacy of the international guidelines, may be an
engagement between all interested agents and parties in continuous dialogue,
on

negotiation, and reflection in an open, transparent way.

Moreover, collective

consideration and acceptance of standards by countries generally will prevent
accusations of hegemony which may arise where one country imposes its own
standards and procedures, even where such standards and procedures are
effective in protecting the rights of research participants.90 The recent debates
about the ethics of externally-sponsored research in developing countries and
subsequent attempts at revision and clarification of both the CIOMS and
Helsinki Declaration, if not entirely successful, indicate a willingness to consider
different perspectives.

In this respect, it would be helpful to include more

representatives and perspectives from developing countries in the process of
creating and amending these guidelines, as well as in developing research
protocols to be employed in developing countries.
But going beyond these suggestions, national ethics policies or
guidelines, in my view, are especially necessary to address areas that have
proved contentious in the international guidelines.
89

National guidelines and

Konrad, supra note 22 at 13. See also, Michael D E Goodyear, Karmela Krleza-Jeric, Trudo
Lemmens, "The Declaration of Helsinki: Mosaic Tablet, Dynamic Document, or Dinosaur?"
(2007) 335 BMJ 625 at 626.
90
See Godfrey Tangwa, "Moral Agency, Moral Worth and the Question of Double Standards in
Medical Research in Developing Countries," (2001) 1:2 Developing World Bioethics 156 at 67.
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policies can also ensure that any gaps in the international guidelines are
specifically addressed in a national context. It is thus necessary for developing
countries to establish national policies and guidelines which address in more
depth the specific contexts and ethical issues which arise in these countries.
This does not suggest that the international ethical guidelines have no further
use.

Their moral authority, (particularly the Helsinki Declaration) remains

considerable. But, in view of the limitations discussed above, and the potential
benefits of domestic guidance, national guidelines are essential.
Some developing countries are already taking this route. Developing
countries which have taken this step include South Africa,91 Kenya, Uganda,92
Nepal,93 and India.94 These countries have adopted national guidelines that are
"tailored to their national contexts, with specific provisions addressing the
vulnerabilities that may have enabled past abuses."95 For instance, the South
African national ethics guidelines adopt a broad meaning of the term "standard
of care" and state exceptions in which the use of placebos may be allowed in
arguably more specific terms than the Helsinki Declaration.

In Kenya, the

guidelines make special provisions concerning research with underdeveloped
91

National Health Research Ethics Council, Ethics in Health Research: Principles, Structures
and Processes Guidelines. (Pretoria: Department of Health, 2004)
92
Uganda, Guidelines for the Conduct of Health Research Involving Human Subjects in Uganda
(National Consensus Conference 1997).
9
Nepal Health Research Council, National Ethical Guidelines for Health Research in Nepal
(2001)
4
Indian Council of Medical Research (ICMR), "Ethical Guidelines for Biomedical Research on
Human Subjects" (2000). See also, Nandini Kumar et al, "The Indian Experience" (2008) 6:4
Journal of Academic Ethics.
95
Adele Langlois, "The UNESCO Universal Declaration on Bioethics and Human Rights:
Perspectives from Kenya and South Africa" (2008) 16:1 Health Care Analysis 39 at 43-44.
National Health Research Ethics Council, Ethics in Health Research: Principles, Structures
and Processes Guidelines. (Pretoria: Department of Health, 2004)online:
<http://www.doh.gov.za/docs/factsheets/guidelines/ethnics/> (December 15, 2008). See
Paragraphs 2.14 and 2.15.
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communities, prisoners, married women in rural areas and pregnant or lactating
women.97

Other countries like Ghana,98 and Pakistan,99 however, still do not

have national guidelines.
Apart from addressing contentious issues and gaps, national
guidelines and policies can also provide specific requirements regarding the
structure and organisation of the governance system. They may also set out the
actors in the governance system, their responsibilities and a system of
accountability. The United Kingdom's Research Governance Framework for
Health and Social Care, is an example. This framework applies to research
conducted under the National Health Service (NHS),100 and specifies the
responsibilities of research participants, research sponsors and ethics review
committees. In like manner, Canada's Tri-Council Policy Statement specifies,
among other things, the operation of ethics review committees, including the
conditions under which an expedited review may take place, the requirement for
institutions to establish a standing committee to hear appeals when a researcher
is dissatisfied with an ethics review committee's decision, matters that are not
addressed in the Helsinki Declaration, for instance. Both ethical principles and
procedural or structural matters may be contained in the same guidance
National Council for Science and Technology, Guidelines for Ethical Conduct of Biomedical
Research Involving Human Subjects in Kenya (NCST No. 45, 2004). See paragraph 9-13.
98
See Paulina Tindana and Okyere Boateng, "The Ghana Experience" (2008) 6: 4 Journal of
Academic Ethics, noting that "The major challenge in Ghana is the lack of national ethics
guidelines governing the conduct of research with human subjects." See also, Harvard School of
Public Health, "Global Research Ethics Map: Ghana" online:
<https://webapps.sph.harvard.edu/live/gremap/view.cfm?country=Ghana> (June 11, 2010).
99
Harvard School of Public Health, "Global Research Ethics Map: Pakistan" online: <
https://webapps.sph.harvard.edu/live/gremap/view.cfm> (June 11, 2010).
100
Department of Health, Research Governance Framework for Health and Social Care (Second
Edition) (United Kingdom, 2005), online:
<http://www.dh.gov.Uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalas
set/dh_4122427.pdf> (June 19, 2009), Section 1.2.
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document,(such as is the case with the Tri-Council Policy Statement and the
Australian the National Statement on Ethical Conduct in Human Research
2007),101 or in separate documents. Given the gaps that exist in the international
guidelines and the procedural matters that need to be attended to, there is need to
provide for both substantive ethical matters and organizational or structural
issues and procedural issues and processes, in domestic policy documents.
Finally, national policies can provide a further layer of protection for
research participants, beyond any protections offered by the international ethical
guidelines. This may be by clarifying the application of certain ethical principles
in the local context and by specifying appropriate procedural mechanisms.
Developing countries therefore need to consider creating national guidance,
where not already in place, to allow for clear and unambiguous application.102
In a hybrid framework of governance as proposed in Chapter Two,
such national policy guidance will retain the positive attributes of a new
governance approach (including flexibility and ease of amendment) while
operating within a domestic context. Such flexibility is important because of
changes that may need to be made in line with international developments,
ongoing evolution in research ethics, and changes in domestic circumstances.
With wide consultations between stakeholders in the research enterprise, these
guidelines could also promote legitimacy. As I argued in Chapter Two, allowing
for guidelines (soft law) in areas where specificity could be elusive, potentially

NHMRC, National Statement on Ethical Conduct in Human Research 2007. The UK's
Research Governance Framework for Health and Social Care focus mainly on processes and
procedural matters.
102
Nuffield Council of Bioethics, note 10 at 66.
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offers not only more legitimacy but a greater level of accountability than would
otherwise exist. However, national guidelines, like international guidelines
typically lack enforcement mechanisms, relying instead on moral suasion in
developing countries.

(Developed countries typically rely on withdrawal of

funding). Thus, as I argue in the next chapter, hard law is also necessary, given
the need to protect research participants in developing countries. Certain basic
requirements, in my view, need to be enforceable in law.

Still, some

controversial ethical issues, like the standard of care issue, may best be dealt
with in national guidelines rather than legislation because of the evolving
understanding of such issues. In the following chapters, I consider in greater
detail the national guidelines that have recently been adopted in Nigeria, and its
impact on research governance.

3.3 Institutional Framework
Beyond the ethical standards detailed in the ethics guidelines
described above, an institutional framework is required, and has developed in
countries around the world, to provide a system of governance. Different
institutions act as the active mechanisms which implement the ethical
framework. Principal among these institutions is the ethics review committee.
Other institutions such as the national drug regulatory authorities and
professional associations also play an active role in the implementation of
ethical standards and principles.

205

Below I describe briefly the institutions that govern health research
involving humans in countries around the world. The account given of these
institutions is by necessity condensed to provide only the most essential details.
Also, while this subsection addresses some of the issues that arise in the
deployment of these institutions in research governance, the analysis undertaken
here is necessarily broad. However, the identification of systemic issues which
affect the functioning and effectiveness of these institutions is necessary for an
understanding of issues that may arise in developing countries like Nigeria. An
in-depth analysis is conducted in the context of Nigeria in Chapters Five and
Six.

3.3.1 Ethics Review Committees
Ethics review is a fundamental part of the research governance
systems of many countries and is now widely recognised as a necessary
safeguard and a formal mechanism for the protection of research participants. A
detailed history of the origins of ethics review is outside the scope of this thesis
and has been engaged in by others.103 McNeill, for instance, traces the history of
ethics review committees in several countries,

and it is unsurprising that,

particularly in the United States where they first began as a system of peer
review,105 these committees were established in response to several unethical

103

Paul M. McNeill, The Ethics and Politics of Human Experimentation (Cambridge: Cambridge
University Press, 1993) at 53-84. See also, Ruth R. Faden and Tom L. Beauchamp, A History of
Informed Consent (New York and Oxford: Oxford University Press, 1986).
104
The United States, Britain, Ireland, Australia, New Zealand and Canada.
105
See Charles McCarthy, "The Institutional Review Board: Its Origins, Purpose, Function and
Future" in David N. Weisstub, Research on Human Subjects: Ethics, Law and Social Policy
(Oxford: Elsevier Science Ltd., 1998) at 307.
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experiments involving humans.

Such experiments include the 1963 Jewish

Chronic Disease Hospital incident, where chronically ill patients were injected
with cancer cells without their knowledge or consent.10 Below, I reflect briefly
on the ethics review process and its significance in research governance. From a
systems perspective, I also describe briefly some of the issues that affect its
effectiveness as a crucial part of research governance, including composition,
structure and financial support, with illustrations from different countries. I then
consider, briefly, ethics review in developing countries.
The ethics review process is one of the principal means of ensuring
that any proposed research is ethical.107 It requires that investigators or
researchers submit the proposed research project or protocol to a committee,
which inquires into its ethical acceptability. Thus it is different from, (though it
may include) peer review of the scientific aspects of research.108 The ethics
review committee is charged with assessing the risks and benefits of the
proposed research, ensuring that the potential benefits of the proposed research
outweigh any foreseeable risks attached thereto, and in this process weighing the
interests of the research participants, the society, and the investigators.

Ethics

review committees review proposed research to make sure that it complies with

See McNeill, for a fuller history of origins of the ethics review system. See McNeill, supra
note 103 at 57.
107
Along with informed consent, ethics review is considered by many to be the other major
safeguard by which research participants are protected in health research. See for instance, Ruth
Macklin, Double Standards in Medical Research in Developing Countries (Cambridge:
Cambridge University Press, 2004) (hereinafter Macklin (2004). See also McNeill, supra note
103 at 1.
108
Richard Ashcroft, "The Ethics and Governance of Medical Research: What Does Regulation
Have to Do with Morality?" (2003) 1:1 New Review of Bioethics 41 at 48.
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ethical standards as articulated in international and domestic guidelines. The
functions of ethics review committees thus include,
identifying and weighing up the risks and
potential benefits of research; evaluating the
process and materials (printed documents and
other tools) that will be used for seeking
participants' informed consent; assessing the
recruitment process and any incentives that
will be given to participants; evaluating risks
to participants' confidentiality (and the related
risk of discrimination) and the adequacy of
confidentiality protections ; and examining
any other issues that may affect the ethical
acceptability of the research. In international
research, the committee represents the interests
of the local population.
In carrying out these functions, they provide a means of accountability, and
boost public trust and confidence in the research enterprise. In this way, these
committees also play an important role in facilitating research.
Ethics review committees typically have authority to decide whether
research proposals are reasonable and ethically acceptable and can proceed, or
whether they are not and should therefore not proceed, or whether they can
proceed with some modification, or if research has already commenced, whether
it is to be terminated.

The extensive powers of ethics review committees have

attracted criticisms from many researchers and commentators, including
complaints that they sometimes prevent and delay beneficial research,
unnecessarily limit academic and research freedom, and that the process is

WHO, Research Ethics Committees: Basic Concepts for Capacity-building (Geneva: WHO,
2009) at 14.
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expensive.

However, even though negotiating the balance between promoting

socially beneficial research and protecting research participants is not always
easy, ethics review is, and is likely to continue being, a critical part of research
governance because the ethics review committee is the component of research
governance which directly oversees research protocols and can most directly
regulate researchers' conduct.
Many of the international ethical guidelines require that health
research involving humans must pass through the ethics review process. The
Helsinki Declaration, for instance, requires that "The research protocol must be
submitted for consideration, comment, guidance and approval to a research
ethics committee before the study begins."111 The committees that carry out such
119

review (referred to here as ethics review committees

) are now regarded as key

in most countries for the purpose of providing independent ethics assessment of
research protocols and protecting research participants. Some countries, like
Denmark11 and South Africa,114 have even taken the additional step of making
M. Schuman, "Clinical Trials: The Balance between Protecting Participants and Promoting
Drug and Product Development" (2009) 180: 6 CMAJ 603; D S Wald, "Bureaucracy of Ethics
Applications" (2004) 329 BMJ 282-4 ; Alysun M Jones, Bryony Bamford, "The Other Face of
Research Governance" (2004) 329: 7460 BMJ 280 (September 16, 2009); C.K. Gunsalus et al.,
"Mission Creep in the IRB World", (2006) 312 Science 1441; Norman Fost and Robert J.
Levine, "The Dysregulation of Human Subjects Research" (2007) 298 JAMA: Journal of the
American Medical Association 2196; Jon Nicholls, "The Ethics of Research Ethics
Committees" (2000) 320: 7243 BMJ 1217.
111
Article 15. Helsinki Declaration 2008.
112
Different countries have different nomenclature: Institutional Review Boards in the United
States, Research Ethics Boards (REB) in Canada, Health Research Ethics Committees (HREC)
in Nigeria and South Africa. But all have basically the same functions.
See Section 1 and Section 8 of the Act on a Biomedical Research Ethics Committee System
and the Processing of Biomedical Research Projects. •
Section 73 of the National Health Act. Sweden also legally mandates ethics review of
research involving Humans. See The Swedish Ethical Review Act,( Lag (2003:460) om
etikprovning av forskning som avser manniskor) issued 5 June, 2003 (SFS no 2003:460),
implemented in January 2004 and amended in 2008, online:
<http://www.riksdagen.se/webbnav/index.aspx?nid=391 l&bet=2003:460> (September 11,
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it a legal requirement that all health research, with certain specified exceptions,
pass through ethics review. Other countries, including the United States, Canada,
and the United Kingdom, legally require ethics review specifically for clinical
trials of drugs. Research governance, for the most part then, is built around the
committees which carry out ethics review, ensuring amongst other things that
research is conducted in an ethical manner and that the rights, safety and welfare
of research participants are protected. Even systems which lack a formal legal
underpinning typically consist of institutional ethics review committees as the
centre-piece of such systems.
The requirements of most research sponsors, and international
journals, particularly journals which publish biomedical research, that ethics
review approval must be obtained for funding or publication,

15

further cements

the centrality of ethics review in research governance. These mechanisms funding requirements and publications - are soft law mechanisms favoured in
new governance thinking, and are thus part of the hybrid framework proposed in
this thesis for effective governance of health research involving humans.
The decisions taken during review by these committees, whether to
approve, disapprove a proposed research protocol, or terminate an ongoing
project, are influenced by international, national, and institutional policy and
guidelines, by law, institutional culture and also, significantly, by the views,

2009).
The Swedish ethical review act was revised in 2008 (SFS 2008:192).
115
International Journal of Medical Journal Editors, "Uniform Requirements for Manuscripts
Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of
Research: Protection of Human Subjects and Animals in Research" online:
<http://www.icmje.org/ethical_6protection.html> (September 30, 2009).
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values and decision-making processes of individual members.116 Further, as
Schuppli and Fraser point out, "Aspects of committee structure and process—
committee composition, deliberation, process, group dynamics and training—
can also affect decisions." Thus, from a systemic perspective, the composition
or membership of committees, and the structure and organisation of ethics
review committees, and the financial support that the committees receive to
undertake their work as a fundamental part of the research governance system,
are some of the factors which can affect their functioning.

I consider these

briefly below.
The composition of ethics review committees is one of the factors
that have an effect on their functioning. As McNeill accurately observes, "It is
very important therefore that the body evaluating the ethics of a research study is
appropriately constituted and competent to decide the issue. Otherwise, ethics
committees could do the opposite of what they are intended to do and, in effect,
act as sponsors of unethical experimentation."117 The adequacy of ethics review
is, for the most part, dependent on the expertise of the members.118

The

adequacy of review depends, in significant ways, also on the discretionary
judgments and personal values of members of the committee,

making the

composition of the ethics review committee a very crucial issue in research

116

C.A. Schuppli and D. Fraser, "Factors Influencing the Effectiveness of Research Ethics
Committees" (2007) 33 Journal Medical Ethics 294.
117
McNeill, supra note 103 at 6.
118
See Jocelyn Downie and Fiona McDonald, "An International Comparative Review of
Research Ethics Review Bodies" (2003) 3 Clinical Researcher 14 at 21.
119
Carl H Coleman and Marie-Charlotte Bouesseau,"How Do We Know That Research Ethics
Committees Are Really Working? The Neglected Role of Outcomes Assessment in Research
Ethics Review" (2008) 9:6 BMC Medical Ethics; C H Coleman, "Rationalizing Risk Assessment
in Human Subject Research (2004) 46:lArizona Law Review 1.
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governance.

There is therefore need to have a broad membership.

Such

membership should include adequate expertise necessary to appropriately
evaluate the soundness and scientific validity of research protocol, capability to
examine research projects for ethical soundness, and ability to take into account
the values of the community in which the research is to take place.
The composition of committees varies in different countries, ranging
from at least five members in countries like Canada,120 the United States,121
South Africa122 and Nigeria,123 to at least seven members in Denmark124 and the
United Kingdom,125 and eight members in Australia.126 There is general
recognition that there should be members that are familiar with the research
methods that are being proposed.127 It is also now recognised that, in order to
achieve a diversity of values and perspectives, and to counter any predisposition
by institutional members towards research or institutional interests, the
committee should be comprised not only of members drawn from the institution
(in an institutional ethics committee), but also that there should be lay members.
These members represent the community in which the research is to take place
and also research participants.128 In this regard, they are necessary to advance

uu

Section 1, Article B- 1.3- Membership of REBs of the TCPS.
Department of Health and Human Services. Protection of Human subjects. 1991; Title 45
CFR& 46.45 CFR 46.107.
South Africa - Section 4.1 of Ethics in Health Research: Principles, Structures and Processes
(Composition).
123
NHREC, National Code for Health Research Ethics (2006), Section D.
124
Section 3.
Section 6 of the Department of Health, Governance Arrangements for NHS Research Ethics
Committees London, UK: The Stationery Office, 2001.
126
Chapter 5.1. 29 of the National Statement.
127
See for instance, Canada - Section 1, Article B- 1.3 (TCPS)- Membership of REBs.
128
See for instance, South Africa - Section 4.1 of Ethics in Health Research: Principles,
Structures and Processes (Composition). Section 6 of the United Kingdom Governance
Arrangements for NHS Research Ethics Committees, which requires that at least a third of the
121
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dialogue with, and accountability to, local communities.

In the United

Kingdom, at least a third of the membership is required to be "lay" members
who are independent of the National Health Service (NHS), and whose primary
personal or professional interest is not in a research area.130 In Denmark, half of
i l l

the regional committee is required to be drawn from lay members.

These may

include non-medical clinical staff who have not practiced as such for at least five
years, and at least half of the lay members must be persons who are not and have
never been involved in carrying out research on humans.132

In a hybrid

governance framework, lay membership, that is, membership drawn from
outside the institution, and from the community, enhances accountability and
responsiveness.

Inclusion of such members in ethics review is therefore

beneficial.
Questions continue to be raised in the literature, however, regarding
whether ethics review members should be part-time volunteers or dedicated

membership should be "lay" members who are independent of the NHS, and whose primary
personal or professional interest is not in a research area. These may include non-medical
clinical staff who have not practiced as such for at least five years and at least half of the lay
members must be persons who are not and have never been involved in carrying out research on
humans.
129
TCPS - Article 1.3 (see discussion).
1
Section 6 of the Governance Arrangements for NHS Research Ethics Committees
131
McNeill, supra note 103 at 102. Holm notes that, in practice, committees have between seven
and fifteen members, each with a majority of lay members. The professional members are
appointed by the Danish Health Sciences Research Council, and the lay members are appointed
by the County Councils. He observes further that although the lay members are politically
appointed, they do not represent their respective political parties in the REC and that the lay
members are not usually lawyers, clergy or philosophers, but "true" lay people. Soren Holm,
'The Danish Research Ethics Committee System—Overview and Critical Assessment in NBAC,
Ethical and Policy Issues in Research Involving Human Participants Commissioned Papers and
Staff Analysis (Washington: NBAC, 2001) at F-10.
1
Section 6 of the Governance Arrangements for NHS Research Ethics Committees.
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professionals,

the need for ethicists on ethics review committees,

the need
1 T5

for representation of research participants on ethics review committees,

and

what lay membership really means, especially given that what is considered lay
membership varies in each jurisdiction. Is a lay member merely one with no
scientific expertise, or one with no connection to the institution?
Questions also arise regarding the role that lay persons can and
should play in the ethics review process, and whether or not lay persons can
effectively contribute to the process, especially in the absence of a certain level
of education and training in matters of research and research ethics.

Some

commentators have suggested that lay persons on committees have difficulty in
participating fully in the review process.

Others have observed that the roles

of lay members need to be more clearly defined as they lack the authority or
knowledge to challenge the interpretation of research by other knowledgeable

"Choosing a Research Ethics Committee System Amongst the Existing Models? Critical
Decision of a Middle Income Country(Chile)"
<http://www.gfbronline.com/PDFs/Eighth_Casestudyl.pdf> (September 14, 2009).
134
Nathan Emmerich, "On the Ethics Committee: The Expert Member, the Lay Member and the
Absentee Ethicist" (2009) 5:1 Research Ethics Review 9; Downie and McDonald, supra note
118.
135
Hadskis, Michael, "Giving Voice to Research Participants: Should IRBs Hear From Research
Participant Representatives?" (2007) 14: 3Accountability in Research 155; McNeill, supra note
103 at 7.
' Denise Avard, et al, "Research Ethics Boards and Challenges for Public Participation"
(2009)17: 2-3 Health Law Review 66 at 67, describing the vagueness of the definition of lay
membership in the Canadian TCPS. What is considered lay membership varies in each
jurisdiction. In the United Kingdom, for instance, it is the persons who are not related to the
NHS as employees or in a non-executive role, but they can be non-medical clinical staff who
have not practiced their profession for five years. See Section 6 of the Governance
Arrangements for NHS Research Ethics Committees. In South Africa, two lay persons are
required. Lay persons are defined as who have no affiliation to the institution, are not currently
involved in medical, scientific or legal work and are preferably from the community in which the
research is to take place." Section 4.1 of the Ethics in Health Research: Principles, Structures
and Processes Guidelines.
137
Avard, ibid;
138
McNeill, supra note 103 at 185-187.
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,and scientific members.139

Lay persons are nevertheless needed to bring a

balanced perspective to such reviews and reduce conflicts of interest. 140 Apart
from lay participation, some jurisdictions require an ethics expert,

l

others

require a lawyer,142 while others underscore the desirability of gender balance in
the composition of such committees.143 Other related issues include provision of
education and training for ethics review committee members in the different
disciplines, methodologies, approaches, and ethical issues implicated in health
research. There are more detailed discussions of these issues in other
literature.144

A fuller description and discussion in the context of Nigeria

follows in Chapters Five and Six.

Sarah Dyer, "Rationalising Public Participation in the Health Service: The Case of Research
Ethics Committees" (2004) 10 Health and Place 339. See also, P E Bauer, "A Few Simple
Truths about Your Community IRB Members" (2001) 23 IRB 7.
140
This need to reduce potential conflict of interest has been noted in the United States where the
current requirement is that there be one non-institutional and one nonscientific member on a
board, a requirement that can be met with the selection of one individual who meets both
requirements. 45 CFR 46.107. The Office of the Inspector General has therefore recommended
increased representation on IRBs of nonscientific and non-institutional members. Office of the
Inspector General, Institutional Review Boards: A Time for Reform (Washington, D.C.:
Department of Health and Human Services, 1998) at 17-18. In the Danish system, Holm notes
that the lay majority works well. However, he adds that there may be little access to the required
expertise in research methodology and may therefore have problems in evaluating certain kinds
of projects. Holm, supra note 131. This lack of relevant expertise has also been noted in the
United Kingdom. See Stauch et al, supra note 31 at 553. For this reason, I would not advocate a
lay majority, especially in a developing country. However, there should be a good number of lay
persons, by which I mean, persons with non-medical or scientific background or background in
the kind of research being considered to bring a balanced perspective to ethics review.
141
Canada - Section 1, Article B- 1.3- Membership of REBs.
South Africa - Section 4.1 of Ethics in Health Research: Principles, Structures and Processes
(Composition). See also Canada, ibid. The lawyer, however, is required only in the cases of
biomedical research. The second edition, which is still under consultation, however, makes no
distinction between biomedical and other types of research. Both editions state that the lawyer is
not to give legal advice or serve as counsel to the committee but to address the legal issues that
arise in connection with the proposed research.
143
See the United States: 45 CFR 46.107;
144
See generally McNeill, supra note 103, Hadskis, Michael, "Giving Voice to Research
Participants: Should IRBs Hear From Research Participant Representatives?" (2007) 14:
3Accountability in Research 155; Raymond de Vries and Carl Forsberg, "Who Decides? A Look
at Ethics Committee Membership" (2002) 14:3 HEC Forum 252; Henry B. Dinsdale, "The
Composition
of
Research
Ethics
Boards"
online:
<http://www.chrcrm.org/main/modules/pageworks/index.php?page=015&id=231>
(September
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The structure of the ethics review system is another factor that
impinges on the effectiveness of the ethics review process because it has
implications for the integrity and independence of the system, and also for its
efficiency. Two main types of structures of ethics review systems - the
institutional system of ethics review or the regional system of ethics review
exist. These may operate in a centralised or decentralised system.

The

institutional system of ethics review involves ethics review committees in
different institutions in which health research takes place. The US model of
Institutional Review Boards (IRBs) represents the pioneering approach of
"local" review of research, that is, conducting review within the institutions in
which the research will take place.145 The strength of the institutional model
lies, then, in the ease of conducting local review, taking into consideration the
local context, values, and issues, including cultural issues.
Regulation, as provided by institutional ethics review committees is,
effectively, self-regulation.14

In this respect, institutional committees are

typically composed of a majority of members who are drawn from the

9, 2009); Sohini Sengupta & Bernard Lo, "The Roles and Experiences of Non-affiliated and
Non-scientist Members of Institutional Review Board" (2003) 14 Academic Medicine 212;
Emily E. Anderson, "A Qualitative Study of Nonaffiliated, Non-scientist Institutional Review
Board Members" (2006) 13 Accountability in Research 135; Joan P. Porter, "How Unaffiliated
/Non-scientist Members of Institutional Review Boards See Their Roles" (1987) 9:6 IRB: Ethics
& Human Research 1; C.A. Schuppli & D. Fraser, "Factors Influencing the Effectiveness of
Research Ethics Committees" (2007) 33 Journal Medical Ethics 294; P E Bauer, "A Few Simple
Truths about Your Community IRB Members" (2001) 23 IRB 7; Denise Avard, Michele
Stanton- Jean, Roberta L. Woodgate,. Daryl Pullman & Raphael Saginur "Research Ethics
Boards and Challenges for Public Participation" (2009) 17: 2-3 Health Law Review 66.
145
"Choosing a Research Ethics Committee System amongst the Existing Models? Critical Decision
of a Middle Income Country(Chile)" <http://www.gfbronline.com/PDFs/Eighth_Casestudyl.pdf>
(September 14, 2009).
146
For the advantages of self-regulation, see generally, Ian Ayres and John Braithwaite,
Responsive Regulation: Transcending the Deregulation Debate (New York: Oxford University
Press, 1992) at 103.
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institutions. Institutional ethics review committees, with many members from
the institution, typically have members with expertise in different fields and in
methodologies that may be used in health research. And, as mentioned above,
they can conduct review taking into account the local context, values and issues,
including cultural issues. Also, institutional ethics review committees can
closely monitor ongoing studies.147 Further, an institutional system makes it
easier to locate the responsibility for ethical review close to where the research
is conducted.
However, many committees are funded by the institutions within
which they operate. The institutions themselves frequently depend on research
funding from external sources. Inherent conflict of interest issues thus arise
from a structure where the institution which seeks to attract research is in some
ways the same institution which will review the research, albeit through an
ostensibly independent ethics committee.149

Members of ethics review

committees, even in the absence of financial conflict of interest, may have
secondary interests, such as approving research in their own area of specialty or
disapproving research which may draw research participants from their own
research.150

Ayres and Braithwaite, ibid at 104, noting that self-regulation can achieve greater inspectorial
depth.
148
M H Walsh, J J McNeil JJ, K J Breen, "Improving the Governance of Health Research"
(2005) 182MedJAust468.
Ezekiel J Emmanuel et al, "Oversight of Human Participants Research: Identifying Problems
to Evaluate Reform Proposals" (2004) 141: 1 Annals of Internal Medicine 282 at 283. In these
countries, ethics review committees can also be independent from the institutions and provide
ethics review in exchange for payment.
150
Eric Campbell, "Concerns about IRBs in the Enterprise of Clinical Research" (2004) 4 Lancet
Oncology 326. Downie describes these situations comprehensively and succinctly in the Canadian
context. See
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Thus, the possibility of regulatory capture increases significantly
under the institutional system of ethics review.

In this respect, the direct

regulators of research, that is the ethics review committees, may be directly or
indirectly interested in attracting research funds to the institution. Such interest
creates a greater possibility of capture by the researchers and research sponsors
whom they are supposed to regulate. The inherent conflicts of interest issues
arising from self-regulation in the context of institutional systems of ethics
review, thus calls into question the independence of committees.

Actual,

potential or perceived conflict of interest permits regulatory capture. This not
only endangers the safety of participants, it has the potential of marring the
promotion of health research by eroding public confidence and trust in the
research process.
A regional ethics review committee, on the other hand, is a model of
committee review that is not based solely at the local institutional level, such as
in a hospital or in a university. These broader regional systems are typically
responsible for "a distinct region, a distinct group of research subjects, a distinct
disease, or projects related to a distinct funding agency."151 A country may,
therefore,

have institutional

committees, but also specialised regional
1 CO

committees that review specialised research.

Other countries, like

1 CO

Denmark,

have regional systems which are typically responsible for a distinct

Jocelyn Downie, "Contemporary Health Research: A Cautionary Tale" (2003) Health
Law Journal (Special Edition) at 12.
151
Alison Shea, "Regional Research Ethics Boards: Canadian and International Models" (2004),
online: via < www.nshrf.ca> (June 23, 2007) at 3.
152
For example, Canada. Shea, ibid.
1 ^

' And other Scandinavian countries, like Sweden and Norway.
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region and all the research conducted in that region are reviewed by one regional
committee.
The regional model, as employed in countries like Denmark,154
would appear to be free from the criticisms of the institutional model because
members are drawn region-wide and there is less likelihood of the conflict of
interest issues arising in the context of the institutional model. As has been
argued in detail elsewhere the "local context" is not lost by regionalization.
As well, there may be more balance between local insight and the necessary
distance from personal prejudice. Riis has therefore noted that, "It is more
appropriate - and a clear advantage for countries having the chance to start from
scratch - to create a regional system instead of an institutional one from the very
beginning."

156

Where appropriately set up, a regional system may be more

manageable and efficient and ensure more uniformity of standards and thus
more protection of research participants. This is because there will be less ethics
review committees and less chance of duplication and inconsistency in reviews.
Both institutional and the regional committees may operate in a
centralised or decentralised atmosphere, or in a dual system that combines
both.157 A centralised system,158 consisting frequently of a national committee,

The regional model is also employed in other Scandinavian countries: Sweden and Norway.
See European Network of Research Ethics Committees (EUREC), "National Information:
Sweden" online: <http://www.eurecnet.org/information/sweden.html> (September 11, 2009).
Downie, supra note 150 at 93-94.
156
Povl Riis, "Ethical Review of Biomedical Research in Europe: Suggestions for Best National
Practices" (1998), online: < http://www.coe.int/T/E/Legal_Affairs/Legal_cooperation/Bioethics/Activities/Biomedical_research/CDBI-INF(1998)6E-ManualDebra.pdf>
(June 22, 2007) at 4.
157
Maureen H. Fitzgerald and Paul A. Phillips, "Centralized and Non-Centralized Ethics
Review: A Five Nation Study" (2006)13 Accountability in Research 47.
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is recommended by some commentators to address issues which institutional or
regional committees may be inadequate to deal with. These include the increase
in applications for review and multi-site or multi-jurisdictional research and the
need to ensure faster, more efficient, consistent, ethics review processes, the
need to ensure co-ordination between different institutional or regional ethics
review committees, and standardisation of the ethics review process.159 The
functions of auditing ethics review committees and providing guidelines and
standards, hearing appeals from the local committees which national ethics
review committees typically have, are helpful in creating a uniform system of
research governance with clear reporting relationships and accountability. Such
national committee would essentially provide what Ayres and Braithwaite call
"enforced self-regulation"160 or regulation of self-regulation. In other words,
institutional or regional committees may develop their own policies and function
independently.

A national or central committee would serve as an "enforcer,"

monitoring institutional or regional committees to ensure that they function as

Fitzgerald and Philips describe a centralised system: "In the centralized system all
applications, other than possibly undergraduate research, would go to a centralized committee or
an overarching national body, and the review process would be conducted by committees
associated with and administered by this body. In this system, the committee that reviews the
application may or may not be located within the geographical region where the researcher is
located. " See Fitzgerald and Phillips, ibid at 63.
159
See Walsh MH, McNeil JJ, Breen KJ, "Improving the Governance of Health Research"
(2005) 182 MJA 468 at 470; Z J Penn and P J Steer, "Local Research Ethics Committees:
Hindrance or Help?" (1995) 102 Br J Obstet Gynaecol 1-2; Department of Health, Ethics
Committee Review of Multi-centre Research (London: Department of Health, 1997); Blunt, J.,
Savulescu, J., and Watson, A. J. M. (1998). Meeting the challenges facing research ethics
committees: Some practical suggestions, British Med J, 316: 58-61; Maureen H. Fitzgerald and
Paul A. Phillips, "Centralized and Non-Centralized Ethics Review: A Five Nation Study"
(2006)13 Accountability in Research 47. D C Whiteman, PM Webb, D M Purdie, and AC
Green, "National Ethics Committee Urgently Needed" (2003) 178 MJA 187. M C Christian, al.
"A Central Institutional Review Board for Multi-Institutional Trials. (2000) 346 N Engl J Med
1405.
150
Ayres and Braithwaite, supra note 147.
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required.

Some commentators have, however, suggested that centralised

systems may exacerbate the burden on researchers and ethics committees by
adding another level of bureaucracy, and that their effectiveness has yet to be
determined.161
It is uncommon for countries to run a fully centralised system, in
which all administrative systems and review activities are centralised.162 It is
more common for countries to operate either a dual system or a decentralised
system.

Thus, some developed countries like Denmark, and developing

countries like Nigeria and South Africa operate a dual system and therefore have
a national ethics review committee. The national ethics review committee may,
amongst other things, audit the institutional committees (in the case of Nigeria
and South Africa) or regional committees (as in Denmark), act as an appeal
body, and also review some types of research.

163

Similarly, others like the

United Kingdom and New Zealand operate a dual system, with multiregional
and institutional committees and a central committee that vets multisite research
protocols (in the case of New Zealand) and a committee for ensuring coordination between the different regions (in the case of the United Kingdom).1

Davina Ghersi, ^Research Ethics Committees and the Changing Research
Environmenf(2005) 5 Lancet Oncology 325;K Alberti, "Multicentre Research Ethics
Committees: Has the Cure Been Worse Than the Disease?" 320 (2000) BMJ 1157-58.
162
Fitzgerald and Philips, cites the example of Tasmania in Australia. Some developing
countries until recently also had systems where research was reviewed by the national ministry
of health and which could thus be considered a centralised system. See Fitzgerald and Philips,
supra note 157.
163
Denmark has a national ethics review committee: the Danish National Committee on
Biomedical Research Ethics. See section 24 of the Act for its functions. See also online:
<http://www.cvk.sum.dk/CVK/Home/English.aspx> (June 21, 2009), see also Holm, ibid.
Sweden operates a similar system. See EUREC, supra note 154.
In the United Kingdom, there is no one national ethics committee that undertakes research
review as in the three countries discussed above. Instead, there is a centrally-administered
system of regional ethics committees that operate within the framework of the NHS assess any
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However, some countries with institutional committees, such as Australia,1

5

Canada166 and the United States,167 although there may be certain specialised
ethics review committees, operate in a mostly decentralised atmosphere with the
institutional ethics review committees reporting only to their home institutions
and multisite or multi-centre research is reviewed by different institutional
committees. What is clearly important is that whatever structure chosen should
be one that is geared to meet the goals of ethics review and of research
governance namely: to protect research participants and to promote socially
beneficial research.
research on humans that uses NHS patients, resources, or that accesses participants through the
NHS. Local Research Ethics Committees are established under the Health Authorities and
review research proposals according to where the research is due to take place. The National
Research Ethics Service launched on 1 April 2007 supersedes the Central Office of Research
Ethics Committees (COREC) and takes over COREC's responsibility of coordinating RECs and
providing operational support and advice to the RECs. Further, the United Kingdom Ethics
Committee Authority (UKECA) is responsible for establishing, recognizing, accrediting and
monitoring ethics committees in the United Kingdom in accordance with the Clinical Trials
Regulations and allows them to review clinical trials applications. The United Kingdom, with its
current system of "recognized" and "authorized" ethics committees would appear to be
somewhat complicated as opposed to the simple and, perhaps, more efficient regional model in
Denmark with the eight regional RECs and the national ethics review committee. A Hedgecoe, et
al, "Research Ethics Committees in Europe: Implementing the Directive, Respecting Diversity"
(2006) 32 JME 484. See generally, Maureen H. Fitzgerald and Paul A. Phillips, "Centralized and
Non-Centralized Ethics Review: A Five Nation Study" (2006)13 Accountability in Research 47.
165
In Australia, HRECs function within institutions. Although it also has a national ethics
committee, the Australian Health Ethics Committee (AHEC), a principal committee of the
NHMRC, this does not act as a national ethics review committee as in South Africa, Nigeria and
Denmark. AHEC is established under sections 35 and 36 of the National Health and Medical
Research Council Act 1992 and is required to oversee the operation of the HREC system.
(National Statement 1999 Principles 2.46-2.48). AHEC does not act as an overall review body
and does not audit HRECs or review particular projects like the NHREC in Nigeria. Further, it
has no power to impose sanctions on non-compliant HRECs or researchers.
166
In Canada, REBs operate within individual institutions such as universities and within Health
Canada. There is no national ethics review committee. Newfoundland has set up its own
Health Research Ethics Authority for Newfoundland and Labrador which appoints an REB and
approves other research ethics bodies. Some REBs also function on a regional basis such as the
Ontario Research Cancer Board. See Downie and McDonald, supra note 118 at 6. Section 3 (1),
7 and 8 of the NewFoundLand Health Research Ethics Authority Act, 2006. See Alison Shea,
"Regional Research Ethics Boards: Canadian and International Models" (2004), online: via <
www.nshrf.ca> (June 23, 2007) at 4.
167
In the United States, IRBs operate within institutions. The National Research Act 197'4
requires each institution conducting federally supported research involving human subjects to
establish an IRB to review the ethical aspects of all research protocols within the institution.
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Ethics review systems can be costly, including expenditures for
documentation, necessary equipment, training, project monitoring and site visits.
They must therefore have adequate financial support. Denmark stands out from
the other jurisdictions in detailing in law a system of funding for ethics review
committees within its legislation.168 In this regard, McDonald and Downie note
that:
Funding for administrative support is
important to facilitate the smooth running of
the committee and to allow the members to
concentrate on protocol review. It also allows
review bodies to access additional support or
expertise, for example, if considering a
particularly complex or emerging issue. For
researchers, it may affect the speed of the
review process. For the public, it may affect
the adequacy of the review and consequently
the safety of the project.169

With the notable exception of Denmark, many countries do not legally require
that ethics review committees be provided with adequate funding to carry out
their work.

It is obvious that a lack of funding and administrative support

jeopardise the protection of participants with which ethics review committees
are charged. Given the paucity of resources in developing countries, this issue is
of particular concern.

Act on a Biomedical Research Ethics Committee System and the Processing of Biomedical
Research Projects 2003 (as amended)online:
<http://www.cvk.sum.dk/English/actonabiomedicalresearch.aspx> (November 6, 2009), section
28.
169
Downie and McDonald, supra note 118 at 24.
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With regard to developing countries, the concept of ethics review,
while relatively new in many such countries,170 is rapidly gaining ground.171
While some developing countries have a relatively long history of ethical review
of studies involving human participants,172 some earlier studies noted the
absence of ethics review committees in some countries.17 In 2001, for instance,
the Regional Committee for Africa of the World Health Organization (WHO)
pointed out that about a quarter of the studies involving humans in the Africa
Region were not subjected to ethics review.174 Other studies undertaken by the
NBAC on research in developing countries found that some research undertaken
by researchers from the United States in developing countries had not undergone

170

Zulfiqar A. Bhutta, "Building Capacity for Ethical Review in Developing Countries" (June
2004) SciDevNet, online:
<http://www. scidev.net/dossiers/index. cfm?fuseaction=policybrief&dossier=5&policy=53>
(October 15, 2007).
171
See Chapter One. See also, A. Nyika et al, Composition, Training Needs and Independence
of Ethics Review Committees across Africa: Are the Gate-Keepers Rising to the Emerging
Challenges?" (2009) 35 J Med Ethics 189.
172
These include countries like South Africa.
173
Cheryl Cox MacPherson, "Research Ethics: Beyond the Guidelines" (2001) 1 Developing
World Bioethics 57-68, noting that some Caribbean countries lacked ethics review committees.
See Alimuddin Zumla and Anthony Costello, "Ethics of Healthcare Research in Developing
Countries" (2002) 95: 6 Med. J R Soc 275, noting that Myanmar and Laos did not have
functional ethics review committees as recently as 2002. See also, K. Ahmad, "Developing
Countries Need Effective Ethics Review Committees" (2003) 362 Lancet 2003 627-628.
174
A A Hyder et al, "Ethical Review of Health Research: A Perspective from Developing
Country Researchers" (2004) 30 Journal of Medical Ethics 30. J. Kiriga, C. Wambebe and A.
Baba-Mousa, "Status of National Bioethics Committees in the WHO African Region" (2005) 6
BMC Med Ethics E10, online: BMC < http://www.biomedcentral.eom/1472-6939/6/10> (April
3, 2007). Ruth Macklin, Double Standards in Medical Research in Developing Countries
(Cambridge: Cambridge University Press, 2004) at 150-151, with two examples of studies
conducted by US researchers in developing countries, for which no ethics approval was
obtained. In another study, a little less than 90 percent of published clinical trials conducted in
2004 did not report having undergone ethics review. D Zhang et al, "An Assessment of the
Quality of Randomized Controlled Trials Conducted in China" (2008) 9 Trials 22. See also,
Abbas, E E "Industry-Sponsored Research in Developing Countries" (2007) 28: 6 Contemporary
Clinical Trials 677.
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any ethics review in the host countries.

But, as discussed in Chapter One,

with the establishment of some form of ethics review and sometimes even
formalized national systems, this situation seems to be changing in many
developing countries, including African countries. Increasingly, studies are now
being undertaken of the functioning of ethics review committees in developing
countries.
However, as important as ethics review and ethics review
committees clearly are in research governance, and even as many ethics review
committees are being developed in developing countries, they face many
challenges.

Ensuring adequate ethical review is crucial. Requiring ethics

review of research protocols and establishing ethics review systems, while steps
in the right direction, do not, by themselves, ensure that the risks attendant to

See also, Nancy Kass and Adnan Hyder, "Attitudes and Experiences of US and Developing
Country Investigators Regarding US Human Subjects Regulations" in NBAC volume 2, supra
note 131 at B-103. Hyder et al, NBAC volume 2, supra note 131 at 69.
17
Examples of recent studies on ethics review committees in developing countries include:
Jonathan Camp et al, "Challenges Faced by Research Ethics Committees in El Salvador: Results
from A Focus Group Study" (2009) 9:1 Developing World Bioethics 11; P. Effa, A.
Massougbodji, F. Ntoumi, "Ethics Committees in Western and Central Africa: Concrete
Foundations" (2007) 7 Developing World Bioethics 136; ; J.K.B. Ikingura, M. Kruger and W.
Zeleke, "Health Research Ethics Review and Needs of Institutional Ethics Committees in
Tanzania" (2007) 9: 3 Tanzania Health Research Bulletin 154; D. Elsayed and Nancy Kass,
"Assessment of the Ethical Review Process in Sudan" (2007) 7: 3 Developing World Bioethics
148; Nancy Kass et al, "The Structure and Function of Research Ethics Committees in Africa: A
Case Study" PLoS Med 4:l:e3; Milford, Cecilia, Wassenaar, Douglas and Slack, Catherine,
"Resources and Needs of Research Ethics Committees in Africa: Preparations for HIV Vaccine
Trials" (2006) 28: 2 IRB: Ethics & Human Research 1; J.M Kirigia, C Wambebe, and A BabaMousa, "Status of National Research Bioethics Committees in the WHO African Region(2005) 6
BMC Med Ethics 10; D. Elsayed, "The Current Situation of Health Research and Ethics in
Sudan" (2004) 4 Developing World Bioethics 154-159; A Hyder, S. Wali, A Khan, N Teoh , N
Kass, et al. "Ethical Review of Health Research: A Perspective from Developing Country
Researchers" (2004) 30 J Med Ethics 68-72; B. Arda, "Evaluation of Research Ethics
Committees in Turkey" (2000) 26 J Med Ethics 26: 459- 461;; R Rivera and E Ezcurra,
"Composition and Operation of Selected Research Ethics Review Committees in Latin America"
(2000) 23 IRB 9-12; R. Coker and M McKee, "Ethical Approval for Health Research in
Central and Eastern Europe: An International Survey" (200) 1 Clinical Medicine 197-199;
WHO South East Asian Regional Office, Ethics in Health Research, (New Delhi: World Health
Organization, 2001).
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health research involving humans are completely eliminated or even minimised
in the face of inadequate structures or reviews.
Thus, as the amount of research conducted in the developing world
increases, concerns have also arisen with regard to the existence, functioning,
effectiveness and independence of ethics review committees in developing
countries. Studies have suggested that some research conducted by indigenous
1 77

researchers did not undergo ethics review.

Other studies have suggested that

even where conducted, ethics review may not be rigorous, due to lack of
capacity and infrastructure. Recent studies have thus identified problems,
including lack of standardization, insufficient funding, inadequate facilities and
equipment for work, understaffing178 imbalance in composition,179 conflict of
interest, lack of transparency, and inadequate training and capacity to review
i or\

research,

i o i

inadequate or non-existent post-approval monitoring systems,

as

well as inactivity in the ethics review committees in developing countries.182
Given such issues as possible political interference, the understandable yet
inappropriate desire of some committees to attract funding and other perceived
Kass and Hyder, supra note 175 at B-109. Elsayed and Kass, ibid, at 148.
J.K.B. Ikingura, M. Kruger and W. Zeleke, "Health Research Ethics Review and Needs of
Institutional Ethics Committees in Tanzania" (2007) 9: 3 Tanzania Health Research Bulletin
154.
179
Keymanthri Moodley and Landon Myer, "Health Research Ethics Committees in South
Africa 12 years into Democracy" (2007) 8 BMC Medical Ethics 1.
180
See Milford et al, supra note 5. See also, Nancy Kass et al, "The Structure and Function of
Research Ethics Committees in Africa: A Case Study" PLoS Med 4:l:e3, online:
<http://medicine.plosjournals.org/perlserv/?request=getdocument&doi=10.1371/journal.pmed.0040003> (May 3, 2009).
181
Kass and Hyder, supra note 163 at B-109.
182
"A Rapid Assessment of Strategic Information Systems for Lesotho's HIV/AIDS
Programme" (June, 2005)
online:
<http://www.rhap.org.za/resources/240.pdf?PHPSESSID=c765d08831cll9ea0b51da8863412bf
2> (April 11, 2008) at 40, noting the inactive state of the ethics review board.
178
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benefits

to

the community

from

proposed research projects,

ad-hoc

1 OQ

establishment of committees to satisfy foreign requirements,

and the

dependence of some ethics review committees on foreign funding for meeting
routine costs, the independence of ethics review committees in developing
i

o ^

countries has also been questioned.
In the African context, a recent study on the structure and function of
ethics review committees found that conflicts of interest arose in the context of
reviewing the protocols of departmental colleagues and protocols which would
bring money into the institutions. In such cases, questions were sometimes not
raised to allow the projects to proceed quickly.185 Given the paucity of resources
in institutions in such countries, the likelihood of conflict of interest and the
harm that could result from such conflict are amplified. Such conflict of interest
issues would affect the independence of the committee and consequently the
protection of participants with which the committee is charged.

Some

commentators therefore argue against the wholesale adoption of the institutional
models operated in some developed countries.186 The alternative would be for
developing countries to consider their circumstances and study different systems
around the world to determine if a regional model would work better in their
specific contexts.

See Kass and Hyder, supra note 314 at B-108.
Nuffield Council on Bioethics, supra note 5 at 104-v106; Macklin (2004), supra note 17;
Lavery, supra note 19 at 233-237.
185
Nancy Kass et al, "The Structure and Function of Research Ethics Committees in Africa: A
Case Study" PLoS Med 4:l:e3.
186
Carl H. Coleman and Marie Bousseau, "Strengthening Local Review of Research in Africa: Is
the IRB Model Relevant?" (2006), online: <http://www.bioethicsforum.org/ethics-review-ofmedical-research-in-Africa.asp> (June 22, 2007).
184
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Many of these recent studies also point to the need for more studies
to identify better the problems that ethics review committees face, including, for
example, what the costs of running an effective ethics review committee are, and
the training needs of ethics review committees.187 In one study in Sudan, it was
found that ethical reviews were carried out mainly as part of the requirements
for obtaining funding from international agencies, and that some of the
researchers could not explain what an ethics review committee was.188 It is,
therefore, crucial to determine why more ethics review committees are being
established in developing countries and how this might affect independent,
effective, ethics review in such countries. For instance, some commentators
have pointed out that, "It is generally felt that collaboration with international
research centres or with industry will remain closed to African researchers until
appropriate structures for the ethical review of clinical trials are in place and
functioning on the national level."

Are these new ethics review systems being

developed, therefore, merely to satisfy foreign requirements and attract research
funding? It is also essential to consider how recent developments in research
governance in developing countries affect the structuring of the system of ethics
review committees, the composition of the committees, the process of
appointing members into the committees, the functions of the committees, the
adequacy of their powers and authority and, ultimately, their effectiveness in

l8/

Nyika et al, supra note 171 at 191-3.
D. Elsayed and Nancy Kass, "Assessment of the Ethical Review Process in Sudan" (2007) 7:
3 Developing World Bioethics 143.
189
P. Effa, A. Massougbodji, F. Ntoumi, "Ethics Committees in Western and Central Africa:
Concrete Foundations" (2007) 7 Developing World Bioethics 136.
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carrying out their assigned functions. I consider these issues in more detail in
the context of Nigeria in subsequent chapters.
In sum, however, ethics review is a central and critical component of
research governance. In the foregoing pages, I have considered its uses and some
of the systemic issues that arise generally, and specifically in developing
. countries.

3.3.2 National Drug Regulatory Agencies
National drug regulatory agencies or authorities are institutions that
protect public health through regulating the efficacy and safety of drugs
consumed by people, implementing legislation, generating rules, and developing
enforcement strategies with regards thereto.

They are typically a national

creation, established by legislation. Their functions are usually dictated by the
statute that establishes them.

These functions may include developing

appropriate standards for the manufacture, import, supply, promotion and use of
drugs. Their functions may also include facilitating access to drugs, inspection
of manufacturing facilities and distribution channels and monitoring adverse
drug reactions. More relevant for the purpose of this thesis, national drug
regulatory authorities typically evaluate the safety of clinical trials.190
Thus, with specific regard to research governance, drug regulation
and drug regulatory authorities are an important component because the drug
development process requires that new drugs be tested on human beings in
190

Andy Gray, Resource Guide on Drug Regulation in Developing Countries (London: DFID
Health Systems Resource Centre, 2004), online:
<www.dfidhealthrc.org/publications/atm/Gray.pdf> (September 19, 2009).
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clinical trials prior to approval for general use.

Clinical research poses risks

and must therefore be regulated. Such regulation is usually undertaken by a
national regulatory authority, pursuant to domestic legislation and regulations.
These detail legal requirements for the conduct of clinical trials, and typically
include Good Clinical Practice (GCP) requirements, such as ethics review
approval, recruitment requirements, consent procedures, the qualifications of
investigators and the duties of sponsors.

The duties of sponsors include

reporting of adverse reactions to an intervention during a clinical trial to ethics
review committees and the regulatory authority.192 These requirements aim to
ensure that clinical trials are credible and that research participants are
protected.193
All functions relating to drug regulation may come under a single
agency
health.'195

which may or may not be part of a country's department or ministry of
Whether or not it is an independent agency is a significant factor

because "if a national drug regulatory authority (DRA) is an arm of an existing

These clinical trials are typically conducted in four phases, with each phase consisting of
testing in increasing number of humans. Supornchai Kongpatanakul and Brian L. Strom,
"Pharmacoepidemiology and Drug Evaluation," in Chris J. Van Boxtel, Budiono Santoso, and I.
Ralph Edwards, (eds.), Drug Benefits and Risks: International Textbook of Clinical
Pharmacology (Second Edition) (Amsterdam: IOS Press, 2008) at 30.
192
The ICH-GCP has been adopted in many countries around the world. See Segev Shani and
Zohar Yahalom, "The Role of the Pharmaceutical Industry in Disseminating Pharmacovigilance
Practice in Developing Countries" (2008) 63 Food & Drug L.J. 701 at 709; Krishan Maggon,
"Investigator and site selection and performing GCP clinical studies in India" (2004) 25
Controlled Clinical Trials 366; Hirtle, supra note 81.
193
Robert H Rowland, "How Are Drugs Approved? Part 3. The Stages of Drug Development"
(2008) 46: 3 Journal of Psychosocial Nursing 17 at 18.
194
Nigeria - National Agency for Food and Drug Administration and Control; South Africa Medicines Council; and United States - Food and Drug Agency.
195
Australia - Therapeutic Goods Administration (Department of Health and Ageing); United
Kingdom (Medicines and Healthcare Products Regulatory Agency - a part of the Department of
Health) and Canada (Therapeutic Products Directorate, Health Canada). In many African
countries, such as Ghana, Botswana, Uganda, Kenya and so on, the Ministry of Health conducts
review of clinical trials.
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ministry, its director may not be able to make major policy decisions on his/her
own. It may well be that many drug regulation activities are carried out by
another agency with overlapping jurisdictions and functions."1
However organised, the role of national regulatory authorities is
essential, especially in light of the fact that the interests of the pharmaceutical
companies which usually sponsor clinical trials for new drugs may sometimes
diverge significantly from the interests of those who participate in research,
public health, and public interests.197 National regulatory authorities regulate the
procedures for the commencement and the implementation of clinical trials.
These authorities monitor the clinical trial process, with the aim of not only
ensuring the safety of medicines but the safety of trial participants. These
authorities typically have to give approval before the commencement of clinical
trials.198 Drug regulatory authorities may also regulate the manner in which
ethics review committees operate in regard to review of clinical trials.199 They
may also conduct inspections of trials to ensure that appropriate safety and
ethical standards are maintained. They are also usually required to maintain
records of clinical trials data submitted by research sponsors.
Several systemic issues arise with respect to the governance of drug
research involving humans, mostly revolving around the effectiveness of such

196

WHO, The World Medicines Situation (Geneva: World Health Organisation, 2004), at 14.
John Abraham, "The Pharmaceutical Industry as a Political Player" (2002) 360 Lancet 1498 at
1500.
198
See for instance, United Kingdom - MHRA, "Medicines and Medical Devices Regulation:
What You Need to Know" online: <http://www.mhra.gov.uk/home/groups/commsic/documents/websiteresources/con2031677.pdf> (September 18, 2009).
199
See Trudo Lemmens, "Federal Regulation of REB Review of Clinical Trials: A Modest But
Easy Step Towards An Accountable REB Review Structure in Canada" (2005) 13:2 and 3
Health Law Review 39.
197
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authorities in carrying out their mandate, including the protection of research
participants. Whether or not drug regulatory authorities in a given country play
a sufficiently active role in research governance is dependent on such factors as
sufficient political and legislative support; the possibility of regulatory capture
of national regulatory authorities by some interested parties; funding of such
agencies; the relationship of the national drug regulatory authorities and the
other interested stakeholders such as the department of health, or any other
related governmental body such as a national ethics body and the ethics review
committees; and how well they regulate sponsors of clinical trials and ethics
review committees; in relation to clinical trials of drugs and devices.
With regard to developing countries, as already pointed out in
Chapter One, a dramatic increase in research in these countries, especially
clinical trials conducted by multinational pharmaceutical companies, has been
noted.

Amidst the advantages for multinational pharmaceutical companies of

cost reduction, shorter timelines for testing, and the availability of a greater
number of treatment-nai've participants and, very significantly, lesser regulatory
hurdles, questions have arisen about the possible exploitation of research
participants in developing countries.
The work of drug regulatory authorities in developing countries is
therefore becoming even more essential with respect to providing a system for
the availability of safe drugs, while ensuring the safety of research participants
200

See Chapter One, section 1.6. See also, Sarita Rai, "Drug Companies Cut Costs with Foreign
Clinical Trials" New York Times, February 24, 2005, online:
<http://www.nytimes.com/2005/02/24/business/24clinic.html> (September 19, 2009). Seth W
Glickman et al, "Ethical and Scientific Implications of the Globalization of Clinical Research"
(2009) 360:8 New England Journal of Medicine 816.
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in this era of globalisation.

Yet a WHO study found several limitations in

regulatory authorities in developing countries, noting that a good number lacked
901

well-developed drug regulation capacity."

Drug regulatory authorities in

developing countries face many challenges including, "operating in an
environment with insufficient

political support, resulting in inadequate

legislative mechanisms, inadequate financial resources, inconsistent application
processes and corruption of an appropriate regulatory culture.""
In addition to inadequate political and legislative support, drug
regulatory authorities in developing countries frequently lack

sufficient

resources as well as access to the high levels of scientific expertise necessary for
the effective assessment or registration of drugs.203 Indeed many developing
countries' drug agencies, in addition to charges to pharmaceutical companies,
depend on foreign aid in order to function.205 The limited resources available
have to be expended to attend to other problems with which developing
countries are besieged, including limiting supplies of counterfeit drugs.

201

WHO, Use of the WHO Certification Scheme on the Quality of Pharmaceutical Products
Moving in International Commerce (Geneva, World Health Organization, 1995) quoted in the
World Medicines Situation, supra note 196 at 94.
202
Suzanne Hill and Kent Johnson, "Emerging Challenges and Opportunities in Drug
Registration and Regulation in Developing Countries" (2004) DFID Health Systems Resource
Centre, online: <http://www.dfidhealthrc.org/publications/atm/Hill.pdf> at 40.
203
Ibid.
204
Ibid, at 14. See also, Warren A Kaplan and Richard Laing, "Paying for Pharmaceutical
Registration in Developing Countries" (2003) 18: 3 Health Policy and Planning 237.
205
See, for instance, Charles Wendo, "Uganda's Drug Regulatory Agency Faces Financial
Crisis" (2001) 358: 9280 Lancet 482.
206
Which is a cause of concern given that there are little or no restraints to purchasing drugs and
many (if not all) drugs can be bought over the counter Kongpatanakul and Strom, supra note
192 at 33. See also, Shani and Yahalom, supra note 192

233

Drug approval processes in developing countries also tend to be less
sophisticated than in developed countries.

The inadequacies of developing

countries have serious implications in light of the increase in clinical trials
exportation by multinational pharmaceutical companies. The financial power
and influence of multinational pharmaceutical companies, the resource
constraints of developing countries, and dependence on user fees to maintain
regulatory processes make regulatory capture a serious concern in the context of
these countries.
Some have therefore argued that developing countries when
considering applications for new drugs, should, and in many cases do,209 rely on
the assessments of drug regulatory authorities in developed countries, including
those in the Europe and the United States.

Others have argued for more

regional co-operation between developing countries. Examples of poorly studied
drugs exist, indicating that mere reliance on drug approval processes in
developed countries does not always guarantee the safety of drugs.

Further,

such arguments while relevant and helpful in the promotion of drug research in
developing countries provide little help with respect to how to effectively protect
research participants, a clear responsibility of drug regulatory authorities.

Drug regulatory authorities in developed countries are often only required to consider the
quality of clinical trial data and the safety of drugs entering their domestic markets. Thus, they
typically have little information on the manner of research conducted in developing countries,
whether ethical or unethical.Glickman, supra note 200 at 818.
208
See John Abraham, 'The Pharmaceutical Industry as a Political Player" (2004) Lancet,
discussing the regulatory capture by pharmaceutical companies in the context of the United
States. See also, Hill and Johnson, supra note 202.
209
Shani and Yahalom, supra note 182 at 709.
210
Gray, supra note 182 at 2. Piero L. Olliaro et al, "Drug Studies in Developing Countries"
(2001) 79:9 Bulletin of the World Health Organisation 894.
211
See the example of Norplant described in The World Medicines Situation, supra note 196 at
99.
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In sum, drug regulatory authorities are a crucial part of the
governance of research involving humans because they directly regulate clinical
trials. In subsequent chapters we focus on the specific systemic issues that arise
with respect to their work in Nigeria.

3.3.3 Policymaking Structures
Other institutions involved in the governance of research are what
could be considered as domestic policymaking structures.

These may be

government departments or ministries of health. Thus, in the United Kingdom
for example, the Department of Health has created the major policy guidance Research Governance Framework for Health and Social Care

- which

governs research conducted under the National Health Service.
Apart from government departments, the policymaking structure
may be a national ethics review committee with a mandate to provide research
ethics policy, as well as an ethics review function as, for example, in Nigeria.
The policymaking structures may also be a national policymaking body
specifically established for that purpose, which may or may not have a statutory
base, and may or may not have direct regulatory functions.213

Thus, for

instance, in Australia, the Australian Health Ethics Committee (AHEC),
established under the National Health and Medical Research Council Act 1992

' Department of Health, Research Governance Framework for Health and Social Care (Second
Edition) (United Kingdom, 2005), online:
<http://www.dh.gov.Uk/prod_consum_dh/groups/dh_.digitalassets/@dh/@en/documents/digitalas
set/dh_4122427.pdf> (June 19, 2009), Section 1.1.
213
For instance, national ethics review committees may audit and accredit local committees, but
also make national guidelines, thus combining regulatory and policy making functions.
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is mandated to issue guidelines for human research.214 In South Africa, the
National Health Research Ethics Council has a clear policy-making role as well.
It has the mandate to determine guidelines for the functioning of health research
ethics committees and set norms and standards for conducting research on
humans and animals, including norms and standards for conducting clinical
trials.215 In Canada, the Interagency Advisory Panel on Research Ethics, created
by the three major federal funding agencies helps develop, interpret and
implement the Tri-Council Policy Statement on Research on Ethical Conduct of
Research Involving Humans, Canada's major research ethics policy.

While it

has a direct role in policy-making, preparing draft policies with input from
various stakeholders, it is not independent from the government funding
agencies, which have the final say on the policies.
These policy structures may be active policymaking bodies in the
sense that they have the mandate to devise or create policies that govern health
research involving humans and other areas of bioethics. The policies made
either by these bioethics policy bodies or government ministries of health may
have a direct impact on the way research is conducted and regulated. However,
there may also be national bioethics advisory councils or commissions, whose
" Section 35 (3) (b). According to Dodds and Thomson, "Other than the specific reference to
medical research involving humans, there is no provision relating to the sources from which
AHEC can derive issues for its work. AHEC can be said, then, to have a specific responsibility
to develop national policy governing. Susan Dodds and Colin Thomson, "Bioethics and
Democracy: Competing Roles of National Bioethics Organisations (2006) 20:9 Bioethics 326 at
330.
215
National Health Research Ethics Council, online: <http://www.doh.gov.za/nhrec/index.php>
(October 29, 2009). Other advisory bodies include the Belgian Advisory Committee on
Bioethics, the Finnish National Advisory Board on Health Care Ethics, the French National
Consultative Ethics Committee for Health and Life Sciences, and the Portuguese National
Council of Ethics for the Life Sciences. See Dodds and Thomson, ibid at 329.
~16 Panel on Research Ethics, "About Us: Terms of Reference" online:
<http://pre.ethics.gc.ca/eng/panel-group/about-apropos/reference> (October 15, 2009).

236

impact on research governance may be more indirect and limited.

These

advisory councils or commissions are typically mandated to make policy
recommendations to the government, including policies and guidelines on
research involving humans. Acting in such an advisory capacity, the government
may or may not follow their recommendations on policy options to adopt,
allowing them only an indirect role on research governance as, for example, in
Denmark. The Danish Council of Ethics is an independent body established
under statute which advises the Danish Parliament and raises public debate
about ethical problems in the field of biomedicine, including biomedical
research relating to human beings.

17

Countries such as the United States have

had several successive bioethics advisory councils, which typically exist at the
pleasure of the executive in power.

A recent example is the recent

disbandment218 of President George W Bush's President's Council on Bioethics,
719

which advised President George W. Bush on bioethics issues,

including

research ethics. This has been replaced by the new Presidential Commission for
the Study of Bioethical Issues, established by President Barack Obama.

217

Danish Council on Ethics (Det Etiske Rid), <http://www.etiskraad.dk/sw293.asp>
(September 8, 2009). The legislation is The Act on The Danish Council of Ethics, Act No. 440
of 9 June 2004. See particularly Section 2 of the Act.
218
Nicholas Wade, "Obama Plans to Replace Bush's Bioethics Panel" New York Times, June 17,
2009, online: <http://www.nytimes.eom/2009/06/l8/us/politics/l8ethics.html?ref=global-home>
(September 20, 2009).
219
See The President's Council on Bioethics, online: <http://www.bioetnics.gov/> (September 8,
2009). There have been other bioethics commissions in the United States, including National
Commission for the Protection of Human Subjects of Biomedical and Behavioral Research
established in 1974 and the National Bioethics Advisory Commission (NBAC) established in
2001.
220
"President Obama Establishes New Presidential Commission for the Study of Bioethical
Issues, Names Commission Leadership" online: <http://www.whitehouse.gov/the-pressoffice/president-obama-establishes-new-presidential-commission-study-bioethical-issues-nam>
(May 6, 2010).
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Such advisory councils may help create policy, although this may not be their
direct function.
Policy structures assist in articulating, and elaborating on issues and
divergent views, permitting the reaching of consensus on areas where there may
be scientific and moral uncertainty and controversy.221 The establishment of
such policymaking structures brings the state into the arena of research
governance and helps define the role that the state has chosen to play in such
governance. In a manner that is clearly part of the new governance approach,
999

such policies may also provide conditions for funding,

and may even

influence legislation.223 And, in countries where no research-related legislation
has been enacted, the policies made by such organizations may be the only
substantive guide that sets parameters for health research involving humans.
Deliberations by such bodies, and any publications put forth, also assist in
keeping the public informed on issues arising in research ethics and governance.
These deliberations may also signal the directions which government regulation
or policy-making more broadly may take, and shape the ultimate policy even
where the council or commission is only advisory because members of such
committees tend to be persons regarded as experts in research ethics and
224

governance issues.

But some argue that bioethics commissions can sometimes prevent a serious debate about
issues by putting on the appearance of reaching a false consensus. See Jonathan D. Moreno, "Do
Bioethics Commissions Hijack Public Debate?" (1996) 26: 3 The Hastings Centre Report 47.
222
Dodds and Thomson, supra note 214 at 329.
223
See Moreno, supra note 221.
224
Weiman Rei and Jiunn-Rong Yeh, "Steering in the Tides: National Bioethics Committee as
an Institutional Solution to Bio-politics?" in Asian Bioethics in the 21s' Century (2003) Eubios,
online: < http://www.eubios.info/ABC4/abc4363.htm> (October 29, 2009).
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Some of the systemic issues which arise with respect to policy
structures and their role in research governance in both developed and
developing countries include issues around legitimacy, community engagement
or public participation, transparency, accountability, representation and
effectiveness.

For

instance,

in terms

of legitimacy,

accountability,

representation, and community engagement, broad-based consultation of the
public are necessary.

What is the nature of public participation in the

development of research ethics policies?225

How broad are attempts to ensure

public participation and how much influence does such participation have on the
resulting policies?

Are there inherent conflicts of interest issues that may

undermine the effect of the policies developed and, more generally, research
governance? As an example, in Canada, it has been argued that an inherent
conflict of interest exists with respect to the creation of an ethics guideline by
the major funding agencies whose major purpose is to promote research, and
who have also created the Interagency Panel Advisory Panel on Research Ethics,
the policy-making body.226 These issues have an impact on the effectiveness of
these policymaking bodies, the resulting policies developed and, ultimately, on
research governance.
These issues also arise specifically in such areas as the process of
appointment into such bioethics councils.

Who appoints members of these

councils? Does membership of these councils or committees reflect a broad

225

Charles Weijer, "Book Review: Society's Choices: Social and Ethical Decision Making in
Biomedicine" online: < http://www.ncehr-cnerh.org/english/communique/npubs_e.html> (March
12, 2008).
226
See Downie supra note 150.
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range, or diversity, of persons? And how does this affect the work that the
councils do? In the United States, for example, President Bush appointed
members of the President's Council on Bioethics, who were viewed by some as
mainly researchers who supported his conservative views on stem cell research,
and whose recommendations were considered to be therefore ideological rather
than objective.227
In terms of effectiveness, particularly with respect to advisory
councils or commissions, how much do they really affect the direction of policy
towards promoting research and protecting research participants, especially if
established for political purposes?228 And are they granted sufficient resources
to carry out their mandate?
These systemic issues arise in different countries, developed and
developing, but perhaps more so in developing countries with less established
democracies. Specifically in developing countries, policies should be made with
an understanding of the context of resource challenges, global inequities, the
limited awareness of rights by many who may participate in research, and the
effect of these on the promotion of research and on the protection of research

^•"Elizabeth Blackburn and Janet Rowley, "Reason as Our Guide" (2004) PLos Biol 2(4). This
was disputed by others. Elizabeth Blackburn, "Bioethics and the Political Distortion of
Biomedical Science" (2004) 350: 14 New England Journal of Medicine 1379. See Paul Elias,
"Scientists Rally around Stem Cell Advocate Fired by Bush" Associated Press, March 18, 2004,
online: <http://www.usatoday.com/tech/news/2004-03-18-eliz-blackburn_x.htm> (September
20, 2009). President Obama subsequently issued an order in March 2009 to lift the ban on
federal funding of embryonic stem cell research may be argued to advance his more liberal
approach to bioetechnology, particularly stem cell research.
228
See, for example, James W. Fossett and Michelle N. Meyer, "Bioethics Panel's Role May Be
Small on Policy, Big on Issues" (July, 2009) The Nelson Rockefeller Institute of Government,
online: <http://www.rockinst.org/observations/fossettj/2009-07next_presidents_council_bioethics.aspx> (October 19, 2009), arguing that bioethics
commissions in the United States play a very limited role in policy development around
bioethics issues.
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participants. Are these policymaking structures sufficiently empowered with the
necessary mandate, resources, and expertise, to take these factors into account in
crafting research ethics policies?

I consider the place of policy-making

structures and the arising systemic issues in Nigeria in subsequent chapters.

3.3.4 Other Institutional Actors: Universities, Research Institutes, Research
Sponsors, Professional Associations
In addition to the institutions described above, other institutions such
as universities and research institutes are also involved in the governance of
health research. The role that the institutions described here play (or should
play) indicates that they have to be a part of the governance framework, and this
adds further justification for the necessity for a hybrid governance framework
that recognises the activity of different actors in analysing the governance of
health research in developing countries.
Many universities, teaching hospitals, and research institutes have
research ethics policies that govern the ethical conduct of research.

These

policies may require ethics review of research and prescribe the manner in which
ethics review committees are organised, administered, and funded.

In some

cases, these policies are a requirement from research sponsors who sponsor
research in those institutions. For instance in Canada, where the major research
ethics policy is a product of the federal funding agencies, institutions are
required to draw up policies in line with the TCPS.229 The inherent conflict of

l

" CIHR, NSERC, SSHRC, Memorandum of Understanding (MOU) on the Roles and
Responsibilities in the Management of Federal Grants and Awards, online: <http://www.nserc-

241

interest issues arising from institutional requirements for and efforts to obtain
funding and the possible impact on ethics review in these institutions have been
discussed above.
In other cases, research sponsors, which may include government
funding

agencies,

pharmaceutical

companies,

and

non-governmental

organizations, draw up policies and provide funding conditions to ensure the
ethical conduct of research. Under those conditions, research sponsors typically
require compliance with the conditions for continued funding eligibility.
Professional organisations also regulate research conducted by their
members, not only in terms of ensuring quality assurance, establishing
professional standards, educating and certifying their members,230 but in
establishing specific requirements regarding ethical conduct of research. "Rules
of conduct or ethical codes," notes Bernard Dickens, "are often considered to be
characteristic of professions, as opposed to craft and trade associations."
According to him, they are particularly common within health care professions,
where they set guidelines for how professionals should act in dealings with their
patients and with each other in, among other things, in experimental studies
involving animals, humans, and social or population groups.
Professional associations' responsibilities to regulate research may
originate from a statutory basis, a duty to maintain professional standards and

crsng.gc.ca/NSERC-CRSNG/Policies-Politiques/MOURoles-ProtocolRoles/index_eng.asp>
(November 23, 2009).
230
Henry Dinsdale, "Professional Responsibility and the Protection of Human Research Subjects
in Canada" (2005) 13: 2 and 3 Health Law Review 80 at 80.
231
Bernard Dickens, "Codes of Conduct and Ethics Guidelines" in Lester Breslow, Encyclopedia
of Public Health (New York: Macmillan, 2002) at 224 - 227.
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promote public trust and confidence, or fiduciary obligations.

In Canada, for

instance, the Alberta College of Physicians and Surgeons, requires physicians
and surgeons in that province to submit their research activities for ethics review
and has set up a centralized Research Ethics Review Committee to oversee such
activities.233 The College of Physicians and Surgeons of Manitoba has also put
in place a similar measure.234 In Nigeria, the Medical and Dental Council of
Nigeria, a professional association of doctors and dentists, has drawn up a code
of ethics which includes requirements for the ethical conduct of research.235
Systemic issues arise with respect to each of these institutions,
including the limitations of scope of the research governed by them, which is
necessarily determined by the scope of their authority and interest.

Some

pertinent issues and some kinds of research may thus fall outside their scope. In
the case of professional associations, while there is an opportunity to regulate
some kinds of research that may fall outside the scope of other policies, for
instance research that takes place in doctor's offices, they cannot provide
comprehensive protections for all health research.

Also, there may be

inadequate interest in research governance and a limited understanding of the
potential role of the professional association in research governance.

See Timothy Caulfield et al, "Research Ethics and the Role of the Professional Bodies: A
View from Canada" (2004) 32 Journal of Law Medicine & Ethics 365.
233
See Ibid.
234
College of Physicians and Surgeons or Manitoba (CPSM). (2005), online:
<http://www.cpsm.mb.ca/> (June 21, 2007).
235
Online: <http://www.mdcn.org/functions.htm> ( April 1, 2009).
26
See Caulfield, supra note 232.
237
See, for instance, Dinsdale, supra note 230 at 82 describing the inadequacy of professional
associations' interest in research governance in Canada.
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In the case of research sponsors, their requirements may conflict
with the interests of research participants. Such conflict of interest also arise in
universities, which may be desirous of facilitating research and require
continued research funding, but also have to protect research participants within
university-affiliated research. The death of a research participant in the United
States, Jesse Gelsinger, in a gene therapy trial, exposed such conflict of interest
issues. In that instance, the principal investigator and the university had an
undisclosed financial interest in the outcome of the trial.

The university

benefited substantially from donations made by the research sponsor to its gene
therapy programs.238 Similarly, the case of Dr. Nancy Olivieri, a researcher at
the University of Toronto whose contract with a research sponsor, Apotex,
precluded publication of adverse findings during a trial and who did not receive
appropriate support from the university, highlights concerns about conflicts of
interest."

These concerns are, of course, exacerbated in the resource-

challenged settings of developing countries.

3.3.5 Non-Governmental Organisations
In the hybrid framework that I proposed in Chapter Two, I discussed
the possibility that non-governmental organisations may serve as checks on
other actors in governance. Although they may lack the type of legitimacy and
238

See D. R. Waring and T. Lemmens, 'Integrating Values in Risk Analysis of Biomedical
Research: The Case for Regulatory and Law Reform' University of Toronto Law Journal (2004)
249 ; W M Kong, "Legitimate Requests and Indecent Proposals: Matters of Justice in the Ethical
Assessment of Phase 1 Trials Involving Competent Patients (2005) 31 Journal of Medical Ethics
205. See also, Barry Schwartz, "Safety in Human Research: Past Problems and Current
Challenges from a Canadian Perspective" (2008) 20: 3 HEC Forum 277.
Downie, supra note 150.
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accountability required of government or state entities, they may bring a balance
to the research governance system that would otherwise be lacking. They may
also, as watchdogs, serve as the voice of research participants, and possibly
prevent regulatory capture which can jeopardise the interests of research
participants and the general public.
governance

or

my

hybrid

Thus, from the perspective of new

governance

framework,

non-governmental

organisations could - along with community and lay participation in ethics
review committees - serve as the entry point for non-state actors, including
those on behalf of whom governance arrangements are employed.

In this

section, I consider these organisations as a potential and important constituent of
research governance.
Under the umbrella of non-governmental organisations come
organizations such as patients' rights groups, consumer organizations, and
community groups. Although they typically do not feature in accounts of the
institutional framework of research governance and may not be considered a
formal part of the framework, in my view, they are particularly necessary
because they provide an avenue for past and potential research participants, and
citizens to participate in research governance in an organised fashion. They also
provide an important means of providing checks and balances on other
institutions through, among other things, publicizing unethical research (in other
words, naming and shaming). They are also particularly essential in developing
countries where weak or fledgling democracies and corruption are major
concerns.
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In developed countries, many patients' rights organizations are
focused mainly on advocacy for funding for clinical research on different
diseases, on gaining access to clinical trials and speeding up drug approval
processes.240 These types of organisations have very often
expressed an enthusiasm for 'the bright side'
of research, and a willingness to assume risk,
that many scientific investigators did not
share... These advocates have tended to avoid
REBs that examine the risks faced by research
participants. They have regarded ethics review
as a paternalistic distraction from the main
goal of promoting benefits to patients.241
949

But there are others, such as the Alliance for Human Research Protection

in

the United States, whose main focus is the protection of participants in
research."

This organisation is a "network of lay and professional people with

a mandate to advance ethical research practices; to ensure that the human rights,
dignity, and welfare of research participants are protected; and to minimise the
risks associated with such endeavours."244 Another such organisation is the
Citizens for Responsible Care and Research,245 whose mission is to raise the
level of ethical and professional conduct of research involving humans,
240

An example of such an organization is the Abigail Alliance for Better Access to
Developmental Drugs, see online: < http://abigail-alliance.org/> Another example is AIDS
Coalition to Unleash Power (ACT UP). See Mark Harrington, "Community Involvement in HIV
and Tuberculosis Research" (2009) 52 (SI) Journal of Acquired Immune Deficiency Syndrome
S63.
241
Waring and Lemmens at 238.
242
Alliance for Human Research Protection, online:
<http://www.ahrp.0rg/cms/content/view/l8/87/>(October 31, 2009).
Another example is the Public Citizen's Health Research Group, also based in the United
States, which was one of the organisations that raised concerns about the standard of care issue
in the zidovudine trials in developing countries mentioned in Chapter One. See P. Lurie and S.
M Wolfe, "Unethical Trials of Interventions to Reduce Perinatal Transmission of the Human
/Immunodeficiency Virus in Developing Countries" (1997) 337 New Eng. J. Med. 853. The
authors are members of the Public Citizen's Health Research Group.
244
Waring and Lemmens, supra note 224 at 281.
245
Citizens For Responsible Care and Research (CIRCARE), online: <http://www.circare.org/>
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especially with respect to the protection of vulnerable participants, like the
mentally challenged, and children.246
In developing countries, non-governmental organizations typically
act as a buffer between the government and citizens, acting as the voice of the
latter, including in areas such as human rights. The activist and advocacy efforts
of such organisations have assisted in the changing of old laws, and the
enactment of new legislation.

Such efforts have brought the need to

accommodate consultations with civil society groups in such legislative
processes to the fore.247 Such organisations may deliver healthcare services.
They may also engage in activism around health issues including, but not limited
to, activities such as promoting access to essential medicines for HIV/AIDS,
reducing

disease-related

stigma

and discrimination,

and liaising

with

international organizations such as the WHO in health-related activities.
With

respect

to

research

governance,

non-governmental

organisations in developing countries have been engaged in presenting
community views on ethical issues in health research, and are increasingly
consulted in designing research protocols.

In South Africa, civil rights

See for example, Obiora Chinedu Okafor, "Modest Harvests: On the Significant but Limited
Impact of Non-Governmental Organisations on Legislative and Executive Behaviour in Nigeria"
(2004) 48:1 Journal of African Law 23 at 24.
In Thailand, community groups consisting of sex workers and their representatives, and drug
users protested the trial of tenoforvir, a microbicide, in 2004, on the grounds that participants
were not afforded enough protections, including provision of treatment in the event that they got
infected. See Seree Jintarkanon et al, "Unethical Clinical Trials in Thailand: A Community
Response" (2005) 365: 9471 The Lancet 1617; JA Singh and EJ Mills "The Abandoned Trials of
Pre-exposure Prophylaxis for HIV: What went Wrong?" (2005) 2:9 PLoS Med 234; and A.
Chua, N. Ford, D. Wilson and P. Cawthorne, "The Tenofovir Pre-Exposure Prophylaxis Trial in
Thailand" (2005) 2: 10 PloS Medicine 346.
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organizations have successfully challenged government research policies
through legal action.249
Non-governmental organisations can assist in the very essential work
of educating research participants at the grassroots levels where most research
activities take place, and where the burden of research is most felt.

At such

grassroots level, there is less likelihood of education and awareness of the rights
of participants. They could also engage in advocacy to strengthen regulations,
establish, and implement research governance policies and legislation. NGOs
may be well placed to act in respect of drawing attention to the requirements of
justice and access to benefits contained in many ethical guidelines.
Even though I am of the view that non-governmental organisations
may be helpful in the governance of health research in developing countries, this
does not mean that they are entirely free of any concerns. Some of the systemic
issues, particularly in developing countries, are that there are too few of these
organisations, and that where they do exist, sufficient resources in terms of
funding and training on the relevant issues may be lacking. Conflict of interest
and regulatory capture issues may also arise where such organisations are
involved in advocacy not only for the ethical conduct of research, but also
advocacy for access to participation in research, two potentially conflicting
goals. The possibility also exists of their being captured by other stakeholders
whose interests may not necessarily be aligned with those of research

249

For prominent examples, see Jerome Amir Singh, "Using the Courts to Challenge Irrational
Health Research Policies and Administrative Decisions" (2009) 112 Suppl 1 Acta Tropica S76.
250
Temidayo O Ogundiran, "Enhancing the African Bioethics Initiative" (2004) 4 BMC Medical
Education 21.
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participants, including the interests of patients who have few alternatives and
therefore seek faster approval processes, or pharmaceutical companies who may
want to circumvent existing ethical and procedural requirements.

In

developing countries, where the adequacy of resources in any sector, including
the non-profit sector, is almost always a concern, the possibility of capture of
advocacy groups raises serious potential issues. A continuous evaluation and
appraisal of their functions is therefore necessary.

3.4 Conclusion
To set the stage for the application of the hybrid governance
framework proposed in Chapter Two, I have sought, in the foregoing pages, to
identify and discuss many of the processes, institutions, and mechanisms
employed in the governance of health research involving humans.

I have

categorised these processes, actors, and mechanisms into ethical and institutional
frameworks. In doing so, I have pointed out that developing countries who do
not already have domestic ethics policies may need to put such in place. These
should address the gaps in the international ethical guidelines.

National

guidelines also retain the positive attributes of the new governance approach.
I have identified systemic issues that have been of concern in
institutional components in different countries.

Emerging governance systems

have to address these concerns. One of such matters is the appropriate ethics
review structure. In this respect, I have noted that an appropriate structure
~51 See for example, Sharon Batt, "Marching to Different Drummers: Health Advocacy Groups
in Canada and Funding from the Pharmaceutical Industry" (2005), online: <http://www.whpapsf.ca/pdf/corpFunding.pdf> (July 23, 2010).
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(whether institutional or regional, centralised or decentralized), in my view,
cannot be one that is set up merely to attract research funding or be one that
adopts foreign structures wholesale. An appropriate structure will be the result
of a reasoned and wide-ranging discussion, take into consideration the local
context and local challenges, and focus on the protection of research participants
in a particular country.

I have also discussed the input of drug regulatory

agencies, policy-making structures, universities, professional associations, and
research sponsors in the governance of health research, and the potential
systemic issues that they may face. I have also pointed out that nongovernmental organisations may be a beneficial constituent of the components
of research governance in developing countries.
The number and diversity of actors and instruments described in this
chapter make obvious the need for a governance framework such as I suggested
in Chapter Two, and convey the necessity for my focus on governance. In the
next chapter I argue that a legal framework is also an essential component of
research governance.
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Chapter Four

The Case for Legislation and the Need to Recognise the Relationship
between Ethical, Legal and Institutional Frameworks

4.1 Introduction
In my analytical framework, discussed in detail in Chapter Two, I argued
that law (a tool wielded by the state) brings something important to the table of
governance. Amid other components of research governance, discussed in Chapter
Three, a legal framework is, I argue, a crucial component of research governance.
The first objective of this chapter, therefore, is to argue for the need for
specific and comprehensive domestic legislation on research governance in
developing countries. In this regard, while ethical and institutional frameworks are
widely accepted in research governance and articulated in the literature, legislation
on research governance is still a contested matter, or one which has not been given
sufficient thought in several countries, including developing countries.
developed countries like Denmark,

l

the Netherlands,

2

Some

and Spain3 have specific

legislation on research governance. Developing countries like South Africa4 and
Chile5 also have legislation dealing with aspects of research governance. But many
other developing countries do not yet have comprehensive legislation addressing
research governance. In the sections below, I provide an account of the possible

Act on a Biomedical Research Ethics Committee System and the Processing of Biomedical Research
Projects 1992.
2
Medical Research Involving Human Subjects Act, 1999, as amended.
3
Law on Biomedical Research, Law 14/2007
4
National Health Act, no 16 of 2003.
5
Scientific Research Involving Human Beings, Their Genome, and Prohibition of Human Cloning, Law
No. 20.120.
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impact of the law on research governance, and argue for a comprehensive legislative
basis to provide a foundation for research governance in developing countries. I also
consider the basic content of such legislation.
The second objective is to argue for the need for the recognition of the
relationship between the three frameworks: the ethical, the institutional and the legal
frameworks. As I discussed in Chapter Two, governance takes a systems approach,
permitting the discussion of steering of activities in terms of the interrelated parts of
that activity, in this case, health research involving humans.6 As discussed in Chapter
Two, governance as an analytical framework allows us to study the configuration of
particular institutions, instruments, and processes, and the interactions and
relationships between them.7

In this chapter, I argue for the importance of the

recognition of linkages between a domestic legal framework, an institutional
framework, and an ethical framework, and contend that such recognition will be
helpful with respect to achieving the stated goals of research governance.
This chapter commences with this introduction.

The second section

examines the legal framework for research governance, discusses generally the role
law plays in the governance of health research and argues for a real role for law in
the form of formal legislation in domestic governance systems in developing
countries.

The third section points out the need for better recognition of the

relationship that exists, and should exist, between the ethical, legal and institutional
frameworks. The fourth section concludes the chapter.

6

Bjoern Niehaves, Karstern Klose, Joerg Becker, "Governance Theory Perspectives on IT Consulting
Projects: The Case of ERP Implementation" (2006) 5:1 E-Service Journal 5 at 9.
7
M. MacDonald (ed.) The Governance of Health Research Involving Human Subjects (Ottawa: Law
Commission of Canada, 2000) at 22.
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4.2 The Legal Framework
It is clear that the ethical framework, discussed in Chapter Three, is a
foundational component of research governance, as is an institutional framework
which actuates the ethical framework. Similarly, a legal framework is an important
component of research governance because of the special characteristics of law
which differentiate it from ethics or bioethics, the broader domain of research ethics.
While both law and ethics aim to define acceptable and unacceptable
conduct,8 there are differences however in these two normative systems in terms of
their goals and methods.9 A major difference is that whereas ethics may only be
aspirational, law sets mandatory minimum standards. In setting minimum standards,
law performs a more restricted function than ethics, identifying and regulating those
kinds of conduct about which there is general agreement.
standards set by law may bring about legal liability if infringed.

These mandatory
The weapon of

legal liability assists in bringing in line the conduct of persons involved in research,
or as Scott so aptly puts it, "Law packs ethics with the 'punch' of potential
10

sanctions."

Further, as some authors have rightly observed, and as discussed in

Chapter Two, law is usually considered the product of authoritative law-making
institutions associated with the nation state. Ethical principles, in contrast, may be
grounded in a wider range of sources with no obligatory connection to the state.
8

Judith Hendrick , "Legal Aspects of Clinical Ethics Committees" (2001) 27: 1 Journal of Medical Ethics
50. See also, Bethany Spielman, "Invoking the Law in Ethics Consultation (1993) 3 Cambridge Quarterly
of Healthcare Ethics 457 at 464.
9
Bethany J. Spielman, Bioethics in Law (Humana Press, 2007) at 2.
10
Thus, for instance, the law will most likely not regulate areas that are ethically controversial. However,
the law is most likely to regulate an area like informed consent where there is, to a large extent, general
agreement. Charity Scott, "Why Law Pervades Medicine: An Essay on Ethics in Health Care" (2000)
Notre Dame Journal of Law and Public Policy 245 at 259.
11
Hendrick, supra note 8.
12
Scott, supra note 10 at 258.
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Moreover, in addition to their different sources, they may occasionally reach
different conclusions on the same issues.13 With respect to their goals, the general
objectives of law, including in dispute resolution and in standard-setting, typically
differ from the more immediate concerns of bioethics.1
But there are also connections in the two fields that allow both to
influence each other, and to provide value in the specific area of research
governance.15 In this regard, the law (in part)16 reflects society's idealism, morality,
and some consensus, at any given point in time, of what society views as acceptable,
ethically appropriate behavior.

In a socio-legal sense, law's most important reason

for existing is as a communal resource18 which society imbues with power (including
coercive power) to express and regulate the basic values that society holds important.
Bioethics (and ethics more generally) is concerned with such values as autonomy,
equity, fairness and justice. To achieve these lofty ideals, society chooses the vehicle
of law, which acts as an enforcer of social values.1

Thus law in its role as the

principal instrument for protecting and upholding human rights, ought to promote
(although there have been instances where it has fallen short of promoting) equity,

John Dawson, 'An Introduction to the Law of Research,' in John Dawson and Nicola Peart, (eds.), The
Law of Research University of Otago Press (2003), 14- 25 at 25.
14
Carl E Schneider, "Bioethics in the Language of Law" (1994) 24:4 Hastings Centre Report 16.
15
Ibid. See also, Hendrick, supra note 8.
16
Legal positivists would argue differently - morality is separate from law. However, law while not
simply equated with morality must show to some extent a reflection of the morality of the society.
17
Scott, supra note 10 at 245.
18
Roger Cotterrell, "Subverting Orthodoxy, Making Law Central: A View of Sociolegal Studies" (2002)
29: 4 Journal of Law and Society 632 at 642-3.
Scott, supra note 10 at 257.
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fairness, and justice.

Law is also a principal means of enforcing policies, including
91

health policies, and a crucial medium for deciding differences about public policy.
In general, then, law may be considered, as Schneider so concisely
summarises it:
essentially a device for social regulation. It is the
means by which society through its government
seeks to establish a framework for human
interactions. This framework helps set minimum
standards for human behavior (criminal law and tort
law exemplify this function), helps establish and
support the institutions and practices people use in
organizing their relations with each other (this is
what contract and commercial law, for instance, do),
and helps people resolve their disputes (which is a
primary function of civil courts). In this century, the
law has broadened that framework by providing
some minimum assurances of human well-being
(what we call the welfare state).22
Governance and regulation through law thus has several uses, including facilitating
certain socially and morally acceptable actions, setting norms and protecting citizens,
including, through setting penalties and sanctions for unacceptable action or
behaviour and regulating or declaring standards thus providing clarity and certainty
in handling controversial areas.23

Formal regulation by means of statutes is
94-

particularly useful where the interests of the weak and vulnerable are at stake.

20

Ibid at 246.
B.R. Dworkin, Limits: The Role of Law in Bioethical Decision-Making (Indiana: Indiana University
Press 1996) at 2.
22
Schneider, supra note 14 at 16. Another useful definition for the purposes of this thesis is the one given
by Dworkin, who describes law in terms of procedure and processes for correcting or refusing to correct
social ills, for the purpose of deciding whether to intervene, who should intervene and in what way in
relationships between persons and the government. See Dworkin, ibid, at 8.
23
Linda Nielsen, 'From Bioethics to Biolaw' in Cosimo Marco Mazzoni (ed.), A Legal Framework for
Bioethics (The Hague: Kluwer Law International, 1998) at 42.
24
Ibid, at 44.
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In the case of health research involving humans, ethical concerns
relate principally to the safety and welfare of research participants, an area in which
the law can play, and has played a crucial role. The legal framework of research
governance in different jurisdictions typically consists of common and civil law
principles in the areas of tort and criminal law, but may also include formal, specific
legislation. While few jurisdictions have specific legislation governing research,
some have legislation governing specific aspects of research such as clinical trials,
while in many others (including developing countries such as Jamaica, Bolivia, and
Vietnam) formal legislation governing many aspects of research involving humans is
absent.
In this section, I begin by describing briefly how the law currently
operates in the context of research governance. I then consider the potential role that
law could play in research governance in developing countries, and argue for the
potential benefits of specific legislation in an area requiring both the promotion of
research, and the protection of those who participate in such research.

4.2.1 Law and Research Governance
In many countries around the world, the law impacts governance of
health research involving humans in various ways. As Jaffe observes, the law "is a
system of decisional organs and their formal and informal products: the legislature
(statutes), the executive administrative (regulations and adjudication), and the courts
(adjudication)."

5

This system, in its entirety - through statute, regulations, and case

law - regulates health research involving humans. Below, then, I provide a brief
25

Louis L. Jaffe, "Law as a System of Control" (1969) 98: 2 Daedalus 406 at 407.
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descriptive account of the impact of the law on the governance of health research
involving humans.
The ethical obligation to secure free and informed consent for
participation in human research is a key requirement entrenched in the law of many
countries.

The law may also influence the conduct of research, and therefore

research governance in relation to competence to provide free and informed consent,
addressing the age of majority, mental competence, and provisions for research
involving mentally disabled persons or children, and who may act as an authorised
representative. These requirements may be found in a variety of pertinent sources of
law, including common law, civil law, legislation, regulations, and even
constitutional law.
Privacy and confidentiality are other areas in which the law may play
a significant role. Personal data may be protected by specific legislation, and the
right to privacy is widely regarded as a fundamental right.26 But law may also
require the reporting of information obtained in the course of research in order to
protect the health, safety, or life of a research participant or third party, including
information about child abuse, sexually transmitted diseases, intent to murder, or
suicidal thoughts.
Constitutional law may contain basic requirements for health research
involving humans such as informed consent (as in South Africa ), and fundamental
rights which impact health research, such as the right to privacy.

Importantly,

constitutional law in most countries also articulates the delineation or distribution of
26

Hazel Biggs, Healthcare Research Ethics and the Law: Regulation, Review and Responsibility (Oxford:
Routledge Cavendish, 2010) at 97.
27
(Section 12(2)(c) of the Constitution of South Africa 2003.
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powers of different authorities, determining which level of government (especially in
a federal system of government) can exercise legislative and regulatory powers.28
Specific legislation or legal regulations may exist on the conduct of
clinical trials, including the creation of drug regulatory agencies as described above
and containing a requirement for ethics review approval. Legislation, as is the case in
Denmark,

may also establish the research governance structure, including the

national ethics review committee, its mandate, and the place of ethics review
committees. Ethics review committees may operate directly or indirectly, under
legislated mandate.30
Further, the law's impact on research governance can be felt through
common and civil law addressing the liability of researchers and research
institutions, including the law of torts, specifically the law on negligence, the law on
battery, and the law on fiduciary duties. In the common law, a claim in negligence
requires the proving of a duty of care, in this case owed by a researcher to a research
participant, the breaching of that duty, and that harm or injury resulted from that

See for instance, Jennifer Llewellyn, Jocelyn Downie & Robert Holmes, "Protecting Human Research
Subjects: A Jurisdictional Analysis" (2003) Special Edition, Health Law Journal 207.
Act on a Biomedical Research Ethics Committee System and the Processing of Biomedical Research
Projects 1992. This is also the case in France, Spain and the Netherlands. France - Biomedical Research
(Loi Huriet-Serusclat), Articles LI 121-1 to LI 126-7 (2004) (French), available at:
<http://www.legifrance.gouv.fr/> Decree No. 97-555 Concerning the National Consultative Ethics
Committee for Health and Life Sciences (1997): available at:
<http://www.ccneethique.fr/english/start.htm> ; Protection of Persons who Participate in Biomedical
Research (Public Health Code, Regulatory Section, Additional Book II, Articles R.2001 to R.2053);
Spain - Medicaments Law 1990; Netherlands- Medical Research Involving Human Subjects Act 1999,
Netherlands, as amended by Decree of 5 March 1999 (Stb. 150) promulgating rules with regard to the
central assessment of medico-scientific research involving human subjects (Decree on the central
assessment of medico-scientific research involving human subjects). Decree of 3 January 2006 (Stb. 39)
amending the Decree on the central assessment of medico-scientific research involving human subjects
(extension of the range of medico-scientific research requiring central assessment)Staatsblad van het
Koninkrijk der Nederlanden, 1999; Law of 20 June 2002 (Stb. 338) promulgating rules governing
medical research.
Michael Hadskis and Peter Carver, 'The Long Arm of Administrative Law: Applying Administrative
Law Principles to Research Ethics Boards" (2005) 13: 2 and 3 Health Law Review 19.
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breach.

The research participant who is harmed in the course of research, whether

through non-disclosure of the harm that could result from participation or the
researcher's failure to meet requisite standards for informed consent, can thus argue
that a duty of care owed by a researcher (or researchers) was breached and resort to
an action in domestic courts for compensation. In the Canadian case of Halushka v
University of Saskatchewan, a student at the University of Saskatchewan was offered
fifty dollars to participate in a clinical trial, in the course of which he suffered cardiac
arrest. The student had been told that a catheter would be inserted into a vein in his
arm but was not told that it would be advanced to and through his heart. The court
found that the researcher had not informed the student of the purpose of the research
and associated procedures. It held that, "the subject of medical experimentation is
entitled to a full and frank disclosure of all the facts, probabilities and options which
a reasonable man might be expected to consider before giving his consent."

An

ethics review committee may also face legal liability on the grounds that the approval
of a study was provided in a negligent way.

In the Canadian case of Weiss v

Solomon, the ethics review committee was found liable for non-disclosure of
material information which caused harm to the research participant (which liability
was to be borne by the hospital which established the ethics review committee).33

See EH Morreim, "Medical Research Litigation and Malpractice Tort Doctrine: Courts on a Learning
Curve" (2003) 4:1 Houston Journal of Health Law and Policy 1.
32
Halushka v University of Saskatchewan, (1965), 53 D.L.R. (2d) 436 (Sask. C.A.). See also Grimes v.
Kennedy Krieger Institute Inc, 782 A.2d 807. See Susan M. Wolf, Jordan Paradise, and Charlisse Cagaanan, 'The Law of Incidental Findings in Human Subjects Research: Establishing Researchers' Duties"
(2008) 36:2 J Law Med Ethics. 184.
33
Weiss v. Solomon (1989) 48 CCLT 280 (Quebec Supreme Court).See Benjamin Freedman and
Kathleen Cranley Glass, "Weiss v. Solomon: A Case Study in Institutional Responsibility for Clinical
Research" (1990) 18: 4 Law, Medicine & Health Care 395. See also, Jennifer L. Gold, "Watching the
Watchdogs: Negligence, Liability, and Research Ethics Boards" (2003) 11 Health Law Journal 153.
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The research participant can also claim that battery occurred against
her if the research took place without her consent.

This situation may arise

particularly in cases where the research participant is undergoing therapeutic
treatment and during the course of the treatment research involving her is conducted
without her knowledge.

Similarly a claim of fraud may be brought against the

researcher or research sponsor where she acts as a result of a misrepresentation by
•jcr

the researcher or the researcher sponsor.

The research participant can also claim

that a fiduciary relationship exists between the researcher(s) and the research
participant, which required the researcher to take special care not to harm the
research participant, a claim that would be stronger if a doctor-patient relationship
also existed between the researcher and the research participant. In the United States
case of Grimes v. Kennedy Krieger Institute Inc,36

where the parents of minor

children brought a negligence action against a research institute affiliated with Johns
Hopkins University for lead-related injuries allegedly suffered by their children
participating in a study concerned with lead abatement in housing, the Appellate
Court found that, as a general rule, a special relationship exists in the research
context between researchers and participants. In the specific context of clinical
trials, which typically entail a doctor-patient relationship, the general law that doctors
have a duty to act in the best interests of their patients, also applies in many

Ian Kennedy and Andrew Grubb, Medical Law (Third Edition) (Oxford: Oxford University Press,
2005) at 1710.
35
Ibid. See also Jaffe supra note 25 at 407-408.
36
Grimes v. Kennedy Krieger Institute Inc 782 A.2d 807. Grimes, 782 A.2d 807, at 846. In the US, a
court has found that a special relationship exists between researcher and research participant, regardless
of whether a doctor-patient relationship existed. See Blaz v. Michael Reese Hosp. Found., 1A F. Supp. 2d
803 (N.D. 111. 1999).
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jurisdictions.

It must, however, be noted that the strict rules of tort would place the

burden of proof on the plaintiff, who may be powerless to produce the required
evidence.38 It may also not be an easy matter to prove causation or the relevant
standard of care.39
Criminal law, especially in regard to assault and criminal negligence,
also regulates research involving humans.

Where a researcher applies force

intentionally and without the consent of the research participant, a researcher may be
criminally liable. Also, where a researcher is under a legal duty under common law
or statute, and acts in reckless disregard for the life and safety of a research
participant, the researcher may be criminally liable. Improper possession of human
tissue samples, for example by possessing them without appropriate consent, may
also constitute theft.40
Administrative law, comprising a set of common law principles that
govern the exercise of public power, understood as "the making of authoritative
decisions affecting the rights or interests of persons in civil society,"

is also

applicable in the research governance context.42 In the United Kingdom, the courts
have extended judicial review to include non-statutory bodies and functions where
the body is providing a public function as ethics review committees undoubtedly

Ian Kennedy and Andrew Grubb, Medical Law (Third Edition) (Oxford: Oxford University Press,
2005) at 1708.
38
See J. K. Mason and R. A. McCall Smith, Law and Medical Ethics (Butterworths, 1994) p.365.
39
Margaret Brazier, "Liability of Ethics Committee and Their Members'" (1990) PN 186 quoted in
Kennedy and Grubb, supra note 37 at 1702.
40
Bernard M Dickens, "Governance Relations in Biomedical Research" in M. McDonald (ed.), The
Governance of Health Research Involving Human Subjects (Ottawa: Law Commission, 2000) at 97.
41
Hadskis and Carver, supra note 30 at 19.
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do.

The situation would be even more clearly the same where there is a statutory

basis for the operation of ethics review committees.

Some administrative law

principles therefore apply to review by an ethics review committee - such as the rules
of natural justice - a fair opportunity to be heard, an explanation of opinions and
decisions, a fair chance of rebuttal, and good grounds for decisions.44

These

principles may also apply to the work carried out by bioethics commissions, such as
the policy structures described in Chapter Three, especially when created under a
legislative mandate conferring on them powers to exercise certain functions.
Other common and civil law principles found in intellectual property
law, contract, and labour law also have an impact of research governance.
Intellectual property laws dictate the intellectual property rights derivable from
research. Contract law and labour law have an impact on research governance, for
instance, in cases where researchers employed by universities are required under
their employment contracts to conduct research according to certain policies or to
comply with certain ethical guidelines. Breach of such contract is actionable in
law.45 In the Olivieri case mentioned in Chapter Three, the sponsor, Apotex, entered
into contracts with the investigator, some of which required her to keep confidential
certain information for a period of time, including information about adverse events
discovered during the trial. Apotex threatened to pursue legal remedies against Dr.
Oliveri for breach of this contractual obligation. This case indicates an area in which
the law (in this case contract law), can conceivably conflict with ethical duties. The

43

See R v Panel on Take Overs and Mergers exp Datafin pic (1987) QB 815. See Kennedy and Grubb,
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matter did not proceed to court, so there is no precedent on how a court would rule in
such a situation, including whether or not the contract would be upheld as valid (in
which case Dr. Olivieri would have been in breach of her contract with Apotex) or
whether the contract would be held null and void for being against public policy.46
Law can also operate in research governance through laying down
rules for entry into relevant professions, and the incorporation of a professional norm
by legislation, thus giving professional guidelines the force of law. Campbell and
Glass point out that courts are empowered to go beyond guidelines to establish legal
norms. More often, however, they refer to the guidelines in determining the legal
standard of care, in the absence of other legislation.47 As discussed in Chapter Three,
these guidelines may be considered soft law, instruments favoured under new
governance arrangements. Similarly, under tort law, courts can refer to, and adopt,
the standards set out in international guidelines such as the Helsinki Declaration or
•d-8

the Nuremberg Code, giving them some legal force.

In essence, therefore, new

governance mechanisms like soft law may interact with the hard law when enforced
by the courts.
Further, decisions made by courts may be applicable in a research
context, even where not specifically relating to a claim arising out of a research

W J Sullivan, "The Law and the Physician as Principal Investigator in Sponsored Clinical Trials"
(2003) 50:5 Canadian Journal of Anesthesia 436 at 439. '
7
Campbell and Glass note that: 'Where legislation explicitly incorporates a professional norm and refers
to it as the standard of care, guidelines will carry the force of law. Otherwise, they will bear no definite
legal authority and will not be considered legally binding.' See Campbell and Glass, in Downie, Jocelyn
et al (ed.), Canadian Health Law and Policy (Second Edition) (Ontario: Lexis Nexislnc, 2002). at 485.
48
The Grimes court, for instance, referred to the Nuremberg Code in identifying the duties of researchers
to those who participate in research. See 82 A.2d 807, at 849. See the Hazel Glenn Beh,"The Role of
Institutional Research Boards in Protecting Human Subjects: Are We Really Ready to Fix a Broken
System?" (2002)26 Law and Psychology Review 1 at 18.
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context.

In the United States case of Abigail Alliance for Better Access to

Developmental Drugs v Eschenbach, for example, the court held that there was no
constitutional duty to provide terminally ill patients the right of access to
experimental drugs that have passed limited safety trials but have not proven safe and
effective. In essence, then, though this case was about access to experimental drugs,
it would apply more widely to other cases, in this instance, indicating the need for
more trials before drugs are made more widely available. The legal duties of
researchers identified in such decisions help define the parameters within which
researchers, host institutions, and research ethics committees must operate and are
thus a crucial part of research governance systems.
The foregoing is by no means an exhaustive account of the law's
impact on research governance. It is, however, obvious that law plays a significant
role, if sometimes indirect, uncoordinated and unplanned role in research
governance. In this respect Dickens writing about the Canadian context observed
that:
Biomedical research involving human subjects
remains governed in Canada by law that is primarily
directed to other purposes. Law applies almost
inadvertently to the enterprise of biomedical
research. Not only does legislation pay litde regard
to biomedical research, but may deliberately exclude
it from coverage.50
Similarly, in many countries around the world, the law provides oversight to
research, but in a manner that is:

Abigail Alliance for Better Access to Developmental Drugs v Eschenbach 495 F. 3d 695 (2007).
Bernard M Dickens, "Governance Relations in Biomedical Research" in M. McDonald (ed.), The
Governance of Health Research Involving Human Subjects (Ottawa: Law Commission, 2000) at 98-99.
(My emphasis).
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piecemeal, uncoordinated, haphazard, issuing from
various federal and state courts applying
constitutional and common law and from federal and
state legislatures and regulatory bodies creating
statutory and regulatory schemes. By the very
nature of how courts work - that is, accepting those
cases brought before them by litigants - courts have
responded issue by issue, and jurisdiction by
jurisdiction, so that the law of one state on a
particular bioethics issue may be opposite that of
another, while a third has not yet considered the
issue at all. Legislatures, in theory at least, have
more freedom to set their own agendas and create
comprehensive statutory schemes, but they have also
tended to react on an issue-by-issue basis, especially
in response to news events or public interest in an
issue.51
As I argue, however, in the next section, this is a situation that needs to change,
especially in developing countries. Legislation can and should play a larger, more
intentional and specific role in developing countries' research governance systems.

4.4.3 The Case for Legislation in Developing Countries
While there is increasing interest in the governance of health research
in many developing countries, and while common and civil law principles and some
legislation may have direct and indirect impact on research governance, most do not
have specific legislation as part of the governance mechanisms regulating such
research. Further, even though some developing countries currently have legislation
dealing with clinical trials for drugs, and some have legislation which encompass
many health matters including establishing ethics review committees (as, for
instance, in South Africa and Nigeria), many lack comprehensive legislation devoted

51

Janet L. Dolgin and Lois L. Shepherd, "Law, Medicine, and Philosophy" in Janet L. Dolgin and Lois L.
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265

to health research involving humans.

It is pertinent therefore to ask broadly again

as I did in Chapter Two: Should law only operate as a legal framework or
background for new governance and an encourager of the regulatory facilities of
organisations or should there be a more extensive role for law in research
governance? My answer, discussed in greater detail below, is that there should be an
extensive role for law in the form of legislation on research governance in
developing countries.
In this section, then, I argue that legal regulation ideally should operate to
protect citizens, preserve their welfare and dignity, and potentially prevent harm as
well as provide an enabling environment for acceptable conduct in research in
developing countries. I contend that specific legislation on health research involving
humans can play a crucial role in the protection of research participants through
providing a legal basis for comprehensive governance systems and addressing
specific issues around which there is some agreement. A comprehensive legal
structure that catches most, if not all, research within its ambit, which extends
protections to all research participants, and which puts in place the basic
requirements is needed in many developing countries. Comprehensive legislation, in
my view, represents the best practical response, providing the protections one can
reasonably expect without sacrificing all the gains that an important activity such as
health research involving humans offers.53

52

In addition, drawing on my hybrid

See the Harvard School of Public Health, "Global Research Ethics Map" online: <
https://webapps.sph.harvard.edu/live/gremap/index_main.cfm?CFID=1294829&CFTOKEN=50159247>
(November 9, 2009). Indeed, many developed countries such as Canada and the United Kingdom also
lack such legislation. But countries such as Spain and Denmark have more comprehensive legislation
devoted to biomedical research.
'" Dworkin, supra note 21 at 155, in relation to the United States regulations.
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framework of governance, comprehensive legislation does not displace other
components of research governance and does not act in isolation. Instead, it provides
a stable, legitimate, and effective foundation within which they can perform
effectively. Below, I make the case for such comprehensive legislation. I begin by
considering the benefits of legislation vis-a-vis other governance mechanisms. I then
consider the need for legislation specifically in developing countries. I also discuss
the possible content of such legislation.
To begin with, why would legislation, understood here as "law made by
elected representatives who may be informed by a large number and wide variety of
sources"

be preferable to any other kind of legal instrument or indeed policy

guidelines? Why not place sole reliance on the institutional framework, in particular
the ethics review committee?

Why not rely on common law and civil law to

continue to right the wrongs that may arise in the course of health research involving
humans? The answer is that legislation is prospective (in that, by comparison to the
common law, it can address issues before they arise), it has the capacity to be more
comprehensive, and perhaps most importantly, it embodies all the authority of law
(unlike guidelines) and has the capacity to protect vulnerable citizens.
Legislation, even where it is only created in reaction to a scandal, can
address issues which have yet to arise in addition to problems that have already
arisen.

Thus, although it may lack the flexibility of the common or civil law,

legislation has the capacity to be prospective and it can be comprehensive,
addressing a whole range of relevant issues. By contrast, courts can only, generally
speaking, address the issues that arise before them and matters relating to health
54

Ibid, at 10.

267

research involving humans may be addressed in a spasmodic manner.

Further, the

common law of tort is reactive and applies only after the harm has been done, and is
thus only indirectly prospective, that is, only with respect to past court decisions
serving to deter harmful conduct. "The common law," writes Dworkin, "is ill suited
to comprehensive, systematic lawmaking. It develops in fits and starts and at any one
time it is likely to contain more holes than fabric."

He notes further that common

law courts have neither the staff nor authority to regulate behavior in detail nor to
supervise ongoing activities,57 matters which can reasonably be provided for in
legislation. The common law undoubtedly has its uses.
comprehensive,

systematic

lawmaking,

instead

of

But reasoned,

piecemeal,

inconsistent,

fragmented lawmaking, in my view, may provide a sounder basis for research to
proceed.

Such legislation will not only provide legal protection to research

participants, but will also provide researchers clear parameters within which research
can be conducted in these countries.
In addition, legislation, the direct fruit of a democratic process, offers
more accountability, uniformity and a more open process for debating issues, and
therefore enjoys more legitimacy. Waring and Lemmens observe that:
[Legislation is debated openly, its provisions are
publicized, and the legislative process provides
accountability.... legislators are subject to the
electoral process and parliamentary debates on
legislative proposals are subject to public scrutiny.
Legislation promotes uniformity and enforceability
and can contain clarifications about the conditions
Jaffe, supra note 25. As Dworkin observes in the federal context of the United States, where state
courts make common law, "for most purposes common law is unlikely to provide uniform, national
resolutions of issues." See Dworkin, supra note 21 at 8.
56
Dworkin, ibid, at 9.
57
Ibid at 13.
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under which vulnerable persons can legally be
participants in research. In short, 'legislation has all
the advantages that have been claimed for
guidelines, and none of the disadvantages.'58
These attributes add to the moral authority of legislation. Legislation is typically
enacted to reflect societal values, and in many ways imbues moral authority in
actions and consequently legitimacy.
Policy guidelines and professional guidance are useful and certainly have
a place in dealing with the kinds of situation which may not always be appropriately
dealt with in law, for instance, where there is continuing controversy and things are
likely to change very rapidly. However, as useful and persuasive as guidance from
national guidelines and professional codes may be, they may not, or may only
indirectly, have the legal, binding and authoritative force that legislation boasts.
Even then, policy guidelines are often offshoots of the legislative process. With
specific respect to professional codes, they may not be as comprehensive since they
typically only regulate the conduct of researchers that are members of the specific
profession. The Nuffield Council on Bioethics notes, rightly in my view, that:
Most of the existing guidance, however, has merely
persuasive force and is only enforceable through
sanctions imposed on members of the profession or
group which was responsible for the particular
guidance. The Declaration of Helsinki, produced by
the WMA, only binds physicians. Similarly, the
CIOMS guidelines only bind members of the
' Duff R Waring and Trudo Lemmens, "Integrating Values in Risk Analysis of Biomedical Research:
The Case for Regulatory and Law Reform (2004) 54:3 University of Toronto Law Journal 249 at 286-287
quoting liberally from Bernard Starkman, 'Models for Regulating Research: The Council of Europe and
International Trends' in David N. Weisstub, (ed.), Research On Human Subjects: Ethics, Law and Social
Policy Elsevier Science, (1998) 264 at 274.
59
As Schneider rightly points out, "But law is not just a structure of regulation backed by force. Law also
enjoys social and moral authority. Laws are often obeyed because people believe they should obey the
law. And people are subtly but truly influenced by the law's expressive capacity (which exploits the law's
power to impart ideas through words and symbols) and by the social force (the force of familiarity,
custom, and legitimacy) acquired by institutions the law supports." Schneider, supra note 14 at 20.
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signatory organisations. Many involved in research
related to healthcare today, however, are not
members of the medical profession and thus may not
be accountable under these guidelines.60

The accountability and legitimacy that should be part of the legislative process is
also largely absent in the development of these guidelines.
Ethics review committees remain important as the part of an institutional
framework that directly considers research protocols. However, they also lack a
comprehensive reach since they must necessarily proceed on a case-by case basis.
Moreover, legislation can provide a legal basis for ethics review, making it a legal
requirement and creating different ethics review bodies. The significance of such
legislative underpinning has been further underscored elsewhere:
However hard they work, however thorough their
examination of research protocols on a case-by-case
basis, however much better constituted and trained,
and however well supported they may be
administratively, unless they have the power to
ensure that all research is submitted to them and to
stop research that they regard as unethical, they will
not be taken sufficiently seriously. For these reasons
and others... there should be proper legislation.

I have considered the benefits of legislation in research governance
generally, but what about legislation in research governance in developing countries
specifically?

One of the most important reasons why legislation as a basis for

research governance in developing countries may be especially necessary is lack of
Nuffield Council on Bioethics, 2002: The Ethics of Research Related to Healthcare in Developing
Countries (London: Nuffield Council on Bioethics, 2002) at 65.
61
S. Verdun-Jones and D .N. Weisstub, 'The Regulation of Biomedical Research Experimentation in
Canada: Developing An Effective Apparatus for the Implementation of Ethical Principles in a Scientific
Milieu' 28 Ottawa L. Rev. (1996) 297 at 316, quoting Neuberger. See J. Neuberger, Ethics and
Healthcare: The Role of Research Ethics Committees in the United Kingdom Research Report (London:
King's Fund Institute, 1992) at 13.
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resources.

Funding is employed in western countries to ensure that researchers

comply with ethical guidelines.

For instance, the Canadian Tri-Council Policy

Statement (TCPS) requires that researchers and research institutions who seek
funding from the three major funding bodies must comply with the TCPS.62 The
United States "Common Rule" has similar enforcement mechanisms.

While some

research is funded domestically, many resource-poor developing countries also rely
heavily on foreign funding of research. Although there are usually requirements for
the ethical conduct of research which accompany such funding, this is regulation
from the perspective of the funders and not from the perspective of country in which
the research is to be conducted. As part of a hybrid framework of governance, such
funding requirements provide some sort of regulation. However, much difficulty is
experienced by developing countries in controlling the types of research that may be
conducted and ensuring that such research is responsive to local needs.64 There are
sometimes differing priorities of external researchers and indigenous researchers and
there is legitimate concern about the power of researchers over research participants
in the resource-challenged contexts of developing countries. As well, there is
inherent tension in producing scientific benefits and protecting research participants.
These circumstances require that there be an authoritative independent mechanism,

" See Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of
Canada, Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement:
Ethical Conduct for Research Involving Humans, 1998 (with 2000, 2002 and 2005 amendments).
63
Protection of Human Subjects: Department of Health and Human Services Regulations, Title 45, Code
of Federal Regulations, (CFR) Part 46. The Federal Policy for the Protection of Human Subjects. See
§46.
54
See M.T. White, 'Refraining International Research Ethics: From Paternalism to Partnership' (2006),
available at: <http://www2.gsu.edu/~wwwphl/ethics/africa_conference/papersAVhite.pdf> (accessed 16
March 2007).
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separate from funding requirements, for the protection of participants in research in
developing countries.
In addition, these countries cannot rely on funding as a means of
regulation as some rich countries do since, to a large extent, they cannot offer or
withhold funding. Moreover, reliance on regulation by funding agencies is not a
comprehensive basis for governance; different kinds of research may be regulated
differently, some may not be regulated at all. There would be no base standard for
engaging in health research involving humans, or comprehensive protection for all
participants.

Further, in the absence of a legislative framework for research

involving humans, there may be inadequate protections for participants in such
research and unclear means for enforcement of compliance with the international
guidelines or any existing domestic guidelines.
Another reason why such legislation is necessary is that, in many
developing countries, legislation is lacking on some of the specific issues that arise in
research. For instance, many developing countries, such as Nigeria, do not have any
legislation on privacy and confidentiality, or the rights of minors, areas in which
many developed countries have legislation.

Comprehensive legislation would

therefore address these and other issues, providing clear legal requirements, rights,
and responsibilities.

The contexts of developing countries, therefore, provide

reasonable grounds for arguments for legislation.
Also, governments of developing countries need to exercise a sense of
ownership with regard to protecting their citizens. In view of the sovereignty of each
nation and the resulting problems for any sponsoring developed country that is
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concerned with in protecting the citizens of host developing countries where their
nationals conduct research in developing countries, national legal regulation on the
part of the developing country may be the best way to protect participants in
research.65 Each country's national laws apply within its territory and principally to
its own citizens.

Laws with extraterritorial effect are mainly enacted for activities

widely condemned such as pedophilia.

Thus, Skene notes that:

It is rare for countries to have laws directly
preventing their nationals doing research overseas
that would not be permitted at home, or even
bringing back the products of such research, unless
they pose a safety risk, such as importing genetically
manipulated organisms created overseas.67
As such, even though some developed countries may wish to provide equivalent
protections for people in developing countries, domestic legislation remains
necessary to protect vulnerable citizens, and the existence of such legislation reflects
a state that is concerned for the welfare of its citizens.
One of the problems that may arise in the area of regulating research
involving humans is that a profusion of ethical guidelines and policies may be
developed. Such profusion may produce confusion instead of providing clarity to
researchers and research participants.

In developing countries, where research

governance is still a relatively new endeavour, the dialogue that necessarily precedes
See William DuBois, "New Drug Research: The Extraterritorial Application of FDA Regulations, and
the Need for International Cooperation" (2003) 36 Vand. J. Transnat'l L. 161; see also, G. F. Tomossy
and J Ford, Globalisation and Clinical Trials: Compensating Subjects from Developing Countries in in B.
Bennett and G.F Tommossy (eds.), Globalization and Health: Challenges for Health Law and Bioethics
(Springer: Dordretcht, 2006) at 30, noting that, despite the difficulties of limited resources 'a substantive
system of research governance entrenched at the national level would be the ideal solution.'
66
L. Skene, 'Undertaking Research in Other Countries: National Ethico-Legal Barometers and
International Ethical Consensus Statements,' PLoS Med 4(2) (2007) elO.
67
Skene ibid., argues,"in the great majority of cases, there are no ethical reasons to prevent scientists
from doing research abroad or using the research results at home, even if the research does not comply
with local laws."
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legislation will improve clarity, with discussions by key stakeholders of the ways to
govern research in such a way as to create an enabling environment for research,
delineate the responsibilities of stakeholders in the research enterprise and protect
research participants.
In addition, policies tend to be more short-lived and less likely to be
adopted by successive governments.

It has been observed generally, in relation to

health policies in developing countries, therefore, that:
Many developing countries have adopted health
policies on an ad hoc or informal basis, with the
result that policies are not memorialised in
legislation and therefore have no force of law.
Enacting policies with no underlying legislation
often means policy initiatives are short-lived and can
be easily repudiated by successive governments.
Even where a country is firmly committed to its
policies, rule of law and existing international
agreements, it is not bound by a policy, much less
programmes, that has not been enacted in
appropriate and enforceable legislation.
To implement relevant policies and plans, and to ensure stability, consistency and
sustainability, legislation is necessary. Legislation can also beneficially serve to
articulate, codify and consolidate values, as well as strengthen and support the goals
and objectives articulated in national policies.
In a similar vein, it is important for there to be a legislative and thus more
legitimate foundation for the work of ethics review committees in developing
countries, which may otherwise operate from a weak position.

Ethics review

committees in developing countries operate in challenging political and socio-

Health Partners International, "Health Policy, Legislation and Biomedical Ethics" online: <
http://www.healthpartners-int.co.uk/our_expertise/health_policy_legislation_and_ethics.pdf> (November
9, 2009).
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economic contexts. They are required to consider general, problematic issues that
accompany health research involving humans but also the special issues that arise in
these contexts, for instance: issues relating to post-trial access to benefit; determining
whether a particular research will benefit the wider community or whether a different
study will be more beneficial to the community given the specific needs of that
community; or the appropriate standard of care to be provided in a challenging socioeconomic context.

Ensuring the independence and legitimacy of these committees

requires that they operate within a statutory framework, not merely national ethical
guidelines.70
The case I make here for employing legislation may, however, attract
opposing views. Legislation (and the legislative process) is not without its flaws.
Dworkin details some of these in his book, Law: The Role of Law in Bioethical
71

Decision Making,

where he describes the ways in which politics interferes with,

and influences the legislative process sometimes negatively, with politicians
undertaking political negotiations between themselves, relying on lobbyists for
expert information, which do not necessarily ensure sound legislation. In developing
countries, particularly those with fledgling democracies, these challenges are of
course greater in magnitude, where electoral malpractice and the failure of elected

C H. Coleman and M Bouesseau, "Strengthening Local Review of Research in Africa: Is the IRB Model
Relevant?" (2006), online: <http://www.bioethicsforum.org/ethics-review-of-medical-research-inAfrica.asp> (June 22, 2007).
Even the international ethical guidelines, like the Helsinki Declaration, recognise that ethics review
committees should be in conformity with the laws and regulation of the country, arguably recognising the
necessity of a legal framework for the work of such committees. See Article 13 of the Helsinki
Declaration.
71
B.R. Dworkin, Limits: The Role of Law in Bioethical Decision-Making (Indiana: Indiana University
Press 1996) at 2..
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leadership to pay attention to matters relevant to their citizenry, amongst other
things, may result in flawed legislation, or no legislation or overall policy direction.
The arguments made above in favour of specific legislation in developing
countries governing health research involving humans may thus raise questions about
the limits of law in such countries. In these countries, the more important question
may not be whether law can have an impact on research governance, but whether in
the specific context of developing countries law is of any use at all. Are laws
generally complied with in developing countries?

Are there adequate means to

enforce legislation in such countries? What about corruption and abuse of power?
One cannot cursorily dismiss the challenges that the rule of law faces in
developing countries or the political and socio-economic realities of such countries.
As I pointed out in Chapter Two, the hybrid framework adopted in this thesis,
including my proposal for legislation-driven governance of research requires some
sort of functional or functioning democracy and a desire by developing countries'
governments to better the lives of their citizens. There may be no viable alternative
to this for, as discussed in Chapter Two, the government and the law remain
formidable repositories of resources and authority.
The potential challenges of enforcement, political commitment, adequate
resources, functioning institutions, in developing countries' contexts, do not, in my
view, obviate the need for a comprehensive legal basis for research governance in
developing countries.

In terms of political commitment, it must be said that a

number of developing countries have begun to tackle, even if imperfectly, some of
the challenging issues. Nigeria, which I focus on as a case study in this thesis,
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recognises the power of law and, as I discuss in subsequent chapters, is moving in the
direction of employing law, although inadequately in my opinion, in the governance
of health research.

Countries like Chile,72 and South Africa,73 have also adopted

legislation as a basis for the governance of health research in these countries. But
many other developing countries, including Bolivia, Jamaica, and Vietnam, have not
enacted legislation to govern health research involving humans.74

In terms of

enforcement, even under imperfect conditions such as exist in developing countries,
legislation creates legal obligations and provides a rallying point for individuals and
organisations. Individuals and organisations would be better able to pressure and
compel the state to meet its obligations to protect research participants by enforcing
compliance.

In developing countries such as Nigeria and South Africa, non-

governmental organisations have had some success in compelling governments to
meet their obligations under the constitution, different legislation, and human rights
instruments.

More broadly, addressing the matter of research governance

legislatively provides the opportunity to build the broader governance capacity of
democratic institutions. The potential of the law to improve research governance in
developing countries should therefore not be exaggerated but neither should the
significant good that it can do in these contexts be overlooked.
Creating basic legal requirements for research would not only provide
protections for research participants but would establish an enabling environment for
Scientific Research Involving Human Beings, Their Genome, and Prohibition of Human Cloning, Law
No. 20.120.
73
National Health Act, Act No. 16 2003.
See OHRP, International Compilation of Human Research Protections, 2010 online:
<http://www.hhs.gov/ohrp/international/HSPCompilation.pdf> (May 30, 2010), which lists many
developing countries and the regulations, guidelines and legislation governing health research involving
humans.
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researchers, who would be equipped with the knowledge of the regulatory structures,
procedures and requirements. Verdun-Jones and Weisstub also note that providing a
legislative basis for the operation of ethics review committees may provide a defence
to a negligence action brought against a researcher where she has acted in good faith
according to a research protocol for which she obtained approval from an ethics
review committee.

Compliance with the law thus offers protections for researchers

and facilitates beneficial research. Legislation could also act as a means of securing
resources, for instance, funding for ethics review committees.

In this way,

legislation would act as a facilitative mechanism as well as a protective mechanism.
The use of legislation will therefore not displace the need for other
components of research governance. It does not, for instance, substitute for effective
self-regulation at the institutional level (institutional ethics review committees or
professional associations).

But legislation has the potential to strengthen these

components of governance and provide a solid foundation for their functioning.
Legislation can address the fundamental weakness of voluntary self-regulation,
which as Ayres and Braithwaite observe, is the possibility that self-regulating actors
will be unwilling to regulate effectively.
In addition to the challenges of the legislative process and the sociopolitical environments of developing countries, a counter argument against
legislation may be that although it is a prospective tool of law, legislation may not
necessarily foresee all the problems and issues that may arise with research involving
humans, an area which is constantly evolving. As such, a legislative approach may
75

Verdun-Jones and Weisstub, supra note 61 .
Ian Ayres and John Braithwaite, Responsive Regulation: Transcending the Deregulation Debate (New
York: Oxford University Press, 1992) at 106.
7
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not be feasible for all the issues that arise. As rightly noted, "changing values,
advances in science, and unanticipated situations combine to create the possibility
that prospective, comprehensive lawmaking will be fundamentally flawed."77
is a legitimate argument.

This

However, it is doubtful that a legal vacuum or an

atmosphere of fragmented and incomplete legal protections for research participants,
is better than enacting a possibly flawed legislation that attempts to protect research
participants, because the legislation does not anticipate all future events. Such an
argument does not detract from the importance of legislation as a crucial tool for
protecting vulnerable research participants, nor does it rebut the argument that
legislation can act as a comprehensive and authoritative basis for research
governance.

In any event, as I discuss further below, the type of legislation

envisaged, is one which addresses the core and basic requirements for the ethical
conduct of research. One of such core requirements may be the requirement for
regulatory authorities to undertake developments as things evolve in certain
instances.
Likewise, the prospective nature of legislation may not necessarily allow
for the evolving nature of fields such as research governance and ethics. Thus it may
be feared that legislation would generate a rigidity which would stifle the conduct of
research, creating worry for researchers who may be concerned about litigation and
penalties.

However, where the legislation is not too detailed as to be too restrictive,

particularly in relation to the powers of the ethics review committees,79

and

articulates basic standards for the conduct of research, the advantages of legally
77

Dworkin, note 21 at 12. See also, Campbell and Glass, note 47 at 486.
Verdun-Jones and Weisstub, supra note 61 at 329.
79
See Verdun-Jones and Weisstub, ibid.
78
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enforceable protections for research participants, clarity and comprehensiveness of
responsibilities and a secure environment within which researchers can conduct
research outweigh the possible disadvantages.

In any event, broad public

consultation prior to enacting such legislation or regulations would be necessary.
on

The need for any sanctions or penalties

and the extent to which certain

controversial ethical issues, such as those around access to post-trial benefits or
standard of care, should be addressed in legislation, can be addressed in such
consultations.
Rigidity need not be an insurmountable obstacle. While it may be
burdensome to amend legislation, particularly with respect to time, financial and
human resources, it is necessary to recognise that amendments may need to be made
to legislation. Indeed, room must be made for such amendments to occur to take into
account changing circumstances, advances in the field of health research, and greater
understanding in research ethics. In other words, such legislation "should not be
01

viewed as an event, but as an ongoing process that evolves with time."

A

mandatory review period provided for in such legislation (as contained for instance
in the Assisted Human Reproduction Act in Canada) would allow the flexibility
needed in an evolving area such as the governance of health research involving
humans.

Certain matters, however, particularly controversial issues on which

opinions revolve on a frequent basis, may not be appropriate matters for the

See B. K. Sovacool, 'Using Criminalization and Due Process to Reduce Scientific Misconduct' 5: 5
American Journal of Bioethics (2005) W1-W7, advocating the use of criminal legislation for the
protection of research participants and to reduce intentional research misconduct.
81
WHO, WHO Resource Book on Mental Health, Human Rights and Legislation (Geneva: WHO, 2005)
at 7.
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legislation.

Such matters can, and should be dealt with in policy or regulatory

guidelines that derive their authority from legislation.
Another argument against comprehensive legislation may be that,
although legislation is said to provide clarity, the uncertainties of and vagaries of
language limit such clarity.82 However, some of the limitations of legislation, as
Dworkin notes, can be remedied by paying special attention to them.83 This would
apply especially to the issues of language and proper drafting.
A different opposing argument would be that with regard to research
governance in developing countries, the major issues that arise would be how to fund
the governance system, provide adequate expertise for conducting thorough ethics
review and ensure the independence of the committees.
different concerns.

These are important but

But again, these do not detract from the argument for

comprehensive legislation. Indeed, the argument that I make here is that, amongst
other things, there should first be a proper foundation for ethics review, preferably a
legal foundation, guaranteeing the important role and function of ethics review
committees. How to ensure that such ethics review is properly carried out is a
separate matter, which does not detract from the need for good legislation, but will in
fact become a more pressing issue to tackle where it is addressed by such legislation.
For instance, as mentioned above, legislation may create a funding scheme, imposing
obligations on the government to create such a scheme, and requiring that research
sponsors pay a small fee to a fund from which ethics committees may be funded.

Dworkin, supra note 21 at 13.
Ibid at 14.

281

Obviously, legislation, by itself, does not make people or organisations
ethical. Researchers must be committed to ethical conduct, and a culture of ethical
conduct in research is a necessity. However, a lack of legislation does not ensure
ethical conduct, but leaves room for exploitation and unethical practices.
Legislation, particularly in the absence of any other strong compliance mechanisms,
may also act as a deterrent against unacceptable conduct.

4.4.4 Content of Legislation
Having made a case for legislation in research governance in developing
countries, several issues may arise, including issues relating to content. One question
that may arise is: what should well-conceived, comprehensive legislation contain? In
my opinion, specialised or dedicated legislation on the governance of health research
involving humans may be best because it is easier to enact than a mixed-model
legislation comprising other matters. There is a greater likelihood that all the
essential aspects of the research governance are addressed, it eliminates the need for
multiple amendments to existing laws, and the process of enacting it provides an
opportunity to raise public awareness about the relevant issues relating to health
research involving humans.

Still, legislation that contains other unrelated matters,

but is comprehensive in its provisions on research governance may suffice.
The Danish legislation on biomedical research: Act on a Biomedical
Research Ethics Committee System and the Processing of Biomedical Research

WHO, supra note 305.
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Projects

is a good example of a legislation dedicated to biomedical research.

Although it covers only biomedical research (thus not including other types of
research covered in the wider umbrella of health research), it provides details of the
organization of the research governance system, the funding of the system, but also
addresses many other issues, including, for instance, conflicts of interest issues.

It

could therefore provide a possible starting point for developing countries interested
in enacting similar legislation. Below I summarise the main matters that such
legislation must deal with. I must emphasise that this is just a broad sketch of what
the legislation should contain.

Developing countries may decide to expand the

contents of such legislation, but the requirements below are, I suggest, basic
requirements that should be contained in such legislation. Such legislation must also
fit within the constitutional frameworks of such countries.
To start with, such legislation should govern all health research involving
humans and stipulate certain basic formal legal requirements.

(It should in fact

cover all research involving humans, but since this thesis is focused on health
research and has made arguments regarding health research only, I will focus here on
legislation on health research involving humans).

It would thus go beyond drug

regulatory processes which many developing countries may have. The legislation
should not be limited to clinical research, although this may cause more immediate
harm than other types of research such as behavioural research. But, as pointed in
Chapter One, even these types of research may result in harm and it would be wise to

Act on a Biomedical Research Ethics Committee System and the Processing of Biomedical Research
Projects 2003 (as amended)online: <http://www.cvk.sum.dk/English/actonabiomedicalresearch.aspx>
(November 6, 2009).
Section 14.
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provide protections for participants in any research and to ensure that no health
research is unregulated.
The basic requirements would include the requirement for all health
research involving humans to undergo ethics review.

As some studies have

revealed,87 not all research conducted in developing countries pass through ethics
review. It is therefore necessary to make it explicit in law and even criminalise
failure to seek such review, creating sanctions for such behaviour. In Denmark, for
instance, it is illegal, and punishable by up to four months imprisonment or the
imposition of a fine, to commence a biomedical research project without the approval
of an ethics review committee or to implement substantial changes in the research
project after commencement without the approval of an ethics review committee.88
Such legislation should require the establishment of ethics review
committees.

It should state which type of organisational structure, whether

institutional or regional committees.89 It should state that research protocols must be
submitted to these committees and elucidate general methods of operation. It should
grant these committees power to review research, to approve or reject research
protocols, propose modifications to research protocols, monitor research, and to
order the discontinuation of research where found to be unethical or unsafe. The
legislation should aim to provide consistency in the rules for the creation,
organization, composition, powers and operation of the ethics committees,90 as well

87

See Section 3.2.1 above.
Section 29 of the Act.
In my opinion, a regional structure may work best for developing countries. I discuss this in subsequent
chapters.
90
Dannie Di Tillio-Gonzalez and Ruth L. Fischbach, 'Harmonizing Regulations for Biomedical Research:
A Critical Analysis of the US and Venezuelan Systems" (2006) Developing World Bioethics 1471-1481.
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as provide secure resources for ethics review committees by addressing sources of
funding, particularly for a national ethics review committee. The provision of secure
resources for ethics review committees in legislation is necessary to ensure the
independence and sustainability of such committees. In Denmark, for instance, the
costs of the regional committees are required to be paid by the county councils,
which in turn can charge a fee payable by research sponsors and research institutions,
thus providing a stable source of funding for the ethics review committees. It even
provides for the reimbursement of members who serve on the regional committees.
Payment for research review might raise ethical questions regarding whether such
payment may undermine the independence of ethics review committees.

But

particularly in resource-constrained developing countries, there may be no viable
alternative. I discuss this in my recommendations for Nigeria.
Thus, in addition to making ethics review a legal requirement, such
legislation should create or recognize other specific institutions, including national
ethics committees and policymaking structures and specify their powers of such
committees, such as the power to create guidelines. Legislation should create
national ethics review committees, which as discussed earlier, are particularly helpful
in easing bureaucratic issues such as those involved in multi-centre research. The
significance of empowering the national ethics review committees to make
guidelines by law is that, depending on the manner in which this provision is
couched, compliance with such guidelines may become mandatory, having a

See section 28 of the Act.

285

derivative force in law. ~ The establishment of these national guidelines would also
be helpful in assuring uniformity of practice among the regional, or institutional
research ethics committees. Such committees should be required to provide public
reports of their activities from time to time, for example, annually.
The law should also provide time limits within which ethics review
committees must reach a decision about whether or not a research project can
The Danish law has similar provisions.93 This is obviously helpful for

proceed.

researchers, and is one example of a situation in which the law undertakes a
facilitative action.

It should also provide a complaints mechanism through which

researchers and research sponsors can present complaints, perhaps to a national
committee where these limits are exceeded. Additionally, the law should delineate
appeal processes for researchers who have submitted projects to ethics review
committees.
It should also define clearly the relationship between the drug regulatory
agency and the ethics review committees to ensure that there is harmony, no
unnecessary duplication of responsibilities or loopholes, and to assist researchers and
research sponsors in understanding what the requirements are.

Similarly, the

proposed legislation should address the place of other existing guidelines,
international or domestic, either by incorporating them or by explicitly recognising
their application or non-application in the country. The legislation should also have

" Bernard Starkman, supra note 58 at 268. Commenting in respect of the legislative approach taken by
the United States, Starkman argues that "[t]he legal basis of the regulations provided an important
rationale for insisting on responsible cooperation with the research review process."
93
See section 10.
94
See section 15.
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a mandatory review period, for instance, every ten years, to take into consideration
any changes in the area of health research involving humans.
With respect to substantive provisions, at the minimum, I suggest that
informed consent, widely recognized as mandatory for the ethical conduct of
research, should be one of the statutory requirements. The details of how to obtain
informed consent should, ideally, be a part of the legislation. It should also include
how to obtain consent in less than ideal situations, such as in emergencies. The law
should also provide penal sanctions for non-compliance with informed consent
provisions.
Such legal regulations should address such issues as legal capacity to
participate in research, legal representation of minors and the protections that must
be available to such vulnerable groups as children, the mentally challenged,
developmentally disabled, and prisoners. The Pfizer incident, which I discuss in the
following chapters, involved children. In the absence of clear legal rules regarding
what constitutes informed consent in the case of children, and who can give such
consent, the safety of children involved in research may be jeopardised. Additional
specific legal protections are needed for vulnerable groups and these should be
provided in legal regulations or legislation.95 As well, it should address the legality
or otherwise of all biomedical research, but particularly non-therapeutic biomedical
research involving children and the mentally challenged, and other persons in
vulnerable situations.

95

See G. Dworkin, Law and Medical Experimentation: Of Embryos, Children and Others with Limited
Capacity 13 Monash ULR (1987) 189, noting that: "There seems to be a strong case for general
legislative consideration, and clarification of the power to give proxy consent for the purposes of research
on children."
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Further, such legislation should deal with privacy and access to
information issues. It should also provide for issues relating to adequate health
insurance for research participants and compensation for injury or harm to
participants. Given the additional protection that research participants require and
the fact that many developing countries lack public health insurance schemes, this
should be an area that should be covered in legislation. A compensation scheme
should be provided for by such legislation such that healthy volunteers in clinical
trials will receive compensation for any injury resulting from participation in such
trials.

According to Burris, such compensation scheme is a structural reform that

does not depend on virtue or participant autonomy to prevent harm, but recognises
that some harms will occur in any case.

But he also questions whether a fault-

based system would repeat the malpractice system's combination of under-and-overclaiming, and if a compensation scheme is worth the effort and cost, given that the
research participants volunteered and harm from research is arguably rare.

It is

debatable that a compensation scheme is not needed because a research participant
volunteered; indeed it could be argued that this is the very reason why such a scheme
is necessary.

Research-related injury may be rare but may be devastating when it

does occur. A compensation scheme provides potential participants with protections,
but also the public with confidence that research volunteers will be adequately taken
care of in the event of any harm.

yb

S. C. Chima, 'Regulation of Biomedical Research in Africa" (2006) 332 BMJ 848-851.
Scott Burris, "Regulatory Innovation in the Governance of Human Subjects Research: A Cautionary
Tale and Some Modest Proposals" (2008) 2:1 Regulation and Governance 65 at 82.
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Conflict of interest issues should also be addressed in such legislation.
The Olivieri case provides an example of a situation where legislation would have
been useful. In that case, if legislation had made it clear that all adverse events must
be reported by law, then any contract with a research sponsor stating otherwise
would have been illegal in that respect. It should be made statutorily mandatory for
adverse events discovered in the course of research to be reported to participants, the
drug regulatory authority, and the ethics review committee which approved the trial.
Where this is a clear legal requirement, a research sponsor would be unable to legally
insert a clause in a contract with an investigator or researcher not to provide such a
report to the relevant persons.

Whistle-blower protections should also be provided

under these laws, so that an investigator or any person who makes a confidential
report about unethical practices in research receives clear protection under the law.
Beyond these, the law should also provide for a mechanism that is increasingly
accepted around the world as necessary in ensuring ethical conduct in health
research, namely, registration of trials in clinical trial registries." The law should
mandate the establishment of such a registry, and make it compulsory for all clinical
trials to be registered in such registry to ensure that it is known at any given time
what trials are ongoing in the country, and be better able to monitor these trials.
Such legislation should also address issues that will begin to arise as
ethics review becomes more entrenched in developing countries, including issues
relating to the legal liability of ethics review committees and insurance for ethics
review committees. In the absence of any law creating ethics review committees and

99
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defining their responsibilities and their legal liability, certain difficulties arise for
research participants in establishing the liability of these committees.10

Difficulties

may also arise for members of these committees in defending themselves in the
absence of any statutory limitations on the degree of possible liability. A system of
liability created by legislation may be more appropriate, both for ethics review
committees whose role is to protect research participants, and for research
participants who require protection.
The foregoing is, as stated at the outset, only a broad sketch of what such
legislation should cover. Legislation on research governance in developing countries
could therefore go beyond the matters proposed here. Developing countries must
take into consideration their contexts and their peculiar challenges in enacting such
legislation. Broad-based consultations with key stakeholders in which vigorous
debate is permitted and an understanding of what other jurisdictions have done in
these areas will obviously be a necessary precursor to a successful enactment of
legislation that has the potential of being effective in promoting health research and
protecting research participants in such research. Enactment of such legislation
would also have to fit within the framework of a country's constitutional distribution
of powers and be consistent with other law in place, including for instance, human
rights laws.101

See M. Brazier, 'Liability of Ethics Committee and Their Members' PN (1990) 186, quoted in Ian
Kennedy and Andrew Grubb, Medical Law (Third Edition) (New York: Oxford University Press, 2005) at
1702. These arise from difficulties in establishing the legal status of ethics review committees.
101
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4.3 Recognition of the Relationship between the Ethical, Legal and Institutional
Frameworks
In Chapter Two, I argued that a hybrid governance framework, as
articulated in this thesis, can be helpful in determining whether current governance
arrangements, including different mechanisms and frameworks, in any country is
likely to help the delivery of better outcomes.

In Chapter Three, I described

generally many of the mechanisms within the ethical and institutional components
employed in governing research in different countries. And above, I argued for the
use of legislation as a foundation for research governance in developing countries.
However, as I have described in those chapters, each of these components has
systemic challenges, whether from their non-existence, from lack of proper use, or
from lack of the mandate or authority to operate more broadly, or from the
challenging context in which they have to operate, particularly in developing
countries. None of the components, it seems, can work by itself to achieve effective
governance of health research involving humans.
It is important to recognise that each of the components brings something
important to the governance of health research involving humans - ethics lays the
value foundation and gives the reason for governance, the legal framework regulates
behavior and lends the "punch" of legal force, and the institutional framework
actuates both the legal and the ethical frameworks. It seems to me, then, that to put
the different components of research governance in silos, whether in scholarship, or
in the actual operation of these components in different jurisdictions, without
realising that they may be more effective
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when they work together, is

counterproductive.

For instance, the issue of ethics review committees, which I

have categorized under the institutional framework, has received so much attention
in the literature that they may therefore be mistakenly considered the governance
system.

McDonald describes accurately this tendency to reduce the governance

system to ethics review, observing that:
[T]he ethics review process by the REB has come to
be, in the minds of the major institutional actors and
their constituents, a surrogate for a comprehensive
ethical approach to research involving human
subjects. In effect, countries around the world have
put in place a social system that loads on to the REB
approval process almost the total burden of ethical
responsibilities for human subjects research. That is,
all the major actors (including research sponsors,
institutions, and regulators) behave as if REB
approval is all that there is to the ethical conduct of
research involving human subjects. The REB
process (and with it the focus on the research
proposal and the consent form) has become the
reification of the sum total of responsibilities and
accountabilities for researchers, research institutions,
research sponsors, and research regulators. In effect,
this rationalizes the avoidance of major
responsibilities that arise before, after and on the
peripheries of the REB review process. "

The literature has tended to focus mainly on the work of ethics review committees.
However, for scholars interested in the governance of health research, researchers
involved in health research, research sponsors, and perhaps most importantly for
research regulators, to see the linkages between the different components of
governance is to take a view of the big picture. These frameworks have to work
together to effectively achieve the objectives of research governance.

McDonald, supra note 68 at 9. See also Susan V. Zimmerman, "Translating Ethics into Law: Duties of
Care in Health Research Involving Humans" (2005) 13 Health Law Review 13 at 13.
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Recognition of

these components assists in identifying instances in

which some issues may not be addressed effectively or do not fall within the ambit of
any legal, policy or institutional framework, or inadequacies in sponsor requirements
(such as reporting of adverse events within a clinical trial or disseminating research
findings). Such identification helps then to find the appropriate mechanisms to deal
with such matters.
An acknowledgement of the possible relationship and the interactions
between these components allows us not only to identify possible gaps and
weaknesses in a particular framework, but to determine if such gaps or weaknesses
can be remedied within that framework or, whether a better remedy can be found in
the context of another framework where appropriate. In the foregoing sections, I
have discussed the systemic issues affecting different mechanisms of the institutional
component, and the limitations of law in a developing country context.

A specific

issue in the governance of research may therefore be more effectively dealt with by
addressing it in the context of that particular component, or in the context of all three
components. For instance, the issues of conflict of interest or reporting adverse
events, may be dealt with not only in the domestic ethics policy, but in legislation,
with researchers and ethics review committees then required to carry out their
obligations under both the ethical and legal framework.

A funding mechanism may

be mandated in legislation to ensure that ethics review committees have the
necessary resources to effectively carry out their functions. Employed appropriately,
the work of non-governmental organisations may be helpful in articulating
community concerns and in promoting the enforcement of legislation.
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Moreover, legislation is a type of legal framework, particularly wellsuited to establishing the connections between the frameworks (including other parts
of the legal framework, such as tort) and to facilitating collaborative functioning
between the components.

It is by its nature a "meta-governance" tool. It can,

however, only be deployed in this way if it is designed in new governance ways, with
much consultation, and with the need for responsiveness and effectiveness at the
forefront of legislators' minds.
Finally, the recognition of the possible relationships between these
frameworks may help streamline the legislation, policies and guidelines and assist in
defining the sources of authority for governing the ethical conduct of health research
which, especially in the case of the developing countries may be myriad and yet
insufficient. In doing this, an investigation of the relationships between institutions
which conduct research and the relationships between the institutions which regulate
research becomes possible. This would in turn help researchers in navigating the
regulatory requirements and ultimately result in better governance of health research.
A systematic approach that recognises the relationships between all three
frameworks, both in scholarship and in the actual operation of these frameworks
would be beneficial.

4.3 Conclusion
In my hybrid framework, I argued that law, as a policy option of the
state, brings something important to research governance. In the foregoing pages, I
have argued that developing countries may need to enact specific legislation devoted
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to health research involving humans. Such legislation does not operate in isolation
nor does it substitute for other components of research governance, including those
which operate as self-regulation. Legislation may, however, provide a firmer, more
legitimate basis for the functioning of other components of research governance.
Legislation inherently incorporates aspects of other components of research
governance, conferring on then legal affirmation and authority, creating appropriate
sanctions not guaranteed within other governance frameworks. I have also described
some of the areas that, in my view, should be covered by such legislation.
I have also argued that the systemic challenges, and the weaknesses in
the operation of each of the frameworks requires that there be better recognition of
the possible relationships that exist and should be present in the operation of these
frameworks.
Having set the stage in this chapter and in the three chapters that
preceded it, in the chapters that follow, I will address specifically governance
arrangements in Nigeria.
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Chapter Five
Research Governance in Nigeria: Context and History

5.1 Introduction
Nigeria is a low-income developing country in Sub-Saharan Africa. It is
Africa's most populous country, with an estimated population of over a hundred and
fifty million people, approximately a quarter of Africa's population.1 It is also the
eighth most populous country in the world.

Nigeria is the eighth largest oil

exporting country in the world and the largest oil producer in Africa.3

Although

blessed with oil, and a large human population, Nigeria has been besieged by
political instability, weak leadership, military rule, human rights abuses, ethnic and
tribal conflicts, corruption, mismanagement, and many squandered opportunities to
effectively utilise its relatively vast resources to provide a high standard of living for
its many citizens.

Notwithstanding these weaknesses Nigeria remains, a "sub-

regional hegemon,"4 "crucial to the future of Africa: the continent's most populous
country and its largest economy after South Africa," "Africa's greatest contradiction

1

World Bank, World Development Indicators 2008 (New York: World Bank, 2008). The Central
Intelligence Agency (CIA), World Factbook: Nigeria, online: <
https://www.cia.gov/library/publications/the-world-factbook/geos/ni.html> (December 27, 2009).
2
Central Intelligence Agency, "Country Comparison: Population" in the World Factbook, online:
<https://www.cia.gov/library/publications/the-world-factbook/rankorder/2119rank.html> (March 2,
2010).
3
BBC, "Nigeria: Facts and Figures" online: <http://news.bbc.co.Uk/2/hi/africa/6508055.stm71sf>
(June 26, 2009). US Energy Information Administration: Independent Statistics and Analysis,
"Nigeria: Oil" online: <http://www.eia.doe.gov/emeu/cabs/Nigeria/Oil.html> (March 2, 2010).
4
L. Bergholm, "Who Can Keep the Peace in Africa?" (2007) 16: 442 African Affairs 147 at 151.
5
Richard Synge, "The Role of Nigeria in the Evolution of West African Regional Security and
Democratisation: Contradictions, Paradoxes and Recurring Themes" (1999) 13:1 Cambridge Review
of International Affairs 55
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... at once the continent's greatest hope and its biggest danger,"6 and, because of its
vast oil and human resources, significant on the world stage.
Nigeria has recently taken several steps with respect to research
governance and provides an interesting context within which to study research
governance in a developing country. In addition, there are significant possibilities for
health research. In this regard, it has a large population, thus providing a large pool
of potential research participants, and also a significant and growing number of
potential researchers. It also has a significant burden of disease, and thus a great
need for health research. With the great need for health research and a large pool of
potential research participants, there is a corresponding need to ensure that whatever
health research takes place occurs within clearly defined parameters.
Despite its oil wealth, Nigeria also has many economic challenges and
myriad problems, including high levels of poverty. Politically, its democracy is still
at a nascent stage. And with respect to health, there is a significant burden of disease
and a weak health system. These characteristics are emblematic of many other
developing countries, particularly in Africa. In these respects, Nigeria provides a
good case study. Its actions with respect to research governance have the potential to
influence other developing countries in their research governance efforts. The efforts
of other countries will, of course, have to be tailored to fit their contexts more
precisely.

6

W. Wallis, "Africa's Greatest Hope—And Danger" Newsweek (February 11, 2002) at 24.
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The objective of this chapter is to provide background information on
Nigeria, and the history of research governance efforts in the country. It aims to
describe the context in which the governance of health research involving humans in
Nigeria takes place. In this chapter, I provide a description of health research in
Nigeria, the health system in which this takes place, and the political and legal
context in which this system operates.

I consider the historical background of

research governance in Nigeria. The history provided here is drawn from bits of
information from various sources, and presents a more comprehensive and detailed
picture of the history of research governance in Nigeria than is currently available.
As part of this history, I consider also the major instance of unethical conduct of
research in Nigeria, the Pfizer incident. This incident has received much attention in
the literature and has become a conspicuous example of the potential room for
exploitation that exists in many developing countries. The discussion of the context
and the history of research governance will reveal some of the issues that need to be
addressed as the emerging governance system is developed.
This chapter is broadly divided into two main parts. The first provides
information on the political and legal context, and on the health system in Nigeria.
The second part provides a history of research governance. The chapter is composed
of seven sections. The first section is this introduction. The second section describes
the political background and the legal context. The third section describes Nigeria's
health profile and health system. The fourth section provides a description of health
research in Nigeria. The fifth section attempts to construct a history of research
governance in Nigeria. It also considers allegations of unethical research in a bid to
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create an appropriate context for the need for research governance in Nigeria and to
identify gaps in research governance and regulation in Nigeria.

The sixth section

draws some conclusions from the history of research governance and the discussion
of the Nigerian context and identifies issues that arise from Nigeria's history of
research governance. The seventh section concludes the chapter.

5.2 Political and Legal Context
Nigeria is a former British colony which will celebrate fifty years of
independence in October 2010. Nigeria is a democratic federal republic with a
multi-party political system. After thirty nine-years of independence, twenty-nine
years of which were spent under military rule, it has, starting in 1999, operated as a
new democracy.7

Although democracy in Nigeria is still very much a work-in-

progress, it remains clear that to many Nigerians, and in light of some achievements
under the democratic regime since 1999, a flawed democracy is better than
authoritarian military rule.8 Many hope, therefore, that the days of military rule will
remain in Nigeria's historical past.

One of the achievements of this recent

7

This is Nigeria's longest experience of democracy. Although the general elections in 2007 resulted
in the first ever handover of political power from one civilian government to another in Nigeria's
history, the elections were criticised by domestic and international observers for pervasive voterigging and fraud. Rotimi T Suberu, "Nigeria's Muddled Elections" (2007) 18:4 Journal of
Democracy 95.
8
Many surveys indicate that Nigerians like and support the idea of democracy. Michael Bratton and
Robert Mattes, "Africans' Surprising Universalism" (2001) 12:1 Journal of Democracy 107 at 112.
And according to Bradley, "The research on attitudes toward democracy in Nigeria looks favorable in
terms of citizens wanting and demanding it. For example, Lewis and Bratton (2000) found that in
general Nigerians have a fervent attachment to democratic values and electrifying optimism about the
benefits of democracy." Matthew Todd Bradley "Civil Society and Democratic Progression in
Postcolonial Nigeria: The Role of Non-Governmental Organizations" (2005) 1:1 Journal of Civil
Society 61.
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democratic period may be the recognition of the need for new legislation to deal with
various recent concerns such as the governance of health research involving humans.
Under the Constitution of the Federal Republic of Nigeria 1999
(hereafter, the 1999 Constitution),9 Nigeria operates a presidential system of
government in a federal state, with powers divided between the federal, state and
local governments.10

The country comprises 36 states11 and a Federal Capital
i o

Territory, and 774 local government areas.

Each of the states is administered by a

governor (the head of the executive branch), and has a House of Assembly, the
legislative arm of government and a judicial arm of government comprising state
courts. The federal government is headed by a President. The bicameral National
Assembly (comprising the Senate and the House of Representatives), whose
members are elected from federal senatorial districts and constituencies, makes
federal laws. The judicial system is comprised of several courts, the highest of which
is the Supreme Court.13 Each local government area is administered by an elected
executive chairman. There is also an elected local legislative council, with members
from electoral wards.

9

Constitution of the Federal Republic of Nigeria, 1999 (CFRN). Yusuf notes that: "it has been
accepted that only a federal polity can ensure equity and protect the rights of hundreds of minority
groups amalgamated by colonial power into a nation state." See Hakeem O. Yusuf, "The Judiciary and
Political Change in Africa: Developing Transitional Jurisprudence in Nigeria" (2009) 7:4 International
Journal of Constitutional Law 654 at 669.
10
Section 2 (2) of the Constitution states that the country shall be a "Federation consisting of States
and a Federal Capital Territory."
"Politically, the country is divided into six geo-political zones - North West, North East, North
Central, South East, South South, and South West.
12
Adetunji Labiran et al, Health Workforce Profile for Nigeria (Federal Ministry of Health, 2008),
online: <http://www.afro.who.int/hrh-observatory/country_information/fact_sheets/Nigeria.pdf>
(January 25, 2010) at 13.
13
See Section 6 of the Constitution.
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In theory, although state are designed to remain fairly autonomous,
following years of military rule in which power was concentrated in the federal
government, the federal government holds much power and resources. According to
Yusuf,
The federal government has acquired so many
powers that it has come to exercise control over
virtually every aspect of day-to-day governance. It
not only controls foreign affairs, the security
agencies, the armed forces, and currency, it also
exclusively controls or oversees commerce and
trade, social security, labor, weights and measures,
and vital aspects of land policy within the states. It
has effectively taken over the arena of "ordinary
governance," extending well beyond the regular
spheres contemplated for a central government
within a regular federation. Predictably, this
dominance by the federal government has secured
for it a disproportionate share of the country's
resources.14
The dominance of the federal government in practice alongside the constitutional
distribution of powers is relevant to note in the discussion of governance and
regulation of health research involving humans in Nigeria. This is because of the
concurrent nature of the powers of the federal and state governments in matters of
health, research, and education as I discuss briefly below and also in Chapter Six. It
is also important to underscore this because, as the history of research governance in
Nigeria indicates, the federal government has taken steps to regulate health research,

See Yusuf, supra note 27 at 667, noting that. See also, Said Adejumobi, "Civil Society and
Federalism in Nigeria" (2004) 14: 2 Regional and Federal Studies 211. See generally, Crisis Group,
"Nigeria's Faltering Federal Experiment" Africa Report Number 119 (October 2006),
online:<http://www.crisisgroup.org/library/documents/africa/west_africa/119_nigerias_faltering_feder
al_experiment.pdf> (January 20, 2010), particularly from 2-4. See also generally Olowu, supra note
21, discussing the centralised federal government system that Nigeria runs.
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whereas the states have not. I discuss the arising concerns in this regard in Chapter
Six.
With respect to the legal context, an assortment of different types of
law, including the common law (which is the result of its English colonial heritage),
customary law which recognise the customary practices of different ethnic groups,
Islamic law, many statutes, and, most importantly, the constitution, operate in the
country.
In the 1999 Constitution, there is no clear-cut delineation of
responsibilities with respect to health, between the federal, state and local
governments. Rather, health is on the concurrent legislative list in the Nigerian
Constitution.15 Thus, health is a matter in which the federal and state governments
have concurrent powers, with the state subordinate to the federal government in any
area of health in which the federal government has made a generally applicable law.
It has been noted, in this regard, that the concurrent responsibilities of all the levels
of government - federal, state and local - in the provision of health care has led to
"chaotic coordination and communication, poor accountability, and considerable
disparities throughout the country."
With regard to health research, the federal government through the
National Assembly may make laws to regulate or co-ordinate scientific research,
including health research involving humans.

In addition, matters relating to drugs

See the Constitution of the Federal Republic of Nigeria, 1999 (CFRN), Second Schedule. The
concurrent legislative list also provides that the functions of the local government council shall
include the "provision and maintenance of health services." Fourth Schedule of the Constitution.
16
Sally Hargreaves, "Time to Right the Wrongs: Improving Basic Health Care in Nigeria" (2002) 359
The Lancet 2030 at 2030.
17
Section 21, Second Schedule, Part II of the CFRN.
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are within the exclusive powers of the federal legislative body, the National
Assembly.18 This does not prevent the state legislature (the House of Assembly)
from establishing institutions or making any arrangements for the purpose of
scientific research.19

Also, under the Revised National Health Policy 2004, which

contains Nigeria's policy on health, the federal government is responsible for policy
formulation, guidance, coordination, supervision, monitoring and evaluation.20
In the area of health, and specifically in the area of research
governance, then, the federal government can set uniform minimum standards,
allowing the states to legislate, provided that such state law does not conflict with the
basic federal law. As discussed more fully in the subsequent pages, it would appear
that the federal government has been more active in the area of regulating research
than the states, mainly through the creation of a national regulatory body for new
drug approvals, the National Administration for Food and Drug Administration
(NAFDAC), and a national ethics review committee, the National Health Research
Ethics Committee. While a strong federal government may have its problems in
other areas, its current role appears to make room for a national and uniform system
of research governance which, as I discuss a little further below, is beneficial for
Nigeria.
In addition to the creation of a national drug regulatory agency and the
national health research ethics committee, a federal bill is currently going through the
legislative process to provide a comprehensive health approach for the country,
18

Section 26, Schedule 2, Part I, of the CFRN.
Section 22, Schedule 2, Part II of the CFRN. The Federal Government has created the Ministry of
Science and Technology which oversees research in Nigeria.
20
See, Federal Republic of Nigeria, Revised National Health Policy, (Abuja, Federal Ministry of
Health, 2004).
19
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defining the roles and responsibilities of the three tiers of government and other
stakeholders in the system. This process had begun with the last administration,
following the recognition in the Revised National Health Policy 2004 that:
One of the major weaknesses in the health sector
currently is the non-existence of some important
health legislations [sic] and the outdatedness,
contradictions and ambiguities of some existing
health laws. For example, the 1999 Constitution fell
short of specifying what roles the various levels of
government must play in the national health care
delivery system. Therefore, one of the important
health legislations [sic] that need to be put in place is
the National Health Act which shall define the
national health system and spell out the health
actions of each level of government, among other
things. Indeed, such an Act is necessary in order to
give legal backing to this revised policy.21

The National Health Bill was passed by the National Assembly in May, 2010.

It

has, however, not yet being signed into law by the President.23 The aim of the Bill is
to "provide a framework for the regulation, development and management of a
national health system and set standards for rendering health services in the
federation, and other matters connected therewith."24 It is enacted primarily to define
the roles and responsibilities of the federal, state and local governments in the
national health system and ensure effective linkages between the three levels of
government. It will also provide a legal basis for the operation of the National
Health Policy. More relevant for the purpose of this thesis, the Bill also provides for
the establishment, composition, tenure and functions of the National Health Research
Chapter 10, section 1 of the Revised National Health Policy.
Adibe Emenyonu, "Withhold Assent on National Health Bill, Lab Scientists Tell Jonathan"
Thisday, June 1, 2010.
23
Federal Republic of Nigeria, National Health Bill, 2009.
24
See Long Title of Bill.
22
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Ethics Committee and the establishment and functions of health research ethics
committees. I examine these provisions in more detail in Chapter Six.
Aside from the Constitution and domestic legislation, Nigeria is a
signatory to international human rights instruments that have implications for the
rights of persons who participate in health research. Such human rights instruments
include the International Convenant on Civil and Political Rights

which provides

in its Article 7 for the requirement of informed consent as a prerequisite to
participation in medical research.26
One of the main problems that may affect governance and regulation
efforts in Nigeria is corruption. Systemic corruption in Nigeria has been written
about extensively elsewhere.

Corruption is a serious problem because it reduces

the resources available to tackle problems, including health-related problems that
affect the citizenry.

Corruption could also subvert regulatory controls, allowing

private interests to capture public lawmakers and administration who develop
regulations or regulatory agencies that implement such regulations, to the detriment
of the public. It may put the lives of the citizenry in jeopardy by allowing unsafe
practices by the private sector for profit motives, (such as, permitting the importation

~ International Covenant on Civil and Political Rights, G.A. res. 2200A (XXI), 21 U.N. GAOR Supp.
(No. 16) at 52, U.N. Doc. A/6316 (1966), 999 U.N.T.S. 171, (entered into force March 23, 1976).
Nigeria, however, operates a dualist system of law and thus requires the domestication of
international treaties for domestic operation in the country. Nigeria has not domesticated the
International Covenant on Civil and Political Rights.
In 2003, Transparency International ranked Nigeria the most corrupt country out of 133 countries.
In 2005, Nigeria was ranked the sixth most corrupt country out of 186 countries. See James T. Gire,
"A Psychological Analysis of Corruption in Nigeria" (1999) 1: 1 Journal of Sustainable Development
in Africa 1.; S.T. Akindele, "A Critical Analysis of Corruption and its Problems in Nigeria" (2005) 7:
1 Anthropologist 7. R. S. O. Wallace, 'Growing Pains of an Indigenous Accountancy Profession: The
Nigerian Experience" (1992) 2:1 Accounting, Business and Financial History. Transparency
International, Global Corruption Report 2009: Corruption in the Private Sector (London: Pluto Press,
2009) at 4, 201-203.
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and sale of counterfeit drugs as has occurred in Nigeria). With respect to research
governance, corrupt behaviour could potentially permit unsafe and unethical
practices in the course of health research involving humans.
The ongoing efforts to root out corruption in Nigeria have met with
mixed results and, frequently, a questioning of motives, zeal, credibility, legitimacy,
and efficacy.

Yet there have been some successes, particularly in the health area.

In this regard, Nnamuchi notes that:
With the demise of military dictatorship in 1999
came new expectations and rekindled hope for a
change in status quo. Perhaps, as a result, the
democratically-elected administration introduced
several innovative policy initiatives some of which
are presently being implemented at the different
levels of government. The aim of these initiatives is
to restructure and revamp the health system, and
concomitantly realize the goals of the recently
revised National Health Policy and health-related
goals of the Millennium Development Goals
(MDGs). Although the process has been far from
perfect, the development and implementation of
these programmes represent a significant departure
from the errors and deficiencies of the past.

Dora Akunyili, "The Fight against Counterfeit Drugs in Nigeria" in Transparency International,
Global Corruption Report: Corruption in the Private Sector, 2006 (London: Pluto Press, 2006), at 96100.
29
See Shola J. Omotola, "Through A Glass Darkly': Assessing the 'New' War against Corruption in
Nigeria" (2006) 36: 3-4 Africa Insight 214. See also, Osita N. Ogbu, "Combating Corruption in
Nigeria: A Critical Appraisal of the Laws, the Institutions and the Political Will" (2008) 14 Annual
Survey of International & Comparative Law 99. Recent efforts include the passing of the Corrupt and
Other Related Offences Act No.5 of 2000 (ICPCAct), the establishment of the Economic and
Financial Crimes Commission (EFCC) under the Economic and Financial Crimes Commission Act,
2004, the Nigeria Extractive Industries Transparency Initiative Act 2007 which aims to facilitate
transparency in the extractive industries, which account for more than 80 per cent of Nigeria's foreign
earnings, and the enactment of the Public Procurement Act 2007, which aims to ensure more
transparency in procurement, increases the fines for corruption and abuse of public funding, and
creates the new Bureau for Public Procurement.
30
Obiajulu Nnamuchi, "The Right to Health in Nigeria" ('Monitoring the Right to Health: a MultiCountry Study', University of Aberdeen), online:
<http://www.abdn.ac.uk/law/documents/Nigeria_%20210808.pdf> (January 26, 2009).
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Recent efforts such as those by Nigeria's drug regulatory agency against counterfeit
drugs,31 and the creation of different initiatives under democratic regimes to tackle
the problem of HIV/AIDS after years of neglect by military governments,32 suggest
that corruption can be mitigated33 and that the necessary political will to undertake
requisite reforms can be found. Recent reforms, as I discuss further below, have also
included steps to create a legislative basis for research governance in Nigeria.
It would be easy to throw one's hands up in the face of Nigeria's many
problems and fledgling democracy. One could engage in a justified polemic about
the challenges Nigeria faces, particularly with regard to democratic governance. It
would be naive if not impossible, then, to proceed with any analysis of research
governance as though there were no obstacles in the way.

Context is important.

However, taking refuge in extreme cynicism and resignation is unhelpful and
unlikely to solve any problems, including those of ensuring the promotion of
necessary and beneficial health research and how to regulate such research.

" The government has recorded successes in recent years in the efforts to eliminate the sale of fake
and adulterated drugs, estimated to have been about 70 percent of all drugs in the country, at one time.
The NAFDAC, "hitherto an inept, moribund and corrupt institution, has launched an elaborate
campaign seeking to restore integrity to the pharmaceutical industry. In furtherance of its campaign,
the agency has shut down many local pharmaceutical businesses and blacklisted several foreign-based
manufacturers of counterfeit drugs, mostly in India and China. NAFDAC s resurgence and
clampdown on peddlers of adulterated drugs have spurred a growth in local production, reported to
have surged to 35% in 2002 and currently stands at 40%. Another positive outcome has been a drastic
reduction in the volume of fake drugs in circulation, reportedly 10% in 2001." See Obiajulu
Nnamuchi, "The Nigerian Social Health Insurance System and the Challenges of Access to
Healthcare: An Antidote or a White Elephant?" (2009) Medicine and Law, Akunyili supra note 28.
Owen Dyer, "New Report on Corruption in Health" (2006) 84:2 Bulletin of the World Health
Organisation 84 at 85.
32
These include the creation of the National Agency for the Control of AIDS (NACA) in 2000, and
government initiatives to provide access to antiretrovirals.
33
Transparency International ranked Nigeria 147th out of 179 countries surveyed in a recent report,
an improvement from its 2001 report, 90fh of 91 countries. See, Transparency International,
"Corruption Perception Index 2007, online:
<http://www.transparency.org/policy_research/surveys_indices/cpi/2007> (January 27, 2010).
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Further, given the difficulties facing the Nigerian polity, the governance
of health research may be argued to be low on the list of challenging concerns that
must be tackled. I have already argued in the first chapter, but it bears reiterating
here that developing countries like Nigeria need health research and that governance
of such research is necessary to retain public trust and prevent unethical behaviour.
To argue that other challenges must be taken care of before seeking to regulate health
research in Nigeria is unhelpful, given that health research continues to be conducted
in Nigeria in the face of other challenges that exist. More importantly, even greater
levels of health research are needed to gain an understanding of, and to provide
treatments for the many diseases afflicting the Nigerian population.

Moreover,

recent efforts in Nigeria with respect to research governance show that arguments
against regulating research would be belated, if not without merit.
Government input in research governance in Nigeria is necessary. Yet it
is also true that the most basic problems of Nigeria are lack of good and effective
political leadership.34 There is obviously, then, much to be said for - and much that
has been said about - good political governance in Nigeria and other developing
countries.

Still, practically, the government, for all its flaws and weaknesses,

remains the possessor of the largest resources, the vehicle for lawmaking, the
interpreter and enforcer of law, the actor in whom responsibility lies for making
crucial decisions about health, and on whom lies the obligation for providing
protections for citizens including in health research.

The many calls for better

political governance in Nigeria in various forums and literature implicitly recognise

34

Chinua Achebe, The Trouble with Nigeria (Oxford: Heinemann, 1983) at 3.
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this.

Further, good political governance can perhaps best be nurtured through

effective governance on important specific policy issues such as the governance of
health research. With respect to the concerns of this thesis, it is unarguable, even
from a human rights perspective, that the government ought to be concerned with
both the facilitation of health research, but also, more importantly, for the safety of
the public. Further, the fact that the government has been a crucial actor in some of
the research governance initiatives puts it squarely in the middle of any analysis on
developing the research governance arrangements in Nigeria.
But the weak legitimacy and accountability of the government means that
placing total reliance on the government with respect to building research
governance structures and arrangements is insufficient, if not impossible, and that
other actors such as the professional associations, research sponsors, and nongovernmental organisations, are crucial. These actors are necessary to provide a
check on political actors.

These actors, however, lack the inherent political

legitimacy that accrues to government as well as a comprehensive reach. They may
also not necessarily be free from the concerns that arise with respect to the
government.

Nor can they provide a uniform and comprehensive system of

governance.
In analysing and making recommendations for improvements in research
governance in Nigeria, then, what is needed is a positive approach which recognises
and does not belittle, but is also not resigned to, the enormity of the challenges. In
addition, a synergistic approach, which effectively employs different sectors of the
Nigerian polity to ensure effective governance of health research, is required.
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Further, it is also necessary to develop ideas to ensure that the structures that have
already been put in place work as effectively as possible in the Nigerian context to
provide protections for research participants and with as little duplication of efforts
and resources as possible. A hybrid framework of analysis as proposed in this thesis
seems therefore apposite for examining and making recommendations for research
governance in Nigeria, and this chapter and the next two chapters proceed with this
understanding.

5.3 Health in Nigeria
In this section, I engage in a brief, general description of Nigeria's
health profile, permitting me to lay the groundwork for establishing health research,
and its governance, as a priority for Nigeria.

I begin by describing briefly health

challenges in Nigeria. I then describe the organization of Nigeria's health system.
This brief description is helpful to provide some information on several of the key
institutions involved in health and, consequently, in research governance in Nigeria.
The aim of these descriptions is to create a broad context for the discussion of health
research involving humans in Nigeria.
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5.3.1 Nigeria's Health Profile
In Nigeria, average life expectancy is estimated to be around fortyseven years, indicating a poor health profile. 35 There is a prevalence of infectious,
endemic, emerging, and re-emerging diseases.
of morbidity.

Malaria is the most significant cause

There are also frequent epidemic outbreaks of infectious diseases

such as cholera, cerebrospinal meningitis, measles, tuberculosis, yellow fever and
Lassa fever.37 Nigeria remains one of the few countries in the world where polio is
yet to be eradicated.38
While malaria remains the most prevalent disease, the incidence of
morbidity and mortality from HIV/AIDS is high. It is estimated that about 4.4
percent of the population is infected with HIV, making Nigeria the third in the world
after India, and South Africa, in terms of prevalence.

There is a high prevalence of

tuberculosis in the country, with Nigeria having the world's fifth largest tuberculosis
burden - an estimated 450,000 new cases each year.40 The incidence of maternal
mortality is one of the highest in the world.

35

Child mortality also remains high,

See the Central Intelligence Agency (CIA), World Factbook: Nigeria, online:
<https://www.cia.gov/library/publications/the-world-factbook/geos/ni.html> (December 27, 2009).
WHO, "Malaria", online: <http://www.who.int/countries/nga/areas/malaria/en/index.html> (January
26, 2010).
37
WHO, "WHO Country Cooperation Strategy: Federal Republic of Nigeria, 2002-2007" at 6,
available at <http://www.who.int/countries/nga/about/ccs_strategy02_07.pdf> (January 25, 2010)
(Hereafter, WHO Country Strategy) at 4.
38
David L Heymann and Bruce Aylward, "Eradicating Polio" (2004) 351:13 New England Journal of
Medicine 1275.
39
WHO Country Office Nigeria, "Annual Report 2007," online:
<http://www.who.int/countries/nga/reports/who_2007_annual_report.pdf> (January 26, 2010) at 10.
40
Patrick O Erah and Winifred A Ojieabu, "Success of the Control of Tuberculosis in Nigeria: A
Review (2009) 2:1 International Journal of Health Research 3 at 10; WHO, "Global Tuberculosis
Control: A Short Update to the 2009 Report," (Geneva: WHO, 2009),
online:<http://whqlibdoc.who.int/publications/2009/9789241598866_eng.pdf> (March 3, 2010).
41
WHO, World Health Statistics 2007 (Geneva: WHO, 2007) at 26.
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Nigeria being one of the five countries in the world that contribute to about half of all
childhood deaths of children under the age of five.42
Although efforts are currently being made to meet the 2015
Millennium Development Goals (MDGs),43 which include reducing child mortality,
improving maternal health, combating HIV/AIDS, tuberculosis, and other diseases,
much remains to be done in these and other areas. There is also a growing incidence
of chronic and non-communicable diseases, such as hypertension, coronary heart
disease, diabetes and cancer.44 Nigeria is one of the 23 countries in the world which
account for 80 percent of the deaths from non-communicable or non-infectious
diseases worldwide.45
In sum, then, as noted elsewhere, "the health profile of Nigeria is
characterised by twin epidemics of communicable diseases such as malaria,
tuberculosis

and HIV/AIDS

and non-communicable diseases like obesity,

hypertension, diabetes, cancers, and mental health disorders. In this respect, it is
similar to most other developing countries."

These diseases present challenges that

can be dealt in part through better knowledge obtainable only by research.47

42

WHO,
"Child
and
Adolescent
Health",
online:
<http://www.who.int/countries/nga/areas/cah/en/index.html> (January 26, 2010).
43
United Nations, Resolution Adopted by the General Assembly: United Nations Millennium
Declaration, Resolution55/2, 8 September 2000, online:
<http://www.un.org/millennium/declaration/ares552e.htm> (January 26, 2010)
44
WHO, "WHO Country Cooperation Strategy: Federal Republic of Nigeria, 2002-2007" at 6,
available at <http://www.who.int/countries/nga/about/ccs_strategy02_07.pdf> (January 25, 2010)
(Hereafter, WHO Country Strategy). See also, WHO, "The Impact of Chronic Disease in Nigeria"
online: <http://www.who.int/chp/chronic_disease_report/media/nigeria.pdf> (February 4, 2010).
5
WHO, Report and Development: Coordination and Financing - Report of the Expert Working
Group (Geneva: WHO, 2010) at 2.
46
Clement A. Adebamowo et al, "Developing Ethical Oversight of Research in Developing Countries:
Case Study of Nigeria" in Olayiwola Erinosho (ed.), Ethics for Public Health Research in Africa
(Proceedings of an International Workshop in collaboration with the Special Programme for Research

312

5.3.2 Nigeria's Health System
The National Health Policy, first introduced in 1988, and last revised
in 200448 provides the main policy for health in Nigeria.
provisions on seven key areas, one of which is health research.

The policy contains
One other key area

is the health system and its management. In this respect, the policy provides for a
system, at the apex of which is the National Council on Health, comprising the
Minister of Health and the Minister of State for Health and the State Commissioners
for Health.50
The National Health Policy also provides that the federal government,
operating primarily through the Federal Ministry of Health, is responsible for disease
surveillance, essential drugs supply, and vaccine management.51

In addition, it

provides specialized health care services at tertiary health institutions namely,
university teaching hospitals (associated with medical schools) and federal medical
centres. Recently, some of the federal university teaching hospitals have been named
"centres of excellence," specialising in treatment of, and research on, specific health
issues, cardiac diseases, cancer, infectious diseases, and dentistry.52 More relevant

and Training in Tropical Diseases (TDR) of the World Health Organisation, with the support of the
Federal Ministry of Health, Abuja, Nigeria, April 21-23, 2008) (Ibadan: Social Science Academy of
Nigeria, 2008) at 15.
47
Anthony C. Ikeme, "Nigeria's Clinical Trials Scene" (2008) Applied Clinical Trials.
48
Federal Ministry of Health, National Health Policy and Strategy to Achieve Health for all Nigerians
(Lagos, Nigeria: FMH, 1988); Federal Ministry of Health, Revised National Health Policy, 2004.
49
See Chapter Ten. The other areas are: National Health System and its Management; National
Health Care Resources; National Health Interventions and Services Delivery; National Health
Information Systems; Partnership for Health Development; and Health Research and Health Care
Laws.
50
See Revised National Health Policy.
51
Ibid.
52
These are the Ahmadu Bello University Teaching Hospital, Zaria (Cancer), University of Nigeria
Teaching Hospital, Enugu (Cardiac disorder),Lagos University Teaching Hospital (LUTH), Lagos
(Dentistry), University of Maiduguri Teaching Hospital, (UMTH)Maiduguri (Infectious Diseases) and
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for the purpose of this thesis, the federal government is also responsible for policy
formulation, strategic guidance, coordination, supervision, monitoring and evaluation
at all levels. The federal government can therefore make major policies relating to
health and health research as is evident in the National Health Policy.
The federal tertiary institutions also serve as referral institutions for
the secondary health facilities operated by the states through the state ministries of
health. These include general hospitals and comprehensive health centres. The local
governments are responsible for primary health centres which make referrals to staterun general hospitals. Aside from referrals, there are different interrelationships
between all three levels of government in the operation of the health system. In this
regard the WHO notes that:
Operationally, the decentralized health structures of
the federal government are in the states, while those
of states are in the LGAs. Some states build and
operate tertiary facilities or specialist hospitals.
While the federal government is responsible for the
management of teaching hospitals and medical
schools for the training of doctors, the states are
responsible for training nurses, midwives and
community health extension workers (CHEWs). The
LGAs provide basic health services and manage the
PHC facilities which are normally the first contact
with the health system.53
In essence, then, the federal and state governments operate differently and have
authority over different institutions in which health research might occur.

the University of Ibadan Teaching Hospital (UCH) Ibadan (Oncology). See Chris Ajaero, "Centres of
Decay" Newswatch, May 17, 2009, online:
<http://www.newswatchngr.com/index.php?option=com_content&task=view&id=951&Itemid=l>
(March 17, 2010).
53
"WHO, "WHO Country Cooperation Strategy: Federal Republic of Nigeria, 2002-2007" at 6,
available at <http://www.who.int/countries/nga/about/ccs_strategy02_07.pdf> (January 25, 2010).
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In addition, there are several independent agencies and parastatals of
the Federal Ministry of Health created to deal with various areas of health, which are
part of the Nigerian public health system. These include the National AIDS Control
Agency, National Primary Health Care Development Agency, National Programme
on Immunization Agency, Population Activities Fund Agency, the Department of
Community Development and Activities, the National Health Insurance Scheme, and
more relevant for the purpose of this thesis, the National Agency for Food and Drug
Administration and Control, and the Nigerian Institute for Medical Research.54
With regard to these health system arrangements, the World Health Organisation has
noted that:
Overall, the roles of the different parastatals of the
public sector are not well delineated, and activities
need to be coordinated in order to avoid overlapping
of efforts. As in other sectors, the federal
governance arrangement constrains the leverage that
the Federal Ministry of Health (FMOH) has over the
State Ministry of Health (SMOH). For instance,
FMOH cannot compel SMOH to implement some
health policies and programmes. This makes
stewardship of the health sector very challenging.
Consequently, the gap between policy formulation
by the FMOH and implementation by states and
LGAs is wide."55

This suggests that the challenges of overlapping, variability in implementation, and
duplication must also be addressed in any research governance efforts.

Further, the

authority of each level of government over separate institutions and the possibility
that research may take place at any institution, indicates that research governance
' See Nkoli I Aniekwu, "Health Sector Reform in Nigeria: A Perspective on Human Rights and
Gender Issues" (2006) 11:1 Local Environment 127 at 131.
55
WHO Country Cooperation Strategy, supra note 53 at 6.
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efforts must be implemented not only at one level, for instance at the federal level,
but at all levels of government.
Apart from the government-run health facilities, there are many
private-run health facilities, including for-profit private sector institutions, mission
hospitals and facilities run by faith-based and community-based organisations and
other non-governmental organisations.56 Non-governmental organisations and donors
play a vital role in Nigeria's health system. Health care delivery is funded from the
monies made available under the national budget, but also frequently with aid and
technical assistance from international aid organizations and development partners
like the World Bank, United States Agency for International Development (USAID),
the Canadian International Development Agency (CIDA), the United Kingdom's
Department for International Development (DflD), Japan International Cooperation
Agency (JICA), the Global Drug Facility, and the World Health Organisation.57
Many donors, including the USAID, the DFID, the World Bank, and CIDA
contribute towards specific health system initiatives and projects. However, as has
been noted elsewhere, state ownership or buy-in into initiatives sponsored by donors
or carried out by non-governmental organisations is important not only for greater
legitimacy but also for effectiveness.58 Indeed, it has been noted that in Nigeria
(which because of its oil exportation activities is not aid-dependent), international
56

I.O. Orubuloye and J.B. Oni, "Health Transition Research in Nigeria in the Era of the Structural
Adjustment Programme" (1996) 6 (Suppl) at 304.
57
DFID, "Nigeria: Country Health Briefing Paper" (2000), online:
<http://www.dfidhealthrc.org/publications/Country_health/Nigeria.pdf> (January 25, 2010). See the
Revised National Health Policy 2004., Section 8.4.
58
Health and Fragile States Network, "Health System Reconstruction: Can It Contribute to StateBuilding?" (2008), online:
<http://www.healthandfragilestates.org/index2.php?option=com_docman&task=doc_view&gid=32&I
temid=38> (January 20, 2010).
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donors have limited influence on shaping behaviour.

What it means, then, is that

alliances and partnerships with the government have to be carefully built and
nurtured.60
Nigeria's health care system was ranked 187th out of 191 members of the
WHO in 2000, making it one of the worst health systems in the world. Many have
suggested that the lack of coordinated efforts by the different levels of governments
and development agencies in the execution of health programs has seriously impeded
improvements in health care delivery in Nigeria and led to duplication of efforts and
waste of resources.61 Similarly, the WHO has attributed the poor state of the health
system in Nigeria to several factors, namely: organisation, stewardship, financing
and provision of health services.

These factors are compounded by other

socioeconomic and political factors in the Nigerian environment.62 As I discuss
below, some of these same factors, particularly, stewardship, coordination,
organisation and financing, are key challenges for research governance in Nigeria.
There is some evidence that the government is taking action regarding
the dismal state of affairs in Nigeria's health system, through various initiatives and
programs. These include the initiation of the Health Sector Reform Plan of Action,
which is to guide investments and actions by all levels of government, the private

^ Ibid, at 37.
It has been noted therefore that: "Most development partners in Nigeria are aware that short-term
support for service delivery can contribute to undermining state capacity, particularly if it bypasses
government. Consequently many have adopted long-term, strategic approaches aimed at building
institutional capacity and fostering longer term sustainability. The major donor-funded health
programmes in Nigeria do appear to contribute to state-building, and are designed and implemented
with core governance objectives in mind." Ibid, at 40-41.
61
See Hargreaves, supra note 16; Nnmauchi, supra note 30 at 6.
62
WHO Country Strategy, supra note 53 at 9.
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sector, donors and all development partners in health.

With respect to epidemic

preparedness, a National Epidemic Preparedness Committee was set up in 2009.
Several policies have been developed or revised in recent years including the
National Health Policy (revised in 2004), and the National Child Health Policy
(developed in 2006).65

Although belated, there is evidence of political will in

tackling the challenge of HIV/AIDS in the country. Evidence of this commitment
includes the establishment of the National Agency for the Control of AIDS (NACA)
and the initiatives to provide access to antiretroviral treatment, beginning in 2001,66
and the recent move to renew the strategic plan for continuing these initiatives, the
National Strategic Framework.67 The WHO notes, also, that:
In recent years, Nigeria has responded positively to
global initiatives such as Roll Back Malaria (RBM),
HIV/AIDS control, Polio Eradication Initiative
(PEI), directly-observed treatment short-course
(DOTS) and the Global Fund to Fight AIDS,
Tuberculosis and Malaria (GFATM). Notable
progress has been made towards eradication of
guinea-worm disease, resulting in a decrease in the
number of cases from over 600,000 in 1989 to about
13,000 per year in the late 1990s. In addition,
Nigeria has reached the WHO leprosy elimination
target of less than one case per 10,000 population.68
w

Ibid, at 6.
"Healthcare: Our Steps So Far, By Minister" The Guardian (October 11, 2009), online:
<http://www.ngrguardiannews.com/sunday_magazine/articlel0/indexn3_htrnl?pdate=111009&ptitle=
Healthcare:%20Our%20Steps%20So%20Far,%20By%20Minister&cpdate=293008> (February 20,
2010).
65
See Federal Ministry of Health, Policies Archives, online:
<http://www.fmh.gov.ng/PoliciesArchive.html#> (March 2, 2010).
66
U.S. Center for Disease Control and Prevention (CDC), "The Emergency Plan in Nigeria", online:
<http://www.cdc.gov/nchstp/od/gap/countries/Nigeria.htm>! (March 2, 2010); Avert, "HIV & AIDS
in Nigeria", available at <http://www.avert.org/aids-nigeria.htm> (September 2, 2009).
67
UNAIDS, "Nigeria to Accelerate Universal Access Efforts in HIV Response" February 23 2010,
online: <
http://www.unaids.org/en/KnowledgeCentre/Resources/FeatureStories/archive/2010/20100223_Nigeri
a_2.asp> (March 17, 2010).
68
WHO Country Strategy, supra note 53 at 6.
64
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The recent efforts with regard to developing governance arrangements in Nigeria,
which I describe below, can be counted as some evidence of increasing political
commitment to matters relating to health. Many challenges described above,
however, remain, including challenges in the area of health research.

5.4 Health Research in Nigeria
In this section, I begin with a short history of health research in Nigeria.
I then consider the need for health research in Nigeria and Nigeria's current policy
on health research.

I point out that, despite the government's low level of

commitment to health research, a significant amount of health research continues to
take place in Nigeria, including health research involving humans, creating a need
for the proper governance of research.

5.4.1 A Brief History of Health Research and the Ongoing Need for Health
Research in Nigeria
Health research in Nigeria has a long history predating Nigeria's
independence from the British colonial regime in 1960.

In this respect, the

descriptions of this history by Ajayi and Nwabueze are helpful.69 Although recent by
western standards, medical research has been undertaken in Nigeria for many

69

01ajide Ajayi, "Health Research in Nigeria." Online: Oxford Research Forum
<http://www.oxfordresearchforum.il2.com/editorials/nigeria.htm> (March 3, 2004).
See also,
Adetokunbo O. Lucas, "Health Research in Africa: Priorities, Promise, and Performance" (1989)
Volume 569 Biomedical Science and the Third World: Under the Volcano, at 17. See also, Remigius
N. Nwabueze, 'Ethical Review of Research Involving Human Subjects in Nigeria: Legal and Policy
Issues' 14 Ind. Int'l & Comp. L. Rev. (2003-2004) 87.
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decades beginning with the establishment of the Rockfeller Foundation Yellow Fever
Commission in 1920. The Yellow Fever Foundation, as it was popularly called, built
a Research Unit in Yaba, Lagos in 1925 where research on yellow fever was
conducted. It is not clear from available sources whether this was meant to benefit
Nigerians. But this is unlikely, following Ochonu's hint that:"Colonial medicine was
70

about keeping British colonial personnel healthy."
In 1952, the British government established the University College
Hospital (UCH) at the University College Ibadan. The UCH had been a campus of
the University of London since 1948. The UCH was mandated, amongst other
71

things, to conduct medical research.

In 1957, a facility for clinical research was

commissioned at the University of Ibadan.
In 1954, the British colonial government made provisions for research
funding in colonial territories, leading to the formation of the West African Council
for Medical Research for the West African territories of Nigeria, Ghana, Gambia,
and Sierra Leone.72 According to the Ordinance which established it,73 its functions
included organising medical research in the territories and providing information
obtained therewith to the British government. The West African Council for Medical
Research consisted of four research units dedicated to helminthiasis, virology, hot
climate physiology, and haematological research.
70

With the establishment of

Moses Ochonu, '"Native Habits are Difficult to Change': British Medics and the Dilemmas of
Biomedical Discourses and Practice in Early Colonial Northern Nigeria" (2004) 5:1 Journal of
Colonialism and Colonial History.
71
University College Hospital Act, Laws of the Federation of Nigeria and Lagos, 1958, Chapter 215,
section 3. As Nwabueze observes, other teaching hospitals established subsequently have also been
mandated likewise. Nwabueze, supra note 69.
72
Ajayi, supra note 69.
73
West African Council for Medical Research Ordinance, Laws of the Federation of Nigeria and
Lagos, Cap. 215 (1958).
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universities in Nigeria, like the University of Ibadan and the University of Lagos, the
West African Council for Medical Research, whose activities had previously
extended to other West African British colonies like Ghana, was dismantled in 1962.
The Medical Research Council of Nigeria, established by military
decree in 1972,74 took over the responsibilities of the West African Council for
Health Research.

In 1977, the National Science and Technology Development

Agency Decree repealed the decree which established the Medical Research Council
of Nigeria, and instituted the National Science and Technology Development
Agency. The Agency's mandate was to advise the federal government on matters
relating to scientific research and development. The responsibilities and assets of the
Medical Research Council of Nigeria were subsequently transferred to the National
Institute for Medical Research established by the Research Institute's Order of
1977.75
It is clear from the history described above that interest in health research
has existed for a long time in Nigeria, and even predates Nigeria as an independent
country. Today, with the many diseases that plague the Nigerian population, there
remains a clear need for health research. As discussed in Chapter One, ten percent of
global research funding is devoted to research in developing countries (like Nigeria)
which bear ninety percent of the diseases,76 a very inequitable distribution. There is

Medical Research Council, Decree No 1.
Research Institute's (Establishment etc) Order of 1977, Annual Volume of the Laws of the Federal
Republic of Nigeria (1977). See The Nigerian Institute of Medical Research, About NIMR" online:
<http://www.nimr.gov.ng/aboutus.php?page=an> (February 22, 2010).
76
Commission on Health Research for Development, Health Research: Essential Link to Equity in
Development (Oxford: Oxford University Press, 1990). See the Nuffield Council on Bioethics, The
75
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relatively little drug research into neglected diseases.

As I pointed out in that

chapter, there is great need for health research in developing countries.
In the context of Nigeria, the HIV/AIDS epidemic is a significant threat
and is one area in which health research remains necessary and appropriate. The
disproportionate burden of HIV infection borne by persons in Nigeria (and other
developing countries) relative to many other countries in the world requires the
development of new interventions and technologies to aid prevention efforts, provide
more effective treatments, and perhaps a cure in the not so distant future.

The

National HIV/AIDS Prevention Plan indicates that there is inadequate research on
prevention methods, and limited research on sexually transmitted infections. 77 More
research is also required for better treatment methods for HIV-related or
opportunistic diseases such as tuberculosis. Research is also needed on other issues
not directly related to treatment and prevention. These include issues such as social
problems like stigma, or the effect of sexual and domestic violence on prevalence
rates, or the social factors contributory to the spread of HIV and other sexually
transmitted diseases in specific populations or communities or risk prevalence, and
attitudinal risk factors, such as vehicular accidents and road safety.
Other common diseases in Nigeria like malaria (which continues to be
the most significant health issue in the country) and infectious diseases such as
trypanosomiasis (sleeping sickness) require further research to provide more
effective, less drug-resistant, less expensive treatments and vaccines. Non-infectious

Ethics of Research Related to Healthcare in Developing Countries (1999) at 21-23, describing the
substantial difference in the levels of research between developed and developing countries.
77
National HIV/AIDS Prevention Plan at 16, 20.
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diseases such as diabetes, cancer, and heart disease, which are affecting an increasing
number of Nigerians, also need to be studied. Apart from treatments, research needs
to be undertaken to provide better disease prevention behaviours and methods (some
of which might be established from studies on environmental and genetic
determinants of non-infectious diseases), and more cost-effective devices.

These

diseases could be studied in other countries. However, genetic differences, such as
among the Yorubas of Nigeria who have a high twinning rate, may make Nigeria not
only attractive to researchers, but even necessary for the development of some
no

interventions.

Further, to provide cost-effective interventions would necessitate

research in a resource-constrained setting like Nigeria. This would also be the case
with interventions that may be easier to use in a country like Nigeria.
Further, the potential benefits of health research could include other
related benefits to the country. These would include, for example, the improvement
of the quality of health care services offered to the population, an increase in the
country's capacity to participate in the international research enterprise and a
possible contribution to economic development and growth by providing
employment, equipment, training and income for local researchers and their
institutions, transferring skills and retention of talented individuals who may be
otherwise lost to the country.
78

For instance, Nigeria is a part of a six-country consortium involved in the HapMap project, which is a
significant project because of the potential information it could provide about the human genome and the
effect it could have on the rest of the world. Yorubas from Ibadan, Nigeria were recruited for the project.
See The International HapMap Consortium, "The International HapMap Project" (2003) 426 Nature 789.
Elizabeth G. Phimister, "Genomic Cartography - Presenting the HapMap" (2005) 553:17 New England
Journal of Medicine 1766. See A. Akinboro, M. A Azeez, and A A Bakare, "Frequency of Twinning in
Southwest Nigeria" (2008) 14:2 Indian Journal of Human Genetics 41.
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Apart from diseases specific to Nigeria, health research conducted in
Nigeria could also be beneficial to other countries around the world. Mabey notes
that many examples exist of trials in developing countries, like Nigeria, which have
influenced clinical and public health practice, even in the developed world.79 One of
the examples he cites is of a trial of chloramphenicol sponsored by the United
Kingdom Medical Research Council in Zaria, Northern Nigeria in 1973 and carried
out by researchers at the Ahmadu Bello University, Zaria. This trial showed that, for
the treatment of group A meningococcal meningitis, a single therapy of
chloramphenicol was more effective than sulphonamides. It was also as effective,
simpler to use, and much cheaper than large and frequent doses of penicillin, the
standard drug at the time.

This was at a time when combination therapy was the

norm in many industrialised countries.81 Today, HIV trials, for example, could
provide potential sources of information beneficial to Nigeria but also to other
countries around the world.
Given the clear need for health research in Nigeria, what is the current
policy for health research?

The current policy on health research in Nigeria is

embodied in several policies, including the National Health Policy, most recently
revised in 2004, the National Drug Policy*2 most recently revised in 2005, and the
National Child Health Policy, 2006.

David Mabey, "Importance of Clinical Trials in Developing Countries" (1996) 348 Lancet 1113.
H C Whittle et al, "Trial of Chloramphenicol for Meningitis in Northern Savanna of Africa"
(1973)3 BMJ 379.
81
Mabey, supra note 79.
82
Federal Ministry of Health, National Drug Policy (Abuja, Federal Ministry of Health, 2005).
83
The Federal Ministry of Health, National Child Health Policy (Abuja, Federal Ministry of Health,
2006).
80
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The National Health Policy recognises that a good health system is the
result, amongst other things, of the appropriate utilisation of health research. In this
respect, it states that: "The health system shall, reflect the economic conditions,
socio-cultural and political characteristics of the communities as well as the
application of the relevant results of social, biomedical, health system research and
public health experience."

The objectives of the health research policy are to:

i. Establish the criteria for identifying priorities;
ii. Provide the operational guidelines for health
research
(ethical,
institutional,
social,
legal,
monitoring and evaluation etc);
iii. Provide the framework for the coordination of
health research;
iv. Identify the roles and functions of various actors
and institutions and empower them;
v. Establish a sustainable mechanism for capacity
development and enhancement of health research;
vi. Establish the mechanism for funding;
vii. Build consensus on health research outcomes
through advocacy;
viii. Disseminate information on health research
outcomes widely; and
ix. Promote the use of health research outcomes in
addressing major health issues and problems. 85
The policy further states that the Federal Ministry of Health in collaboration with the
Federal Ministry of Education and the Federal Ministry of Science and Technology,
the Federal Ministry of Justice, and other related Ministries shall set and review the
priorities for health services and biomedical research in Nigeria; the scope, location,
capacity and content of activities in the field of biomedical and health services
research at academic and other institutions. Matters that are considered to be of high
priority include: co-ordinating the activities of scientists, researchers and institutions,
Revised National Health Policy, 2004, section 4.3.
Section 9.1 of the Revised National Health Policy (emphasis mine).
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and training of research scientists, technicians and other support staff especially in
the priority disciplines where there are marked shortages, such as epidemiology,
medical biologists, and health care law specialists. Also of importance under the
policy are the strengthening of Ministries of Health and other institutions to enhance
their capabilities to undertake relevant research, and the establishment and
sustainability of a programme that will encourage private sector participation in
health research activities. It also states that the government shall provide more
resources including tax exemptions and rebates for research in the health sector and
encourage the private sector, especially companies that engage in health related
activities, to sustain research activities that enhance health.

The policy also

provides for the allocation of resources for relevant drug research, including
traditional remedies.87
In addition, the National Child Health Policy requires the Federal
Ministry of Health to initiate and support research relevant to child development in
collaboration with different organisations. It also requires that ministries of health
and other institutions be supported in order to enhance their capability to undertake
relevant research in child survival, development, protection and participation.88
As will become clear in Chapter Six, the National Health Bill has
assigned some of the responsibilities of the Federal Ministry of Health related to
research governance under the National Health Policy to other bodies created under

86

Section 9.3.
Section 5.14 (e). See also the National Drug Policy.
88
Sections 3.5 and 4.16 of the Child Health Policy, supra note... at 14 and 46. Local government
councils have a similar mandate under the policy.
87
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that Bill. And when it is signed into law, the National Health Policy will only operate
in relation to matters not contained in the National Health Bill.

5.4.2 The Current State of Health Research in Nigeria
Health research in Nigeria, as in many developing countries, is a complex
issue with different angles. These angles include the fact that Nigeria needs health
research but not enough is currently taking place.

Another angle is that the

government has directed insufficient resources for health research in Nigeria. Yet
another angle is that external sponsors, as in many developing countries, support a
significant amount of health research.

Further, there is the challenge of setting

national health research priorities, ensuring that those priorities are met, and that all
of the research that does take place is effectively regulated. I address these different
angles in explaining the current state of health research in Nigeria briefly below.
With more than twenty medical schools,89 eleven of which have public
health programmes,90 there are a significant (though underutilised) number of
avenues for health research, including research involving humans.

Health research

is conducted in all the medical schools (which have affiliated teaching hospitals) in
Nigeria.

The University of Ibadan and the University of Lagos are, however,

See MDCN, Medical Schools in Nigeria, online: <http://www.mdcnigeria.org/MedSchools.htm>
(March 17, 2010).
90
CB IJsselmuiden et al, "Mapping Africa's Advanced Public Health Education Capacity: the
AfriHealth Project" (2007) 85:12 Bulletin of the World Health Organization 914 at 916.
91
Dianne Miller et al, "Knowledge Dissemination and Evaluation in a Cervical Cancer Screening
Implementation Program in Nigeria" (2007) 107 Gynecologic Oncology S196 at S197.
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particularly active in this respect.

These universities are some of the earliest

established universities, are located in cosmopolitan cities, and host many externallysponsored research projects. Generally speaking, the government provides much of
the funding for different kinds of research that takes place in Nigerian universities,
including health research.93
The federal government also funds some research through research
institutes such as the Nigerian Institute of Medical Research, a parastatal of the
Federal Ministry of Health, which carries out research on parasitic, infectious and
non-infectious diseases.94 The National Institute for Pharmaceutical Research and
Development was established by the government principally to advance indigenous
pharmaceutical

research

and

development

and enhance

development

and

commercialization of pharmaceutical raw materials, drugs, and biological products.95
The Institute has recently produced a drug for the treatment of sickle cell disease.96
Another is the National Institute for Trypanosomiasis Research, which conducts

The University of Ibadan has a Postgraduate Institute for Medical Research and Training
(PIMRAT). FAHAMU Oxford, Healthcare Training and Internet Connectivity in Sub-Saharan
Africa, A Report for Nuffield Department of Medicine and Department for Continuing Education
University of Oxford, October 2002, online:
<http://tall.conted.ox.ac.uk/globalhealthprogramme/report/Nuffieldwebreport.pdf> (January 29, 2010)
at 84.
93
See P. A Donwa, "Funding of Academic Research in Nigerian Universities" online
<http://portal.unesco.Org/education/en/files/51642/11634301905Donwa-EN.pdfyDonwa-EN.pdf >
(March 2, 2010).
Established by the Federal Government under the Research Institute (Establishment etc) Order
1977, pursuant to the National Science and Technology Development Agency Decree (No 5) of 1977,
it succeeded the Medical Research Council of Nigeria created in 1972. The National Science and
Technology Development Agency Decree repealed the Medical Research Council Decree of 1972. The
Clinical Science division of the NIMR has the mandate to conduct research into "human health
problems in Nigeria."
95
National Institute for Pharmaceutical Research and Development online:
<http://www.niprd.org/niprdceovoices.htm> (February 2, 2010).
96
Adole Hassan, "Nigeria Takes over Sickle Cell Drug" (2009) SciDev.net, online:
<http://www.scidev.net/en/science-and-innovation-policy/research-ethics/news/nigeria-takes-oversickle-cell-drug.html> (March 28, 2009).
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research

into

the pathology, immunology

trypanosomiasis or sleeping sickness.

and methods

of treatment of

Twenty research institutes operate as

parastatals under the umbrella of the Federal Ministry of Science and Technology.
Also involved in research is the Nigerian Natural Medicine Development Agency, a
parastatal under the Federal Ministry of Science and Technology,97 whose main
mission is to collate, document, research, preserve, develop, and promote traditional
medicine practices and products in Nigeria.
However, there is still an inadequate level of health research in Nigeria.
This may, as some commentators suggest, be partly a result of potential participants'
scepticism and mistrust, and limited technical knowledge and expertise." But this
has also largely been attributed to lack of government commitment to health
research, even given the limited resources available. 10° Although, my extensive
research provided little information on exact amounts spent by the Nigerian
government on health research in more recent years due to lack of data, a WHO
study on health research expenditures in Nigeria for the year 2001 provides some
clue. This study estimated government expenditures on health research to be about
0.1 percent of around 2-3 percent of the national budget, the latter being the total

It is mandated by statute to formulate, promote administer, monitor, coordinate and review science
and technology policies and activities including research in the health sciences.
98
Nigerian Natural Medicine Development Agency, "About NNMDA" online:
<http://nignaturemed.net/index.php> (February 10, 2010). Some but not all of these institutes require
human participants in carrying out their areas of research, for instance, the Nigerian Natural Medicine
Development Agency, does not carry out research involving humans.
99
See for example, Darren Roblyer et al, "Objective Screening for Cervical cancer in Developing
Nations: Lessons from Nigeria" (2007) 107 Gynecologic Oncology S94 at S96.
100
See also, Christina Scott and Abiose Adelaja, "Key African Countries 'Not Keeping Health
Research Promises'" SciDev.net November 18, 2008, online: <http://www.scidev.net/en/news/keyafrican-countries-not-keeping-health-research-.html> (February 22, 2010).
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government expenditure on health.

The 2-3 percent is much less than the ten to

fifteen percent recommended by the WHO to be devoted to health102 or the 15
percent of the annual budget to which Nigeria committed itself in the Abuja
Declaration on HIV/AIDS, Tuberculosis and Other Related Diseases.10

Much of

the 2-3 percent allocated to health is spent on health care delivery, obviously leaving
very little for health research, as evidenced by the WHO study.
Insufficient political commitment to health research is also evident from
inadequately funded research institutions, inadequate facilities, poor infrastructure,
ill-developed policies as well as significant brain drain in the medical field,104 and
poor support and funding for essential health research.10

This situation was

especially evident during military rule, but remains so today. In this regard, Ajayi
rightly notes that:
It is not often credible to accept the official excuse
of unavailability of funds side by side with glaring
financial abuse by military and other types of
dictatorship. With what may have been available in
human and material terms, there has been a lack of
co-ordination between policy-makers, National

WHO, Regional Office for Africa, "Expenditures on Health Research in African Countries:" 2008
Algiers Ministerial Conference on Research for Health in the African Region (2008), online:
<http://www.tropika.net/specials/algiers2008/technical-reviews/paper-3-en.pdf>(March 9, 2010). See
Adedoyin Soyibo, "National Health Accounts of Nigeria, 1998-2002, Report Submitted to the WHO,
2005, online: <http://www.who.int/nha/country/Nigeria_Report_1998-2002.pdf> (February 8, 2010).
102
WHO, "Proposal on Innovative Sources of Funding to Stimulate Research and Development
Related to Diseases that Disproportionately Affect Developing Countries" online:
<http://www.who.int/phi/Nigeria.pdf> (March 23, 2010). A study has also pointed out that all the
research funding provided by the government to Nigerian universities did not exceed0.03 percent of
the GDP. See Donwa, supra note 93 at 3.
103
Abuja Declaration on HIV/AIDS, Tuberculosis and Other Related Diseases OAU/SPS/ABUJA 3.
104
Ajayi, supra note 69. See also, Nwagwu, supra note 109 at 21. However, some commentators have
pointed out that the absence of directories of research activities tends to minimize the amount of
research that actually takes place. Temidayo O Ogundiran, "Enhancing the African Bioethics
Initiative" (2004) 4 BMC Medical Education 21.
105
See for example, National HIV/AIDS Prevention Plan, supra note 77 at 22.
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Health Research Council administrators, and
research institutes whether related to health or not.10
The lack of a health research council, whose mandate would include funding health
research in the country, is also evidence of insufficient understanding by the
government of the necessity for health research in the Nigerian context. A National
Health Research Committee is one of the bodies to be established by the National
Health Bill. It is unarguable that the government could, and ought to, commit more
resources to health research, given the need for, and the potential benefits of, health
research.
In 2006, African governments in a High Level Ministerial Meeting on
Health Research in Africa convened by the Federal Ministry of Health in Nigeria and
the Ministry of Health in Ghana, through their Ministers of Health and Heads of
Delegation agreed, amongst other things,:
To strive to ensure the allocation of 2% of the
national health budget and to further mobilize other
resources from national and international sources for
health research.107
This suggests that African governments, including the Nigerian government,
understand the need for health research. It remains to be seen, however, if this will
actually be implemented.
Although the proportion of health research conducted in Nigeria remains
inadequate, the recent political shift to democracy has played, and continues to play,

106

Ajayi, supra note 69.
See Communique, High Level Ministerial Meeting on Health Research in Africa, Abuja, Nigeria,
March 8-10, 2006, online:
<http://whocc.who.ch/countries/nga/reports/Health_Research_meeting_Communique.pdf>(March2,
2010).
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a role in boosting health research activities in Nigeria. Nwagwu, analysing empirical
evidence on biomedical research literature in Nigeria since independence, points out
that "judging by the pattern of growth, biomedical research in Nigeria has proceeded
rather slowly since 1967 [when the Civil War began] but made more rapid advances
in 1998-2002 attributable probably to the civilian administration that came into
power in June 1999."108 Democracy has also brought a greater flow of resources
from international sources.109 Others have argued that, despite infrastructural and
personnel limitations, Nigeria remains an attractive venue for health research,
including clinical trials. Ikeme, for instance, notes that:
Because of relative lack of access to medical
treatment and medications, participating in a clinical
trial is a unique and beneficial opportunity for many
patients. Rapid recruitment is thus an advantage for
conducting a clinical trial in Nigeria when compared
to the Western countries. Despite these compelling
qualities, a lot of myths still exist about the country's
capacity for [clinical] trials.
Thus, there is both need and ample room for growth in health research, to provide the
necessary knowledge to improve health in Nigeria.
Apart from the small and inadequate proportion of health research
funded domestically, a significant amount of health research is, as in most African

Williams Nwagwu, "Mapping the Landscape of Biomedical Research in Nigeria Since 1967"
(2005) 18: 3 Learned Publishing 200 at 204.
1
Nwagwu notes elsewhere that: "The relative peace and freedom in the new government and the
introduction of new favourable policies could account for the increase in scientific publications in the
field during 1999-2002. During this period, most of the embargoes placed on Nigeria by the various
international communities were lifted; foreign aid, most of which had been withdrawn during the
period, was restored." See Williams E Nwagwu, "Patterns of Authorship in the Biomedical Literature
of Nigeria" (2007) 17: 1 Libres 1 at 23.
110
Anthony C. Ikeme, "Nigeria's Clinical Trials Scene" (2008) Applied Clinical Trials, online:
<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltri als/CRO%2FSponsor+Articles/Ni
gerias-Clinical-Trial-Scene/ArticleStandard/Article/detail/522051> (February 2, 2010).
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countries, funded by foreign sponsors, including multinational pharmaceutical
companies,

foreign

governments,

and

foreign-based

non-governmental

organisations.111 Several studies, including clinical trials, epidemiological studies
and social science health-related studies are, and continue to be, funded by external
sponsors such as the WHO Special Programme for Research and Training in
Tropical Diseases and the United States National Institutes of Health (NIH).112
Other foreign development initiatives which partner with developing countries, such
as the European and Developing Countries Clinical Trials Partnership, have been
i n

very active in promoting clinical trials in Nigeria and other developing countries.
The Family Health International, a non-governmental organization, has sponsored
many HIV prevention trials, including microbicides trials.114 Further, cooperative
groups such as the International Breast Cancer Study Group and the International
Breast Cancer Research Foundation have established collaborating centers in
111

See Temidayo O Ogundiran, "Enhancing the African Bioethics Initiative" (2004) 4: 21 BMC
Medical Education.
See the National Institute for Medical Research, online: <http://www.nimr-ng.org/> (October 4,
2008).
112
Among some of the studies funded by external sources are the NIH-sponsored studies of the social,
environmental and genetic determinants of hypertension in African populations, studies in breast
cancer genetics, and studies in the genetic and environmental determinants of diabetes type 2. Patricia
Marshall, "The Relevance of Culture and Informed Consent in U.S-Funded International Health
Research in NBAC, Ethical and Policy Issues in International Research: Clinical Trials in
Developing Countries, Volume II (Commissioned Papers and Staff Analysis) (Bethesda, Maryland,
2001)atC-ll.
113
P Olliaro and P G Smith, "The European and Developing Countries Clinical Trials Partnership"
(2004) 9 J. HIV Ther 53. See also, "HIV/AIDS, Tuberculosis, and Malaria Research and Programs in
Sub-Saharan Africa" online: <
http://researchafrica.rti.org/index.cfm?fuseaction=home.country_view&country_id=14> for examples
of some research funded by different international organizations in Nigeria.
114
These include the vagina gel, SAVVY, and Tenoforvir, a microbicide, both of which have been
discontinued. The SAVVY Trial was discontinued in 2007 for safety reasons. See P J Feldblum et al,
"SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in
Nigeria" (2008) 3:1 PLoS ONE 3(1): el474. Until 2005 when the controversial trials were stopped,
Family Health International conducted clinical trials of Tenoforvir, a drug for the prevention of HIV
infection, in Nigeria among sex workers. Jon Cohen, "More Woes for Novel HIV Prevention
Approach" (2004) 307: 5716 Science 1808. See also, Jerome A. Singh, Edward J. Mills, "The
Abandoned Trials of Pre-Exposure Prophylaxis for HIV: What Went Wrong?" (2005) PLoS Med
2(9): e234.
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Nigeria, thereby providing access to cancer clinical trials for patients with cancer.
Another key research project conducted in Nigeria is the Human Genome and the
International Haplotype Mapping Project (HApMAp).

Nigeria is part of a six-

country consortium involved in HapMap project which is significant because of the
potential information it could provide about the human genome and the effect it
could have on the rest of the world.11
Additionally, although the level of drug research in developing
countries is much lower than necessary, multinational pharmaceutical companies
have conducted, and continue to sponsor, clinical trials for the purpose of testing new
drug interventions in Nigeria.117

Clinical trials currently ongoing include, for

instance, trials of probiotics for urogenital infections.118 Nigeria's drug regulatory
agency, NAFDAC, periodically publishes some of information on its website

Clement A Adebamowo, "Cancer in Nigeria" (April 2007) Asco News and Forum, online:
<http://pda.asco.org/anf/Past+Issues/April+2007/Cancer+in+Nigeria?cpsextcurrchannel=l> (February
28, 2010).
The purpose of the HapMap project is to find out the common patterns of DNA sequence variation
in the human genome and to make this information freely available in the public domain. Such
information will allow the discovery of sequence variants that affect common disease, and will
facilitate the development of diagnostic tools, and improved methods of treatment. This project,
amongst other things, "fulfills the need for a new approach to ferreting out genes that participate in
complex multigenic disorders such as diabetes mellitus."Yorubas from Ibadan, Nigeria were recruited
for the project. See The International HapMap Consortium, 'The International HapMap Project (2003)
426 Nature 789. Elizabeth G. Phimister, "Genomic Cartography — Presenting the HapMap" (2005)
353: 17 New England Journal of Medicine 1766.
117
See for instance, B N Okeahialam et al, "Lacidipine in the Treatment of Hypertension in Black
African People: Antihypertensive, Biochemical and Haematological Effects" (2000) 16: 3 Current
Medical Research and Opinion 184.
118
Kingsley Anukam, "Oral use of probiotics as an adjunctive therapy to fluconazole in the treatment
of yeast vaginitis: A study of Nigerian women in an outdoor clinic" (2009) 21:2 Microbial Ecology in
Health and Disease 72. Natarajan Ranganathan, et al, "Probiotic Dietary Supplementation in Patients
with Stage 3 and 4 Chronic Kidney Disease: A 6-month Pilot Scale Trial in Canada" (2009) 25: 8
Current Medical Research and Opinion 1919 at 1919. See also, "Use of Oral Probiotics as an
Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis" online: <
http://clinicaltrials.gov/ct2/show/NCT00479947> (April 26, 2010).

334

regarding clinical trials.119 In addition to sponsoring drug-related research,
multinational pharmaceutical companies have in the past donated medical equipment
and drugs. In 2008, for example, the government commissioned the first centre
dedicated solely to clinical trials, donated by the multinational pharmaceutical
company, GlaxoSmithKline, at the Lagos State University College of Medicine.120
Externally funded research is essential to the growth of knowledge
about the prevention and treatment of diseases in Nigeria and forms a substantial part
of the health research which occurs in the country. But in this regard, Ogundiran
notes that:
Collaborative research with colleagues from the
developed countries is often externally funded. ... Of
particular ethical concern in collaborative research is
the fact that external sponsors may differ in their
motives for conducting research and there may be
limited applicability of research benefits to the
country or local community.121
Thus intertwined with the need for greater levels of health research in Nigeria and
the role of external sponsors in meeting that.need are the related themes of research
priorities and research governance. As discussed in Chapter One, there has been
concern in the literature about how research agendas are set, and who sets the
research agenda in developing countries such as Nigeria. There has also been
concern about the conduct of research in developing countries like Nigeria which

NAFDAC notes on its website that five drugs are currently undergoing clinical trials (as at
February 2010), although it does not name the specific drugs or the companies conducting the trials
NAFDAC, Registration and Regulatory Affairs Directorate, online:
<http://www.nafdac.gov.ng/index.php ?option=com_content&view=article&id=84&Itemid=117#p26>
(February 4, 2010).
120
Zakariyya Adaramola, "Nigeria: Country Gets its First Clinical Trial Site," (November 2, 2008)
Daily Trust.
121
See Ogundiran, supra note 111.
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will not ultimately benefit the population for reasons including the non-affordability
of the resulting intervention or the ineffectiveness of the research results in the
developing country context. These concerns are clearly pertinent in the Nigerian
context. For instance, in a research survey undertaken by the UK Department for
International Development, many respondents were of the view that funding
provided by donors was mainly driven by donor priorities rather than national
priorities.122

The Pfizer incident, discussed below, is an example of research funded

by a multinational pharmaceutical company which, because of the potential high
costs of the resulting intervention, would not have been of significant relevance to
the Nigerian public. These are issues that require continued government attention
and engagement with research sponsors. They are also issues that need to be taken
into consideration in establishing governance arrangements.
In sum, health research has a long history in Nigeria, dating back to the
colonial era.

At present, there is a significant, if inadequate, amount of health

research currently conducted in Nigeria, with much of it sponsored by external
sponsors.

There continues to be need for health research in Nigeria. The Revised

National Health Policy recognises this need.

In light of the increasing health

research activities in Nigeria, and the recognition in national policies of the necessity
for even more health research, it is necessary to ensure that there are adequate
arrangements to regulate current and potential health research involving humans in

DFID, "DFID Research Strategy, (2008-2013) Consultation - Africa: Country Report for Nigeria"
(2007), online:
http://www.research4development.info/PDF/Outputs/Consultation/NigeriaCountrypaperFinal.pdf>(Fe
bruary 10, 2010).
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Nigeria. Allegations of unethical research, some of which are described below,
emphasise this need even more.

5.5 A Brief History of Research Governance in Nigeria
One of the aims of this thesis is to detail recent developments in research
governance in a specific developing country context like Nigeria. Examining the
origins of these new developments in this area will, as I pointed out in Chapter One,
allow for the identification of gaps, weaknesses, and areas for potential
improvement. In other words, a description and analysis of where Nigeria has been,
will be helpful in determining where Nigeria now needs to go with respect to
research governance, and perhaps how it should get there.
Although, as I described above, health research involving humans has
been conducted in Nigeria since colonial times, there has been very little effort to
document the history of research governance in Nigeria. What follows, therefore, is
an attempt to piece this history together from fragments of information available in
the public domain.

I consider this necessary because as research governance

arrangements are developed in Nigeria, it is important to learn what challenges
existed in establishing and operating such arrangements in the past and then to take
steps to address them in current and future arrangements. In this section, then, I
provide a brief history of research governance in Nigeria. This description includes
accounts of alleged unethical practices in Nigeria which indicate the necessity for
effective research governance in Nigeria.
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The history of research governance in Nigeria can be roughly divided
into two broad stages: pre- 2006 before the establishment of the National Code on
Health Research Ethics and post 2006 when the most recent and more concerted
efforts were made to formalise governance arrangements in a national and countrywide manner. In the first subsection, I recount the history of research governance
from the earliest available accounts. Many of the allegations of unethical research
fall into the pre-2006 era. I describe them in a subsection after the description of the
pre-2006 era. In doing so, I underscore the need for effective research governance. I
describe the period from 2006 briefly. A more in-depth analysis of current research
governance arrangements is conducted in the next chapter.

5.5.1 Research Governance in Nigeria Prior to 2006
While health research was conducted during the colonial era pre1960, there are no documented attempts to establish mechanisms for research
governance in Nigeria during the colonial times.123 Nor are there any documented
efforts to establish such mechanisms in the post-independence era until 1980 when
the first attempts to create a formal regulatory structure began.
However, in a 1980 article,124 Ajayi proposed a three-tier structure for
research governance in Nigeria.

This would consist of a National Ethical

Committee, comprising biomedical researchers and social scientists, which would

123

See Nwabueze, supra note 69.
O. O. Ajayi, "Taboos and Clinical Research in West Africa" (1980) 6 Journal of Medical Ethics 61
at 62.
124
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determine the relevance of proposals for research on large populations, articulate
national health research priorities, and ensure that the source and funding of such
programmes do not conflict with political goals and policies. The second tier was to
be Peer Review Committees to be situated in a hospital, communities, or research
institutes, which would review research proposals according to ethics standards. The
third tier would be a sub-committee situated in individual research departments or
laboratories to determine scientific validity and technical competence.
Ajayi's suggestions appear, at least in part, to have been adopted. A
national ethics review committee, was established sometime afterwards in 1980.
However, it became non-functioning as a result of lack of funding and lack of
political interest.

According to Adebamowo and others:
The earliest attempts to set up a national ethics
regulatory infrastructure in Nigeria took place in
1980. However, this effort faltered largely because
of lack of sustained interest and funding. Subsequent
attempts were also unsuccessful because the decades
of the 1980s and 1990s were marked by military
misrule and socio-economic dislocation.12

From my research, there appears to have been no significant activities with respect to
research governance at the national level until 2002. Until 2002, there was no
functioning national ethics review committee. Any reviews conducted at the national
level were done through the Directorate of Clinical Services, Research, and Training

EDCTP, "Support for Ethics Review Boards: Strengthening the National Health Research Ethics
Committee of Nigeria (NHREC)" online: <
http://www.edctp.org/uploads/tx_viprojects/Project_Profile_-_CB_EthicsReview_41302_Clement_Adebamowo.pdf> (February 25, 2010).
1 6
Adebamowo et al, supra note 64 at 16.
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in the Federal Ministry of Health.127 The Federal Ministry of Health, as described
earlier, has been the key health policymaker in Nigeria. It had the mandate to make
policies, including research ethics policies, but did not make any general research
ethics policies that applied in every situation and to all institutions.
There were also several ethics review committees in different
institutions, particularly the teaching hospitals attached to some federal universities.
Some of them had been established in the 1980s, have since been reconstituted
severally and only became truly functional in recent years.128 The University of
Ibadan in Nigeria is a good example. According to a recent article written by the
current chairperson of the University College Hospital Ethics Committee at the
University of Ibadan, Professor Adeyinka Falusi, and others:
In 2002, we reviewed the status of the University
College Hospital, University of Ibadan Ethics Board
that had been in existence since 1980. We found that
the Board had not been active and was poorly
organized with no constitution or written standards
or policies in place to guide the review of research
proposals. There was no established infrastructure
such as a designated secretariat, staff, or records of
previous IRB reviews and approvals. Meetings were
held as needed, or as infrequently as every 6 months,
as there was very little research at the University due
to pervasive academic strikes and the dire economic
condition of the country. The Director of the
Institute for Medical Research and Training
(IMRAT) who ultimately approved all institutional
research studies made the selection of suitable
reviewers for each submitted protocols. On
occasion, the Director gave executive approvals after
review of the protocol without the benefit of a full
127

Adefolarin O. Malomo et al, "The Nigeria Experience" (2009) 6:4 Journal of Academic Ethics 305.
See Networking for Ethics on Biomedical Research in Africa (NEBRA): Final Report, online:
<http://elearning.trree.Org/file.php/l/NebraReport/FinalReport-2006-english.pdf> (February 22, 2010)
at 69-70.
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committee. Despite the importance of this essential
review process for promotion of research activities
within the University, there was no budget allocation
to support the activities of the ethics board.
Predictably, there was little or no awareness of the
existence of an IRB by faculty and staff and not
surprising; there was no international registration or
recognition of the existence of a duly constituted
IRB.129
The above is especially interesting because University College Hospital, Ibadan is a
pioneer medical establishment in Nigeria, and much of the externally-sponsored
health research which occurs in the country is conducted there.

As described by

Ajayi in the following subsection, the public had a negative perception of research
practices in the hospital. A situation in which researchers and staff at the University
did not know of the existence of an ethics review committee in the institution clearly
suggests the dire conditions of research governance at the University in which a
significant portion of health research in the country took place. The situation was
unlikely to have been different in other institutions with even less research. Indeed,
according to Nwabueze, it appeared that the few Nigerian institutions with ethics
review committees which functioned at all provided ethics review of mainly
collaborative studies (especially those conducted in collaboration with United Statesbased institutions). Apart from any other reservations that one might have to this adhoc manner of functioning, it could be argued as Nwabueze does, that research
participants were likely to be denied "the protections afforded by the existence of a
regular, functional, and competent ethics committee."130

~ Adeyinka G Falusi, Olufunmilayo I. Olopade and Christopher O. Olapade, "Establishment of a
Standing Ethics/Institutional Review Board in a Nigerian University: A Blueprint for Developing
Countries" (2007) Journal of Empirical Research on Human Research Ethics 21 at 22.
130
Nwabueze, supra note 69 at 104.
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According to a survey131 conducted between 2003 and 2005, there were
thirty ethics review committees in institutions in Nigeria in the early 2000s. These
institutions were mainly in federal institutions including the major teaching hospitals,
some of the federal hospitals and the major research centres like the NEVIR. These
ethics review committees were variously called the Institutional Review Board (as in
the United States), the Institutional Review Committee, the Ethical Review
Committee.132
committees.

However, many state hospitals did not have ethics review
As the Pfizer incident which occurred in 1996 shows, this did not

mean that research never took place in them, or that such a possibility did not exist.
Many of the existing committees, as described in the case of the ethics review
committee at the University of Ibadan above, were grossly underfunded and lacked
the necessary expertise to carry out their duties.134 Many of them had no significant
activity.135
In 2002, the National Ethics Review Board was created.136 Its mission
was to promote "good ethical practice in Nigerian scientific research, safeguard the
dignity, right, safety and well-being of all actual or potential research participants'
through the auditing and accreditation of ethics review committees, and the training
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Networking for Ethics on Biomedical Research in Africa (NEBRA): Final Report, online:
<http://elearning.trree.Org/file.php/l/NebraReport/FinalReport-2006-english.pdf> (February 22,
2010).
132
Ibid.
A few state hospitals but not all state hospitals have ethics review hospitals. See Ogundiran, supra
note 111.
134
Ogundiran, ibid.
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See Malomo et al., supra note 127 at See National Ethics Review Board, Draft National Ethical
and Operational guidelines for Research on Human Subjects, Nigeria, online:
<http://elearning.trree.Org/file.php/l/NebraReport/nebra-Annex-15.pdf> (February 24, 2010).
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of ethics review members, and advising the government on ethical matters.137 The
Board was never recognised either legally or in a government policy and it has now
been by replaced by another national body.138 A draft national guideline: Draft
National Ethical and Operational Guidelines for Research on Human Subjects,
was prepared but never took effect.
In 2005, another national committee, called the National Ethics
Committee of Nigeria, was established by the Chairman of the National AIDS
Control Agency.

Its mandate was to coordinate and provide oversight for

institutional ethics review committees. This national committee was also not legally
recognised and had no financial support from the government. It existed for a time
alongside another national committee, the National Health Research Ethics
Committee, established by the Federal Ministry of Health, which is currently
functioning.140

This indicated the challenges of duplication of functions, and the

lack of clarity about which government department could legally establish a national
ethics review committee.
Prior to 2006, there were no national domestic ethics guidelines
providing guidance, either in terms of substantive ethical standards or with regard to
procedures and compositions of ethics review committees. Marshall, in a 1999 study
commissioned by the United States National Bioethics Advisory Commission, noted
137
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that there was considerable variation in the implementation of the process of ethical
review between institutions, especially in terms of their composition.141 Nwabueze
also noted that some of the existing ethics review committees operated not
consistently, but on an ad hoc basis.142 For guidance on ethical standards, the
defunct NERB described above relied on different documents, including the
Constitution, the Helsinki Declaration, the CIOMS Guidelines, the WHO/TDR
Guidelines, the ICH-GCP Guidelines, the Council of Europe's Convention for the
Protection of Human Rights and Dignity of the Human Being with Regard to the
Application of Biology and Medicine: Convention on Human Rights and Biomedicine
among others.143 Some institutional ethics review committees employed the Helsinki
Declaration as their main reference document, or the CIOMS Guidelines, while
others used internal guidelines developed by the institutions.144
Apart from the ethics review structure, the National Agency for Food
and Drug Administration and Control (NAFDAC) was established by the National
Agency for Food and Drug Administration and Control Act in 1993. NAFDAC is a
parastatal of the Federal Ministry of Health and is responsible for ensuring drug
safety and compliance with approved specifications and quality and regulates the
importation, exportation, and manufacture, registration, and marketing of drugs. Its
functions also include the regulation of clinical trials for drugs. In regard to research
for pharmaceutical production, NAFDAC drew up a set of guidelines around 2002
141
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for the purposes of regulating clinical trials of drugs in Nigeria (NAFDAC
Guidelines).145 The application of the NAFDAC Guidelines is limited, however, to
drug research and does not apply more generally to all health research involving
humans. Thus, the guidelines could not be regarded as providing general protections
for participants in health research in Nigeria.
With regard to legal regulation of health research involving humans,
although there were common law principles that could be argued to have provided
some sort of legal framework for research, there was no direct legislation to regulate
health research involving humans. Prior to 2006, there was also no law requiring the
existence of ethics review committees in research institutions, or setting down their
structure or composition and functions or even requiring that research protocols must
pass through ethics review. However, NAFDAC, the drug regulatory agency, which
had previously drawn up guidelines as described above, drew up draft Clinical Trials
Regulations 2004,146 which were never passed.

Among other requirements,

according to the NAFDAC Guidelines, clinical trials of drugs now have to pass
through ethics review and meet other procedural requirements.
Apart

from

legal

regulation,

self-regulation

by

professional

association is, as discussed in Chapter Three, another potential means of regulating
health research involving humans. The Medical and Dental Council of Nigeria is the
professional regulatory body, established by statute,147 which determines the
standards for educating medical and dental professionals and makes rules for
145
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maintaining universally acceptable professional standards of practice and conduct.
Although there is not much literature on the Medical and Dental Council of Nigeria's
regulation of the conduct of health research by its members, it took a step in that
direction in the 2004 revision of the code of ethics,148 entitled: Code of Medical
Ethics.

This most recent edition of the Code provides amongst other things that,

"Every Teaching Hospital or Medical Research Institute MUST constitute an Ethical
Review Committee composed of competent individuals to examine the research
protocol of every researcher in the institution."149 The Council imposes penalties for
the infringement of standards or bad conduct. However, no researcher, from my
research, has been punished for not adhering to the standards laid down by the
Medical and Dental Council of Nigeria.
Governance of health research involving humans in Nigeria is, as the
foregoing discussion in Nigeria suggests, not a recent phenomenon, having begun
formally in 1980. Research governance in Nigeria prior to 2006 consisted of a
spectrum of formal and informal mechanisms with little formal or comprehensive
engagement with, and oversight of the conduct of, health research involving humans
on a national level, with the exception of drug-related health research. There was no
direct legal regulation except for drug research regulation, beginning in 1993 with
the creation of NAFDAC. Existing regulations were hardly implemented, as the
Pfizer incident described below, shows. As I describe below, this state of affairs
148
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allowed much room for exploitation and unethical practices and left participants with
minimal options for legal redress.
Further, research governance appears to have proceeded in a very
haphazard, fragmentary fashion, with little coordination between the various bodies
involved in regulating health research involving humans. For instance, a cursory
look at the different guidelines and regulations, including the NAFDAC Guidelines,
the Medical Dental Council of Nigeria, Code of Medical Ethics, National Ethics
Review Board, and the Draft National Ethical and Operational Guidelines for
Research on Human Subjects, Nigeria, shows that they provide varying requirements
for the conduct of health research involving humans. There are different
requirements for the composition and structure of ethics review committees, and
somewhat different

substantive ethical standards. Moreover, ethics review

committees, both nationally and institutionally, have been non-functional over the
years.
The early 2000s, however, signalled a new direction in research
governance in Nigeria, with the establishment of national ethics review committees,
the drawing up of guidelines for clinical trials by NAFDAC, the preparation of the
Draft National Ethical and Operational Guidelines for Research on Human Subjects
(which was never adopted), and the Medical and Dental Council of Nigeria revision
of the Code of Ethics to include requirements for the ethical conduct of health
research involving humans.

These events paved the way for a potentially more

comprehensive, nation-wide, scheme for research governance. Prior to this scheme,
however, research participants in Nigeria experienced several instances of unethical
347

research, including the Pfizer incident which has been discussed widely in the
literature.

5.5.2 Unethical Conduct of Research in Nigeria Prior to 2006
Prior to 2006, there were several allegations of unethical research,
many of them revolving around lack of informed consent and failure to obtain
approval from an ethics review committee prior to marketing drugs. Some of these
allegations were based on anecdotal evidence, and although not independently
verified, nevertheless affected public perception and trust in some cases.

For

example, Ajayi in a 1999 paper, points out that:
[The] University College Hospital, Ibadan has not
lived down the perception of the local population
that unethical human experimentation went on in the
hospital. The selection of cases for admission (often
linked to the severity of illness and types that could
not be handled outside a tertiary centre) were
misunderstood to be related to research interests.
Mortality in the very ill patient was often ascribed to
injections given for research purposes.150
Similarly, Anya, a physician, detailed his experiences as a medical student in
Nigeria in the 1990s, noting in the Lancet that:
Training to be a doctor in Nigeria a decade ago
included little more than cursory attention to either
clinical or research ethics: a single hour-long lecture
on ethics and professional practice, delivered close
to the final examinations, sufficed. As a house
officer at a major teaching hospital, it was not
unusual to be instructed to take samples for a
Ajayi, supra note 69.
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research project without any research protocols or
consent forms being provided. Ethics committees
were weak or non-existent at most hospitals.

Another example, although not strictly about the conduct of research,
was a 1999 controversy involving the marketing of HIV/AIDS drug and vaccine
which highlighted the vacuum in Nigeria's regulatory procedures. In that incident, a
Nigerian doctor, Dr. Jeremiah Abalaka, claimed to have found the cure for
HIV/AIDS as well as a vaccine to prevent the diseases.

At this time, there was

very little access to antiretroviral treatment in Nigeria. Several infected persons
received treatment from the doctor at exorbitant costs.

The drug and vaccine

received support from top army officers who proceeded to make it available to
1 S^

soldiers suffering from AIDS.

Dr. Abalaka claimed to have performed clinical

trials (involving testing the drug on himself) before making the drug available to the
general public. However, in 2000, after much opposition from different scientific
bodies, including the Nigerian Medical Association (NMA) and the Nigerian
Academy of Science, the Federal Ministry of Health banned the drug and vaccine.154
The Nigerian Academy of Science had criticised the methods of Dr. Abalaka, on the
grounds that the drug and vaccine had not passed through any clinical trials or ethics
review procedures. They could not, however, refer to any domestic legislation or
Ike Anya and Rosalind Raine, "Strengthening Clinical and Research Ethics in Nigeria—An
Agenda for Change" (2008) 372 Lancet 1594.
152
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153
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policy that required these steps because none existed at this time.

Accusations of

political machinations were made by the doctor and his supporters against the
government and different associations of medical doctors.

The lack of clear

regulatory procedures meant there was no impartial domestic standard against which
to judge such claims.156
Beyond the anecdotal evidence described above, studies have noted that
many research projects were conducted in Nigeria without ethical review.
Pfizer incident which occurred in 1996 is a prime example.

The

That incident

encapsulates many of the problematic issues in research governance in Nigeria in the
past, underscores Nigeria's challenging context, and has had consequences beyond
the arena of health research. An account of the history of research governance in
Nigeria is thus incomplete without a discussion of the Pfizer incident.
In 1996, there was an outbreak of a meningitis epidemic in Kano, a state
in the northern part of Nigeria. About 250,000 people were infected during the
epidemic and about 15,000 people died.158 Humanitarian organisations such as the
Medicins Sans Frontier went to Kano and began providing the cheap and effective
antibiotic, chloramphenicol (which interestingly had been tested in the Northern part

Lumumba C. Achilonu, "The Politics of Abalaka's Vaccines" Thisday, February 9, 2001, online:
<http://www.thisdayonline.com/archive/2001/02/09/20010209com01.html> (March 10, 2010).
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<http://news.bbc.co.Uk/2/hi/africa/740523.stm> (March 10, 2010).
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158
Emmanuel R Ezeome and Christian Simon, "Ethical Problems in Conducting Research in Acute
Epidemics: The Pfizer Meningitis Study in Nigeria" (2010) 10: Developing World Bioethics 1. Other
sources put the death toll at 15,000. See The BBC has a figure of 15,000 people. "Nigerians Sue
Pfizer Over Test Deaths" BBC News (30 August 2001). Available at:
<http://news.bbc.co.Uk/l/hi/business/1517171.stm> (22 January 2007).
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of Nigeria about twenty years earlier).159 At the same time, Pfizer, an American
multinational pharmaceutical company, sent in staff to conduct a trial of an
antibiotic, Trovafloxacin (commonly called Trovan).1 °

The Kano Infectious

Diseases Hospital, where the trials took place, was reported to be at the time, a poor,
dirty hospital with few beds, poor power supply, and no clean water.161
Pfizer's main reason for conducting the clinical trials in Kano was to
obtain approval for the drug from the United States Food and Drug Agency. " The
trial was to investigate whether the oral form of Trovan was more effective and
efficient in treating children infected with meningitis than other existing treatments,
including Ceftrixacone, the gold standard treatment.

Later, when charges of

unethical conduct were made, Pfizer also alleged that another major reason for
conducting the trials was to provide humanitarian services to the infected victims
who were obviously in need of medical assistance at the time.

Sometime after the

trial had ended, several allegations were made regarding the unethical manner in
which Pfizer conducted the trials. These were first publicised by the Washington
Post in a series of investigative articles on the conduct of clinical trials by developed
country researchers in developing countries.'

4
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Available at: Washington Post

351

Pfizer's Trovan had not been previously tested in children. However,
about 200 children, aged between 1 and 13 and infected with meningitis were
enrolled in the Kano trials. 100 of the children were thus put on the Trovan while
another 100 were put on the Ceftrixacone.165

Out of the enrolled number, it was

alleged that 11 died in the trials,166 5 of whom were on the experimental drug,
Trovan, given orally, while the other 6 were on injections of the standard drug
1 fn

Cetrifaxone.

It was also reported that other children involved in the trials suffered

seizures, or became paralysed.1

It was also reported that at least one child was not

taken off the experimental drug and given the standard drug when it was clear that
her condition was not improving, which was clearly unethical.169 The trials were
conducted within three weeks and Pfizer left Kano immediately.
The allegations made against Pfizer include that there was no informed
consent, and no follow-up of the children after conclusion of the trial. The parents of
the children alleged that they had not been adequately informed about the trial and
would not have subjected their children to it had they been informed that their
children were participating in a trial rather than simply receiving treatment. No
written consent was obtained, although Pfizer had prepared an informed consent
form. Due to the illiteracy of the parents, only verbal consent was obtained after oral

<http://www. washingtonpost.com/ac2/wp-dyn ?pagename=article&contentId=Al 19392000Decl5&notFound=true> (March 3 2007).
165
Ibid.
166
S Bosely, New Drug 'Illegally Tested on Children': Pfizer Accused of Irregularities during Clinical
Trials in Nigeria The Guardian (London), (17 January 2001) at 19.
167
Stephens, supra note 162.
168
Ibid.
169
Washington Post, ibid. See also Jacqui Wise, Pfizer Accused of Testing New Drug without Ethical
Approval" (2001)322 BMJ 194, online : <http://www.bmj.com/cgi/content/full/322/7280/194>
(March 2, 2010).

352

explanations had been made to the parents of the children in English and Hausa (the
language of the participants).170 Also, there was no follow-up of the children partly
because many of them did not show up after leaving the hospitals, and also because
171

Pfizer reportedly did not send people to check up on them.

It is necessary to note

that Nigeria had no direct policy on research involving children, although
commonsense suggests that obtaining informed consent from poor and illiterate
parents, whose children were in danger of dying in an epidemic, would be a difficult
172

matter.
A puzzling issue was why Pfizer would choose to conduct a trial during
an epidemic in a poor area when other organisations were seeking to provide
assistance. Was it ethically permissible to conduct tests for a drug that would, if
things went well, yield huge profits for Pfizer during an epidemic? Was it ethically
acceptable to conduct a trial in a developing country like Nigeria, which had minimal
chances of actually being used in that country due to its exorbitant costs?173 Pfizer
defended itself on the grounds that acute epidemics of meningitis are rare in
developed countries, that drug response may differ from one setting or population to
another, and that it is necessary to determine what kinds of drugs will be most

" u Ibid. Barnaby Phillips, Nigeria's Drug Trial Fears BBC News 14 March 2001. Available at: BBC
News <http://news.bbc.co.Uk/l/hi/world/africa/1220032.stm> (1 September 2005).
171
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effective in an epidemic situation.

According to a press statement it made in 2006:

"At the time of the epidemic - the largest in the country's history, according to health
officials - Pfizer believed that Trovan would provide a life-saving treatment for
meningococcal meningitis that was afflicting tens of thousands of Nigerians. The
goal of the study was simple - to find an effective treatment for a disease that was
having a devastating effect on the people of sub-Saharan Africa."

Also, in its

statement of defence in a case eventually filed against it by the Nigerian government,
Pfizer stated that it had donated over 18 million naira to Kano State (about 180,000
dollars) in medicine equipment and materials to fight the concurrent epidemics.17
There were also apparent procedural defects, for instance, proper records
of the trials were not kept as required in such trials.17

Further, there was no

approval of the research protocol by an independent ethics review committee. Pfizer
stated that it had obtained the necessary approvals from NAFDAC, the Federal
Ministry of Health, and the Kano State Ministry of Health.178 When the incident was
publicized by the Washington Post, Pfizer also stated that it had received approvals
from an ethics review committee in the hospital. But, there was no ethics committee

Ezeome and Thomson, supra note 157 at 5.
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176
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in the hospital at the time of the trial179 and no evidence exists that any ethics review
1 SO

committee in Nigeria examined the research protocol before the trial commenced.
A purported letter of approval was not given at the time of the incident and was
backdated by at least a year.181

It may be stated, however, that there were no

domestic regulations or guidelines in Nigeria, at the time of the trials, requiring
Pfizer to obtain any such approval. Pfizer in its statement of defence sought to rely
on this gap in Nigerian law and policy, stating:
Pfizer contends that there was no regulation or law
in Nigeria requiring ethical committee approval
before conducting a clinical trial or investigative
study. Therefore, there was no need to obtain what
the law did not require. In addition, there was no
formal ethics committee sitting at either Kano's IDH
or at the nearby Bayero Teaching Hospital. There
were, however, numerous other forms of approval
by local physicians and government officials
authorizing the study to go forward including, but
not limited to, the head of the IDH and Dr. Idris
Mohammed. At no time was patient care
compromised in any way.182
However, the requirement for ethics review approval was also a
requirement of the international ethical guidelines, such as the Helsinki Declaration.
There were also questions as to whether the foreign physicians used by Pfizer in the
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study were licensed by the Medical and Dental Council of Nigeria to treat patients in
Nigeria.183
The drug was approved by FDA in 1997, a year after the trials in Nigeria.
One of the grounds of the approval was the beneficial impact of the drug as
manifested in the clinical trials conducted in Kano.184

Later, in 1999, the FDA

issued a public health advisory limiting the use of the drug to certain categories of
1 Of

patients and restricting its use because it was shown to cause fatal liver damage.
The European Union also withdrew the drug from the market in 1999 because of
liver problems.186 The drug was not registered or marketed in Nigeria since it was
too expensive and therefore not affordable.1

7

The parents of the children involved in the trials brought action in the
Federal High Court in Nigeria alleging lack of informed consent, and seeking
1 88

compensation from Pfizer.

This case was dismissed in 2002. Another suit was

filed by thirty families in a District Court in the United States in August, 2001 while
the case filed in Nigeria was pending, seeking punitive damages against Pfizer under
the United States Aliens' Tort Claims Act,lS9 alleging that Pfizer had violated the law
183
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of nations due to its alleged non-conformity with international ethical standards for
research.190 The plaintiffs in this case sought to rely on internationally recognised
guidelines for ethical clinical research, the Helsinki Declaration and the Nuremberg
Code and the ICCPR. The suit was later dismissed by the District Court on the
grounds of non forum conveniens finding that, despite acknowledged problems of
corruption and bias, Nigerian law recognises medical malpractice, negligence and
personal injury claims and Nigerian courts thus afforded an adequate forum for
trying the matter.191 The plaintiffs appealed. The suit was remanded to the District
Court by the Court of Appeals in October, 2003.192 This appeal was also dismissed
in August, 2005 on similar grounds, with the court stating that Nigeria was the
proper forum for action.19

In that case, the judge noted that language used in the

instruments relied on by the plaintiffs was merely 'aspirational' language which
could not be characterized as creating well-defined and universally accepted legal
obligations under international law to sustain an action under the Aliens Tort Claims
Act.194 However, in January 2009, the Court of Appeals for the Second Circuit, in a
decision remarkable for its potential impact not only on US law but on international
law and multinational companies' liability, held that the District Court had
jurisdiction under the Alien Torts Claims Act for a violation of the norm of
customary international law prohibiting medical experimentation on non-consenting
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human participants.195 In June 2010, the United States Supreme Court dismissed an
appeal by Pfizer against the Court of Appeals ruling, effectively allowing the case to
proceed further in the US court system.196
The Nigerian government, now under a democratic regime, opened an
inquiry of the incident in 2001, five years after the trial took place. The findings of
the panel of inquiry were not made public until the Washington Post obtained a
leaked copy in May 2006.197 The panel found, among other things, that Pfizer had
not obtained the informed consent of the participants in the trial since they were not
informed that they were engaged in a trial and that no ethics approval was
obtained.198

The panel also criticised NAFDAC, the Nigerian drug regulatory

agency, and the Federal Ministry of Health, for failure to take action after the
chairman of the task force for the epidemic made complaints to them about the
trial.199
In June 2007, the Kano State government and federal government
instituted civil200 and criminal proceedings against Pfizer, respectively.201
195
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legal actions were settled out of court in 2009, with no admission of liability by
Pfizer. 202 The settlement amounted to 75 million dollars in total. Under the terms of
the settlement with Kano State, Pfizer agreed to establish a Healthcare/Meningitis
Fund from which study participants can receive financial support. Pfizer also agreed
to finance several healthcare initiatives selected by the Kano State government that
benefit the people of Kano State, amounting to US$30 million over a period of two
years and reimburse Kano State for US$10 million in legal costs associated with the
litigation. The Healthcare/Meningitis Fund would pay out a maximum of 35 million
dollars to be divided amongst persons who could show that they participated in the
Trovan clinical trial.

The settlements do not, however, resolve the claims brought

by the trial participants in the United States since the government actions were not
brought on behalf of these participants.
The Pfizer incident raised troubling questions about the motives of
research sponsors, particularly pharmaceutical companies, in conducting research in
developing countries like Nigeria, possible corruption in developing countries in the
area of health research, and the vulnerability of participants in these countries to
exploitation. It also raised questions about the existence, and adequacy of domestic
legal, ethical, and policy requirements and governance structures for the conduct of

Facing 4 Court Cases in Nigeria" Associated Press August 11, 2007 online:
<http://www.washingtonpost.com/wp-dyn/content/article/2007/08/ll/AR2007081100435.html>
(March 2, 2010).
202
Pfizer, "Pfizer, Kano State Reach Settlement of Trovan Case" (2009) online:
<http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&newsId=2009073
0005769&newsLang=en> (March 15, 2010). Joe Stephens, "Pfizer Reaches Settlement In Nigerian
Drug-Trial Case" Washington Post, April 4, 2009, online: <http://www.washingtonpost.com/wpdyn/content/article/2009/04/03/AR2009040301877.html> (March 15, 2010).
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research in Nigeria. The incident further called into question the government's role
in ensuring the protection of research participants in Nigeria.
Further, as some research has suggested, the trial was partly responsible
for a boycott of polio vaccine immunisation from 2003 to 2004 in the Northern part
of Nigeria, where polio has been endemic.204 This is particularly significant because
Nigeria is one of only six countries in the world where polio has remained
endemic."

The continued survival of the polio virus in Nigeria has been cited as

potentially jeopardizing the global efforts to eradicate polio.206

Political and

religious leaders in the Northern states specifically alluded to the Pfizer incident in
support of their stance against polio immunisation. In a statement in 2004, Dhatti
Ahmed, the Secretary of the Supreme Council of Sharia (SCSN) said that:
[t]he SCSN harbours strong reservations on the
safety of our population, not least because of our
recent experience in the Pfizer scandal, when our
people were used as guinea pigs with the approval of
the Federal Ministry of Health, and the relevant UN
207

agencies.

204

Maryam Yayha, "Polio Vaccines - "No Thank You" Barriers to Polio Eradication in Northern
Nigeria (2007) 106: 423 African Affairs 185. See also, Ebenezer Obadare, "A Crisis of Trust:
History, Politics, Religion and the Polio Controversy in Northern Nigeria" (2005) 39:3 Patterns of
Prejudice 265.
205
David L Heymann and Bruce Aylward, "Eradicating Polio" (2004) 351:13 New England Journal of
Medicine 1275. There is evidence more recently that progress is being made to eradicate polio in
Nigeria. See Stephanie Nebehay, "Nigeria Makes Gains in Polio Eradication" Reuters, March 6,
2010).
206
See Lancet, "Vaccine-Derived Poliomyelitis in Nigeria" (2007) 370 Lancet 1394.
207
Abiodun Raufu, "Polio Vaccine Plans May Run Into Problems in Nigeria" (2004) 327 British
Medical Journal 380.
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Thus, although there were other factors, the rejection of the polio vaccine in the
Northern states of Nigeria has been attributed in part to the fears engendered by the
Pfizer incident.
In conclusion, Nigeria's history of health research and research
governance includes instances of unethical conduct, some documented, and others
only anecdotal. These instances, as the Pfizer incident shows, damage public trust in
a context where health research is very much needed. These instances, particularly
the Pfizer incident, also exposed the vacuum that existed in Nigeria's research
governance arrangements prior to 2006.

5.5.3 Research Governance in Nigeria Since 2006
The recent move towards a domestic ethical framework and a new
national regulatory structure, as discussed above, began around 2002. The impetus
for this move came from both domestic and international events. As I discuss below,
international interest in research governance in developing countries like Nigeria, the
Pfizer incident, and growing domestic interest in health research and research ethics,
appear to have been contributory to increased national attention to research
governance in Nigeria.
In 2000, the Fogarty International Centre of the National Institutes of
Health in the United States, through the International Bioethics Education and Career

208

See Bolu Olusanya, "Polio-Vaccination Boycott in Nigeria" (2004) 363 Lancet 1912. A S Jegede,
What Led to the Nigerian Boycott of the Polio Vaccination Campaign? PLoS Med (2007) 4(3): e73.
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Development Award, began to train several researchers in research ethics and ethics
review.

These researchers have been influential in the recent developments in the

ethics review infrastructure in Nigeria. According to Adebamowo and others, by
2004, several Nigerians had graduated from the Fogarty-funded training programme
in the United States, Canada, and South Africa, and set out to assist their institutions
in setting up ethics committees where none previously existed, to strengthen existing
ones and to provide local bioethics training.

In addition, the need to meet

requirements of foreign sponsors, particularly government institutions in United
States, was contributory.211 Moreover, the Pfizer incident, as described above,
exposed the vacuum that existed in Nigeria's governance arrangements for health
research involving humans.
The international interest (particularly from the United States) and the
Pfizer incident generated a desire among local researchers to engage the government
in efforts to develop a national structure for research governance. According to
Adebamowo, several researchers advocated at the national level to encourage the
federal government to develop a national structure. The government subsequently
established the National Health Research Ethics Committee in 2005.212 Further,
during a 2006 Presidential Retreat on the Health of Nigerians, the fact that Nigeria
See Adnan A. Hyder et al, "A Case Study of Research Ethics Capacity Development in Africa"
(2007) 82:7 Academic Medicine 675.
210
Adebamowo, supra note 64 at 18.
211
See for example, Falusi et al, supra note 127 noting the importance of gaining the FWA in the
University of Ibadan. For instance, the United States National Institutes of Health, requires that any
research institution in the world that receives US government funds for research must have a
certification known as the Federal Wide Agreement (FWA) showing that the standards of current
United States human subjects' regulation have been met.
212
Eyitayo Lambo, Address of the Federal Minister of Health, Prof. Eyitambo Lambo at the Inaugural
Ceremony of the National Health Research Ethics Committee, Held at Conference Hall of the Federal
Ministry of Health, Abuja on 5th October 2006, online: < http://nhrec.net/nhrec/news2.html> (March
2, 2010). See also the National Health Research Ethics Code at 3.
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needed domestic regulatory structures to meet its Millennium Development Goals
targets was strongly emphasised.

In addition, a High-level Ministerial meeting was

convened by the Nigerian Federal Ministry of Health and the Ghana Ministry of
Health in March 2006, at which health research and the need for good systems of
research participants' protection was discussed.214
The federal government through the Federal Ministry of Health then
signed a technical cooperation agreement with the West African Bioethics Training
Programme, a programme funded by the Fogarty International Centre. According to
the agreement, the West African Bioethics Training Program was to provide training
and support for members of the National Health Research Ethics Committee and
several members of staff of the Federal Ministry of Health. The West African
Bioethics Training Program was also required under the agreement to assist the
Federal Ministry of Health in drafting a national code for health research ethics,
develop standard operating procedures for ethics committees, and other relevant
documents, with the aim of strengthening health research ethics in Nigeria. The West
African Bioethics Training Program developed the National Code on Health
Research Ethics, according to Adebamowo, taking into account the Nigerian
Constitution, the federal structure of the country, relevant laws, the history of
research and research ethics in Nigeria as well as the needs of local and international
researchers.

Adebamowo, supra note 64 at 18.
See Communique, supra note. 107 and see the Preface to the National Code on Health Research
Ethics.
214
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Adebamowo and others note that: "Previous bioethics needs'
assessment studies had indicated that the potential for bureaucratic delays, corruption
and obstructionism were the most important concerns that biomedical researchers in
Nigeria have about a national ethics committee."215 The committee within West
African Bioethics Training Program which drafted the National Code were therefore
required to pay attention to these matters as it developed the National Code. The
draft code developed by West African Bioethics Training Program was submitted to
the National Health Research Ethics Committee in 2006 and it was adopted by the
9 1 f\

Federal Ministry of Health after consultations and amendments.
Thus, in 2006, the government of Nigeria established the National
Health Research Ethics Committee as well as a National Code for Health Research
917

Ethics (the National Code) designed to provide oversight for research.

According

to the Preface to the National Code written by the then Minister of Health, Professor
Eyitayo Lambo,
The National Code of Health Research Ethics
represents the collective concern of the government
and the people of Nigeria to ensure the protection of
human participants in scientific research to the
highest ethical standard that is possible.218
The National Code applies to "all health research involving human participants,
conducted, supported or otherwise subject to regulation by any institution in

Adebamowo, supra note 64 at 18.
Federal Ministry of Health, National Code on Health Research Ethics:
<http://www.nhrec.net/nhrec/> (January 14, 2010) at 3.
217
Federal Ministry of Health, National Code on Health Research Ethics:
<http://www.nhrec.net/nhrec/> (January 14, 2010).
218
Ibid. See Preface.
216
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Nigeria."

It therefore provides overarching governance for health research in

Nigeria and is not limited to drug research like the NAFDAC Guidelines or the
NAFDAC Clinical Trials Regulations.

The National Code contains several

substantive ethical and procedural requirements for the conduct of health research
involving humans in Nigeria. I discuss some of these requirements in Chapter Six.
The National Health Research Ethics Committee operates at the
national level.

The National Health Research Ethics Committee has the

responsibility for registering Health Research Ethics Committees, updating, revising,
editing and modifying the Code, providing oversight of functions of the Health
Research Ethics Committees, including registering and auditing them. It can also
mete out penalties against persons found to be in violation of any norms and
standards, or guidelines, set for the conduct of research under the National Code. It
also has the responsibility of advising the federal and state ministries of health on
any ethical issues concerning research. The Department of Planning, Research and
Statistics in the Federal Ministry of Health serves as the secretariat of the National
Health Research Ethics Committee. "
Health Research Ethics Committees, operating at the institutional
level in the different states, conduct actual reviews of protocol and report to the
National Health Research Ethics Committees.221 These committees are now required
to register with the National Health Research Ethics Committee. All institutions that

219

Section B.
Federal Ministry of Health , "Department of Planning Research and Statistics" online:
<http://www.fmh.gov.ng/Organisation-PRS.htm> (March 8, 2010).
221
See Section C (a) of the National Code for Health Research Ethics. See also, NHREC, online:
<http://www.nhrec.net/nhrec/about.html> (February 2, 2007).
220
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seek to conduct health research must establish Health Research Ethics Committees.
These committees must be registered with the National Health Research Ethics
Committee. Clinical trials of drugs still have to pass through the requirements of
NAFDAC, the drug regulatory agency. Medical and dental practitioners still have to
abide by the Medical and Dental Council of Nigeria's Code of Medical Ethics.

I

discuss these matters in more detail in Chapter Six.
However, there is still no overarching legislation on health research
involving humans. Hope, however, is close on the horizon. A National Health Bill,
which will provide the statutory basis for the establishment of the NHREC, was
passed by the National Assembly in May 2010. It now awaits the President's
222

assent.
The influence of the Pfizer incident on development of the Bill is not
expressly documented anywhere but the provisions of the Bill suggest that the
incident may have had some influence. In this regard, the Bill makes provisions for
informed consent, including what constitutes informed consent in the case of a minor
participating in research.

However, the Bill is much narrower than the scope of

legislation discussed in Chapter Four. Also, because of constitutional divisions in the
federation, the application of the Bill may not necessarily be as wide in scope as may
be assumed from its provisions. These matters are analysed in greater detail in
Chapter Six.

222

Speaker's Office, "2008 to 2009" Acts, online:
<http://www.speakersoffice.gov.ng/resources_acts_2009.pdf> (March 2, 2010). See also, Emmanuel
Ogala, "Finally, Federal Lawmakers Pass a Bill" Next, March 14, 2010, online:
<http://234next.com/csp/cms/sites/Next/News/Metro/Politics/5539991147/finally_federal_lawmakers_pass_a_bill.csp> (March 14, 2010).
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Adebamowo and others, point out the role democracy has played in
encouraging the development of a national ethics review structure in Nigeria. They
note that, "[t]he advent of civilian democracy in Nigeria in 1999 coincided with a
period of increased international attention to the problems of unethical health
research that occurred particularly in developing countries."23

Apart from

sponsoring research, as described above, several foreign bodies are involved in
promoting research ethics capacity building in Nigeria. One of these is the Fogarty
awards which, as described above, have had a direct impact on the development of
research governance structures in Nigeria. Another is the European Developing
Country Clinical Trials Partnership, which has funded several research ethics
programs in Nigeria, including the Research Ethics Capacity Building Programme at
the Nigerian Institute of Medical Research and the European Developing Country
Clinical Trial Partnership Research Ethics Capacity Building Collaboration, which
aims to train Nigerian researchers and members of ethics review committees in
Nigeria.223
On the whole, there is now a formal, more comprehensive, national
system of ethics review in Nigeria.

There is also more clarity about research

governance structures in Nigeria. Many of these developments can be attributed to
the recent democratic regime in the country, increased international attention to
health research and to regulation, and to instances of unethical research in Nigeria.

"Research Ethics Capacity Building Programme, "About Us" online: <
http://www.recbp.org/about_recbp.htm> (February 28, 2010).
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5.6 Conclusions and Issues Arising
What salient points, apart from background information, can be gleaned
from this brief discussion of the general context of Nigeria and the history of
research governance in Nigeria? Have gaps, weaknesses and areas for potential
improvement been revealed? How are these likely to impact research governance in
Nigeria today?

Below I point out some of these essential points and potential

problem issues. I analyse them more fully in Chapter Six, and propose solutions in
Chapter Seven.
First, while democracy has brought a few positive changes, including
generally in health, the area of health research is one which has yet to receive all the
attention it deserves. Yet, there continues to be significant need for health research in
Nigeria. Major national policies recognise this need. On the other hand, there has
been an increase in health research activities in Nigeria, particularly from external
sponsors, under the recent democratic regime. In light of this increase and the
recognition in national policies of the necessity for even more health research, it is
crucial to make sure that there are sufficient arrangements to regulate current and
potential health research involving humans in Nigeria. The instances of unethical
research serve to call even more attention to this need. The federal government
which, as described above, is responsible for policy formulation, strategic guidance,
coordination, supervision, monitoring and evaluation at all levels in the country, has
taken the lead in establishing a system of research governance in Nigeria.
Further, research governance efforts, particularly with respect to
development of ethics review structures at the national and institutional levels, have
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been long in the making, beginning in 1980. There have been many fits and starts
along the way, with ethics review committees at all levels failing and being
reestablished over the years. The issues of sustainability and political commitment
are therefore matters that have great relevance in the Nigerian context. In developing
current research governance arrangements in Nigeria, it is necessary to consider also
the potential for these new arrangements to be sustained.
The development of research governance structures have somewhat but
not strictly followed the pattern of the paradigm shifts described by Emmanuel and
Grady, discussed in Chapter Two. Regulatory movements in research governance in
Nigeria appeared to have moved from the self-regulation of doctors to a national
ethics review to institutional ethics review and now to an increased government role.
However, enabling research participants and ordinary citizens to be part of research
governance is, as I describe in the next chapter, still a work in progress, as is the
effective use of comrnand-and-control techniques like formal legal regulation. As I
argued in my analytical framework in Chapter Two, a strong government presence in
addition to increased participant involvement in governance processes, amongst
other steps, may yield more effective results in a developing country like Nigeria.
Indeed, this is hardly debatable in the Nigerian context, where ethics review in
institutions floundered partly as a result of insufficient support from the government.
As I argue further in the next Chapter, there is still room for the Nigerian government
to work more effectively in its role in research governance in Nigeria.
Also, as both anecdotal evidence and actual documented incidents of
unethical research indicate, there is need for effective research governance in Nigeria
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not only to protect research participants but to preserve the trust and confidence of
the Nigerian population in health research activities and institutions.

Such

confidence is necessary also, perhaps more crucially, for the uptake and effectiveness
of basic, beneficial health programs in a challenging health context (like
immunization programmes).

The incidents of unethical conduct of research

described here also emphasise the existence of several socio-economic factors, such
as illiteracy and poverty, which render potential research participants more
vulnerable to exploitation and thus emphasise the need for effective governance of
research.
Further, the Pfizer incident which was heavily publicized in domestic and
international media might cause research sponsors to be wary about conducting
relevant and essential research in Nigeria.

Clear and effective governance

arrangements which delineate the parameters for the ethical and responsible conduct
of research in Nigeria (which were lacking during the Pfizer incident) can, however,
counter such wariness.
Related to the above, the positive impact of democracy is another issue
that must be borne in mind. During the years of military rule, there was very little
progress on research governance. Although Nigeria's democracy has not necessarily
brought all the dividends that the Nigerian citizenry would have hoped for, and
remains very much a work-in-progress, it appears that democracy has been good for
the needed growth in health research activities in Nigeria as well as for research
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governance efforts.""

During this current democratic era, more efforts have been

made to develop and improve research ethics structures in Nigeria than had been
made in previous years. There has also been greater support in this area from foreign
agencies in developed countries, particularly the United States and the European
Union. Democracy, it seems, has not only encouraged more political commitment
from the Nigerian leadership but has encouraged foreign assistance in research
governance initiatives. Research governance in Nigeria is likely to benefit from
continued efforts to retain and build a more democratic government.
Related to this impact of democracy, it would appear that research
governance efforts in Nigeria have been significantly impacted by initiatives
developed in other countries - from the institutional ethics review committee to the
ethical values underlying these arrangements - and from all indications are likely to
continue to do so. "

Much of what Nigeria might do in terms of research

governance thus appears likely to be constrained by the current culture of research
governance in the countries from which the research funding is coming. Although
this means that not all the initiative for establishing governance structures in Nigeria
has been indigenous or domestic, this may not necessarily be a negative thing, at
least by comparison to the previously existing vacuum. In any case, it is only partly
true, given that key research governance structures like ethics review committees had
previously been in place, if not necessarily effectively utilized or sustained.

Adebamowo et al supra note 64. Even the research participants in the Pfizer incident benefited
from steps taken by the government during the democratic era.
225
For instance, the National Code, the primary document for research governance in Nigeria, was
drafted with funding from the Fogarty International Centre of the NIH although it remains a document
emanating from the Federal Ministry of Health.
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Also, foreign support may provide some of the resources required for the
working of research governance arrangements. However, it does raise the concerns
that have been articulated elsewhere, such as potential bioethical colonialism.22 It
also raises potential serious conflict of interest issues, the possibility of adoption of
arrangements that may possibly not be workable in the Nigerian context, and issues
of sustainability. Foreign support of research governance also raises the issue of the
degree of political commitment to the research governance process. Is the Nigerian
government merely rubberstamping initiatives developed by donors and sponsors of
research? To what degree are the new research governance arrangements geared
towards domestic concerns? Is it reasonable or even possible to sustain the
governance of health research in Nigeria mainly through foreign support? And given
limited resources and other challenges requiring attention, how can resources be
provided domestically for the maintenance of research governance arrangements? I
address these issues in the next chapter.
Another salient point is that, with the creation of a national code and a
national ethics review committee, there is now a national context for research
governance.

A more concrete and predictable system for governing research is

emerging. This national system of governance will apply everywhere, irrespective of
geographical location or even prevailing conditions of knowledge and resources. As
the Pfizer incident showed, health research involving humans can take place
anywhere and in any hospital, even in previously unusual instances. A national

Ogundiran, supra note 130.
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system makes room for the same principles to apply in all cases and thus affords the
same protections to every potential participant in research in Nigeria.
There are several other bodies involved in research governance,
including NAFDAC, the Medical and Dental Council of Nigeria, the National Health
Research Ethics Committee. There are also different guidelines and regulations.
Thus, while major steps towards a national, comprehensive structure have been
taken, there is still a potential risk of duplication, overlap, and inefficient
coordination. These are already challenges experienced in the health system as a
whole, as discussed earlier. And this has been experienced in research governance in
the past, with two national ethics review committee operating concurrently.
On the other hand, the history of research governance in Nigeria
indicates that, apart from the federal government, other institutions and organisations
have not been very active in research governance. As I have argued in previous
chapters, a hybrid framework of governance requires that different mechanisms,
institutions or organisations are involved in research governance for greater
effectiveness.
A different point is that research governance arrangements in Nigeria
appear to have focused on ethics review which is certainly a crucial and central piece
in research governance. However, as I argued in Chapter Three and Chapter Four,
there should be recognition that there other components to research governance,
including a well-developed ethical framework, a comprehensive legal and
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institutional framework. The next chapter delves deeper into this issue and argues
that these frameworks need further development in the Nigerian context.
Finally, the discussion of the political and legal background, and the
health profile of Nigeria, indicates the fact that these recent research governance
arrangements will operate within a challenging milieu. For instance, how are critical
issues in research governance, such as conflict of interest, to be dealt with where
poverty is widespread, the health system is poor, pharmaceutical companies donate
clinical trials centers, and major research governance endeavours are undertaken with
foreign funding?
In sum, the history of research governance in Nigeria indicates that there
are likely to be challenges in research governance in Nigeria, including systemic,
operational, and contextual challenges. There are also likely to be challenges in the
areas of the sustainability and political commitment to implement and enforce
relevant law and policy. As I discuss in Chapter Five and Six, these challenges are
not insurmountable.

5.7 Conclusion
In recent years, Nigeria has established (and re-established) research
governance policies and arrangements. For developing countries intent on doing the
same, Nigeria's experience might be a point of reference, if not wholesale adoption.
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In this chapter, I have sought to describe the broader political and legal
context in which this has taken place. I have also attempted to describe the health
context of Nigeria, including diseases requiring research in the Nigerian context,
Nigeria's health system, and Nigeria's policies on health and health research.
There is a significant need for health research in Nigeria. With this need
comes the responsibility to ensure that not only is health research promoted, but that
research participants, many of whom might be poor, illiterate and vulnerable in other
ways, are protected. The Pfizer incident shows that this is a responsibility that must
be taken seriously by all actors in research governance in Nigeria.
The best research governance arrangements in Nigeria would be, in my
view, arrangements that take into consideration the context and challenges of
Nigeria. This would include its federal structure, its history of ethnic strife, its
limited resources, the problem of corruption, and the need for transparency. The next
chapter focuses on a detailed analysis of current research governance arrangements
in Nigeria and addresses the issues highlighted by the history of research governance
in Nigeria.
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Chapter Six
Research Governance in Nigeria: Analysis and Assessment of Current Governance
Arrangements
6.1 Introduction
Research governance in Nigeria, as I explained in Chapter Four, formally
began on a national level in 1980. It has, however, since 2006, entered a phase of
renewed attention and commitment. The aim of this chapter is to analyse and evaluate
the current arrangements for research governance in Nigeria. The analysis is based on a
need for a comprehensive view of research governance, using a hybrid framework of
governance, the groundwork of which has been laid in previous chapters.
To reiterate, this hybrid framework recognises the necessity of harnessing the
synergies of different actors (such as policymaking bodies, drug regulatory authorities,
institutional ethics review committees, non-governmental organisations), and policy
mechanisms, such as ethical guidelines, but also a formal legal framework.

This

framework involves an explicit role for government, as well as a space in which private
actors, including non-governmental organisations, could contribute to research
governance. And, as I argued in Chapter Four, for research governance arrangements to
be truly effective, there is need to recognise, and take advantage of, existing and
potential interrelationships between the different frameworks and actors in research
governance.

The discussion of the Nigerian context in Chapter Five indicated that

there exists the beginnings of an institutional framework. It also showed that an ethical
framework exists with a new national code of research ethics established in 2006. The
developments in Nigeria also show that the government plays a significant role in the
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governance of research. The role of law as a significant mechanism to facilitate other
mechanisms and to ensure accountability is beginning to gain acknowledgement,
particularly with the development of the National Health Bill.

A universal and

comprehensive system involving different actors appears to be emerging. As I will
show below, the lines of responsibilities and accountability are becoming more
apparent, even though this is still a work in progress. Yet several questions remain: Are
the existing arrangements adequate? If they are not, what is missing? This chapter
attempts to answer these questions.
In this chapter, then, I undertake two main tasks. The first task is to describe
and analyse in greater detail all the different components of research governance in the
Nigerian context - the ethical framework, the legal framework, and the institutional
framework.

It is important to undertake this description because of the paucity of

literature describing the current landscape of research governance in Nigeria. In my
analysis, I identify within each framework, current and potential problems, gaps, and
weaknesses. I draw from previous discussion in Chapter Three of the concerns that
have arisen in other jurisdictions, especially within the institutional components of
research governance, and also from Chapters Four and Five, dealing with the legal
framework and the Nigerian context respectively. The weaknesses and gaps identified
include systemic, operational and contextual issues.
In light of the discussion and analysis, I then undertake the second task which
is to assess the current research governance arrangements and the potential they have of
performing the required functions.

I examine this through the criteria identified in
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Chapter Two namely: effectiveness, legitimacy, clarity, comprehensiveness, efficiency,
adequacy, uniformity, and simplicity.
This chapter is divided into six parts. The first is this introduction. The
second is a two-pronged discussion of the ethical framework. It considers the general
values of the country as an entry point and a basis for research governance. It then
examines the specific ethical principles for health research involving humans in Nigeria.
The third section discusses the legal framework of research governance in Nigeria,
exploring the legal structure offered by common law concepts and legislation which
have direct implications for research governance. The fourth section considers the
institutions involved in research governance in Nigeria - the ethics review committees,
the drug regulatory authority, policy structures, other institutions, and the potential role
of non-governmental organisations. The fifth section examines the potential of current
arrangements in Nigeria to meet the goals of research governance based on several
criteria discussed in Chapter Two. The sixth section concludes the chapter.

6.2 The Ethical Framework of Research Governance in Nigeria
The ethical framework of research governance, as discussed in Chapter Three,
provides the foundation and the value basis for research governance, and the true goals
and objectives of research governance. The international ethical guidelines, such as the
Helsinki Declaration, provide the basic international standard for the ethical conduct of
health research involving humans. These international ethical guidelines may also
influence conduct within countries or be formally adopted as national guidance. As will
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become clear in the discussion that follows, even with the establishment of a new
national code on research ethics, the Helsinki Declaration, in particular, retains a large
influence in Nigeria.
Within a national context, however, there may be several other domestic
sources from which ethical values may be drawn.

In Nigeria, ethical values relevant

for health research involving humans may be identified, generally speaking, from basic
and fundamental sources such as the Constitution, which describe broadly how people
ought to be treated in Nigeria.

For instance, under the fundamental objectives and

directive principles of the Constitution, it states that:
....(2) In furtherance of the social order-...
(b) the sanctity of the human person shall be
recognized and human dignity shall be
maintained and enhanced;
(d) exploitation of human or natural resources
in any form whatsoever for reasons, other than
the good of the community, shall be prevented;
1

The sanctity of the human person and human dignity are concepts which can
be hard to define, and there are different controversial ways in which these terms may
be used. But in the Nigerian context, where different kinds of abuses of human rights
have occurred in the past, these terms, though not justiciable, articulate important
national values. They also have important implications, particularly with respect to how
persons ought to be treated by the government and other persons. This clause also

1

Chapter II section 17 (2)
" Abortion, cloning, embryonic stem cell research, and euthanasia are some examples.
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articulates a value which has important implications for health research involving
humans.
With respect to health research involving humans, Spears articulates an
arguably straightforward explanation of the value of the sanctity of human life, stating
that:
The sanctity of the human person is derived from
Immanuel Kant's philosophical restatement of the
Golden Rule: Always treat other persons as ends and
not as means only. This means that while we may at
times use persons as a means, we always recognize
their inherent dignity as human beings. While we
may use patients in our clinical research studies, we
do so only after informing them of the possible
harms and benefits and after obtaining their
informed consent.3
In other words, a person who is to participate in health research must be treated with
respect, and not merely as an object or a means to an end. The Constitution thus
restates a basic value - the fundamental worth of persons, including persons who
participate in research in Nigeria.

In the same vein, exploitation of human beings is also not permitted in the
Nigerian context. However, the addition of the clause "other than the good of the
community" creates concern in the context of health research involving humans that the
good of the community may override the good of the individual volunteering herself for
participation in research. To make sense in the specific context of health research
involving humans, therefore, the clause dealing with the prevention of exploitation of
3

Karen Spear, "Response to 'On the Ethics of the Therapeutic Cloning'" (2003) 12 Journal of
Hematotherapy and Stem Cell Research 135 at 135.
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human resources has to be read in conjunction with the clause as to sanctity of the
human person and human dignity.
In addition, the Constitution also includes the value of respect for human
rights. Specific rights are therefore protected by the Constitution, reflecting the
important value of persons, including participants in research, in the Nigerian context.
Specific rights such as the right to privacy4 and the right of every person to the dignity
of his or her person,5 further reflect the importance of the person. The core value
articulated in the Constitution, the fundamental law of the land, is thus the fundamental
importance of the human person, including persons who volunteer to participate in
research. Research governance arrangements in Nigeria must therefore reflect, and
protect, this essential value.
Ethical values in Nigeria can also be drawn from the Revised National
Health Policy.6 The Policy lists several "Underlying Principles and Values."7 The most
relevant values for research governance as provided in the Policy are: social justice,
equity, accountability, effective partnership with actors in health, and gender

4

Section 37 of the Constitution.
Section 34. The term "dignity" is a controversial concept. Some argue that it is too loose a concept to
mean anything. According to Macklin, it is no more than respect for persons and their autonomy. See
Ruth Macklin, "Dignity is a Useless Concept" (2003) 327 British Medical Journal 1419. To others,
however, "dignity " has a specific meaning. Thus according to Jordan, '"Human dignity' refers to a
collection of intangible, distinctively human goods. To affirm that there is such a thing is to affirm that
genuine human flourishing requires at least the following: moral virtue, appreciation of beauty, awareness
of oneself as a unique individual, participation in human community, receptivity, and personal agency."
See Matthew Jordan, "Bioethics and 'Human Dignity" (2010) 35 Journal of Medicine and Philosophy 180
at 184. See also, S. Killmister, "Dignity: Not Such A Useless Concept" (2010) 36 Journal of Medical
Ethics 160. See, Thomas De Koninck, "Protecting Human Dignity in Research Involving Humans"
(2009) 7 Journal of Academic Ethics 17.
6
See Federal Ministry of Health, Revised National Health Policy (Abuja: Federal Ministry of Health,
2004).
7
See Section 3.2 of the Revised National Policy.
5
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sensitivity. These values ought therefore to guide the development of the research
governance system. For instance, the system must be designed to be accountable to the
Nigerian people and should therefore include clear reporting lines. Gender sensitivity
would be crucial in areas such as inclusion of women as participants in research, and in
the membership of national and regional or institutional review committees.

Effective

partnership would require ensuring good interrelationships between different levels of
government in research governance, and effective linkages with other stakeholders in
research governance.

Interestingly, these values also reflect some of the strengths of

the new governance approach, in particular, effective partnership with other actors,
indicating the need for recognition of the different actors and instruments in research
governance.

They also reflect some of the criteria developed in Chapter Two, in

particular, effectiveness and legitimacy.

Below, I assess the emerging research

governance system in Nigeria using these criteria.
In addition to the general values of the Nigerian state as provided under the
Constitution and documents such as the National Health Policy, the ethical framework
of Nigeria can be deciphered more specifically from the provisions of the National Code
for Health Research Ethics ("the National Code).9 As I noted in Chapter Three, national
guidelines and policies, such as the National Code, which take into consideration the
contexts and the values of different countries may be one way of resolving the existing
ethical dilemmas of conducting research in developing countries. As soft law, favoured
under the new governance approach and adopted in my hybrid framework, it offers
8

Ibid.
Federal Ministry of Health, The National Code for Health Research Ethics (Abuja, Federal Ministry of
Health, 2007).
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greater potential for flexibility, responsiveness and participation. The establishment of
the National Code in Nigeria is therefore a significant achievement, of great importance,
and potential benefit.
As well as the National Code, other instruments contain ethical guidance.
These include the Code of Medical Ethics made by the Medical and Dental Council of
Nigeria, which regulates medical and dental practitioners in Nigeria, and the regulations
and guidelines made by the National Administration for Food and Drug Control
(NAFDAC). I discuss and analyse the provisions of these instruments below.

6.2.1 The National Code for Health Research Ethics
The National Code defines health research as being a systematic
investigation, including research development, testing and evaluation, designed to
develop or contribute to generalisable knowledge. Such investigation may consist of
therapeutic procedures, including interventions administered with the intent of
providing direct benefit to the research participant.

It may also consist of non-

therapeutic procedures, and interventions only intended to answer scientific questions.10
There are, however, some types of research exempted from the requirements of the
National Code, including ethics review. These include research on the effectiveness of
or comparison between teaching methods, curricula or classroom management methods,
research involving the evaluation of outcomes of procedures, programs and services

Section A.
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designed to produce information leading to improvement in delivery, and so on.

The

definition of research in the National Code is therefore broad, encompassing clinical
trials but also other types of health research.
The National Code applies to all health research conducted in Nigeria. It
states that: "Health research that is conducted anywhere in Nigeria must comply with all
sections of this code."

Thus, the National Code has broad coverage, both

geographically, and with regard to the types of health research covered. Its provisions,
including the ethical principles contained therein, thus apply to all kinds of health
research in Nigeria.
The National Code, taking a different approach from the Belmont Report,
distils the ethical principles that provide guidance for ethics review committees in
reviewing research into ten principles.13 While many of the principles might be
considered to fit into the Belmont framework of respect for persons, beneficience, and
justice, a broader set of principles allows for the capturing of many moral
considerations. These include considerations that might have specific implications in a
developing country context like Nigeria, particularly in the area of community
engagement, and with respect to issues with implications for vulnerability in resourcechallenged settings.
11

Section B.
Section A.
13
Under the section titled: "Ethical Principles and Guidelines for HREC's Approval of Research," it
states: "In order to approve research covered by this code the HREC, shall determine a balance between
the various principles guiding the ethical conduct of research, some of which are outlined below. Since
some of these will inevitably conflict, judgement and consensus are essential in determining whether a
research should be conducted." Researchers, research sponsors, and research institutions are thus not
expressly required to ensure the application of these principles in health research. Instead, it is implied
that these principles should guide the conduct of research by researchers by the fact that all research must
pass through ethics review as required under the Code, but this should have been made explicit.
12
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The first principle is that research must have social or scientific value to
either participants, the population they represent, the local community, the host country
or the world, in order to justify the use of finite resources and risk of harm to
participants.14 While this is generally good, it would have been more helpful to specify
that research undertaken in Nigeria should be relevant to local needs {and the world).
Simply stating that research must have value for the host country or the world leaves
room for the possibility of research which may have value for the rest of the world but
perhaps not for Nigeria. An example is research on developing expensive medication
that may not be affordable in Nigeria after the research. One could contrast this with a
similar principle in South Africa's guidelines which provides that researchers in South
Africa have an ethical responsibility to ensure that their research is relevant both to the
broad health and development needs of the country and to individual needs. The South
African guidelines specifically require that research findings must be translatable into
mechanisms for improving the health status of South Africans.15
The second principle is the requirement for scientific validity. Thus, it must
have clear scientific objectives, use valid methodology, have equipoise in the case of

Section F (a). (Emphasis mine).
Section 2.2 of the National Health Research Ethics Council, Ethics in Health Research: Principles,
Structures and Processes Guidelines. (Pretoria: Department of Health, 2004). The Kenyan Guidelines
contain similar provisions, requiring that "Externally sponsored research designed to develop a
therapeutic, diagnostic or preventive product must be responsive to the health needs of Kenya. That
means the research to be conducted must address health problems that are important in Kenya." National
Council for Science and Technology (NSCT), Guidelines for Ethical Conduct of Biomedical Research
Involving Human Subjects in Kenya, NCST no. 40 (Nairobi, NCST, 2004)
3(hereafter, "Kenyan Guidelines"). The National Code does, however, require that in international
collaborative studies, research should be accompanied by "comprehensive capacity building, technology
transfer and health care delivery strategies that address significant local health problems and add value to
local participants of research, including researchers, institutions, communities and the country." Section
F(a).
16
Section F (b).
15
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clinical trials, have adequate operational!sing plans within the context of the
environment in which the study is to take place, have a plausible data analysis plan,
including a specific role for Data and Safety Monitoring Boards in clinical trials, and it
must use correct measurement for outcomes. In the absence of these requirements, a
research project is deemed unethical.
The third principle is that there must be fair selection of participants based on
the scientific objective(s) of the research while minimizing any attendant risk.17
However, it goes on to state that this should not be construed to allow the exclusion of
groups such as women, children, groups of people disadvantaged in any way, and other
vulnerable people especially from research that would benefit them without explicit
reasons for doing so, but specific safeguards are required to protect the vulnerable. This
is a very useful principle, especially in a context that remains to a large extent
paternalistic. Further elaboration of this principle beyond the brief, general discussion
i o

contained in the National Code would have been helpful.

For instance, while it can be

argued that under the National Code, pregnancy is not, by itself, a ground for exclusion
from health research (as, for instance, in the Kenyan Guidelines),19 the principle could
have been couched in more specific terms, with respect to pregnancy and reproductive
capacity. Might these be considered sufficient reason for exclusion and why? What
other grounds could constitute good reasons (or insufficient reasons) for excluding
17

Section F(c).
See, for instance, a discussion if this principle in the Australian context: Angela J Ballantyne, Wendy A
Rogers on behalf of the Australian Gender Equity in Health Research Group, "Fair Inclusion of Men and
Women in Australian Clinical Research: Views from Ethics Committee Chairs" (2008) 188: 11 Medical
Journal of Australia 653.
See for instance, the Kenyan Guidelines, section 14 which deals with research involving pregnant
women.
18

386

persons from participating in research? It would have been helpful if examples of
reasonable grounds for any exclusion were provided in the National Code.
The fourth principle20 requires that there must be valid attempts to minimize
risks and maximize health related benefits for participants to ensure a favourable risk
and benefit ratio. These benefits are distinguished from risks and benefits of therapies
that participants would be exposed to even if they were not participating in research or
incidental risks or benefits. In the weighing of risks, the principle requires that risks and
benefits should be considered at the level of both individual participants and
community. It does not delineate specifically how such risk should be weighted. (For
instance, if the risk to the community is minimal but the risk to the individual is higher,
what happens?).
The fifth principle requires that for research to be ethical it must undergo
independent review. It states that independent review, through a system of ethical
review and oversight of such systems provides assurance that reasonable attempts have
been made to minimise the potential impact of the conflicting interests of the different
parties involved in health research including participants, researchers and sponsors of
research, and ensures balanced judgement.
The sixth principle is informed consent. It states that informed consent is a
prerequisite for the ethical conduct of research. It delineates the process for obtaining
informed consent in Nigeria. Consent forms are to be no longer than 8 pages and
should not contain unnecessary jargon and legalisms. Importantly, it also requires that
20

Section K (d).
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all consent activities be documented and where written consent is not possible,
witnessed thumb-printing or witnessed audio-recording may be acceptable if approved
91

by the ethics review committee."" It permits verbal consent and states that information
about the research is to be provided at an educational level no higher than for
individuals with 9 years of education in Nigeria. This is essential in the Nigerian
99

context because of the considerable degree of illiteracy in certain parts of the country."
Translation of documents may be required in other situations. Consent in instances such
as research involving persons with diminished autonomy, children, and other
extraordinary instances are to be provided in other guidance documents issued by the
National Health Research Ethics Committee. These documents have yet to be produced
but are clearly essential, especially in light of the Pfizer incident.
The National Code emphasises procedural requirements and the informed
consent form. However, the focus on crucial substantive issues is, in my view, much
less than desirable. For instance, it provides the size of the paper documenting informed
consent (A4), the font, the font size, spacing and margins.23 Substantively speaking, it
does require that "adequate information"24 be provided to research participants but does
not specifically state what constitutes adequate information. This is a matter that would
have benefited from a clearer discussion in a country like Nigeria, with its diverse

21

Section F (f) (9)
See UNESCO, Education For All (EFA) Global Monitoring Report 2010: Reaching the Marginalised
(Oxford: Oxford University Press, 2010). Ben Chuks Okeke, "Literacy/Numeracy and Vocational
Training among Rural Women in Nigeria for a Good Livelihood and Empowerment" (2004) 23:3
International Journal of Lifelong Education 287.
23
Section K (f) (2) and 9.
24
Section K (f)(1).
22
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circumstances."

For instance, it has been noted that in some parts of Nigeria, a strict

disclosure of all possible risks as required in many developed countries may
unnecessarily frighten potential participants and may cause huge difficulties in enrolling
research participants.26

This cannot be generalized, however, as many educated

Nigerians would prefer to have as much information as possible. Although it requires a
statement of all the risks and benefits in the discussion of another principle, clearly
stating that in the section dealing with informed consent, would have been very helpful.
Fadare and Porteri note that it would also have been appropriate to discuss the
dependent relationship between researchers (who are often physicians acting in the dual
role of doctor and researcher) and research participants. They contend that, in a
paternalistic context where doctors are still often regarded as having all the knowledge,
it would have been appropriate for the National Code to emphasise or itemise the rights
of research participants even within such relationships." In such a relationship, it may
be best for informed consent process to be conducted by a physician not directly in
charge of the potential participant's care and treatment.28
Related to the above point, although parts of informed consent issues are dealt
with in the discussion of other principles (including respect for persons, maintaining of

Elsewhere, the Code requires the consent processes to include explicit information about the
researchers, their affliation, qualification and contact details that will allow research participants or ethics
review committees to contact them. But this cannot be all the information required in the informed
consent process. See Section S (1) (i).
26
Ezeome and Marshall, supra note 222 at 3. Are there circumstances in which it could be ethically
appropriate to withhold any information and what effect would this have on the validity of any consent
obtained for participation in the research project? This question would have been answered by a clearer
definition of informed consent than is currently contained in the National Code.
27
Joseph O Fadare and Corinna Porteri, "Informed Consent in Human Subject Research: A Comparison
of the International and Nigerian Guidelines" (2010) Journal of Empirical Research on Human Research
Ethics 67 at 71.
28
This is required by the Helsinki Declaration and the Code of Medical Ethics, 2004, s.31.
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trust relationships), there is no clear definition of informed consent. Nor is there any
discussion of related concepts such as voluntariness, coercion, incentives, and undue
inducement. There is, instead, a requirement for some of these matters to be contained
in the informed consent document. Presumably, it is assumed that everything contained
in the informed consent document would be discussed by the ethics review committee.
The committee may, however, focus exclusively and erroneously on the document
rather than the process. Moreover, these issues are vital in health research involving
humans, and have particular relevance in a developing country context like Nigeria, as
discussed in Chapter One. They deserve to be articulated in fuller and clearer terms in
the Code, especially in light of the circumstances of the Pfizer incident.29 It appears to
me that there is room for elaborating further on informed consent in the Code.
The seventh ethical principle under the Code is that there must be respect for
potential and enrolled research participants from the commencement to the end of the
research project. According to the Code, this requires that their right to privacy may not
be compromised, their involvement is voluntary, and that they can withdraw at any
time. However, it makes an exception to the ability to withdraw at any time, stating:
"However, data, samples, etc. already contributed to the research up to that point may
not needlessly be withdrawn as this may jeopardise the scientific validity of the
research, unjust to those who remain in the study and all or part of their sample or data
may have been used or modified into different form(s), including presentation at

The Kenyan Guidelines, for instance, state that undue inducement is not to be permitted. It will be
recalled that one of the issues that arose in the Pfizer incident discussed in Chapter Four was that the
parents alleged that they had inadequate understanding of information because they assumed that the
children would receive treatment.
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meetings or publications by the researchers."

This provision has particular

significance in light of other research that has occurred in Nigeria, including the
HapMap project mentioned in Chapter Five. The use of the word "needlessly" is
troubling, if not inappropriate. Who determines what is "needless" - the ethics review
committee, the researcher, or the participant who submitted the sample or data and the
community?
The current statement in the seventh ethical principle thus needs revision as it
is tantamount to unduly limiting the rights of research participants and communities.
What is required is clear guidance on when it would be possible or not permissible to
•2 1

withdraw data.

A revision is necessary, especially given that the National Code states

elsewhere that a Materials Transfer Agreement required for samples and biological
materials does "not vitiate the right of research participants or communities to request
that their samples be withdrawn from research according to the terms of the informed
consent process."32 For instance, it would be better to state that data can be withdrawn
at any time except, when the data has been modified or is impossible to extricate from
other data (such as when it has been anonymised).
In like manner, the requirement for privacy is treated rather cursorily with the
National Code stating that: "Their right to privacy may not be needlessly
compromised."'

While it requires the informed consent document to contain a section

3U

Section F(g).
For a discussion of this issue, see generally, OECD, Creation and Governance of Human Genetic
Research Database (Organisation for Economic Cooperation and Development, 2006) at 95.
32
Section N.
33
Section F (g).
31
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on confidentiality , the National Code does not address what might comprise
"needless" interference with privacy, or needful limitation of privacy. Nor does it
address possible mechanisms for maintaining privacy.
Respect for participants also requires that participants be informed of the
progress of the research and any finding that may have a potential effect on their health
and wellbeing and their continued participation in the research. This would ostensibly
include any adverse events. Thus, in a situation such as arose in the Olivieri incident in
Canada, described in Chapter Three, a researcher would be under an ethical duty to
inform research participants of any adverse events.
The respect principle also includes engagement with the community where
the research is to take place. According to the National Code, community consultations
or assent may have to precede research activities so as to ensure community acceptance
and to respect the socio-cultural values of the community and its institutions. The
community "may" also be informed of the progress of the research, relevant findings
that may influence their health and well-being, and the outcome of the research. The
use of the word "may" indicates that this is not mandatory. One would have thought
that it would be mandatory to inform communities of relevant findings that may
influence their health and well-being.

Further, there is, although implied, no explicit

emphasis on the continued importance of individual consent. The Kenyan Guidelines,
for instance, note that due to cultural reasons married women in some rural areas may
not be allowed to give their consent to participation without the express permission of

Section K (f) (5 (x).
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their husbands. However, the Kenyan guidelines also emphasise that in such instances,
the woman must still give her consent.

Such emphasis is also present in the Canadian

guidelines with respect to Aboriginal participants in research.36 The Nigerian context is
pluralistic, making more direct guidance useful.

In a study on informed consent

practices in Nigeria, it was observed that: "Nigeria, like most nations in Africa, is too
pluralistic in its culture and social norms for any of the factors to uniformly apply, and
most significant generalizable factors are shaping informed consent practices in Nigeria
along a Western model."

Another study on informed consent to genetic

epidemiological research on hypertension and breast cancer in Nigeria noted that
women in rural areas in Nigeria were more likely to state that they needed spousal
permission to participate in research than women in urban areas.

In Nigeria, where

communities, particularly in rural areas, play crucial roles in the lives of their members
and women in some areas may require permission from their husbands, or where parents
seek endorsement of adult children on important matters, an emphasis on the continued
necessity of the individual's informed consent would have been appropriate. This
would be in line with the fundamental value of each person in Nigeria, a value
articulated in the Constitution.
The eighth principle in the National Code states that for research to be ethical
the trust relationship between researchers and research participants must in no way be

5

Kenyan guidelines, section 6.
CIHR Guidelines for Health Research Involving Aboriginal People (Ottawa: CIHR, 2008), Article 4.
37
Emmanuel R. Ezeome and Patricia A. Marshall, "Informed Consent Practices in Nigeria," (2009) 9:13
Developing World Bioethics 138 at 140.
38
Patricia A Marshall, "The Individual and the Community in International Genetic Research" (2004) 15:
IThe Journal of Clinical Ethics 76. See Anant Bhan, Mina Majd, Adebayo Adejumo, "Informed Consent
in International Research: Perspectives from India, Iran and Nigeria" (2006) 3 Medical Ethics 36.
36
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undermined.

This also requires transparency between researchers, participants and

communities, including an explanation of goals, risks, benefits.

Like the principle of

respect for persons, the trust principle also encourages the engagement of individual
participants and communities, respect for local socio-cultural values, and the provision
of relevant and timely feedback to communities.
The ninth principle40 states that for research to be ethical, the interest of
participants, researchers, sponsors, and communities must be protected. This principle
requires the transfer of technology where appropriate, capacity building and respect for
socio-cultural and other differences. It also requires that intellectual property,
indigenous knowledge and contributions of all parties must be taken into consideration,
adequately protected, and compensated particularly where research leads to tangible or
intangible benefits. Satisfactory parameter(s) that shall determine sharing of commercial
and other benefits should be clearly articulated. Where appropriate, benefit sharing
agreements, materials transfer agreements, patent rights, intellectual property and
royalty distribution agreements should be signed before the commencement of the
research project.

In light of the controversy that has arisen with respect to the

distribution of benefits in developing countries, this is an important principle.
Unfortunately, it does not state what happens where the interests of participants and

" It also includes explanations of and "alternatives to participation and voluntariness." The phrasing here
is confusing.
40
Section K (i).
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others conflict. It would have been appropriate to state explicitly that the interests of
participants are paramount, in the event of a conflict.
The tenth principle42 requires that for research to be ethical, it must be
conducted according to the principles of good clinical and laboratory practices. Any
clinical trial conducted in Nigeria has to be conducted according to the principles
articulated in the National Code, relevant laws, the provisions of guidelines or
regulations set periodically by the Federal Ministry of Health, the provisions of the
current Harmonized Tripartite Guideline for Good Clinical Practice (ICH-GCP E6) and
the provisions of the current ISO 14155-1, 14155-2 (2003): Clinical Investigation of
Medical Devices for Human Subjects.
In addition to the ethical framework, the Code also provides for the specific
responsibilities of the ethics review committees, sponsors, host institutions, and
researchers. The National Code also includes procedures for institutional ethics review
committees to register with the National Health Research Ethics Committee.44 I discuss
these below.
The ethical framework provided in an instrument such as the National Code
should provide an ethical foundation for the operation of the research governance
system. This would include providing coherent guidance for ethics review committees
reviewing research. It should also provide specific protections for research participants.
41

Ibid. In one of several confusing provisions, it also states: "Risks, benefits, and responsibilities of
research must be shared during the development, planning, conduct, dissemination of results." It is not
clear what is meant by this clause.
42
Section K (f).
43
Section S.
44
Section C.
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The National Code attempts to meet these expectations. It articulates guidance for ethics
review committees in Nigeria. It provides a ready reference source for researchers
conducting research in Nigeria, thus covering the gap that previously existed. It applies
to all health research conducted anywhere in Nigeria, thus providing broad protections
for all research participants in Nigeria.
Health research anywhere in Nigeria, according to the National Code "must
comply with all sections of this code."46 It also uses mandatory words in describing
several of the responsibilities of sponsors, researchers, and ethics review committees,
thus making it clear that these cannot be waived.

The use of strong language is

commendable, as is the reach of the National Code, that is, health research conducted
anywhere in Nigeria. The National Code thus creates ethical standards but also creates
obligations. In so doing, it elevates protections for research participants, while creating
parameters for other parties involved in health research in Nigeria.
Moreover, the National Code addresses several issues that have much
significance in the developing world, especially matters relating to distributive justice.
Thus the ethical framework provided by the National Code includes the principle of a
trust relationship, which invokes the concept of fiduciary relationship between
researchers and research participants, but also between researchers, research sponsors
and communities. Issues such as conflicts of interest, which evoke divided loyalties,
would be antithetical to such a relationship. Further, in many of the principles, the need
to bring communities into the research process, a matter that is of great significance in a
45

Section A.
Section A (emphasis is mine).
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developing context like Nigeria, is emphasised.

As well, the need to ensure that

research benefits communities in which a project takes place is highlighted.

7

However, in my opinion, there are important areas in the National Code that
would benefit from fuller discussion, especially in view of the Nigerian context. These
include the areas of informed consent and privacy. Particularly with regard to informed
consent, the National Code leans towards procedural matters rather than substantive
issues. For example, it lists what needs to be contained in the informed consent
document but does not even define the concept. Nor does the National Code engage in
a comprehensive discussion of issues arising in informed consent and how they should
be addressed by researchers and ethics review committees in the Nigerian context.
There are similar issues with the concept of privacy as dealt with in the National Code.
As stated above, use of words, such as "Code"48 and "must" throughout the
National Code, indicate that the responsibilities of researchers, sponsors and ethics
review committees are mandatory. However, what may have been sacrificed in the
pursuit of such directness is the provision of guidance in areas that have proved
controversial in research ethics in developing country contexts like Nigeria. Thus,
issues that have caused controversy in research in developing country settings, such as
the use of placebos, standard of care, undue inducements, and paying research

Section S(6) (iv) further provides that: "The investigator must provide assurances that reasonable efforts
shall be made to ensure that the benefits of research is made available to the community where the
research was conducted. Details of any arrangement to ensure this shall be worked out by the researchers,
sponsors, HREC, community leaders and Community Advisory Committees."
48
The word "Code" in some legal traditions indicates that a document is legally binding. See Bernard
Dickens, "Codes of Conduct and Ethics Guidelines" in Lester Breslow (ed.), Encyclopedia of Public
Health (New York: Macmillan Reference, 2002) at 226. As I explain further, the National Code is not yet
legally binding but will be if the National Health Bill is signed into law.
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participants, do not, unfortunately, receive specific or significant attention in the Code.49
These matters are very relevant in the Nigerian context. For instance, with regard to
undue inducements and paying research participants, Marshall, in a study commissioned
by the United States National Bioethics Advisory Commission, records the apparent
limitations in choices that prospective research participants face as a result of poverty
and lack of education. She reports a Nigerian physician as stating that:
Because of the scarcity of everything [in Nigeria], to
be talking about a choice [is questionable]...in the
United States, you can ask questions, you can ask for
a second opinion, but that doesn't happen here. We
are challenged by [our] culture, by poverty, by lack
of literacy, by education of what basic rights a
person has... [the] power [of these factors] is too
awesome."50
Thus, the Nigerian context demands specific guidance as to what might constitute undue
inducement. As Dickens and Cook suggest, payments to research participants may not
necessarily be considered "undue inducement" in every instance, and in some
circumstances payment may be ethically acceptable.5

But specific guidance would

have been helpful.

4

This contrasts with the provisions in other developing countries' guidelines like South African and
Kenyan research ethics guidelines. See for example, section 2.14 of the South African Guidelines.
50
Patricia Marshall, "The Relevance of Culture for Informed Consent in U.S.-Funded International
Health
Research" in National Bioethics Advisory Commission Ethical and Policy Issues in International
Research: Clinical Trials in Developing Countries Volume!- Report and Recommendations of the
National Bioethics Advisory Commission (Bethesda, Maryland: National Bioethics Advisory
Commission, 2001) 212 at C-26 to C-27.
51
B M Dickens and R J Cook, "Challenges of Ethical Research in Resource-Poor Settings" (2003) 80
International Journal of Gynecology and Obstetrics 79 at 80.
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In the case of the use of placebos and standard of care, old articles show that
placebos have been used in trials in Nigeria when there was effective treatment.52 The
National Code provides that an investigator "must ensure that the investigational
product and any comparator products are of appropriate quality and are subject to
quality assurance procedures. This information must be accurate and adequate to justify
CO

the nature, scale, and duration of the clinical trial."

This does not, however, address

whether the use of placebos is appropriate or in what circumstances. It could, of course,
be argued that the use of placebos with respect to drug trials is addressed in the Code
because the National Code requires compliance with the ICH-GCP, which allows the
use of placebos under certain circumstances.54 As some commentators55 have pointed
out, however, the ICP-GCP's stance on placebo use in drug trials is permissive by
comparison to other international guidelines such as the Helsinki Declaration (which

See for instance, L. A. Salako, A. O.Falase, and A. Fadeke Aderounmu, "Placebo-Controlled, Doubleblind Clinical Trial of Alprenolol in African Hypertensive Patients" (1979) 6 Current Medical Research
Opinion 356.
5
Indian Council of Medical Research, Ethical Guidelines for Biomedical Research on Human Subjects
(New Delhi: ICMR, 2000) at 21..
54
See International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline: Choice of Control Group and
Related Issues in Clinical Trials E-10 (Geneva: International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use, 2000), online:
<http://www.ich.org/LOB/media/MEDIA486.pdf> (April 1, 2010).
55
See for instance, Ruth Macklin, "The Declaration of Helsinki: Another Revision" (2009) 6:1 Indian
Journal of Medical Ethics 2; Heather Sampson, Charles Weijer and Daryl Pullman, "Research
Governance Lessons from the National Placebo Initiative"(2009) 17:3 Health Law Review See Patricia
Huston & Robert Peterson, "Withholding Proven Treatment in Clinical Research" (2001) 345 New Eng.
J. Med. 912. See "FDA Abandons Declaration of Helsinki for International Clinical Trials" (2008),
online: < http://www.socialmedicine.org/2008/06/01/ethics/fda-abandons-declaration-of-helsinki-forinternational-clinical-trials/> (May 5, 2010). Adriana Petryna, When Experiments Travel: Clinical Trials
and the Global Search for Human Subjects (Princeton, NLPrinceton University Press; 2009). The ICHGCP, itself, notes that: "Whether a particular placebo controlled trial of a new agent will be acceptable to
subjects and investigators when there is known effective therapy is a matter of investigator, patient, and
institutional review board (IRB)/independent ethics committee (IEC) judgment, and acceptability may
differ among ICH regions." (My emphasis). See The ICH E-10 Guideline: Choice of Control Group and
Related Issues in Clinical Trials.
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has been revised severally on this point). This suggests that this is an area which needs
to be debated domestically and addressed in greater detail in domestic guidelines. Also,
as I discuss below, the Medical and Dental Council's Code of Medical Ethics adopts a
different standard. It would have been appropriate, therefore, to specifically address the
use of placebos and standard of care in the National Code.
There are other matters, such as informed consent in studies involving
children57 and the mentally ill, which have been left out deliberately, and which the
CO

National Code states are to be tackled in other guidance. These are important matters,
especially in light of the Pfizer incident, which involved children. It is not clear why
these matters were not dealt with in the National Code, which deals with many other
issues, and there appears to be no good reasons for not providing protections for
children, the mentally ill, and other vulnerable persons within the National Code. This is
especially significant because the National Code states that it supersedes other guidance
and sub-codes, and is therefore the principal instrument for health research and other
The ICH E-10 Guideline: Choice of Control Group and Related Issues in Clinical Trials indicates that
placebo use is permitted, except when there "is proven effective treatment [that] is life-saving or known to
prevent irreversible morbidity." Thus the effective treatment need not be the "best" treatment, and apart
from fatal diseases or extensive harm, no other exceptions appear to be made. Elsewhere it states that:
""Even when the primary purpose of a trial is a comparison of two active agents or assessment of doseresponse, the addition of a placebo provides an internal standard that enhances the inferences that can be
drawn from the other comparisons." On the other hand, Article 32 of the current version of the Helsinki
Declaration states that: 'The benefits, risks, burdens and effectiveness of a new intervention must be
tested against those of the best current proven intervention, except in the following circumstances: The
use of placebo, or no treatment, is acceptable in studies where no current proven intervention exists; or
Where for compelling and scientifically sound methodological reasons the use of placebo is necessary to
determine the efficacy or safety of an intervention and the patients who receive placebo or no treatment
will not be subject to any risk of serious or irreversible harm. Extreme care must be taken to avoid abuse
of this option." The Helsinki Declaration is clearly stricter than the ICH -GCP.
57
Other trials have included children in the past. See for instance, H. B. Jibril, A. S. Ifere, D. U. Odumah,
"An Open, Comparative Evaluation of Amoxycillin and Amoxycillin plus Clavulanic Acid ('Augmentin')
in the Treatment of Bacterial Pneumonia in Children" (1989) 11:9 Current Medical Research and
Opinion 585.
58
Section (f) 13.
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issues. Consequently, any gap in respect of these and other issues in the National Code
is problematic, and potentially exposes participants to harm and researchers and
research sponsors to confusion. Further, as I argued in Chapter Three, domestic ethical
codes and guidance, such as the National Code, can have more positive impact than the
international ethical guidelines, if they go beyond such guidelines and address any
problematic or controversial issues more clearly. They would thus create room for
easier implementation in domestic contexts, and offer greater protections to research
participants. The National Code has done this only partially.
Related to the above, the National Code does not expressly address the place
of other guidelines, such as the Helsinki Declaration and the CIOMS Guidelines (with
the exception of the ICH-GCP in respect of drug trials) in research governance in
Nigeria. It does state, however, that all health research in Nigeria must comply with the
National Code.60 Thus, it would appear that the National Code would, at the very least,
be the first reference point for health research involving humans in Nigeria. And, at the
most, the National Code rules out the application of other guidelines. As will become
clear shortly, this is problematic mainly because other instruments in Nigeria that
provide guidance for health research involving humans essentially require compliance
with the Helsinki Declaration. These include the Clinical Trial Guidelines61 which
currently provide guidelines for drug trials in Nigeria, and the Code of Medical Ethics,
which regulates medical and dental practitioners in Nigeria. This creates potential room
for debate and confusion.
59
60
61

See p. 68 of the National Code.
Section A.
Section 3 (b) of the NAFDAC Regulations.
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According to the provisions of the National Code, the National Health
Research Ethics Committee is required to update, revise, edit, and modify the National
Code in accordance with international research ethics and local laws, and at its
discretion. "

The National Health Research Ethics Committee may also provide

additional guidelines in sub-codes, although the National Code takes precedence when
there is a conflict between it and a sub-code. It is hoped that gaps in the discussion of
the ethical principles will be addressed either in a revision of the National Code in the
near future or in the development of additional guidelines.

6.2.2.2 Code of Medical Ethics and the NAFDAC Guidelines
In Nigeria, the Medical and Dental Council of Nigeria is the regulating
professional council which regulates medical and dental practitioners. It has drawn up a
Code of Medical Ethics in Nigeria, which provides rules, including rules relating to the
ethical conduct of biomedical research. The coverage of the Code of Medical Ethics in
Nigeria is therefore more limited than the National Code, as the former regulates
medical and dental practitioners and covers only biomedical research.63 In addition to
the ethical implications discussed here, it also has legal implications considered later in
this chapter.
The Code of Medical Ethics in Nigeria lays down certain ethical principles
derived from the Helsinki Declaration of 1996. One principle requires that informed

62
63

Section P.
MDCN, Code of Medical Ethics in Nigeria, 2004.
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consent be obtained from research participants.

It requires that every subject of

biomedical research must be informed of the aims, methods, potential benefits and
hazards of the research. Where the research is conducted by the physician treating the
subject, informed consent must be obtained by another physician.
Amongst other things, the Code of Medical Ethics in Nigeria also requires
that the importance of the objective be in proportion to the inherent risk to the research
participant, and that physicians must cease trials if the harm outweighs the risk. Further,
precautions must be taken to protect the privacy of the research participant, and to
minimize the impact of the research on the physical and mental integrity, and
personality of the participant. In addition, it requires that biomedical research must be
conducted only by scientifically qualified persons under the supervision of a clinically
competent person. It requires informed consent to be obtained prior to participation in
research. It requires that the privacy of persons participating in research be protected.
The physician must ensure that potential benefits outweigh potential risks. Further, it
requires that the research must conform to generally accepted scientific principles and
be based on well-conducted animal experimentation and knowledge of scientific
literature.65
Also, in medical research combined with medical treatment, it states that the
potential benefits and hazards of a new method should be weighed against the
advantages of the best diagnostic and therapeutic methods.66 Since the principles are

Section 31 (vii) - (xi),
Section 31 (B).
Section 31 (B).
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drawn verbatim from the 1996 version of the Helsinki Declaration, it requires that: "The
patient must be assured of the best-proven diagnostic and therapeutic method. This
does not exclude the use of placebo in studies where no proven diagnostic or therapeutic
methods exist."67 As I discussed briefly in Chapter One, this is an area that has caused
much controversy. This particular provision has been revised severally since the 1997
controversy surrounding the placebo-controlled trials of AZT in several developing
countries.68 Further, the standard of the "best-proven diagnostic or therapeutic method"
is not the standard required under the National Code which, as I described above,
requires compliance with the ICH-GCP in clinical trials of drugs, which requires
"effective treatment". There could, therefore, potentially be conflict between the two
codes with respect to what the standard of care should obtain in biomedical research.
Further, it requires that in the event of legal incompetence, informed consent
must be obtained as prescribed under relevant legislation. And, in the event of mental
incapacity or in the case of a minor, the consent of a "responsible relative replaces that
of the subject."

9

These latter provisions raise some concerns. Who is a "responsible

relative"? Moreover, the word "replaces" is problematic as it gives the impression of

b

' Section 31 (B) (iii).
Principle 32 of the Helsinki Declaration (2008) in its entirety now reads: "The benefits, risks, burdens
and effectiveness of a new intervention must be tested against those of the best current proven
intervention, except in the following circumstances: • The use of placebo, or no treatment, is acceptable
in studies where no current proven intervention exists; or • Where for compelling and scientifically sound
methodological reasons the use of placebo is necessary to determine the efficacy or safety of an
intervention and the patients who receive placebo or no treatment will not be subject to any risk of serious
or irreversible harm. Extreme care must be taken to avoid abuse of this option." See also, R. K. Lie, E.
Emmanuel, C. Grady, and D. Wendler, "The Standard of Care Debate: the Declaration of Helsinki versus
the International Consensus Opinion" (2004) Journal of Medical Ethics 190. See also, Zulfiqar A. Bhutta,
"The "Standards of Care Debate": Some Perspectives from the Developing World
<http://www.microbicides2004.org.uk/abstract/oral/sc_02.html> (August 25, 2005). BMJ, "Beyond
Helsinki: A Vision for Global Health Ethics" (2001) 322 BMJ 747.
69
Section 31.
68
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disrespect for the potential research participant and paints a picture of objectification.
Again, it will be recalled that this is an area in which the National Code does not
provide any guidance.
The issue of informed consent and who might be a "responsible relative" in
the Nigerian context is an illustration of the general problem with the Code of Medical
Ethics in Nigeria - one comes away with the impression that the ethical concerns have
not been carefully deliberated on, nor has much attention been devoted to the Nigerian
context. As such, there is no discussion of community engagement, nor is there any
emphasis on research priorities, or on how research might benefit the community
(matters dealt with in the National Code). This is not surprising as the principles are
taken verbatim from the Helsinki Declaration of 1996 (which has since been revised
7ft

severally).

6.2.4 The NAFDAC Guidelines
Guidelines drawn up by the National Administration for Food and Drug
Administration and Control (NAFDAC) also contain certain requirements for drug
trials, including informed consent and the requirement of ethics review. Under the
"Clinical Trials of Drugs in Nigeria: Guidelines, Procedures and Protocols" (NAFDAC

See R. K. Lie, E. Emmanuel, C. Grady, and D. Wendler, "The Standard of Care Debate: the
Declaration of Helsinki versus the International Consensus Opinion" (2004) Journal of Medical Ethics
190. See also, Zulfiqar A. Bhutta, "The "Standards of Care Debate": Some Perspectives from the
Developing World <http://www.microbicides2004.org.uk/abstract/oral/sc_02.html> (August 25, 2005).
BMJ, "Beyond Helsinki: A Vision for Global Health Ethics" (2001) 322 BMJ 747.
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Guidelines),

"all novel drugs must undergo clinical studies in Nigeria before being

granted marketing authorization in Nigeria."72

The guidelines require independent

ethics review of clinical trials by an independent ethics committee. The independent
ethics committee is required to review objectively the suitability of investigators,
facilities, protocol, the eligibility of trial subject groups, and the adequacy of informed
consent and confidentiality.73

Like the Code of Medical Ethics in Nigeria, the

guidelines also have legal implications considered later in the thesis.
With regard to ethical standards and protection of participants in trials, the
guidelines state that: "The current revision of the Declaration of Helsinki is the
accepted basis for clinical trial ethics, which must be fully known and followed by all
engaged in research on human beings."74 This would put the Guidelines in potential
conflict with both the National Code and the Code of Medical Ethics in Nigeria (which
replicates the 1996 version of the Helsinki Declaration) in different respects, including
areas that have been amended, such as the appropriate use of placebos. Unlike the
National Code, however, both the Code of Medical Ethics in Nigeria and the NAFDAC
Guidelines are limited in applicability - to the regulation of medical and dental
practitioners, and to clinical trials of drugs respectively.

6.3 Legal Framework

71

National Agency for Food and Drug Administration and Control, "Clinical Trials of Drugs in Nigeria:
Guidelines, Procedures and Protocols" (NAFDAC Guidelines), on file with me.
72
Introduction, NAFDAC Guidelines.
"Article 1.6.
74
Article 1.1 of the NAFDAC Guidelines, p.l 1 (My emphasis).
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As described in Chapter Three, the law may impact research governance in a
number of ways. The law may provide requirements relating to privacy, confidentiality,
legal competence to make choices and decisions, informed consent, mandating ethics
review, and disclosure of information among other things. As in many developing
countries, there is currently no specific legislation on health research involving humans
in Nigeria. However, it is anticipated that there will soon be legislation dealing with
different aspects of research governance. The legal framework of research governance
in Nigeria currently consists primarily of the common law, judicial precedents, and
statutes.75

Below I describe the current legal framework and identify problematic

issues. I also discuss the National Health Bill, which though not as yet law, will have
significant implications for research governance in Nigeria when it becomes law.

6.3.1 The Common Law and Judicial Decisions
Various aspects of the common law in Nigeria such as the law of torts
(negligence, battery, privacy, informed consent), equity, (fiduciary relationships),
administrative law and judicial review, have implications for research governance.
Actions could be brought in Nigerian courts on matters related to health research
involving humans such as breach of confidentiality, breach of contract, violation of
privacy, and product liability.

Another source of law is the customary law, but this is not one of the areas implicated in research
governance.
76
See Fay Rozovsky and Rodney K Adams, "Medical Malpractice Liability in Human Research" (2007)
3:9 Journal of Clinical Research Practices 1.
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At present, no cases specifically relating to health research involving humans
77

have been decided by the Nigerian courts.

The Pfizer case would have been the first

decided case specifically on facts relating to health research involving humans. It was,
however, settled out of court. Even so, in the event that any such cases should arise,
Nigerian courts would draw on cases on related matters to reach a decision.

For

instance, in the case of Medical and Dental Council Tribunal v Okonkwo,78 the Supreme
Court of Nigeria held that a person can refuse treatment, and in such a case, the
physician must respect such refusal. While this was a case on the right of a Jehovah's
witness to refuse a specific treatment (requiring blood transfusion), the requirement for
informed consent is clear, even in a life-threatening situation as was the case in this
matter. It would be even more so where a person is participating in research as a
volunteer. Lack of informed consent may also ground actions in battery, as decided by
the Supreme Court in Okekearu v Tanko.19 In that case, the court also held that consent
must be sought from the person whose body is involved in a treatment procedure. This
position would no doubt apply to research.
Similarly, there is as yet no negligence case brought in the specific context of
health research involving humans. However, a few cases have been decided on the basis
of the tort of negligence in Nigeria.80

These include cases related to professional

See Jill Cotterell, "The Functions of the Law of Torts in Africa" (1988) 31 Journal of African Law 161
at 167. The Pfizer incident yielded three main cases which never came to conclusion 78
Medical and Dental Practitioners Disciplinary Tribunal v Okonkwo (2001) 7 NWLR 206.
79
Okekearu v Tanko, [2002] 15 N.W.L.R. 657, 660, 665-67 (S.C.).
80
See generally, Jill Cotterell, "The Tort of Negligence in Nigeria" (1973) 17:1 Journal of African Law
30.
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negligence involving a doctor-patient relationship.81 Negligence, with the basic
ingredients of a duty of care owed by one party to another, where both parties have a
relationship, such as a researcher-research participant relationship,82 a breach of that
duty, and harm suffered as a direct or foreseeable consequence of the breach83 could
thus ground an action against a researcher or an ethics review committee. The standard
of care required from a researcher may also be affected by whether or not a doctorpatient relationship existed between the researcher and the research participant. A
physician would be required under the law to act in the best interests of their patients.
In this case, the court is likely to refer, as they have done in several cases, to the Code of
Medical Ethics.84 Failure to comply with the requirements of the Code of Medical
Ethics, some of which specifically address biomedical research, could be considered by
the court in determining the existence of a duty or a standard of care and whether or not
such duty or standard was breached. Ethics review committees could also be found
liable for failure to exercise reasonable care in the discharge of their duties. As I
mentioned in Chapter Four, the burden of proof rests on the plaintiff, which may not be
easy to discharge.

Medical and Dental Practitioners Disciplinary Tribunal v Okonkwo 7 NWLR 206; University ofllorin
Teaching Hospital v Akilo (2000) 22 WRN 117, Ajegbu v. Etuk (1962), 6 E.N.L.R. 196; Igbokwe v. Board
of Governors of University College Hospital [1961] W.N.L.R. 173.
82
There must be a relationship between the parties, including a contractual relationship, fiduciary
relationship as in certain professional relationship like doctor-patient, or researcher-research participant
relationship. Such a person would be a "neighbour" as articulated by Lord Atkin in Donoghue v
Stevenson.
83
As articulated by Lord Atkin in Donoghue v Stevenson . This has been cited with approval by the
Nigerian courts. See H A Olaniyan, "Liability for Medical Negligence in Nigeria" (2005) 4:2 Nigerian
Journal of Health and Biomedical Sciences 165 at 166. Hazel Biggs, Healthcare Research Ethics and
Law: Regulation, Review and Responsibility (Oxford: Routledge-Cavendish, 2010) at 61.
Medical and Dental Practitioners Disciplinary Tribunal v Okonkwol NWLR 206.
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Moreover, as the Supreme Court has decided in cases like Adigun v AG Oyo
State (No.2),85 and Araka and Egbue,

foreign decisions are persuasive, save for when

there are rightly decided Nigerian cases on the same point. Since there are no decided
cases on informed consent in the research context in Nigeria, other cases from common
law jurisdictions dealing with health research involving humans, would be of great
persuasive authority in Nigerian courts. Thus, cases such as the Canadian case of
Halushka v University of Saskatchewan and the United States case of Kus v. Sherman
Hospital?8 (both deciding that liability would lie against the physician and the hospital
if informed consent was not obtained from the research participant), could be persuasive
in Nigerian courts. Cases such as Grimes v. Kennedy Krieger Institute

(United States),

discussed in Chapter Four, which decides that a special fiduciary relationship exists in
the research context between researchers and participants, could also have similar
effect.
Apart from domestic and foreign judicial precedents, employment contracts
drawn up between researchers and research institutions, or contracts between
researchers and research sponsors, which may include requirements as to the conduct of
all parties in health research, could also ground actions for breach of contracts in
*s Adigun v AG Oyo State (No. 2) (1987) 2 NWLR pt 56 at 197.
86
Araka v Egbue (2003) 17 NWLR 1 at 1 at 22 per Tobi, JSC: ""Of course, this court will not hesitate to
use any foreign decision if it is correct, even though contrary to our decision; if the court comes to the
conclusion that its decision is wrong, In such case, this court will, in the light of the foreign decision
which is correctly given." However, foreign decisions are persuasive not binding on Nigerian courts. See
Adetoun Oladeji (Nig.) Ltd. VNigerian Breweries Pic (2007) 5 NWLR 415 at 423, paragraph 11.
87
Halushka v. University of Saskatchewan et al. (1965), 53 D.L.R. (2d) 436, 52 W.W.R. 608 (Sask.
C.A.).
88
Kus v. Sherman Hospital 644 N.E. 2d 1214 (111. App. 2 Dist. 1995). In this case in which a research
participant was not fully informed of the risks of the research, the court held that a physician as well as
the hospital (which had instituted an ethics review committee to ensure that informed consent was
obtained), were liable for failure to obtain such consent.
89
Grimes v. Kennedy Krieger Institute Inc, 782 A.2d 807.
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Nigerian courts where one party fails to comply with the agreed requirements. This
will, however, be to the extent permitted by law. In other words, the contract will be
invalid if it requires one party to do an act in contravention of any law. For instance, to
breach the privacy of a research participant, where not required by law, or to require
confidentiality from a researcher on issues that are required by law to be reported to an
ethics review committee, would be void and unenforceable under Nigeria law.
Administrative law and the law relating to judicial review are other arenas in
which the common law as it operates in Nigeria, and judicial decisions, would affect
research governance. Again, there have not been specific cases decided on health
research involving humans involving the legal ramifications of the work done by ethics
review committees. However, there are other administrative law cases from which the
courts may draw in deciding on matters such as the legal liability of ethics review
committees, or the members of such committees, or institutions.
In sum, the courts in Nigeria have not decided any cases on health research
involving humans.

There are, however, cases on other matters, and also foreign

decisions on health research involving humans, which the courts may rely on. As I
pointed out in Chapter Three, judicial response to health research involving humans
does not provide a comprehensive framework or clear parameters for research. This is
especially so in Nigeria, where that response is currently absent and can only be
surmised by analysing decisions in other instances and foreign decisions. The absence
of judicial response is largely because much litigation has not occurred in the area of

90

Pans Bisbilder (Nig.) Ltd. V First Bank Nigeria (2000) 1 NWLR 684.
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health research. This suggests the need for comprehensive legislation as I argued for in
Chapter Four to address any gaps.

6.3.2 Legislation
Aside from the instances under which the common law and judicial decisions
apply, legislation is an important source of law, and is regarded as superior to other
kinds of law (excepting the Constitution).91 There is as yet no specific statute such as
the one I argued for in Chapter Three, but several pieces of legislation cover areas of
health research involving humans, in ways that are often not cohesive. A bill is awaiting
Presidential assent. Much of the statutory law in Nigeria applies indirectly, that is, they
were not written with the specific intention of covering health research, thus they apply
to other things as well. Others, like the Medical and Dental Practitioners Act confer
powers that authorise the Medical and Dental Council of Nigeria to establish the Code
of Medical Ethics in Nigeria. Others apply to specific areas of health research, such as
regulations on clinical trials for drugs.

Below I discuss the Constitution, the Child

Rights Act, the Code of Medical Ethics in Nigeria, the NAFDAC Guidelines, the draft
NAFDAC Clinical Trials Regulations and, lastly, the National Health Bill which, it is
anticipated, is to become law soon and which will have a significant impact on research
governance in Nigeria.

yi

See the Supreme Court decision, in ARCON v Fassassi (No. 4) (1987) 2 NWLR (Part 59) 42; 45 - 46,
where it was noted that a decision of the court can only be overturned by a legislation. In addition,
legislation may abolish customary law, and is required in Nigeria to make international treaties applicable
within the country.

412

6.3.2.1 The Constitution
The Constitution is the grand norm, or the fundamental law of the land.
It also delineates the division of responsibilities for the Nigerian federation. This
demarcation of authority has important consequences for research governance in
Nigeria.

It also contains other specific provisions on human rights which have

implications for the rights of research participants and thus research governance.
As described in Chapter Four, matters relating to drugs are within the
no

exclusive powers of the federal legislative body, the National Assembly.

This would

include the regulation of clinical trials of drugs which, as I describe below, comes
within the remit of NAFDAC, the federal drug regulatory agency. However, health,
scientific research, and education fall under the concurrent legislative list.94 The
governance of health research therefore comes within the powers of both the federal and
state governments.
However, under the doctrine of "covering the field," the federal
government can legislate on any matter on which it has legislative competence.9

As

In Daniel Orhiunu v. Federal Republic of Nigeria, Suleiman Galadima J.C.A said: "The Constitution is
what is called the grund norm and fundamental law of the land. All other legislations in the land take their
hierarchy from the provision of the Constitution. By the provisions of the Constitution, the laws made by
the National Assembly come next to the Constitution; followed by those made by the House of Assembly
of a State. By virtue of section 1 (1) of the Constitution, the provisions of the Constitution take precedence
over any law enacted by the National Assembly even though the National Assembly has power to amend
the Constitution itself." Daniel Orhiunu v. Federal Republic of Nigeria (2005) 1 NWLR, Part 906 55 56, paragraphs H- B.
93
Section 26, Schedule 2, Part I, of the CFRN.
See the Constitution of the Federal Republic of Nigeria, 1999 (CFRN), Second Schedule., Section 21,
22, 27 and 28.
95
Section 21, Second Schedule, Part II of the CFRN, Section 26, Schedule 2, Part I, of the CFRN, Section
22, Schedule 2, Part II of the CFRN.
96
See section section 4(5) of the Constitution, provides that: "If any Law enacted by the House of
Assembly of a State is inconsistent with any law validly made by the National Assembly, the law made
by the National Assembly shall prevail, and that other Law shall, to the extent of the inconsistency, be
void."
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emphasized by the Supreme Court in the 2002 case of Attorney General of Abia State
versus Attorney General of the Federation,

and in other cases before it, under that

doctrine any state law which conflicts with a federal legislation on a subject-matter on
which both governments have concurrent legislative powers, and on which the federal
legislature has enacted a law, or which law can be taken as evincing an intention to
cover the field, shall to the extent of its inconsistency, be void.

The state is thus

subordinate to the federal government in any area of health or scientific research in
which the federal government has made a law of general application.
What this means, then, is that the federal government can create a
generally applicable law on research governance, as it has done (partially) with the
development of the National Health Bill. The states may also make laws to regulate
health research, including addressing any issues omitted in the federal legislation, so
long as the state law does not conflict with the federal law.
Practically speaking, it would also be easier for the tier of government
which has exclusive authority over drugs and related matters, such as clinical trials, and
which has also enacted law to regulate professionals in the area of health research, to
make law regarding all health research involving humans. Further, as rightly stated in
the National Code:
The Federal Government of Nigeria acting through
any of its organs and establishments has the overall
duty of protecting the welfare of the citizens of
Nigeria. It may therefore exercise all the powers of
protecting citizens according to the law, including
97

AG Abia State v Ag Federation (2002) 6 NWLR (pt 763) 264.
See AG Abia State v Ag Federation (2002) 6 NWLR (pt 763) 264; AG of Ogun State and Anor. v AG of
the Federation (1982) 1-2 SC 13, 1982 13 NSCC 1. See NA Inegbedion and E Omoregie, "Federalism in
Nigeria: A Reappraisal" (2006) 4:1 Journal of Commonwealth Law and Legal Education 69.
98
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citizens participating in research. In addition, some
agencies of state in discharge of their duties
according to law may also exercise regulatory
functions within the research environment.
Similarly, under National Health Policy, one of the roles of the government is to
coordinate efforts in order to ensure a coherent, nationwide health system.100 An active
role by the federal government, in my opinion, offers the possibility of a uniform set of
standards for health research involving humans for the country. A uniform set of
standards in turn offers the same protections for research participants across the country.
It permits clarity of responsibilities and roles for other actors in research governance,
thus potentially promoting health research, which is needed in Nigeria.
Apart from the division of powers, there are specific matters that come
within the umbrella of research governance, which may be covered generally under the
Constitution.

An example of such a matter is privacy. The right to privacy is a

fundamental right protected under the Constitution.

Section 37 of the Constitution

provides that, "The privacy of citizens, their homes, correspondence, telephone
conversations and telegraphic communications is hereby guaranteed and protected."
The phrase, "the privacy of citizens" could be inferred to cover various aspects of a
citizen's life. In Medical and Dental Practitioners Disciplinary Tribunal v Okonkwo,
the Supreme Court, per Ayoola, JSC, noted that the constitutional right of privacy
includes the right of a competent, mature adult to refuse life-prolonging treatment.101
One could logically infer from this decision that a right to privacy includes the right to

99

Section M of the National Code.
See Revised National Health Policy, section 3.5.
Medical and Dental Practitioners Disciplinary Tribunal v Okonkwo (2001) 7 NWLR 206 at 245-246.
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refuse consent to participate in research (which is, essentially, a voluntary activity).
Also, the protection of health information, and information collected in the process of
health research, could reasonably come within the scope of that right, which would be
applicable generally to all research.
In addition to the right of privacy, the Constitution also provides under
section 34 that: "Every individual is entitled to respect for the dignity of his person."102
Accordingly, the section continues, "No person shall be subjected to torture or to
inhuman or degrading treatment."103

A broad construction of this provision could be

argued to include debasing or humiliating psychological treatments in pursuit of
scientific knowledge, mental harm, or unnecessary bodily harm in the course of
research.
Fundamental rights can be enforced by applying to a State or Federal High
Court for redress.104 And a claim relating to the violation of rights of a research
participant can be made both under the common law and the Constitution as decided by
the Supreme Court in Minister of Internal Affairs and others v. Shugaba Abdurrahaman
Darman}05

Thus, persons who claim that they were compelled to participate in

research may bring a claim in battery106 or a claim under the right to dignity of their
persons.

mz

Section 34.
Section 34(1).
104
Section 46(1) of the Constitution. A High Court is a superior court of record in Nigeria. A claim can
also be filed in the Federal High Court. See Zakari v IGP (2000) 8 NWLR (pt.670) 666.
105
Minister of Internal Affairs v Shugaba Abdurrahaman Darman (1982) 3 NCLR 915 at p. 927
See Medical and Dental Practitioners Council v Okonkwo.
103
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Further, the Constitution applies to all bodies - public and private. Thus,
following the Court of Appeal's decision in Onwo v. Oko and Others,

a fundamental

rights claim can be brought not only against the state but against an individual
researcher or a research sponsor.

6.3.2.2 The Child Rights Act
The Child Rights Act,ws

enacted in 2003, does not have any direct

provisions on the involvement of children in health research. But it does have certain
provisions that may have implications for health research involving children.

For

instance, section 1 of the Act, provides that in any actions concerning a child,
undertaken by an individual, public or private body, institutions or service, court of law,
or administrative or legislative authority, the best interest of the child shall be the
primary consideration. Thus, researchers, research sponsors, ethics review committees
must consider whether any research involving children would be in their best interest.
Section 33 of the Act also provides that a person who exploits a child in any other form
not already mentioned in the Act, in a manner prejudicial to the welfare of the child
commits an offence and is liable to a fine of five hundred thousand naira or
imprisonment to a term of five years. Exploitative practices in the course of research
arguably come within this provision.

The National Health Bill contains specific

provisions on obtaining informed consent for the participation of children in research. I
consider that in a subsection below.
107
108

Theresa Onwo VNwafor Oko and 12 Others (1996) 6 NWLR pt456 584.
Child Rights Act, Act No.26, 2003.
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6.3.2.3 Medical and Dental Practitioners' Act and the Code of Medical Ethics
The Medical and Dental Practitioners' Act1

is another statute that has

significance for research governance in Nigeria. It establishes the Medical and Dental
Council of Nigeria as a statutory body.

Medical and dental practitioners, who wish to

practice in Nigeria, are required to register with the Medical and Dental Council of
Nigeria.111 The Act also establishes the Medical and Dental Practitioners Disciplinary
Tribunal, which tries cases brought by the Medical and Dental Practitioners
Investigation Panel also established under the Act.112
One of the responsibilities of the Medical and Dental Council of Nigeria, as
provided in the Act, is to prepare and review from time to time a statement on the code
of conduct for the practice of the medical and dental professions in Nigeria.113 Under
this power, the Medical Dental Council of Nigeria has drawn up rules for the conduct of
medical practitioners, which it has reviewed over the years. The most recent revision of
the rules is the Code of Medical Ethics in Nigeria, (hereafter Code of Medical Ethics)
drawn up in 2004. 114 I have discussed the Code of Medical Ethics as part of the ethical
framework.

The discussion that follows dwells on the legal nature of the Code of

Medical Ethics and its requirements with respect to biomedical research. I consider the
Medical and Dental Council of Nigeria also under the institutional framework.

Medical and Dental Practitioners' Act Cap M8, Laws of the Federation of Nigeria, 1990, as amended.
Section 1 of the Medical and Dental Practitioners' Act.
111
Section 6 of the MDCN, Code of Medical Ethics in Nigeria, 2004.
Section 15 of the Medical and Dental Practitioners' Act.
n
" Section 1 (c) of the Medical and Dental Practitioners' Act.
1M
Medical and Dental Council of Nigeria, Code of Medical Ethics in Nigeria, 2004.
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The Code of Medical Ethics is subsidiary legislation. The Interpretation Act
defines subsidiary legislation as "any order, rules, regulations, rules of court or bye-laws
made either before or after the commencement of this Act in the exercise of powers
conferred by an Act."115 Thus, because of its establishment under the power granted the
MDCN by section 1 of the Medical and Dental Practitioners' Act, the Code of Medical
Ethics is regarded as subsidiary legislation, albeit applying specifically to medical and
dental practitioners in Nigeria.

Furthermore, similar rules, such as the Rules of

Professional Conduct in the Legal Profession made pursuant to the Legal Practitioners'
Act116 have been ruled by the Supreme Court in Fawehinmi v. Nigerian Bar Association
(No.2)ul to be subsidiary legislation. The significance of this is that, as decided by the
Supreme Court in Abubakar v. Bebeji Oil and Allied Products Ltd., subsidiary
110

legislation, such as the Code of Medical Ethics, has the force of law.
decided in Olarenwaju v. Oyeyemi,

However, as

as subsidiary legislation, its scope, validity, and

authority cannot go beyond the scope of the enabling statute from which it derives its
authority, in this instance, the Medical and Dental Practitioners Act.
The legal status of the Code of Medical Ethics has significant implications for
research governance in Nigeria.

First, it moves medical and dental practice and

research from merely professional self-regulation to the domain of legal regulation. The
provisions of the Code of Medical Ethics have legal force, to the extent that they do not
go beyond the remit permitted under the enabling statute under which the rules were
115

Section 37 of the Interpretation Act, 1964.
Legal Practitioners' Act, 1962.
117
Fawehinmi v Nigerian Bar Association (No.2) (1989) 2 NWLR (pt. 105) 558.
118
Abubakar v Bebeji Oil and Allied Products Ltd., (2007) NWLR (pt. 1066) 319, at 385, paragraph E.
119
Olarenwaju v Oyeyemi and Others (2001) 2 NWLR (pt 697)229 at p.255-256. Din vAG Federation
(1988)4 NWLR (pt. 413) 292.
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made.

Any requirements

regarding biomedical research involving medical

practitioners and dental practitioners are therefore legal requirements. And, as a legal
instrument, it can ground actions in Nigerian courts.

The movement of medical

research into the legal domain indicates a role for the state which, as discussed in
Chapter Two, is the main wielder of the weapon of law.
This does not, of course, mean a complete displacement of self-regulation,
since the professional disciplinary bodies are still the primary custodians of authority,
except when a medical or dental practitioner's activities are a criminal offence.122 Selfregulation thus remains a central reality for medical and dental practitioners in Nigeria,
including in the area of biomedical research.

In the hybrid framework adopted by this

thesis, such self-regulation is still an important piece of the puzzle of research
governance, and is complementary to other types of regulation, including legal
regulation. In this regard the Code of Medical Ethics, like many professional codes,
provides certain legal protections for medical and dental practitioners who act within its
11^

boundaries, " thus facilitating research within professionally agreed confines. But, it
also, if employed effectively, protects the interests of patients and research participants
who can hold medical and dental practitioners to the standards articulated in the code.

120

See ibid. See also Ishola v Ajiboye (1994) 6 NWLR pt. 352 at 506; Governor of Oyo v Folayan (1995)
8NWLR(pt413)292.
121
See for instance, Okatta v The Registered Trustees ofOnitsha Sports Club (2008) 13 NWLR (pt 1105)
632, decided on the basis of the Legal Practitioners Rules.
122
The Supreme Court ruled in Denloye v Medical and Dental Practitioners' Disciplinary Committee that
the disciplinary body of the Medical and Dental Council of Nigeria cannot decide criminal matters. Such
matters are dealt with through the normal venues for criminal matters, namely the courts. Denloye v
Medical and Dental Practitioners' Disciplinary Commitee (1968) 1 All NLR 306.
123
See Angela Campbell and Kathleen Cranley Glass, "The Legal Status of Clinical and Ethics Policies,
Codes, and Guidelines in Medical Practice and Research" (2001) 46 McGill Law Journal 473 at 477.
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The Code of Medical Ethics makes specific provisions regarding "biomedical
research involving human subjects."124

Biomedical research is a subset of health

research involving humans, and thus the application of the Code of Medical Ethics is
more limited than the National Code. However, unlike the National Code, (which does
not yet have any legal basis in law until the National Health Bill is passed) the Code of
Medical Ethics does have legal force over the conduct of biomedical research in
Nigeria.
It provides that the basic principles of the Helsinki Declaration, which it lists,
have to be respected by medical and dental practitioners involved in biomedical
research. Thus, while the status of the Helsinki Declaration in international law may
still be debatable,125 in the Nigerian context, the principles of the 1996 version of the
Helsinki Declaration, as contained in the Code of Medical Ethics, have legal force, and
are binding on medical and dental practitioners in Nigeria.

Following from this point,

it is important to emphasise that the Code of Medical Ethics does not indicate that the
Helsinki Declaration, as amended, should be followed. Instead, it lists the principles
culled verbatim from the 1996 version. This may seem to be a minor point, except that
the Helsinki Declaration has been revised severally since then, most recently, in 2008.
As discussed earlier, some of the revisions are significant, especially in light of

124

Section 31.
The US Court in the Pfizer case appeared to consider the requirement for informed consent under
diverse instruments such as Nuremberg Code, the Helsinki Declaration, domestic law to be a norm of
customary international law, allowing the appellants to bring a claim under the Aliens Torts Claims Act.
See George J. Annas, "Globalized Clinical Trials and Informed Consent" (2009) 360: 20 New England
Journal of Medicine 2050.
126
Campbell and Glass supra note 119 at 475.
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controversies about the conduct of internationally sponsored research in developing
countries.
1 97

The Code of Medical Ethics articulates certain basic principles

which I

have described under the ethical framework, including requirements relating to
informed consent, privacy, that the potential benefits outweigh the risks, and the
circumstances under which using a placebo would be acceptable.

It is important to

note that these requirements have legal force as previously stated.

They would,

therefore, take precedence in law over any opposing requirements under other
documents that do not have legal force including, for instance, the National Code
(although this is expected to change soon).
The Code of Medical Ethics, following the Helsinki Declaration, also states
that protocols must be submitted for "consideration, comment, and guidance to a
specially appointed committee independent of the investigator and the sponsor,
provided that the independent committee is in conformity with the laws and regulations
of the country."129 The Code of Medical Ethics applies this principle by requiring that
every teaching hospital and medical research institute must constitute an Ethical Review
Committee, which should be composed of competent individuals to examine the
research protocol of every researcher in the institution.130 It thus seems to require an
institutional system of ethics review.

Section 31 (A)(l)-(xii)
See p. above.
Section 31( iii).
Section 31 (C) i.
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However, it also requires that in the case of research which has a "state
outlook," every State Monitoring Committee of the Medical and Dental Council of
Nigeria must be able to constitute within a short notice a "State Ethical Review
1 Q 1

Committee" which will be an ad-hoc committee, to consider the research proposal.

It

does not define what "state outlook" means, but it may be inferred that this refers to
multisite or multicentre trials within the same state. Further, it also states that the
Directorate of Research of the Federal Ministry of Health must constitute an ethical
review committee to consider proposals that have a "national outlook." Again, it does
not define "national outlook" but this may be inferred to mean multisite or multicentre
research in different states and the Federal Capital Territory.

Essentially, these

requirements, if complied with, would create a hybrid system of both regional and
institutional ethics review.

This would differ from the requirements of the National

Code, which as I discuss later under the institutional framework, adopts a national
system of ethics review, with institutional committees reviewing research on the local
level.
Requiring the creation of ethics review committees may seem outside the
responsibility of making a "code of conduct which the Council considers desirable for
the practice of the professions in Nigeria."132 However, the Medical and Dental
Practitioners' Act confers power under the Act to "do anything which in its opinion is
calculated to facilitate the carrying out of its activities under this Act."133 A broad
reading of this power would arguably include the requirement for ethics review
131

Section 31 (C) ii.
Section 1 of the Medical and Dental Practitioners Act.
133
Section 3 of the Medical and Dental Practitioners' Act.
1
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committees in institutions, or in states, for the purpose of ensuring that medical and
dental practitioners involved in biomedical research can submit their protocols to these
committees. On a narrower reading, however, it is debatable if the powers of the
Medical and Dental Council of Nigeria under the Medical and Dental Practitioners' Act
can be construed to extend to compelling the federal government through the federal
ministry of health to create an ethics review committee in the federal ministry or to
compel state ministries of health to do likewise. This is important to note because some
of the requirements of the Code of Medical Ethics are somewhat different from those
contained in the National Code, particularly with respect to the requirements of ethics
review committees, but also with respect to substantive ethical matters such as standard
of care and the use of placebos. This creates room potentially for confusion. However,
as I have stated previously, the Code of Medical Ethics has legal force (to the extent
permitted under its enabling statute), while the National Code does not as yet have any
legal force.
In any event, even if the Code of Medical Ethics goes too far in mandating
ethics review committees at state and federal level, it does indicate the need for ethics
review committees in the country, however constituted. However, especially in view of
its non-implementation so far, the Code of Medical Ethics is not effective in this respect
and indicates the need for other legislation in respect of research governance.
In the case of drug trials, the Code of Medical Ethics also contains provisions
on new drug investigations, requiring among other things that such investigations must
be approved by an ethics review committee, the Federal Ministry of Health, and
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NAFDAC, the drug regulatory agency, in a manner reminiscent of collaborative
governance.134 The ethics review committee of the Federal Ministry of Health must
consider the Investigation of New Drug Application (INDA) within six weeks.135
Among other requirements, progress reports on ongoing clinical trials must be
submitted annually to the Federal Ministry of Health. NAFDAC, the drug regulatory
agency, must also approve or disapprove a New Drug Applications within a maximum
of six months.136 There are no time limits in the NAFDAC's regulations. However,
these are matters that fall squarely within NAFDAC's authority. In this particular
instance, regulations and guidelines made by NAFDAC would take precedence in law,
because as I discuss below, this is the specific province of NAFDAC under statute.
The Code of Medical Ethics is an important component of the legal
framework for research governance, including elements of both self-regulation and legal
regulation.

However, there are gaps, weaknesses and problems that limit its usefulness

as an instrument for governance of research. First, its applicability is limited to medical
and dental practitioners in Nigeria. '

Thus, it would not apply to other researchers,

such as social scientists or domestic entities, who may sponsor research, or to external
research sponsors. Second, it does not address several key issues, including conflict of
interest. Third, the Code of Medical Ethics does not provide specific penalties for
failure to comply with the requirements. In this respect, section 26 provides that failure
to adhere to the Rules 1 to 25, including requirements for registration and various facets
134

Section 31 (D).
Section 31(D).
136
Section 31 (E).
137
This would include medical and dental practitioners from other countries, who are required by the
Code of Medical Ethics to register with the Medical and Dental Council of Nigeria, in order to practise in
Nigeria. See Section 6 of the Code of Medical Ethics.
135
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of practice, may amount to infamous conduct. If the Medical and Dental Practitioners
Tribunal, a tribunal of the same standing as a High Court, finds the practitioner guilty of
such conduct, it may suspend or strike him off the register of medical and dental
practitioners in Nigeria, and render him legally unable to practice medicine and
dentistry in Nigeria. Presumably, if the practitioner is negligent in the treatment of a
patient who is also involved in research, then the practitioner may be disciplined by the
Tribunal. There is, however, no specific penalty for failure to comply with the sections
on biomedical research under sections 31, for instance, failure to submit a research
proposal for ethics review. Furthermore, some of its provisions may conflict with
provisions in other instruments regulating health research, potentially leading to
confusion.
In sum, a more comprehensive legal framework than that afforded by the
Code of Medical Ethics is needed.

6.3.2.4 National Agency for Food and Drug Administration Act and Regulations
Other legislation with implications for research governance are the National
Agency for Food and Drug Administration And Control Act 1993 (the NAFDAC Act),
and the Drug and Related Products (Registration, Etc.) Act 1993,m both federal laws.
The NAFDAC Act establishes National Agency for Food and Drug Administration and
Control (NAFDAC), which regulates food and drugs in Nigeria.

138

Section 1, National Agency for Food And Drug Administration And Control Act 1993 (NAFDAC Act),
CapNl.
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The Drug and Related Products (Registration, Etc.) Act 1993 provides that
clinical trials for the importation, manufacture, or supply of a sample of drug, or a drug
product, can only be undertaken after a permit has been granted by NAFDAC, which
would issue a valid clinical trial certificate for that purpose.139 Applications for a
clinical trial certificate are to be made as prescribed by regulations provided by
NAFDAC and clinical trials are to be conducted under regulations made by
NAFDAC.140
Pursuant to powers conferred on it by the NAFDAC Act, NAFDAC has
drawn up guidelines for regulating drug trials in Nigeria.141 The NAFDAC Guidelines
states that: "The current revision of the Declaration of Helsinki is the accepted basis for
clinical trial ethics, which must be fully known and followed by all engaged in research
on human beings."

It also requires that "The principles of informed consent in the

current revision of the Helsinki Declaration should be implemented in each clinical
trial."143 These requirements essentially indicate that the Helsinki Declaration is the
standard for the conduct of clinical trials of drugs currently in Nigeria. As described
above, there are areas of potential conflict between the National Code and the Helsinki
Declaration, particularly with respect to matters like the use of placebos in clinical
trials.

There also areas of conflict between the National Code and the Guidelines

including, for instance, the process for obtaining informed consent from a person who is
unable to provide verbal or written informed consent. In this respect, the National Code
139

Section 1(2) and 5 of Drug and Related Products (Registration, Etc.) Act 1993.
Section 5(2) of the Drug and Related Products (Registration, Etc.) Act 1993.
141
Section 29 NAFDAC Act. NAFDAC Guidelines,
142
See p. 11, section 1 of the NAFDAC Guidelines.
143
Section 3.2, p. 13.
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requires a record such as audio-recording or witnessed thumb-printing, and this must be
approved by an ethics review committee.144 The NAFDAC Guidelines, on the other
hand, state that where it is impossible to obtain verbal or written informed consent, the
researcher should merely document the reasons why it is impossible to do so. While it
is understandable that there would be differences in the requirements of both documents
given that they were produced at different times, the divergences in both documents are
worrisome because they may create confusion for researchers and research sponsors.
Perhaps to remedy this matter, NAFDAC has recently prepared a new set of
regulations which have not yet come into force - the Good Clinical Practice
Regulations, 2009.145 These draft regulations will presumably replace the NAFDAC
Guidelines currently in use. These draft regulations are drawn from the ICH-GCP. This
is not surprising, especially since many countries have adopted the GCP as the basis for
clinical trials of drugs. It is expected that every clinical trial of drugs in Nigeria must
comply with these regulations when they are passed.146 As provided in the ICH-GCP,
the regulations reiterate the importance of the Helsinki Declaration stating: "Clinical
trials shall be conducted in accordance with the ethical principles that have their origin
in the Declaration of Helsinki, and that are consistent with the requirements of these
regulations."147 This may be construed to mean ethical principles in any other guidelines
that are of the same import as the Helsinki Declaration, which may arguably include the
National Code, although the draft regulations do not refer specifically to the National
144

Section F(f) of the National Code.
Good Clinical Practice Regulations, 2009, made under the National Agency for Food and Drugs
Administration, 1993.
146
Section 8 (a).
Section 6 (s).
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Code. The draft regulations provide requirements for many matters, including matters
not contained in the National Code, including requirements for obtaining a minor's
consent for participation in clinical trials, and the consent of adults incapable of giving
consent.148

It would be appropriate to ensure that the requirements of the draft

regulations are in line with the National Code to provide clarity for researchers and
research sponsors.

6.3.2.5 The National Health Bill
As mentioned in Chapter Four, a National Health Bill has been passed by
the National Assembly. Although the National Health Bill has yet to be signed into law,
and is therefore not strictly part of the legal framework of Nigeria yet, I consider it here
because, when it becomes law (after the Presidential assent), it will have significant
impact on research governance in Nigeria.
The National Health Bill establishes a National Health Research Committee
whose responsibilities include ensuring that the health research agenda and the
resources available for research focus on priority health areas.14 It also confers power
on the Minister of Health to establish the National Health Research Ethics
Committee,

whose functions include registering and auditing health research ethics

committees in Nigeria and setting norms and standards for conducting research on

Section 9 and 10.
Section 31 of the National Health Bill.
Section 33 of the National Health Bill.
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humans and animals, including clinical trials.151 The import of the Minister creating the
committee is that the committee is not a juristic body, although it is recognized by law.
It can, therefore, not sue or be sued.
The Bill also requires that every institution in which health research is
conducted must establish or have access to a health research ethics committee. The
functions of the health research ethics committees in Nigeria include reviewing,
approving, or disapproving of health research protocols.152
Aside from creating these bodies, it makes informed consent a legal
requirement, and requires the informed consent of a parent or guardian in the case of a
minor.

Surprisingly, however, it does not expressly state that all health research must

pass through ethics review or provide penalties for failure to submit research projects
for approval. In view of the Pfizer incident, this is a crucial provision, which should be
expressly stated, not merely deciphered from other provisions in the Bill or from
subsidiary legislation.

„ The National Code which contains that requirement will,

however, become subsidiary legislation if the National Health Bill is passed. But until
the National Health Bill is passed, the National Code remains a policy, subordinate to
other instruments which have legal force such as the Code of Medical Ethics, and the
NAFDAC Regulations and NAFDAC Guidelines.

As a federal policy, institutions

created under state law can arguably not be compelled under law to comply with the
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Section 33(6) of the National Health Bill.
Section 34 of the National Health Bill.
153
Section 32 of the National Health Bill.
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provisions of the National Code.

Signing the National Health Bill, when necessary

amendments are made, and as soon as practicable, is therefore necessary.
Clearly, the National Health Bill has a potentially significant and beneficial
impact on research governance in Nigeria. If and when the Bill is passed, it will provide
a formal, legislative basis for the governance of all health research in Nigeria. It will
confer legal force on the National Code which contains many vital provisions lacking in
other legal instruments, and which has a wider reach and coverage.

It will clarify the

responsibilities of many key actors in research governance in Nigeria.
However, there are gaps in the Bill which should be remedied before the
Bill is passed. For instance, the National Health Bill does not contain a requirement for
ethics review. In my opinion, just like the requirement for informed consent, this
requirement is so fundamental that it should be contained in the principal legislation.
While the National Code contains such a requirement, there are no sanctions for failure
to meet such basic requirement, as I suggested in Chapter Four. Also, the Bill does not
establish a compensation scheme for research participants. Further, it does not contain a
mandatory requirement for registration of a clinical trial in a clinical trial registry, nor
does it mandate the creation of a clinical trials registry. No penal sanctions are provided
for failure to comply with the Bill.

The Bill is therefore not sufficiently

comprehensive in its provisions on research governance.
There are also areas of potential conflict with existing legislation. In this
respect, the Bill confers power on the National Health Research Ethics Committee to
make guidance for clinical trials. As described above, NAFDAC has powers under the
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NAFDAC Act to make regulations for drugs, including clinical trials.

While the

National Code requires that there should be compliance with both the NAFDAC
regulations and the National Code,154 it does not make it clear what would happen in the
event of a conflict between any guidance promulgated by the National Health Research
Ethics Committee, such as the National Code, and any regulations on clinical trials
made by NAFDAC. It would be helpful if the National Health Bill would include a
provision stating that the guidance provided by the National Health Research Ethics
Committee supersedes all other regulations in the event of a conflict.
Given the gaps pointed out above, it is necessary that the Bill be amended to
address them as soon as practicable before Presidential Assent.

6.4 Institutional Framework for Research Governance in Nigeria
In the foregoing pages, I have considered the ethical and legal frameworks
of research governance in Nigeria. Below I consider the institutional framework which
actually implements the ethical and legal frameworks. Following the outline laid out in
Chapter Three, I consider ethics review committees, the drug regulatory authority,
NAFDAC, policymaking structures in Nigeria, and non-governmental organisations. I
examine their functioning in the past, and the systemic issues identified in Chapter
Three that have affected such functioning, and which should be addressed in the
emerging institutional framework.

Section M (a).
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6.4.1 Ethics Review Committees
In the foregoing discussions of the ethical and legal frameworks of research
governance in Nigeria, the fundamental prerequisite of ethics review is emphasized in
the different instruments. Below, I recapitulate very briefly the main points about the
past functioning of ethics review committees already discussed under the history of
research governance in Chapter Four. I then describe and analyse the requirements of
ethics review committees under the National Code, drawing from the systemic issues
discussed in Chapter Three.

Such systemic issues include the composition or

membership of committees, the structure and organisation of ethics review committees,
capacity and funding issues.
The major function of ethics review committees in Nigeria, as in many
countries around the world, is to approve research which meets ethical standards and
disapprove research which does not meet such standards. The requirement to submit
research protocols to ethics review was not a formal requirement under domestic
instruments until 2004 when it was required for biomedical research in the Code of
Medical Ethics. As the Pfizer incident showed, there were instances where research
projects did not undergo ethics review. I have described the inconsistent, and ad-hoc,
manner in which several of the ethics review committees operated in Chapter Five.
Many of them suffered gross underfunding, and lacked the expertise to carry out their
functions. In some institutions, researchers were not even aware of the existence of
ethics review committees

As discussed in Chapter Five, at various times national

committees were established and then became non-functional. And, at certain points,
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there were two national committees in operation. Financial support, stability, and
sustainability are therefore key concerns with respect to the functioning of ethics review
committees in Nigeria.
Traditionally, ethics review committees in Nigeria have been organised on
an institutional basis, sometimes with a national committee in operation. As described
in Chapter Five, these institutions were established mainly in federal institutions,
including the major teaching hospitals, and the major research centres like the Nigerian
Institute of Medical Research. Although each institution could have established
guidance and operating procedures for ethics review committees, many had none.
Governance at the institutional level was therefore practically non-existent, except
where external sponsors specified certain requirements. On the national level, there was
no set guidance for the composition of such committees or how they were to be funded.
There was no clear way of ensuring that members were educated and had the necessary
expertise and diversity to provide balanced reviews.
The National Health Bill confers power on the Minister of Health to
create a national committee known as a National Health Research Ethics Committee,
and requires institutions to create their own Health Research Ethics Committee.155 The
National Health Research Ethics Committee has the responsibility for registering Health
Research Ethics Committees;156 updating, revising, and editing the Code;157 auditing
Health Research Ethics Committees.158 It also has the responsibility of advising the
155

Sections 32 and 34.
Section C.
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federal and state ministries of health on any ethical issues concerning research. Further,
the National Health Research Ethics Committee has the power to sanction any
researcher that commits a violation of an ethical or professional rule by referring such
researcher to the relevant statutory council prescribing penalties against any person
found to be in violation of any norms and standards, or guidelines, set for the conduct of
research under this Act.
The National Code also requires that all institutions that seek to conduct
health research must have a Health Research Ethics Committee, which must be
registered with the national research ethics committee.160 The National Code provides
the manner for registering Health Research Ethics Committees with the National Health
Research Ethics Committee, and requires that such registration must be renewed after
two years.161

Part of the requirement for registering Health Research Ethics

Committees is that the institution provides a statement committing itself to taking
responsibility for members' actions. All members of the proposed Health Research
Ethics Committee must have completed training programs in research ethics approved
by the National Health Research Ethics Committee and copies of the certificates of
completion of such programs must be submitted along with the application. The
institution setting up the Health Research Ethics Committee must provide resources for
such training. The institution must also agree to comply with the National Code in the
discharge of its responsibilities for protecting the rights and welfare of human
participants of research conducted at or sponsored by the institution. The institution
159

Section N.
Section C.
161
Section C (b).
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must also commit to providing meeting space of sufficient quality, office and storage
space, sufficient staff and funds to support the Health Research Ethics Committee in its
review and recordkeeping duties. It also requires that the line of reporting authority
should be from the chairperson of the Health Research Ethics Committee to the Chief
Executive of the institution.
Health Research Ethics Committees (HRECs) review research proposals
and protocols in order to ensure that research conducted by institutions, will promote
health, contribute to the prevention of diseases or disability or result in cures for
diseases. They have the power to approve, disapprove, suspend, and terminate research
protocols in accordance with the requirements of the National Code.

163

To address

circumstances where an institution may not be able to meet the requirements for
establishing an ethics review committee, the National Code requires that an institution
that has no ethics review committee may enter into an agreement with another
institution that has such a committee to provide ethics review of any research which
would take place in such an institution.164 Such agreement may only exist between
institutions in the same state or in the same geopolitical zone.

Where the research

involves more than three sites, the NHREC may review such research or may mandate
another research committee to do so on its behalf.166
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In the case of international

Section C (a) (1) - (6). According to the website of the National Health Research Ethics Committee,
there are currently 19 ethics review committees from various health institutions registered with the
National Health Research Ethics Committee (NHREC). See NHREC, "Registered HREC Database,"
online: <http://www.nhrec.net/nhrec/hrec_db.php> (May 2, 2010).
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Section C (n).
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collaborative research, a HREC may adopt the approval of another HREC or that of any
other local or international ethics review committee provided that such approvals
comply with the requirements of the Code and take account of local circumstances.167
HRECs are also required to monitor already reviewed research at intervals appropriate
to the degree of risk involved in participation in the research. HRECs may initiate the
oversight process in the event of receipt of any complaints or information from any
168

source.
To promote efficiency, the National Code requires that HRECs must review
and provide decisions within three months. Where the HREC is unable to provide a
decision in three months, it must refer it to the NHREC, which may reallocate the
review to another HREC. Where the HREC does not provide a decision within the
specified period and does not refer it to the NHREC, the researcher may make a report
to the NHREC which may sanction the HREC.169 The National Code also provides the
procedure for reviewing multi-centre trials.170 Further, among other procedural rules,
HRECs are required to keep records of proceedings and maintain such records for ten
171

years.
Conflict of interest is addressed in different provisions of the National Code.
These include provisions requiring that any conflict of interest of any members,
including employment, ownership of stock, and receipt of honoraria, or grants from
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potential research sponsors, be indicated to the NHREC at the time of registration.172 It
also requires that a member must not participate in the review of a project in which she
has a conflicting interest.173 Also, the director of a medical institution in which clinical
trials is to be conducted must ensure that there is no conflict of interest in conducting
the trial at the medical institution between the sponsoring company and the researcher
who is an employee of the medical institution.174 The informed consent form should
also contain information on any apparent or actual conflict of interest.175
In terms of composition, according to the National Health Bill, the National
Health Research Ethics Committee is to consist of 15 members from different fields of
endeavour, appointed by the Minister of Health. They would include a Chairman; a
Medical Doctor; a Legal Practitioner; a Pharmacist; a Nurse; at least two Religious
Leaders, one each from the Christian and Muslim religions; a Community Health
Worker; one Researcher in the Medical Field; one Researcher in the Pharmaceutical
Field; three other persons, one of whom must be a woman, all of whom in the opinion
of the Minister are of unquestionable integrity.176 The members are appointed for an
initial period of three years. There may be a renewal of another three years, after which
that member can no longer serve on the NHREC.177 A member of the NHREC is

Section C.
Section D.
Section O (8).
Section F (f).
Section 33 of the National Health Bill.
Section 33 (3).
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required to vacate her office if she resigns, or is requested in the public interest by the
1 "7Q

Minister to do so.
Health Research Ethics Committees are required to have at least five
members.

The National Code lists several criteria for choosing members of the

committee, namely, experience, expertise and diversity of its members, age, gender,
socio-cultural backgrounds, religion, and sensitivity to such issues as community
attitudes, to promote respect for its advice and counsel in safeguarding the rights and
welfare of researchers and research participants. Members are also required to have
varying academic and professional backgrounds to promote complete and adequate
review of health research. It also requires the membership of a lawyer "whenever
feasible."

The National Code does not specifically require lay membership, but it

requires at least one scientific member and one non-scientific member. Further, if the
HREC wishes to review research that involves vulnerable participants, such as children,
prisoners, pregnant women, physically and psychologically disabled persons, the HREC
is to appoint one or more individuals knowledgeable about, and experienced in, working
with such participants for the review process. However, these individuals are not
allowed to vote.179
To conduct ethics review effectively adequate financial support, including
expenditures for documentation, administrative support and necessary office equipment,
training, project monitoring, site visits, any honoraria for ethics review committee
members, other direct and indirect costs, is essential. In this respect, the National Code
178
179

Section 33(4).
Section D.
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provides that HRECs may charge fees for any or all of their activities, at its discretion,
and in consultation with the principal officers of the institution. The fees must be
commensurate with anticipated expenses required for adequate oversight of research.180
The National Code further provides that as part of its oversight functions, the NHREC
shall review the commitment of institution(s) to provide resources for proper
1 81

functioning of HRECs.

There are no provisions for remunerating members of either

the NHREC or the HRECs.
Another key systemic issue is the development of capacity for ethics review.
This would include knowledge about the requirements of relevant policies and
guidelines for the ethical conduct of health research in Nigeria.182 The National Code's
requirements for registration with the NHREC include a prerequisite for the members of
the HREC to undergo NHREC-approved training programmes. Most NHREC-approved
training programmes are provided through the West African Bioethics Training
Programme, a program affiliated with the University of Ibadan and supported by a
National Institute of Health grant, the Fogarty International Center, and the National
Human Genome Research Institute.183
In terms of ensuring compliance, the National Code provides that in
international collaborative research, NHREC shall report its findings of misconduct
against researchers, sponsors and collaborators to the national ethics regulatory agency
180

Section E(r).
Section L (c).
182
See Jocelyn Downie, "The Canadian Agency for the Oversight of Research Involving Humans: A
Reform Proposal" (2006) 13 Accountability in Research 75 at 80.
183
West Africa Bioethics Training Programme, online:
<http://www.westafricanbioethics.net/wabcms/index.php?option=com_content&task=view&id=50&Itemi
d=l> (May 30, 2010).
181
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of the country of origin of the researcher.184 This step does not prevent the institution or
participants from taking appropriate legal action against such researchers and their
representatives in Nigeria, thus allowing room for participants and other interested
parties to seek legal redress outside the ethics review system. More generally, the
NHREC has powers to undertake other punitive action against researchers found guilty
of unethical practices, including barring them from conducting research for variable
periods of time depending on the severity of findings of misconduct. The National
Code also provides that NHREC shall recommend disciplinary action against
researchers, report all cases of fraud, deception, infamous conduct, plagiarism,
fabrication, falsification to the appropriate regulatory authorities, including the police,
and NHREC shall bar researchers from conducting research for variable periods of time
depending on the severity of findings of misconduct.185
Thus, a national system of research governance is emerging in Nigeria, with
a national overseeing committee at the top of the structure and an institutional system of
ethics review below. The adoption of a national ethics committee as part of the ethics
review system in Nigeria provides a potentially uniform and comprehensive system of
research governance, clear reporting relationships, and, arguably, greater accountability.
As well, the NHREC s requirements for registering and auditing Health Research Ethics
Committees, particularly with respect to education and training of members, will also be
helpful for developing much needed expertise in ethics review in Nigeria. The NHREC
has recently obtained the United States Federal Wide Assurance so that "when the

Section N (f).
Section N (a) to (f).
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NHREC functions as an ethics committee according to the National Code and reviews
protocols, such protocol review meets the requirements of United States Federal
Government funded research."186 Thus, the establishment of different components of
research governance in the country may also facilitate research.
However, at present, the basis and authority on which the NHREC is
functioning is not clear. Is it a legal body at present? It would appear not. Is it
functioning as a committee set up by the Minister? It would appear so. It is anticipated
that the National Health Bill will soon be signed into law, but, as things stand, it does
not have legal authority to compel institutional ethics review committees, including
those created under state laws to register with it or to oversee these committees, or to
create the National Code or require compliance with the National Code.

Still, as

articulated in the National Health Policy, the federal government can make health
policies, such as contained in the National Code. But such policy is arguably not a
statute binding on states and state institutions. Given the importance of the national
committee, a legislative basis for such committee would ensure its legitimacy,
effectiveness, and sustainability. Without a legislative basis, a new Minister of Health
may decide to discontinue its operation, jeopardizing its sustainability. Moreover,
without a legislative basis, there really is no compelling compliance mechanism to
ensure that institutions respect and comply with the National Code emanating from the
NHREC. Signing the National Health Bill into law after the necessary amendments and
as soon as possible is therefore essential.

Culled from the website of the NHREC, see online: <http://www.nhrec.net/nhrec/> (May 2, 2010).
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As described in Chapter Three, the institutional system of ethics review
comes with certain challenges.

These include inherent conflict of interest issues

because the ethics review committee is housed within an institution that is typically
intent on attracting research funds. In a developing country setting like Nigeria where
resources are limited, this is a great concern. One way to tackle this potential problem
is to ensure that membership of such committees includes persons from outside the
institution. In the past, most members were drawn from the institution.187 As I describe
below, this position has not changed significantly as the National Code does not
specifically require that members must be drawn from outside the institution.
Moreover, the National Code attempts to tackle the matter of the potential
inability of some institutions to establish a Health Research Ethics Committee by
requiring them to adopt the Health Research Ethics Committee of another institution.
There is likely, however, to still be a multiplicity of ethics review committees in
Nigeria, if all institutions establish an ethics review committee. This is a problem
mainly because of limited resources. In my opinion, it might be better to have fewer
ethics review committees organised in a regional system.

These ethics review

committees could then provide ethics review for all the institutions in a particular state
or geo-political zone. In this way, the main strength of institutional review would still
not be lost as such regional committees would still be able to take into account the local
context, which would not vary significantly being within the same state or geo-political
zone. This would limit the resources expended both locally and nationally since there
Jean-Paul Rwabihama, Catherine Girre, Anne-Marie Duguet, "Ethics Committees for Biomedical
Research in some African Emerging Countries: Which Establishment for which Independence? A
Comparison with the USA and Canada" (2010) 36 J Med Ethics 243 at 244.
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would be fewer ethics review committees. It would also ensure that ethics review is
available for all states and all institutions. This will be helpful should the kind of
situation that arose in Pfizer occur again. Thus, even where an institution does not
ordinarily conduct health research and therefore has no cooperative agreement with
another institution, but unexpectedly has to permit some sort of health research
involving humans, there will be a ready ethics review committee in the state to review
such research.
Given the need to ensure the independence and effectiveness of such a
national committee, the membership of, and the appointment process into, the
committee are key factors to consider. An analysis of the composition of the NHREC
as provided in the National Health Bill, shows a concentration of persons in the health
field, which would reflect the focus of ethics review in Nigeria. But it also means that
people with other backgrounds are very much in the minority and may not bring the
necessary diversity and balance for proper consideration of the issues raised in ethics
review. There is also no requirement for gender balance. In a country where women
remain underrepresented in many sectors, the mandatory requirement for only one
woman is, in my view, insufficient. Further, while Moslems and Christians are in the
majority, an argument could be made that other religions, including traditional religions,
are left out unjustifiably.
Additionally, the appointments process for the national ethics review
committees also has implications for the independence of the national committee and
consequently, the protection of participants. An open and transparent system is thus
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essential. There is much that is good about the appointment process outlined in the
National Health Bill, including a specific tenure, and a requirement that removing a
member can only be on grounds of "public interest," reducing potential political
interference. However, a situation where the Minister, appoints all the members of the
NHREC, out of whom three are simply persons whom he considers to be of high
integrity, may not be the most transparent way to appoint persons into a committee with
huge responsibilities or to secure the independence of such committee.

The South

African system where the Minister calls for nominations, after consultation with the
National Health Research Council (which determines research priorities) and
consultation with interested parties out of which she or he makes appointments may be a
more transparent means,

and, as new governance proponents would argue, encourage

more participation in the process. Such interested parties could be the Medical and
Dental Council of Nigeria, other professional

associations, non-governmental

organisations, community advisory bodies, and so on.
Regarding the composition of the HRECs, the National Code could, in my
view, have been more direct in its requirements with regard to membership of ethics
review committees. Merely listing several criteria, as the National Code does, leaves
the institution with the discretion to meet some but not necessarily all the criteria.
Further, drawing from the new governance approach in my hybrid
framework, participation by those on behalf of whom regulation is undertaken is
essential. Surprisingly, with the emphasis on community participation in the ethical

Section 72 of the National Health Act, 2003.
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framework outlined in the National Code, there is no specific requirement for a
community member or a requirement for the inclusion of research participants. Nor
does it expressly require that the institution must go outside to seek members. An
institution could therefore argue that they have met the requirements, even if all the
members come from the same institution, which would usually be a university. A
survey of several African countries, including Nigeria, showed that before 2002, all
committee members were fulltime employees of the institution, except in South
i on

Africa.

There has therefore been a propensity for using only institutional employees

in these committees. With the way the requirements are couched, such a tendency is
likely to continue. There is also no requirement for gender balance as is the case in
South Africa,190 the United Kingdom,191 and Canada.192 Further, the requirement for
consultation of someone familiar with working with vulnerable persons without an
accompanying requirement that such persons be allowed to vote (as is the case in South
Africa and the United States) seems incongruous and may adversely affect the
protection of such persons as research participants.

Perhaps, this is because such

Jean-Paul Rwabihama, Catherine Girre, Anne-Marie Duguet, "Ethics Committees for Biomedical
Research in some African Emerging Countries: Which Establishment for which Independence? A
Comparison with the USA and Canada" (2010) 36 J Med Ethics 243 at 244.
190
The composition of HRECs in South Africa is different from the Nigerian requirements. The main
guidance Ethics in Health Research: Principles, Structures and Processes requires that there should be at
least nine members with sixty percent quorum including members who are representative of the
communities it serves and, increasingly, reflect the demographic profile of die population of South Africa;
members of both genders, although not more than 70% should be either male or female. See s.4.1.
Section 6 of the Governance Arrangements for NHS Research Ethics Committees. The US regulations
also require that although effort should be made to include members include those whose interests are in
scientific areas and those whose concerns are in nonscientific areas of both genders but no selection is to
be made on the basis of gender. 45 CFR 46.107
192
Section 1, Article B- 1.3- Membership of REBs., the TCPS requires that the REB shall be composed
of at least five members, including both men and women, of whom at least two members have broad
expertise in the methods or in the areas of research that are covered by the REB, at least one member is
knowledgeable in ethics and another in law for biomedical research, and at least one member has no
affiliation with the institution, but is recruited from the community served by the institution.
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persons with familiarity with vulnerable persons may not have undergone the training
required for regular members. But this means that vulnerable persons, or a professional
who is familiar with their situation, are effectively excluded from actual decisionmaking on the HRECs. Accountability, the need for balance and diversity, and the
necessity to prevent inherent conflict of interest, require that the compositional
requirements of ethics review committees be revisited.
Further, the provisions on financial support for Health Research Ethics
Committees sound good on paper and attempt to cover all possible loopholes. For
example, if an institution intends to conduct research, it must commit to provide
resources and if the resources are not provided, the NHREC may revoke its registration.
But past experience has shown that institutions have often failed to provide resources
for ethics review committees. Governments, too, have also failed to provide resources
for ethics review committees. As Falusi and others note with respect to the ethics
review committee at the University of Ibadan, a federal institution, "Despite the
declared interest in fostering research, the University of Ibadan has never had sufficient
resources from the Federal Government to operate an IRB."193 Interestingly, the ethics
review committee in that university resorted to a "public/private partnership" in order to
obtain resources. In this partnership, The University of Chicago through a generous
grant from the Ralph and Marion Falk Medical Research Trust provided $40,000 in
grant support.

With the funds the committee was provided with basic necessities for
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Adeyinka G Falusi, Olufunmilayo Olopade, and Christopher O Olopade, "Establishment of a Standing
Ethics/Institutional Review Board in a Nigerian University: A BluePrint" (2007) Journal of Empirical
Research on Human Research Ethics 21 at 23.
194
Ibid.
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running. It is not clear how the committee will continue to be funded when the grant
support runs out, and if the institution intends on continuing to seek grants to support
the ethics review committee.
Further, even though the National Code requires fees from research
sponsors to be commensurate with the anticipated expenses of the review, charging fees
raises the spectre of conflict of interest and regulatory capture in a resource-limited
setting like Nigeria. Yet, it may be difficult for institutions, which are already straining
under the burden of limited funds to provide resources, independent of such fees, for
ethics review committees. In addition, it may not be desirable to charge fees for all
types of research, including research conducted by students, projects for expedited
review, and non-funded research. Perhaps, a better approach might be to establish a
scheme through which ethics review committees in Nigeria, including the National
Health Research Ethics Committee, are funded.

Such scheme, which would be

independent of the institutions, apart from providing resources for the functioning of
ethics committees, will also ensure greater independence than would otherwise be the
case. I discuss this scheme further in my recommendations in Chapter Seven.
Conflict of interest and the related concomitant of regulatory capture are
serious concerns for the governance of health research in countries around the world. In
a telling observation, a survey on ethics review in African countries, observed that, "No
committee has rejected a research protocol."195 Of course, this may be because each
protocol reviewed met the requisite ethical standards. But it is also a reminder that
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Rwabihama et al, supra note 189 at 244-245.
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many institutions in all countries, but especially institutions in the developing world and
specifically in African countries like Nigeria, have many reasons to desire to attract the
resources represented by research, especially externally sponsored research.
There are various provisions on conflict of interest in the National Code as I
described above. There are requirements that HREC members must not vote on matters
in which they have a conflict of interest, and for directors of medical institutions to
ensure that no conflict exists between researchers and research sponsors. There are,
however, no direct injunctions on what should happen in other cases. Instead, there is a
requirement for any potential conflicts of interest to be indicated to the NHREC at the
time of registration, and for informed consent forms to contain an indication of any
conflicts of interest. It does not state what indicating such potential conflict of interest
would mean for either registration with the NHREC or what the ethics review
committee should do if the informed consent form indicates that a researcher has a
conflict of interest.
More generally, the provisions do not address institutional conflicts of
interest, that is, circumstances in which an institution would benefit from proposed
research projects, and therefore has an interest in ensuring that the project is approved.
Presumably the establishment of an "independent" HREC would take care of this
circumstance. Nevertheless, the potential for such conflict becomes even more
significant, given the wording of the membership requirement in the National Code that
allows members to be drawn solely from the institution. There is therefore, an increased
potential for perceived, if not actual, conflict of interest. Further, as already described,
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many institutions rely on foreign funding for maintaining ethics review committees.
The peculiarities of the establishment of some of these committees in the past also
contribute to a perceived lack of independence. As Rwabihama and others describe it in
the African context,
fault may lie in the peculiarity of the origin of these
committees. The establishment of the first African
ethics committees is connected to the need of
conducting Western research projects in developing
countries. While African scientists are managing to
conduct local research in order to solve some
endemic or tropical diseases in the region, ethics
committees are still working with the dependences
of Western agencies. Committees are not
independent enough, according to the history of their
creation and the socio-economic context.196
The creation of a national system of governance has the potential to deal with the
problematic beginnings of ethics review as described by Rwabihama and others,
especially if it takes into account these challenges. Given its importance, and the
adoption of an institutional system (where members of ethics review committees could
include members of the same department as a researcher or previous or potential
collaborators on research projects), a specific section on conflicts of interest, would
have been helpful in the National Code.

Such section could include a detailed

expatiation on what may constitute conflict of interest in different circumstances, and
how institutions, ethics review committees, research sponsors and researchers should
deal with such conflicts.

Rwabihama, et al, supra note 189 at 249.
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With respect to the powers of the NHREC to compel compliance with the
National Code, it can impose several sanctions. However, as things stand currently, it
cannot legally enforce compliance because it is not yet a legally established body. Even
when the National Health Bill is passed, the sanctions which the NHREC can impose
are limited. Particularly in relation to external researchers, it may be argued that the
sanctions in the National Code are insufficient, since these researchers may not face any
direct penalties for any unethical conduct.

This would be different, however, if there

were penalties, especially for basic infractions, such as failure to obtain informed
consent, or failure to submit projects for ethics review.
In sum, there is significant progress in the development of a uniform ethics
review system in Nigeria. There is currently a desire to establish and register functional
ethics review committees in Nigeria. But the history of research governance in Nigeria
shows that sustainability is crucial and has been lacking in the past. Efforts to establish
or re-establish committees must therefore proceed in a manner that takes this into
account. Even with these developments, then, several important issues remain, including
the continued lack of a legislative basis for both the NHREC and the National Code
with its attendant effect on the sustainability of the emerging ethics review system in
Nigeria. And, of course, it remains to be seen how rigorous the implementation of the
National Code's requirements for ethics review committees will be.
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6.4.2 Drug Regulatory Authority: NAFDAC
Established in 1993, NAFDAC is the principal regulator of drugs in
Nigeria.197

I have already discussed the guidelines that NAFDAC has developed, and

the regulations it is currently developing, pursuant to its powers under the NAFDAC
Act. 198
In recent years, NAFDAC has engaged in a public, and by many accounts,
largely successful, war against the importation, production, and sale of counterfeit and
substandard drugs in Nigeria.19 In this respect, it has enforced the registration of drugs,
confiscated large amounts of counterfeit drugs, and prosecuted offenders. Its work in
this respect has been lauded widely, and referred to as a model for other developing
countries that have the same problem.200
However, very little is known about NAFDAC s current work as the main
regulator of clinical trials. But its past left much to be desired. In this respect, there
have been contradictory accounts of whether or not Pfizer received permission from

19

' Section 5 of thee NAFDAC Act.
Section 29 NAFDAC Act
199
Owen Dyer, "New Report on Corruption in Health" (2006) 84: 2 Bulletin of the World Health
Organisation 84. 12. 24. A I Raufu, "Nigeria Leads Fight Against "Killer" Counterfeit Drugs" (2006) 84:6
Bulletin of the World Health Organization 685. The National Agency for Food and Drug Administration
and Control (NAFDAC) "NAFDAC Destroys N10B Fake Drugs in 4 Years" (2006) 1: 10 NAFDAC
News 4.
200
Ibid.
198
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NAFDAC for its infamous clinical trial in 1996.
provided no clear answers.

Even after the trials, NAFDAC has

The panel of inquiry that investigated the Pfizer incident

criticised the NAFDAC for failing to take action after the chairman of the task force
907

made complaints about the trial.
NAFDAC clearly has the legislative authority required to carry out the
mandate of regulating clinical trials of drugs. Since 2001, it has also enjoyed significant
political support in carrying out reforms, particularly with respect to reducing the
infiltration of counterfeit and substandard drugs in Nigeria. Its success in that respect is
a major indicator that governance and regulation, as well as law, can be effective in
Nigeria. There is now need for NAFDAC to broaden its efforts to include effective
regulation of clinical trials. The new draft regulations based on the ICH-GCP, as
described above, indicate that NAFDAC is aware of its regulatory role with respect to
clinical trials. These new regulations must be carefully pondered and put in place as
soon as possible. It is heartening that they were made available for public comment on
NAFDAC's website, suggesting a desire to engage and involve the public in the
process.
However, NAFDAC's regulatory role must be coordinated properly with
other actors, including national and institutional review committees, in research
governance in Nigeria in order to provide comprehensive protections for participants in
health research and to prevent potential confusion for research sponsors.
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202

Sam Eferaro, "NAFDAC Okayed Pfizer's Trovan Trials" Vanguard 8 January, 2001.
See Chapter Five.
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Greater

uniformity in the provisions of the regulations provided by NAFDAC and other
documents such as the National Code is desirable. Further, as the Pfizer incident
indicates, NAFDAC must take its role as a regulator of clinical trials of drugs in Nigeria
seriously.
Aside from the regulations of NAFDAC, Garuba, Kohler, and Huisam, in a
recent survey of the work of NAFDAC (regarding registration, procurement, inspection,
and distribution of drugs), noted that there have been significant improvements over the
years.

These include on-the-job training for officials of NAFDAC, and public

availability of some information. However, several weaknesses remain. These include
an inadequate number of trained staff, a lack of conflict of interest guidelines,
inconsistency in the documentation of procedures, and lack of public availability of
such documentation.203 These are systemic issues that will also impact adversely on the
proper regulation of clinical trials of drugs in Nigeria if they are not dealt with. For
instance, an adequate number of trained staff is necessary to monitor trial sites, and
review documentation among other things. An investment of resources by the Nigerian
government is clearly necessary to assist NAFDAC in its regulatory functions. Thus,
with respect to NAFDAC, adequacy of resources, implementation, accountability, and
uniformity of regulatory requirements are key issues as research governance develops.

Habibat A Garuba, Jillian C Kohler, and Anna M Huisman, "Transparency in Nigeria's Public
Pharmaceutical Sector: Perceptions from Policy Makers" (2009) 5: 14 Globalization and Health . See
also, Hart O Awa and Christen A Nwuche, "Cognitive Consistency in Purchase Behaviour : Theoretical
and Empirical Analyses (2008) International Journal of Psychological Studies 44 at 50.
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6.4.3 Policy-Making Structures

According to the National Health Policy, the federal government, through
the Federal Ministry of Health, is the main policymaker for the country on healthrelated matters, although states may make policies within the state health system. Until
the establishment by the Minister of the National Health Research Ethics Committee,
therefore, the Federal Ministry of Health was in charge of making policies relating to
health research.
The current policy for health research is articulated in the National Health
Policy drawn up by the Federal Ministry of Health. However, the National Health Bill,
when signed into law will confer policymaking powers on the National Health Research
Committee which is to make research policies. The core of any policies emanating
from this committee would be to ensure that the research conducted in the country
would be research which meets Nigeria's priorities. As discussed in Chapter Four, the
determination of research priorities in developing countries like Nigeria is crucial to
prevent exploitation of research participants in Nigeria.

The establishment of a

committee charged with this responsibility will therefore be a welcome development.
The National Health Bill will also legally empower the National Health
Research Ethics Committee (NHREC) to make policies for research governance in
Nigeria. Indeed, that committee, inaugurated by the Minister of Health, has already
begun to develop policies such as contained in the National Code.
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Recently, the creation of a "National Bioethics Committee" in Nigeria, with
the support of the United Nations Educational Scientific and Cultural Organisation
(UNESCO), has been under contemplation.

4

There are thus several policymaking

bodies in Nigeria either currently functioning or in the process of being established.
As I pointed out in Chapter Three, legitimacy, community engagement and
public participation, transparency, accountability, representation and effectiveness, are
key concepts in my hybrid framework of governance (drawn from new governance)
important systemic issues for policy structures like those listed above. To these issues
may be added a clear delineation of roles and responsibilities to prevent duplication. In
the Nigerian context, legitimacy strictly in terms of a statutory basis is clearly a problem
currently, although that it expected to change soon. The NHREC which is already
operating and providing policies has no clear basis in law. In terms of representation,
especially as described under the section on ethics review committees, there is room for
improvement.

Independence, plurality, diversity and multi-disciplinary focus are

necessary.
With respect to transparency and public participation, the National Health
Research Ethics Committee currently has a website on which it has posted the latest
version of the National Code and the list of Health Research Ethics Committees
registered with the national committee.

These steps are clearly steps in the right

direction. However, it is stated in the National Code that the NHREC may revise the

UNESCO, UNESCO Assisting Bioethics Committee: Meeting to Discuss the Establishment of the
National Bioethics Committee, online: <http://unesdoc.unesco.org/images/0018/001847/184765e.pdf>
(May 2, 2010).
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National Code at any time. In the three years since I began my research, various
changes, some minor and others major, have been made to the document.205 It has been
difficult to obtain information on how much public consultation there was prior to the
establishment of the National Code. But the provision that the NHREC may revise the
National Code at any time clearly suggests that broad engagement of stakeholders in
health research is not a priority.

This in turn undermines the legitimacy of the

document, and may affect compliance with, and respect for, the document. Further, it
potentially creates a strict top-down governance approach (instead of a new governance
or a hybrid governance approach) that does not lend itself to responsiveness and
effectiveness.
It remains to be seen if, and when, the other policymaking structures will
become active. It is important, however, that the mandates for each of these bodies are
clearly mapped out and that there is no duplication in authority or roles. Not only
would any duplication result in policies which may be potentially confusing for
researchers, it would be inefficient and a waste of limited resources. Given limited
resources, it must be determined clearly if a National Bioethics Committee is really
needed alongside a National Health Research Committee and a National Health
Research Ethics Committee or if one can be subsumed within the other.

If it is

determined that all three are required, a clear delineation of roles is necessary. Further,
political support is necessary to ensure the effectiveness of these bodies.
resources are also necessary to ensure effective functioning of the research.

I have various versions of the National Code on file.
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Sufficient

6.4.4 Universities,
Associations

Research

Institutes,

Research

Sponsors,

Professional

Prior to the recent developments in research governance in Nigeria,
regulation took place mainly at the institutional level, that is, in Nigerian universities,
teaching hospitals, and research institutes.

However, from the history of research

governance discussed in Chapter Five, the institutional framework of governance was
non-functional.

During this period, much of the governance that existed emanated

mainly from the requirements of research sponsors. Research funded by international
organisations such as the World Health Organisation and the United Nations Joint
Programme on HIV/AIDS (UNAIDS) or national organisations such as the United
States National Institutes of Health or Wellcome Trusts therefore had to meet the ethical
requirements of these organisations.
Universities, research institutes, research sponsors and professional
associations lack the wide remit and authority to ensure a comprehensive framework of
research governance.

However, to permit a truly functional hybrid governance

framework as contemplated in this thesis, it is important for these institutions, including
universities and research institutes, to have and implement regulatory frameworks
governing research within their authority.

The National Code has now provided

standards for the ethical conduct of research, which institutions must adopt. But it also
allows institutions to "elaborate guidelines for the conduct of research in accordance
with their enabling law and consistent with the need for maintenance of the highest
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ethical and scientific standard as outlined in this code."

Thus, institutions can still

create guidelines that are in line with the National Code. They can also create other
guidelines on specific issues such as conflict of interest.
Research sponsors can, and will, most likely, continue to employ their own
guidance, using their own means for ensuring compliance, which is typically the threat
of withdrawing funding. However, they must also comply with the requirements of the
National Code and ensure that their contractual and ethical requirements of researchers
and research institutions do not conflict with requirements under the National Code.
Pharmaceutical companies, in particular, must ensure that contracts drawn up with
researchers do not conflict with the National Code's requirements.
With respect to professional associations, the Medical and Dental Council of
Nigeria, as already discussed under the legal and ethical frameworks above, regulates
medical and dental practitioners in Nigeria, under a statutory framework. Medical
doctors, should they be found to have violated the Code of Medical Ethics, would thus
be liable under mechanisms authorised under the law. However, while the Medical and
Dental Council has established a Code of Medical Ethics which contains requirements
for ethical research by medical and dental practitioners, as already discussed, that code
is limited in scope and application.
More importantly, self-regulation is a crucial part of the framework of
professional regulation.

In this respect, both the Nigerian Medical Association, an

association of all medical and dental practitioners in Nigeria,207 and the Medical and
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Dental Council of Nigeria, which is a statutory body, operate to provide such selfregulation. The Nigerian Medical Association, which is the largest medical association
in West Africa208with over 35,000 members, is recognised under the Medical and
Dental Practitioners Act.209 It nominates eleven members of the Medical and Dental
Council of Nigeria. It is consulted on an ad-hoc basis by the federal government and
contributes to health policies. It also provides continuing education to medical and
dental practitioners. 210
The Medical and Dental Council of Nigeria still has to ensure that medical
and dental practitioners comply with the code, and must be willing to take measures
against practitioners who fail to comply. However, both the Medical and Dental Council
of Nigeria and the Nigerian Medical Association have not, in my view, been sufficiently
active in ensuring proper research governance in Nigeria. There is, for instance, no
evidence that either has tried to push for the establishment of ethics review committees
at the institutional and state levels as required in the Code of Medical Ethics. As
another example, neither body publicly condemned or took any actions against the
doctor who reportedly provided a backdated letter to Pfizer in the 1996 trial.
Interestingly, one of the sanctions that the National Health Research Ethics Commitee
can apply against an erring researcher is to report her to the appropriate professional
911

council.

If the professional council shows no interest in disciplining erring members,

this sanction becomes merely illusory. Such inadequate professional interest is, as I

" NMA, "About Us" online: <http://www.nigeriannma.org/aboutus.htm> (May 2, 2010).
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About Us, supra note 223.
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National Health Bill, section 33.
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discussed in Chapter Three, one of the systemic issues that adversely affects research
governance in many countries.212
Also, although medical and dental practitioners are required to know and
comply with the requirements of the code, there is not much public awareness of the
code, and many potential participants in Nigeria have little knowledge of their rights
and the obligations of medical and dental practitioners.213
At present, other professional associations have yet to develop frameworks
for the ethical conduct of health research involving humans. It would be appropriate for
these professional associations to, at the least, formally adopt the National Code and
require their members to comply with it on pain of sanction by the professional
association. The trust that the public places in professional associations, and the interest
of these associations in maintaining that public trust, require that they begin to show
greater interest in the ethical conduct of research by their members.214
It is important that universities, research sponsors, and professional
associations engage more actively in ensuring that health research involving humans
conducted within their realms of authority meet high ethical standards. Even though
their scope of authority is limited, regulating effectively within their domains, and
actively participating in the national effort, will provide non-governmental governance
of research, and allow a hybrid, potentially more complete, and thus more effective
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model of governance, to emerge in Nigeria.

At present, the degree of accountability

and community engagement is inadequate as is effectiveness, particularly in relation to
professional associations.

6.4.5 Non-Governmental Organisations
As I have explained

in other chapters, while

non-governmental

organisations (NGOs) are not a typical component in many accounts of research
governance, they are particularly essential in the hybrid framework that I think is
necessary both in gaining an understanding of, and in creating, effective research
governance systems in developing countries. As I argued in Chapters Two and Three, a
government role is crucial but these NGOs can serve to increase the responsiveness of
government, and hopefully as a voice for research participants. And NGOs who work
to promote the rights and welfare of research participants could be particularly
beneficial in the specific context of Nigeria as described in Chapter Four.
Non-governmental organisations (NGOs) have provided many services in
Nigeria, including in the areas of democratic governance, public participation, civil
liberties and human rights, and health.215 As in many developing countries where the
state may not always meet the expectations of the people, NGOs often attempt to fill the
gap or advocate for changes in the state's actions, policies or proposals. While their
achievements in some respects may only be modest, their impact in Nigeria has been
significant. For instance, Okafor observes in a very interesting study on the impact of
human rights NGOs on legislation, lawmaking and executive actions in Nigeria that:
~15 Matthew Todd Bradley "Civil Society and Democratic Progression in Postcolonial Nigeria: The Role
of Non-Governmental Organizations" (2005) 1:1 Journal of Civil Society 61.
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One remarkable feature of the state-NGO
relationship in Nigeria is that even during the
darkest days of military rule in that country, NGOs
were still able to exert a modest measure of
influence on legislation and legislative action in
Nigeria. Laws were repealed or modified by various
military regimes in part as a result of sustained
campaigns launched by many of these NGOs. The
legislative process itself was also positively affected.
NGOs have also been able to achieve the same
modest measure of success during the period of
civilian rule between 1999 and 2001.216
In the health sector, NGOs have been actively involved in different aspects
of health delivery, advocacy and education.217 For instance, NGOs have been closely
involved with advocating for human rights of people afflicted with the disease, assisting
the development of policies for HIV/AIDS prevention and treatment in Nigeria,
soliciting support from other countries and international organisations, and with
educating the public about the disease.218 NGOs could also play such roles in the
context of research governance by promoting awareness of issues surrounding health
research and research governance, and by participating in related policymaking. Many
of them work at the grassroots level, allowing them significant access to, and
719

opportunities in, communities in which research may take place.
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Currently, there are few NGOs which provide different services with respect
to research governance. These include the Association for Good Clinical Practices in
Nigeria (AGCPN) and The New HIV Vaccine and Microbicide Advocacy Society. The
Association for Good Clinical Practices in Nigeria was founded in 2006 and has over
200 members, including physicians, nurses, pharmacists, and biomedical scientists.
Its goal is to build up the infrastructure for biomedical research in Nigeria by increasing
the number of physicians and institutions capable of conducting clinical research. It also
trains researchers in good clinical practices for clinical research. The New HIV Vaccine
and Microbicide Advocacy Society advocates for the use and availability of new
prevention technologies such as microbicides in Nigeria.221 The work of these
organisations touches on research governance, but is also focused on research
promotion. While vital, research facilitation or promotion sometimes conflicts with
research regulation aimed principally at protecting research participants.
There is, however, presently no NGO currently whose work focuses solely
on research governance and on the rights, safety, and welfare of research participants.
Such an organization would be a welcome addition to the research governance
landscape of Nigeria.

An NGO focused on the rights and welfare of research

participants could advocate for the passing of relevant legislation, formulation of
policies that take into account the needs of communities in which research takes place,
and advocate for practical implementation of legislation and policies. It may educate
research participants about their rights and the risks and benefits of participation in
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research. It could liaise with, and act as a bridge between different stakeholders, some
of whom may be primarily involved in conducting or sponsoring research and
communities.

It may also, as has occurred in South Africa, take legal action to '
999

challenge government or sponsors' actions or policies.

It may also act as a

whistleblower on issues relating to research governance, including obvious cases of
conflict of interest, corruption, or government inaction. The Pfizer incident, for
example, would have benefited from the presence of such an organization. Such an
organization would have kept the matter in the public eye and perhaps it would not have
taken as long as it did for participants and their families to receive justice. In short,
such an organization could potentially act as a check on the emergence of a lumbering
bureaucracy that may lose sight of the main issues, and potentially keep other actors in
research governance accountable by different means.
NGOs are nevertheless not completely free of systemic problems that may
limit their positive impact on research governance. Concerns about NGOs in Nigeria
and other African countries have been raised about their accountability, legitimacy, lack
99"?

of autonomy, utility, and efficacy.

NGOs which ordinarily ought to keep

governments accountable have sometimes failed to be accountable themselves. These
are important concerns, necessitating a constant reappraisal of any NGOs that
eventually fill the current gaps in this area. Yet, there is also evidence that there are

New HIV Vaccine and Microbicide Advocacy Society, online: < http://www.nhvmas-ng.org/> (May
30, 2010).
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NGOs which live up their responsibilities.

Moreover, these concerns do not vitiate

the potential usefulness of an organization that can challenge, persuade, and support
other institutions involved in research governance.
In any event, it would be impossible and unhelpful to rely completely, or
even primarily, on NGOs to provide all that is necessary for effective research
governance. This is not their role. Still, given the specific challenges of Nigeria, there
is a distinct possibility that NGOs can, as they have on other issues, act as voices for
research participants.

6.5 Assessing Nigeria's Governance Arrangements
In Chapter Two, I discussed a number of criteria distilled from various
sources that could be used to measure assess whether the goals of research governance
are being, or have the potential to be met. The values drawn from various sources in
Nigeria, including the National Code, indicate that the goals discussed in that chapter
remain the same - the facilitation of socially beneficial research, the maintenance of
public trust in research and, most importantly, the protection of the welfare, safety, and
rights of research participants.

The criteria discussed in that chapter were Clarity,

Comprehensiveness, Efficiency, Adequacy, Uniformity, and Simplicity. Through each
of these criteria run the criterion of effectiveness (can the current arrangements meet the
objectives) and the criterion of legitimacy (do current arrangements emanate from the
right authority and do they show the right degree of public participation, transparency

Hearn, ibid.
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and accountability). In the specific context of Nigeria, current research governance
systems are at an emergent or nascent stage, which makes it difficult to provide a
detailed assessment. Even so, the potential for these arrangements to meet these criteria
can be assessed, and hopefully will be helpful in addressing any gaps and weaknesses
moving forward.
With respect to clarity, the National Code is clear about the roles,
responsibilities and rights of stakeholders, to an appreciable degree. Without recounting
all that has been already discussed, it will suffice to say that the National Code
specifically addresses the roles of ethics review committees at the national and
institutional levels, the responsibilities of sponsors and investigators. However, some
issues remain. For one thing, until the National Health Bill is signed into law, the
clarity provided by the National Code remains in doubt, especially given that other legal
instruments have different provisions.

For instance, the Code of Medical Ethics

requires that there should be ethics review committees at the state level; the National
Code requires only institutions in which research is to take place to establish ethics
review committees. For another, until the National Health Bill is passed, it is not clear
that the National Code can compel state institutions by any consequential means to
comply. In addition, it is also not clear, as the Code of Medical Ethics appears to
anticipate, that the states have any role in research governance. But while the National
Health Bill will provide a national system and promote uniformity, state legislation will
aid implementation of the National Code.
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Regarding uniformity and adequacy, the National Code provides a
considerable degree of uniformity in terms of the ethical standards its sets.

The

potential consistency that the National Code represents is, to my mind, the strongest
feature of the emerging governance system in Nigeria. However, as I have described,
there remains an issue of legitimacy and authority because the National Code, as it
stands today, is, at best, a policy of the Federal Ministry of Health. That issue (in terms
of a statutory basis) will hopefully be addressed when the President assents to the
National Health Bill.
Current legal requirements are also inconsistent in some respects. Much of
the legal framework in Nigeria arises inadvertently and by inference and implication.
Judicial decisions and common law, as I have previously pointed out, are necessarily
fragmentary in nature, since issues are decided on a case by case basis. Thus, many
important aspects of research governance may not be articulated in the existing law as
decided by the courts. In the Nigerian context, where no case specifically on health
research involving humans has been decided, the gaps, especially with respect to the
structures of governance (such as ethics review) are even more conspicuous. Related to
this point, reliance on the common law in the development of research governance
would require litigation by parties in Nigeria, which is not as frequent as in most
developed countries. It would therefore take a long time, if ever, to develop research
governance systems by such means.

Some commentators like Cotterell also suggest

that the law of torts in the context of Nigeria and other African countries appears to
cater more to the needs of the elite rather than poor persons, who are in the majority.
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Without going into the merits of this observation, the necessity for equal protections for
every potential research participant in Nigeria requires that a prospective tool, like
legislation, be enacted.
There are some varying requirements in other instruments with legal force
including the Code of Medical Ethics and the NAFDAC Guidelines. If all existing
instruments are enforced strictly, the potential confusion will impede rather than
facilitate research, and may hinder the protection of research participants. This will
consequently result in a failure to meet the important goals of research governance.
This necessitates a more comprehensive framework, such as the one arguably provided
by the National Health Bill. However, even if the National Health Bill is signed into
law, it would have to make it clear that regulations emanating from the National Health
Research Ethics Committee override other regulations. And even after the National
Health Bill is signed into law, these instruments would still have to be amended to bring
them in line with the National Code. The uniformity of standards and requirements for
research governance is still in need of improvement.
The passing of the National Health Bill also affects the National Health
Research Ethics Committee's adequacy of independence, resources, and authority to
operate. The matter of resources will require close attention and practical solutions,
given the history of research governance in Nigeria. In this respect, even if the National
Health Bill is passed in its current form, several provisions in the National Code will
have to be revisited.
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It is too early to determine if the system in place is efficient. In my view,
however, efficiency might best be achieved with having fewer instead of more ethics
review committees. This may limit costs, thus maintaining sustainability, and
consequently, protecting research participants in the long term.
In terms

of

comprehensiveness,

the current research

governance

arrangements as articulated in the National Code address all health research involving
humans in Nigeria, regardless of the funding source and geographical location. There
are, however, matters which do not receive consideration which remain important.
These include ethical issues such as undue inducement, standard of care, the consent of
children and mentally challenged individuals, or accountability issues such as creation
of clinical trial registries, or legal issues such as providing sanctions for infractions of
certain basic requirements. There are also ethical issues which require a rethink as
discussed above, including the approach to privacy, or which are insufficiently
addressed, such as conflict of interest. Aside from these, the legal underpinning of the
National Code is also a problem in this respect, given varying requirements under other
legal instruments which do not have a comprehensive scope.
Regarding equitable distributions of harms and benefits, all the instruments
which govern research in Nigeria require fair selection of participants. More generally,
if the National Code is properly implemented and is provided legal authority, it will
provide equitable benefits and risks for most research participants, with the important
exception of children and mentally challenged individuals. It also has the potential to
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be efficient if seamless relationships between institutional and national ethics review
committees are maintained.
Even in a fledgling democracy such as Nigeria's, legitimacy remains
crucial. As Issalys observes, legitimacy or the appropriate derivation of authority has
obvious consequences for both effectiveness and efficiency of any mechanism of public
intervention.226 As is clear from the foregoing discussion, major issues remain with
regard to legitimacy. This is not only with respect to passing the National Health Bill,
although this is an essential part of that legitimacy. In other words, legality and the
force of law (and I have explained why this is necessary) is only a part of the necessary
legitimacy, in my view.

In this respect, there are questions regarding public

participation in the processes. At the moment, the National Code can be (and has been)
revised by the National Health Research Ethics Committee at will, and without any sort
of public consultation or formal consultation with other institutions involved in research
governance. The National Health Research Ethics Committee is chosen by the Minister,
who has very wide latitude in doing so. There are currently no provisions in any of the
instruments requiring an accounting to the government (the National Assembly) of any
activities relating to research governance.
With regard to effectiveness, other institutions such as professional
associations, research sponsors and universities would have to become active regulating
their spheres of authority. This would allow not only a top-down approach from the
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national level, but also a bottom-up approach to the governance of research, allowing a
hybrid framework which is potentially more effective. Unfortunately, this has not often
been the case because many of these institutions have not been active in regulating
research. Further, there are currently no organisations, such as the NGOs suggested
here, which might act as checks and thus encourage these institutions to remain
accountable. These issues may adversely affect effectiveness. Beyond these matters,
practical implementation is crucial for effectiveness.

The history of research

governance suggests that this, in addition to uniform policies, had been lacking in
Nigeria, and requires close attention now.

6.6 Conclusion
The ethical framework of health research involving humans in Nigeria,
includes domestic sources that provide ethical values such as the Constitution, the most
essential of these values being the fundamental value of the human person in Nigeria.
The ethical framework is, however, more specifically articulated in the National Code.
It contains a set of ethical principles which are to guide the conduct of health research
involving humans.
There are, however, gaps and issues in the National Code that would benefit
from a review by the National Health Research Ethics Committee. Moreover, there is
room for potential conflict, and confusion, as other documents that provide ethical
guidance in Nigeria draw principally from the Helsinki Declaration, which has different
requirements in certain respects.

This is a situation, however, that could be readily
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managed within national systems of governance, and is indeed one of the reasons why a
national or domestic system of governance is advocated in this thesis.
A legal framework for research governance exists in Nigeria.

But that

framework is currently incomplete. The common law is, by its manner of development,
deficient. Other aspects of the legal framework which focus squarely on research
governance, namely the Code of Medical Ethics and the NAFDAC Clinical Trial
Regulations, are limited in scope and applicability. While each instrument is necessary
in research governance, neither of these instruments provides comprehensive
protections for research participants and complete parameters for researchers and
research sponsors. Important aspects of research governance are not provided for, for
instance, the composition of ethics review committees. In addition, they do not have
uniform requirements in all respects.

While it may be argued that each of these

instruments provides a form of regulation, there is bound to be confusion for researchers
trying to comply with all the requirements, some of which may conflict. Thus, in my
view, the narrow remit of the Medical and Dental Council of Nigeria and the Code of
Medical Ethics, indicate the need for a more comprehensive, and overriding legislation.
The National Health Bill may be argued to be such legislation. However, as I have
discussed, there are currently several gaps that need to be remedied.
With respect to the institutional framework, the National Code has articulated
requirements for ethics review committees at the institutional level, with a national
committee acting as an overseeing authority. There are also other institutions such as
NAFDAC, professional associations, research sponsors and research institutions which
473

regulate research.

I have identified issues in the National Code, and contextual and

operational systemic issues which have the potential to impact research governance
adversely. I have also discussed the need for a non-governmental organization whose
work would focus on the protection of research participants.
To conclude, a national research governance system is emerging. There are,
however, still issues with respect to clarity, comprehensiveness, uniformity, and
adequacy, as well as legitimacy and effectiveness.

In the next chapter I make

recommendations to improve research governance in Nigeria, taking into consideration
the context, analyses and assessments discussed in Chapter Five and this chapter.
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Chapter Seven
Moving Forward: Some Recommendations for Research Governance in
Nigeria

7.1

Introduction
Nigeria is a developing country with much need for health research. It

also has a large population, offering a great potential for researchers and research
sponsors. Recently, it has established research governance arrangements to ensure
that the rights and welfare of research participants are protected while creating clear
parameters for researchers. These recent arrangements, discussed in Chapters Five
and Six, may serve as a guide for other developing countries which may be
considering establishing research governance structures. The major question in this
chapter, therefore, is: How can the emerging governance arrangements in Nigeria be
improved and made to work?
It is necessary to begin by acknowledging that Nigeria has taken some
laudable steps towards better governance of research. With respect to the political
context, the current democratic dispensation in Nigeria is more likely to provide a
sustaining environment for research governance.

There is likely to be more

political interest, interest by other actors, and international assistance, in addressing
the continuing need for health research, and for such research to be conducted
ethically.
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Generally, Nigeria has taken considerable steps, and appears to be on the
right track, to establishing a good system which will protect research participants and
facilitate research. In this respect, Nigeria has adopted a framework of governance
with a strong government role, particularly at the federal level. This is appropriate,
given that the federal government, both constitutionally and practically, has the
powers, the mandate, and greater resources than other actors, to ensure a good
system of governance for health research in the country. However, as I recommend
below, the active input of other actors is necessary to ensure effectiveness.
Further, the ethical framework of the National Code and other relevant
documents recognise the important values of the fundamental worth of persons in
Nigeria (which includes autonomy and respect for persons and the need to protect the
wellbeing of persons including research participants), the need for research
relationships built on a foundation of trust, and the need to engage with the
communities in which research is to take place.
By establishing a national code on ethics at the federal level, a uniform
standard appears to be emerging for the entire country with regard to health research
sponsored by any organization, public or private, and research conducted in all parts
of the country.
achievement.

The creation of a national committee is also a significant

Its functions include providing uniform standards, auditing ethics

review committees, and acting as a central ethics review committee registry. There
is likelihood that it will provide a more uniform system of governance and better
oversight of research than has hitherto been the case. There is also now a greater
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potential for delineation of roles and responsibilities, and accountability, than had
previously existed.

Although this remains a work-in-progress, there is also an

emerging recognition of the need for the interaction of the ethical, legal and
institutional frameworks in Nigeria.
However, as the discussion in the preceding chapters indicates, several
gaps, weaknesses, and potential problems remain. These include problems arising
from the Nigerian context such as limited resources, issues arising from the
configuration of current arrangements such as different requirements in instruments
with varying legal force, and systemic issues such as ensuring adequate
accountability.

More steps could be taken to provide the emerging system with

greater legitimacy and authority. More could also be done to improve the emerging
arrangements in terms of comprehensiveness, clarity, uniformity, adequacy, and
efficiency, all in an effort to make these arrangements more effective than they
currently are. More could also be done by other non-governmental actors to improve
governance within their realms of authority.
Below, I make some recommendations to improve the emerging research
governance arrangements, in order to ensure better protection of participants,
maintain public trust, create clearer parameters for researchers and, consequently,
facilitate more research in Nigeria. I make several recommendations below.
In making these recommendations, I take into consideration the findings
from the previous discussion of the Nigerian context and history of research
governance in Chapter Five, and the potential gaps and weaknesses from the analyses
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and assessment in Chapter Six. I have made a number of suggestions in my analyses
in Chapter Six, such as adding some sections to the National Code or revising some
sections, but I focus here on more macro-level matters. Further, the need for a
hybrid framework for developing countries flows through these recommendations
because I believe that this will ensure better governance in Nigeria. In this regard,
what appears certain is that there is no one magic pill for ensuring functional and
effective governance system in Nigeria. As I stated in Chapter Two, in a developing
world context like Nigeria, and with Nigeria's peculiar challenges described in
Chapter Five, it is necessary to tread the line between the practical and the ideal, the
descriptive and the prescriptive, and using what is to achieve what ought to be. In
this respect, because of the inherent and operational weaknesses of different actors the government, research institutions, research

sponsors, non-governmental

organisations - it is imperative that the strengths of all actors, institutions, and
systems are fully utilised. A strong government role (as is becoming apparent in
Nigeria), without the accompanying effectiveness of other actors will mean a return
to traditional or "old" governance, with all the attendant problems of inflexibility,
legalism, unresponsive bureaucracy, and a government with still limited capacity in
governance generally. On the other hand, active steps by other actors without a
strong government role will result in a non-comprehensive, inconsistent, potentially
inadequate, unaccountable and unclear system which may jeopardise research
participants' welfare.
Below, then, I suggest several steps to improve the emerging system of
research governance in Nigeria. For consistency, I have made recommendations on
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the three major components of research governance, that is, the ethical, legal, and
institutional frameworks, addressing the potential issues arising from the context, as
discussed in Chapter Five, and the gaps and weaknesses identified in Chapter Six.

7.2 Ethical Framework: Revising the National Code
In Chapter Three, I suggested that one way of dealing with the
controversial issues that have arisen in the interpretation and application of the
international ethical guidelines would be to address such issues in domestic
guidelines. The National Code on Health Research Ethics (the National Code), has
attempted to do this.

But there are still gaps and areas that require a review as I

pointed out in Chapter Six. Important ethical issues such as standard of care and
undue inducement which have been controversial and the subject of much debate
require attention and clarification. Other matters that were addressed inadequately,
such as informed consent require more substantive attention. Other gaps such as
research with children and the mentally challenged should also be addressed. Gaps
in areas requiring clearer guidance, such as privacy, and conflict of interest, require a
review. Finally, there is currently no mandatory review period in the National Code.
A mandatory review period is necessary to ensure continuous development.
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7.3 Legal Framework
7.3.1 Enacting Federal Legislation on Research Governance or Amending the
National Health Bill

Earlier in the thesis, I made the case that law in a facilitative, regulative
and protective role brings something important to the governance table.

More

specifically, I have contended that comprehensive legislation is needed for health
research involving humans. My arguments for legislation regarding the advantages of
comprehensiveness, clarity, accountability, and legitimacy, are applicable to the
Nigerian context. Indeed, Nigeria recognises the need for new health legislation, and
has developed the National Health Bill which includes some specific provisions on
health research involving humans. Even the Medical and Dental Council of Nigeria,
which regulates medical and dental practitioners, operates under law. The crucial
issue, therefore, is not whether law, in the form of formal legislation, might be useful
in Nigeria or whether law can be recognized in Nigeria as a crucial part of research
governance. This is already acknowledged in the health sphere, as is articulated in
the National Health Bill, and in other policy spheres.1 The important question would
be how effective legislation might be in Nigeria. In other words, can legislation be
effective not merely in theory and on paper but in reality in a fledgling, democratic
society like Nigeria?
While it would be an overstatement to say that legislation is frequently
effectively enforced in Nigeria, there are certainly instances in which law has been
Legislation has been passed in this democratic dispensation to govern important policy spheres,
including most recently, the Oil and Gas Industry Content Development Act, the Pensions Act.
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effective in Nigeria.

Drawing from an example in the health sphere, the National

Administration for Food and Drug Control in Nigeria (NAFDAC) has made
remarkable progress in the war against the sale of counterfeit drugs in Nigeria since
2001.2

NAFDAC has been aided in this work by the powers granted it under

legislation and by political commitment. This suggests that legislation can, and does,
work in the Nigeria, and that corruption need not be an insurmountable problem.
There is, however, a greater chance of success where there is political commitment.
But political commitment and support without the necessary legislative support (for
instance, using the example of NAFDAC, legal power to seize counterfeit drugs, to
prosecute offenders, and for the courts to impose punishments of fines or
imprisonment) would have been insufficient. Thus legislation is necessary.
Given other successes in the health sphere, including in the struggle to
eliminate counterfeit drugs, and the equally admirable efforts to provide access to
antiretroviral drugs in Nigeria,4 I am optimistic that the necessary political
commitment to implement legislation can be found. Indeed, given the history of
research governance in Nigeria discussed in Chapter Five, the priority given to the
issue by the government (even if influenced by incidents like the Pfizer incident and
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in Nigeria", available at <http://www.avert.org/aids-nigeria.htm> (September 2, 2009).
481

foreign initiatives) indicates some level of commitment. Without such legislation,
however, there would be little point in speaking of enforcement or effectiveness.
It is important to recall that in my hybrid framework, legislation does not
displace other components. It does not, for instance, act as a substitute for effective
self-regulation by the Medical and Dental Council of Nigeria. It does not replace
policymaking structures.

It does not detract from the fact that ethics review

cornrnittees in institutions need to be properly constituted to provide effective review
of research protocols. Institutions and research sponsors can still provide their own
requirements for ethical research, which may be stricter but not less stringent that the
basic standards mandated by law.
What legislation provides is a more authoritative foundation for these other
components to function effectively, and a legal system of accountability. It can also
clarify the roles of different actors and the legal confines within which research can
be undertaken. For instance, one of Pfizer's defenses was that ethics review of
research protocols was not a legal requirement in Nigeria at the time of its Trovan
trial. One could, of course, argue that this was an ethical requirement as stated in
international ethical guidelines, and that Pfizer's stance in employing such a defense
was unethical. However, this is a loophole that can easily be plugged by legislative
means, consequently protecting research participants in Nigeria from similar
unethical research.
Further, beyond the direct benefits of legislation, there are indirect
advantages.

Legislation provides a potential advocacy tool for institutions like
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pressure groups or non-governmental organisations to promote the interests of
research participants, to pursue legal actions in court where appropriate and to put
pressure on the government. The National Health Bill is itself partly a result of
advocacy from civil society groups and international aid agencies in Nigeria.
Political commitment can, therefore, result from enacting legislation, because it gives
other parties an instrument for pressuring the state.
In addition, the history of research governance in Nigeria indicates that
sustainability, an important component of effective governance, has been a major
concern. At present, both the National Health Research Ethics Committee and the
institutional ethics review committees are operating without a legislative mandate,
creating doubts about their legitimacy and sustainability. As things stand currently, a
new Minister of Health may decide not to establish the National Health Research
Committee. But legislation would help to ensure the continued existence of these
committees, and impose a legal obligation on any minister of health to constitute the
committee. It would also prevent duplication, ensuring that there is clarity on who
can constitute such a committee, and that two national committees (as had previously
occurred) would not be in operation at the same time.
The varying requirements under different existing subsidiary legislation
are another good reason for legislation in Nigeria.

Comprehensive legislation,

especially one that is specifically focused on health research, would be generally
applicable.

It would override other subsidiary legislation, and therefore ensure

uniform requirements, reducing potential confusion.
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The National Health Bill, which has just been passed by the National
Assembly and which is now only awaiting the President's assent, can be argued to be
such legislation, even though it includes other unrelated matters. Very importantly,
the National Health Bill provides a legal basis for a National Health Research
Committee which determines priorities for health research and advises the Minister
of Health. It also provides a legal basis for the National Health Research Ethics
Committee, and gives it the power to make guidelines for the conduct of health
research in Nigeria.
However, there are several important matters that are not addressed either
in the National Health Bill or in the National Code.

For instance, the National

Health Bill does not contain the basic requirement for ethics review.

While the

National Code contains such a requirement, there are no sanctions in the Bill for
failure to meet such basic requirement, as I suggested in Chapter Three. Nor is there
any sanction for failing to obtain informed consent, even though this is the only
substantive ethical requirement contained in the National Health Bill. A sanction of
fines, at least, would have been appropriate. There is no mandatory requirement for
registration of a clinical trial in a clinical trial registry, nor is the creation of a clinical
trials registry mandated under the National Health Bill or the National Code. These
are basic requirements which demand penal sanctions in the form of fines and
imprisonment for failure to comply.
Further, a means for providing resources for the ethics review committees,
both at the institutional and national levels, is not provided. There is no provision for
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a compensation scheme for research participants. A new law on health research
involving humans, or an amendment of the National Health Bill, would thus be
necessary to take into account these important elements that are currently lacking.

7.3.2 Establishing Uniform Standards and Requirements
Uniform standards provide participants with the same protections and
researchers with clarity about ethical and legal requirements. The National Health
Bill or specific legislation on research governance should address the place of other
existing instruments, such as the Clinical Trials Regulations, and the Code of
Medical Ethics. It could do this by explicitly stating that guidance provided by the
National Health Research Ethics Committee overrides other guidance, where there is
a conflict. Moreover, it would be appropriate for a harmonization of instruments to
occur between the NAFDAC and the National Health Research Ethics Committee,
particularly as NAFDAC considers a new set of draft regulations on clinical trials.
NAFDAC should also consider amending the draft regulations on clinical trials to
reflect the place of the National Code and the NHREC.

It would be appropriate for

NAFDAC and National Health Research Ethics Committee to come together to
address these matters.
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7.4 Institutional Framework
7.4.1 A Regional System or Institutional Ethics Review System?
At present, the institutional system of review is operated in Nigeria with
a national committee at the top. However, it is important to consider whether a
regional system would be more effective. The arguments of Coleman and Bouesseau
offer an insight into the need to reconsider the institutional ethics review committee
system in African countries. They observe that:
The structure of the American IRB system is a poor
fit for African countries. The IRB system is
premised on the importance of "local" review of
research (i.e., review in the institution in which the
research will take place), as well as a separation
between IRBs and the agencies that regulate them.
In many African countries, however, institutionallevel committees that exist independently of
regulatory authorities may lack sufficient legitimacy
to be effective. In addition, they may find it difficult
to reject research protocols, or to insist on
substantial changes that might lead sponsors to
reconsider working with the institution, if foreign
research is an institution's primary means of
financial support. By contrast, a centralized
committee housed within a government agency may
be in a better position to take strong positions and
ensure that those decisions are respected. In
addition, creating a single centralized committee is
likely to be simpler, and less costly, than attempting
to create separate committees at every research
institution in the country.5
I agree with much of their observation, including the need for a national committee
and that such a committee would have greater legitimacy than merely institutional
5

Coleman, Carl H. and Bousseau, Marie, "Strengthening Local Review of Research in Africa: Is the IRB
Model Relevant?" (2006), online: <http://www.bioethicsforum.org/ethics-review-of-medical-research-inAfrica.asp> (June 2, 2010).
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committees.

Indeed, Nigeria has established such a national committee which

provides oversight of institutional ethics review committees - the National Health
Research Ethics Committee. Their arguments relating to a single centralized national
ethics review committee raise very important issues of conflicts of interest, intricacy,
and costs where separate institutions each have committees. However, it seems to
me that a centralized national committee may be overburdened with reviewing every
single research protocol. What may be more helpful would be retaining a national
committee, but perhaps creating fewer regional committees as opposed to many
institutional committees.
A regional system of ethics review would situate ethics review
committees out of hospitals or universities but provide reviews for research protocols
in these institutions.

A regional system, as I explained in Chapter Three, has a

greater potential to reduce conflict of interest because it is situated outside the
institution, which typically is intent on attracting research funds.

As previously

discussed, such conflict of interest is a serious concern in many countries, but
particularly in a resource-limited setting such as Nigeria where institutions are in
great need of funding and other benefits that may come with execution of a research
project.
A regional committee, by its nature, is also more likely to draw members
from the community and from different institutions, further increasing the potential
for independence. As discussed in Chapter Five, currently most if not all members
of institutional committees in Nigeria are drawn from the institution, and as
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discussed in Chapter Six, the provisions of the National Code do not suggest that this
is likely to change. A regional committee is more likely to be independent as, by its
very definition, members have to be drawn in a region-wide manner. Moreover, the
adoption of a regional system could result in less ethics review committees, which in
turn would be limit costs, a great concern in a resource-constrained setting like
Nigeria.
The Medical and Dental Council of Nigeria's Code of Medical Ethics
appears to anticipate the creation of a mixed system of ethics review, with both
institutional and state (which can be considered "regional") ethics review committees
in operation. The state ethics review committees would review projects with a "state
outlook" which appears to mean multisite projects within a state. These would,
however, operate on an ad-hoc basis,6 eliminating the benefits of predictability.
Others like Jegede have suggested the creation of ethics review
committees in different local governments. These ethics review committees would be
funded by the local government councils.7 These would also operate like regional
ethics review committees since they would be situated outside the institutions. The
positive aspect of this suggestion is that such committees would be situated outside
institutions and they would include community members, thus reducing the inherent
conflict of interest that afflicts institutional ethics review committees.

The

problematic aspect of this suggestion is that there would be a multiplicity of ethics
review committees given that there are currently 776 local government councils in
Section 31 (IV) of the Code of Medical Ethics in Nigeria.
A S Jegede, "What Led to the Nigerian Boycott of the Polio Vaccination Campaign?" PLoS Med (2007)
4(3): e73
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Nigeria. This would potentially increase costs and even variations in the application
of standards.
If a regional system were to be adopted, in my opinion, it might be better
to consider establishing regional committees along geo-political lines, which would
result in six ethics review committees. These would be funded by an independent
scheme which I propose a little further below. Alternatively, in line with the federal
structure that obtains in Nigeria, a committee could be established in each of the
thirty-six states and in the Federal Capital Territory. These committees may be
formally affiliated with the state ministries of health, but will be registered with, and
audited by, the national committee. Proposals for research projects to be undertaken
in any institutions in that state would be submitted to those committees. These
would also be funded by the independent scheme. Members would be drawn statewide, from institutions and from the community.
Even if these suggestions are not accepted, it is necessary to reconsider
the institutional system now in place. Membership must be drawn more widely,
including members from outside the institution.

Institutions must put in place

conflict of interest guidelines, which must then be actively implemented.

7.4.2 A Funding Scheme for Ethics Review Committees
It is also important to consider a scheme from which ethics review
committees in Nigeria, whether regional, institutional, or national, may be funded.
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From the history of ethics review committees in Nigeria and from information
obtained from several individuals involved in ethics review in Nigeria, funding for
ethics review committees is a major concern. Other studies on developing countries,
including African countries, have identified the lack of financial support as a key
concern.8
Although the National Code requires institutions to support ethics review
committees, it is not clear that this will ensure that ethics review committees actually
receive the needed resources to do the important work for which they are established.
The National Code also permits ethics review committees to charge fees for ethics
review. However, this may result in conflicts of interest issues, where an institution
places too much reliance on such fees.

In any event, even if an ethics review

committee charges strictly for the expenses for a specific research project, there will
be other ongoing general expenses, including expenses for administrative personnel,
maintenance of equipment, and internet access.
As Nwabueze suggests, a central fund into which all research sponsors
may pay in may be a good alternative.9 In the scheme I propose, however, both the
federal government and the state government would be required to contribute
specific amounts each year. In this way, governments will take greater ownership of
the need to protect research participants in Nigeria and curtail complete dependence
8

See for instance, See Cecilia Milford, Douglas Wassenaar, and Catherine Slack, "Resources and Needs
of Research Ethics Committees in Africa: Preparations for HIV Vaccine Trials" (2006) 28: 2 IRB: Ethics
& Human Research 1.
9
Remigius N Nwabueze, "Ethical Review of Research Involving Human Subjects in Nigeria" in Angela
Long et al, The Regulation and Organisation of Research Ethics Review: Report of a Comparative
International Workshop Held at the Faculty of Law, University of Toronto, June 16-18, 2005 (Toronto,
Canada: Brown Book Company Limited, 2006) at 66.
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on foreign support for the operation of the ethics review system. While foreign
support of ethics review committees provides necessary assistance in a resourcelimited setting like Nigeria, there is no guarantee that such funding will continue in
perpetuity. Further, there is also the matter of independence. The perception, if not
reality, that regulation and ethics in developing countries like Nigeria, are merely an
endeavour funded and determined by foreign entities undermines the independence
that is a necessary part of research governance in these countries.
Institutions will also be required to contribute to the fund annually.
Foreign programs which support ethics review systems, such as the Fogarty Program
in the National Institutes of Health which currently supports different ethics-related
programs, may contribute to the scheme. In addition, certain researchers could be
exempted from the requirement to pay into this fund, including non-funded
researchers and student researchers. This funding scheme would be administered by
an independent body which would report to the Federal Minister of Health. This
body being separate from the National Health Research Ethics Committee would
permit that committee to focus on its oversight functions and reduce the conflict that
may arise in exercising the dual functions of auditing Health Research Ethics
Committees and funding them. Such a scheme would also be given legal backing in
new legislation on research governance or in an amended National Health Bill and
any state legislation, thus imposing legal obligations on the parties that must
contribute to the scheme.
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The major challenge of such a fund lies in implementation, that is, the
possibility that such a scheme will be ill-managed.

This is a real possibility.

However, the alternative (that is, institutions providing ethics review committees
with funding), has not been effective. In conversations with several researchers in
Nigerian universities, some suggested that the funding problem could only be solved
with foreign funding since many institutions would be unable to provide support,
given limited resources.

This suggestion raises the issue of the degree of

independence that can reasonably be exercised under such circumstances. I believe
that the scheme I propose may provide not only resources for the ethics review
system in Nigeria, but will ensure legitimacy, independence and sustainability, and
should, at least, be considered.

7.4.3 Development of Capacity for Ethics Review
Apart from the need for resources, the lack of expertise for ethics review
in developing countries like Nigeria has been noted in several studies on ethics
review systems in developing countries.10 The National Code already contains a
requirement for the training of ethics review committee members. It is necessary to
ensure that such training actually occurs.
In Nigeria, there are few programs which provide training to members of
ethics review committees. The main one is the Fogarty-supported West African
10
See for instance, Milford et al, supra note 5. See also, Nuffield Council on Bioethics, The Ethics of
Research Related to Healthcare in Developing Countries (London: Nuffield Council on Bioethics, 2002)
at 25.
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Bioethics Training Program, which is the approved training program of the National
Health Research Ethics Committee, which also runs degree programs in bioethics at
the University of Ibadan. The Fogarty program has also supported several scholars
in bioethics programs in universities in Canada and the United States. ' There is also
the Nigerian Bioethics Initiative, one of outcomes of the Pan-African Bioethics
Initiative (PABIN) founded in 2001 at a workshop organised by the World Health
Organisation.

It organises multidisciplinary bioethics workshops in Nigeria and

participates in African continental and regional bioethics networks.12
More programs are necessary. These programs should provide ethics
training to researchers and ethics review members. Training must be provided on the
regulations in place, including the National Code. Such training could include inperson training by research ethics experts and online courses. It could include the
sort of online tutorials offered in countries like Canada,13 which typically includes
case studies which test the principles set out in the regulatory documents. This
would be helpful particularly in areas with internet access.
The government must consider sponsoring some of these programs to
ensure the development of adequate ethics review capacity in Nigeria. This would
be one way of taking greater ownership of its responsibility to preserve the welfare

Sue Eckstein, "Efforts to Build Capacity in Research Ethics: An Overview" (2004) SciDevnet, online:
< http://www.scidev.net/en/middle-east-and-north-africa/policy-briefs/efforts-to-build-capacity-inresearch-ethics-an-ov.html> (May 30, 2010). See also, A J Ajuwon, N Kass "Outcome of a Research
Ethics Training Workshop among Clinicians and Scientists in a Nigerian University"(2008) 9:1 BMC
Med Ethics
l
" See PABIN, online: <http://www.pabin.org/home.aspx> (June 1, 2010).
13
See the Interagency Panel on Research Ethics,rri-Co«nc;7 Policy Statement Tutorial online:
<http://www.pre.ethics.gc.ca/english/tutorial/> (June 2, 2010).
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of Nigerians, including research participants. While foreign assistance in this area is
welcome, government support would also enhance the sustainability of these
programs.

7.4.4 Developing Expertise in Ethics and Including an Ethics Component in
Medical Schools' Curriculum

In addition to training members of ethics review committees, it is
important to include an ethics or bioethics component in the curriculum of medical
schools in Nigeria. Anya's observation about the "little more than cursory attention
to either clinical or research ethics" in "a single hour-long lecture on ethics and
professional practice, delivered close to the final examinations"14 succinctly captures
the need for more thorough bioethics education for medical students. Other students
in other fields that may be involved in health research also require more bioethics
education. As Anya further points out:
When ethics is on the curriculum, it has mostly been
restricted to a brief overview of clinical ethics, with
little mention of issues related to ethical practice in
research. Within the nursing profession, the
curriculum issued by the Nigerian Nursing and
Midwifery Council mentions ethics just once, within
the context of quality.15
There is currently no requirement for expertise in ethics or bioethics in the
membership of both the National Health Research Ethics Committee and the Health

Ike Anya and Rosalind Raine, "Strengthening Clinical and Research Ethics in Nigeria—An Agenda for
Change" (2008) 372 Lancet 1594.
15
Ibid, at 1595.
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Research Ethics Committees.

The reason may be because there is very little

expertise in ethics or bioethics in the country.
It is suggested, therefore, that both the National Universities Commission
and the Medical and Dental Council of Nigeria, which regulate medical education in
Nigeria, should make ethics a mandatory component of the medical curriculum.
Such ethics training must be more thorough and rigorous. The National Code should
also be required reading for students in medical schools and in other fields of study
which involve health research, including in the social sciences. The West African
Bioethics Training Program has recently established a degree program in bioethics at
the University of Ibadan.1 More of such programs are needed in other universities.

7.4.5 Developing Expertise in Regulation and Governance
Apart from developing expertise in ethics, developing better knowledge in
other disciplines implicated in research governance, including law, policy analysis,
regulatory theory and practice, and governance, is important. Persons involved in
research governance, including in the NHREC and NAFDAC should be provided
with training in these areas and exposure to the research governance systems of other
countries.

This may include courses in foreign universities or training provided in

Nigeria with experts from around the world.

16

West African Bioethics Training Program supported MSc, MPhil/PhD program in Bioethics at the
University of Ibadan, online:
<http://www.westafricanbioethics.net/wabcms/index.php?option=com_content&task=view&id=14&Iterni
d=60> (May 30, 2010).
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7.4.6 Enhancing Transparency, Public Participation, and Accountability
The hybrid framework of governance includes important components
drawn from the concept of good governance and the new governance, including
transparency, participatory, reflexive and inclusive processes, responsiveness,
accountability, and public awareness and engagement.17 Enhancing transparency
requires clarity of roles, responsibilities, and processes. As things stand currently,
the National Code can be revised without any public or even stakeholder input. This
jeopardises transparency and puts power into the hands of few people with no
checks. It is also worrisome that the Minister has wide latitude in choosing the
persons who serve on the National Health Research Ethics Committee.
It is suggested therefore that public consultations would be helpful in any
revisions of important policy documents such as the National Code. The provisions
of the National Code should therefore be revised to accommodate greater public
consultation.18

Such consultations should also be announced in newspapers and in

other media to ensure wide coverage.
In addition, the National Health Research Ethics Committee should
provide annual reports of its activities on its website, as well as any policies
developed. Currently, there are no public records of health research. As Ogundiran
has pointed out, the absence of directories of research activities in African countries

See generally, Victoria Armstrong et al, "Public Perspectives on the Governance of Biomedical
Research: A Qualitative Study in a Deliberative Context" (United Kingdom: Wellcome Trust, 2007).
18
There is precedent for public consultations in drafting regulations. For instance, the draft Good Clinical
Practice Regulations drawn up by NAFDAC were put up on its website for a public consultation.
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like Nigeria tends to minimize the amount of research that is actually conducted.
Such directories in the Nigerian context would provide policymakers and research
sponsors with information about existing gaps. It is necessary to create a clinical
trial registry and a registry for other ongoing health research projects to encourage
transparency and accountability."

With respect to clinical trials, "The virtue of [a

requirement of registration in a clinical trial registry] notes Macklin, "is that it makes
transparent just which clinical trials fail to reach a successful conclusion, either
91

because of demonstrated lack of safety or absence of efficacy."

Such records will

also encourage access to important information and assist researchers in identifying
potential problems and weaknesses in the research governance system which could
then be addressed. I have suggested that the creation of such clinical trial registry
and the requirement for registration of trials should be provided in any legislation on
research governance.

Alternatively, mandating registration in a regional registry

such as the Pan-African Clinical Trials Registry22 may suffice.
Transparency also means avoiding any semblance or perception of
conflict of interest and maintaining the integrity and independence of the review
process.

This is particularly important if institutional committees are retained.

Transparency includes creating specific provisions addressing conflicts of interest in
the National Code, as I discussed in Chapter Five. Such provisions should include a
19

Temidayo O Ogundiran, "Enhancing the African Bioethics Initiative" (2004) 4 BMC Medical
Education 21.
20
An example of a domestic clinical trials registry is the South African registry. See South African
National Clinical Trials Register, online: <http://www.sanctr.gov.za/> (July 28, 2010).
21
Ruth Macklin, "The Declaration of Helsinki: Another Revision" (2009) 6:1 Indian Journal of Medical
Ethics 2 at 3.
22
Pan-African Clinical Trials Registry, online: <http://www.pactr.org/> (July 28, 2010).
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clear definition of conflict of interest. It should address both institutional and
members' potential conflict of interest. It should address potentially problematic
situations such as how reviews should be conducted when an institution (if
institutional committees are retained) has previously accepted a major donation from
a research sponsor (such as the donation of a clinical trial centre), which
subsequently seeks to conduct research in the institution. In such circumstances, the
National Health Research Ethics Committee may perform the review, or the National
Code may preclude institutional administrators from participating in ethics review.
The National Code should also address an existing lacuna in the current provisions
by stating clearly what happens in cases where members declare a potential conflict
of interest at the time of registration with the National Committee. It should require
institutions to put in place conflict of interest policies. It should also state clearly the
penalties for non-compliance with the conflict of interest provisions.
Transparency, inclusion, and responsiveness also require drawing
members of national committees and programs widely. For instance, it may raise the
spectre of conflict of interest where members of the National Health Research Ethics
Committee run training programs which typically require institutions or members of
ethics review committees to pay fees for such training. There should be a clear
separation of functions such that members of the National Health Research
Committee cannot serve in other roles which may suggest a conflict of interest. I
have already suggested in Chapter Six that the conflicts of interest provisions in the
National Code need to be revised.
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Similarly, it is crucial that the membership of the National Health
Research Ethics Committees which is determined by the Minister of Health should
be drawn broadly and with all attention to the need for transparency, accountability,
participation, and effectiveness. It is suggested that nominations should be drawn
from different stakeholder groups in appointing members of the National Health
Research Ethics Committee and that the National Health Bill be amended
accordingly. Members of institutional ethics review committees (if regional
committees are not adopted) must also include members drawn from outside the
institution to enhance transparency and limit any potential conflict of interest.

7.4.7 Ensuring a Grassroots and Broad-based Spread of Governance Efforts
At the moment, much of the initiatives appear to be focused at the national
level. The National Health Research Ethics Committee appears to be functioning
and it has a website (although it has not been updated in a year).23 These initiatives
must, however, filter down to the institutional level (or the regional level if that is
adopted) in order to be effective.
In addition, any initiatives must target not only a few institutions (or
regions) but must encompass a broad spectrum of institutions.

From my research,

certain institutions, in particular the University of Ibadan, the West African Bioethics
Institute, the Nigerian Institute of Medical Research, have also been at the forefront

NHREC, online: <http://www.nhrec.net/nhrec/> (July 28, 2010).
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in the emerging governance system.

This is understandable, given that much

externally sponsored research is undertaken in these institutions.

Furthermore,

many persons who have been crucial to research ethics development in Nigeria work
in these institutions.26 It is important, however, that governance efforts are spread
throughout the country, and that more institutions (if the institutional system is
continued) are engaged actively in the process. This would mean drawing
membership of national committees broadly around the country. It would also entail
site visits by the National Health Research Ethics Committee.
It also requires ensuring greater public awareness of the rights of research
participants, and education about the potential benefits and risks of research and the
regulatory roles and responsibilities of ethics review committees, NAFDAC, and
other regulatory bodies. This information will build public confidence and trust, and
allay anxieties about the research enterprise, which may in turn help to facilitate
research. Such information is still lacking.
Moreover, for the governance system to retain a hybrid flavor, it is
important that other actors in addition to institutions and government are involved in
the process. I focus on this below.

See for instance, Adeyinka G Falusi, Olufunmilayo I. Olopade and Christopher O. Olapade,
"Establishment of a Standing Ethics/Institutional Review Board in a Nigerian University: A Blueprint for
Developing Countries" (2007) Journal of Empirical Research on Human Research Ethics 21; Adefolarin
O. Malomo et al, 'The Nigeria Experience" (2009) 6:4 Journal of Academic Ethics 305.
25
Ibid.
26
Ibid.
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7.4.8 Strengthening NAFDAC
NAFDAC has been lauded for its war against the sale of counterfeit
drugs in Nigeria.

It must now devote greater attention to its role in regulating

clinical trials in Nigeria, which is one of its legal responsibilities.
As discussed in Chapter Six, NAFDAC currently lacks trained personnel
among other things. Particularly in this era of globalisation of clinical trials, it is
necessary that the Nigerian government invest more resources into addressing these
inadequacies in NAFDAC to ensure greater regulatory effectiveness and better
protection of research participants.

Such resources could be devoted to training

personnel, monitoring trial sites, maintaining records and clinical trial data submitted
by research sponsors, providing up-to-date information on ongoing clinical trials, and
other related activities.
Maintaining open channels of communication between NAFDAC and the
National Health Research Ethics Committee is also crucial. As discussed above, it is
essential for purposes of clarity that regulations developed by NAFDAC on clinical
trials should not diverge significantly from guidance provided by the National Health
Research Ethics Committee.

NAFDAC must ensure that it utilises only health

research ethics committees registered with the National Health Research Ethics
Committee. These matters will require communication and an ongoing relationship
between the two bodies.
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7.4.9 Clarifying Roles in Policy-Making
In addition, it is important to define clearly the remit of the different
policy structures that are currently emerging. As discussed in Chapter Five, one of
the problems in the functioning of the health system has been duplication and lack of
clarity of the responsibilities of different sectors and actors. It is crucial, therefore,
that policymaking structures have clearly defined authority. It should be clear, for
instance, that the National Health Research Committee (which defines and addresses
priorities in health research) does not interfere with the work of the National Health
Research Ethics Committees. The National Health Bill defines the remit of these
bodies and should be strictly complied with. Both committees report to the Federal
Minister of Health. The Federal Ministry of Health must, however, not interfere with
the functioning of these committees.
More importantly, with the ongoing discussions regarding the creation of
a National Bioethics Committee, consideration must be given to the possibility of
overlap and duplication of functions as well as to costs.

7.4.10 Active Involvement of Professional Associations, Universities, and
Research Sponsors

Professional associations in Nigeria have a legal and ethical duty to act in
the public interest.

This requires becoming more active in research governance

efforts. Self-regulation is a crucial component of the hybrid framework of
governance advocated in this thesis. In this regard, professional associations should
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educate their members on the necessity for ethical conduct in research. Statutory
councils must be prepared to investigate and penalize members found to have
breached codes of conduct in relation to health research involving humans. They can
also act as a check on the powers of government with respect to the governance of
health research.
In the specific case of the Medical and Dental Council, it would be
appropriate to revisit the Code of Medical Ethics in Nigeria to bring it in line with
national requirements, for instance, with respect to the requirements of informed
consent and the requirements of ethics review. It should also revise the code to
ensure that the sanctions for ethical misconduct in biomedical research are clear.
Furthermore, it should address other issues not currently covered by the code,
especially the issue of conflict of interest. It should also create more public
awareness of the code, the rights of patients and research participants, and the duties
of medical and dental practitioners.
The Medical and Dental Council of Nigeria and the Nigerian Medical
Association should also participate actively in efforts to govern health by providing
its input on research ethics policies to the National Health Research Ethics
Committee and to the Minister of Health. In this respect, it could bring more balance
to regulatory efforts.

The Council, and other professional associations involved in

health research involving humans, such as the Nursing and Midwifery Council and
the Nigerian Anthropological-Sociological Association, should adopt the National
Code, require their members to comply with it, and participate in policymaking.
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Federal universities, state universities, and research institutes will need to
comply with legislation and policies on health research. Even if a regional system of
ethics review is adopted, it will still be necessary that these institutions become more
actively involved in research governance by developing internal policies. Privately
owned universities must likewise commit to the regulation of health research within
their realms of authority.

Universities must require an extensive study of, and

engagement with regulation, governance and ethics in health research-related fields.
Moreover, it would be helpful for universities to contribute to the policymaking
efforts of the national committees by providing comments on new and impending
policies.
Research sponsors, domestic and external, will, in all probability,
continue to regulate how research funded by them should be conducted. But they
must seek information on regulatory requirements in the developing countries in
which they sponsor research.

And they must ensure that any agreements or

guidelines do not conflict with domestic laws and policies.

7.4.11 Development of Non-Governmental Organisations
I have argued in previous chapters that a non-governmental organisation
focused on the rights and welfare of research participants may contribute positively
in keeping other actors involved in research governance accountable. This does not
suggest that these organisations are always wholly free of problems, including
problems relating to accountability and effectiveness. But there is a role for external
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actors such as NGOs to help keep other actors accountable, provide a voice for
research participants, and provide surveillance over Nigeria's research governance
landscape. The integration of such organisation in the research governance system
will keep it from being a strict top-down arrangement and draw on the advantages of
a hybrid framework in a fragile political and economic environment. Currently, no
NGOs focusing on research governance exist in Nigeria. It would be helpful and
beneficial for the emerging research governance system in Nigeria if that vacuum
was filled.
Such organisation would educate and engage with communities in which
health research is to be conducted and educate potential research participants about
their rights and obligations in health research, participate in policymaking by making
representations to the National Health Research Ethics Committees, and act as a
whistleblower should concerns arise about a study or the conduct of a regulatory
body.

7.5 Conclusion
The above suggestions will, hopefully, improve research governance in
Nigeria. Practical implementation is, however, crucial for the success of emerging
governance efforts. The Nigerian government, and other actors such as universities,
research sponsors, researchers, and any interested NGOs, must implement, and
comply with any legislation and policies made.
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Assistance from international sources remains helpful, but such
assistance must also respect the domestic policies and the need for the development
of a domestic system of research governance. The Nigerian government must take
greater ownership of, and invest in, research governance in Nigeria by devoting
resources to this very important policy matter, and bringing pending efforts in this
regard to fruition.

A periodic assessment of the research governance system is also

necessary to ensure its smooth functioning and to identify and address problems as
they arise.
The need to protect research participants and prevent unethical conduct
of health research involving humans, which has occurred in Nigeria in the past,
require all actors in research governance to take the necessary steps.
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Chapter Eight
Conclusion

The ethics of health research conducted in developing countries has been,
and continues to be, a topical issue. Concern about the welfare of participants in
research particularly in the resource-limited circumstances of many developing
countries, the arguably increased vulnerability of research participants in these
countries, and the potential for exploitation has generated much discussion. The
economic disparities between developed and developing countries, the impact of
such disparities on global health, and on the continuing need for research in these
countries is likely to continue to draw attention from researchers.

However,

although much of the literature has focused on the ethical issues, this thesis has
emphasised the need for an expanded focus which would include the emerging
governance and regulatory systems in developing countries. Most literature in the
past has pointed out the regulatory vacuum that exists in developing countries with
respect to regulating health research involving humans. But several developing
countries have recently put, or are in the process of putting in place, regulatory
mechanisms to protect research participants.
These recent developments need to be understood, especially because
other developing countries may seek to consider, and perhaps even replicate these
systems. In addition, any gaps and weaknesses may be corrected in these early
stages.

Domestic governance systems also allow developing countries to take

greater ownership of the protection of participants in health research, whether
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domestically or internationally sponsored. I have argued in the preceding chapters
that, while international research governance efforts are important, developing
countries

need to address research

governance domestically.

Issues of

implementation and enforcement, among other reasons, make it necessary for
developing countries to set up domestic systems of research governance.
The aim of this thesis has therefore been to present a comprehensive and
systemic approach to the governance and regulation of health research involving
humans in developing countries. It has focused on Nigeria as an example of a
developing country which has taken recent steps to regulate health research involving
humans.
To assist my analysis in this thesis I adopted the analytical framework of
governance. Governance, generally speaking, takes a systems approach, permitting
the discussion of steering or managing of activities in terms of the interrelated
components of that activity including the values, institutions, organisations,
processes, and goals. Further, it recognises the institutions within a system and all
the actors in the policy field, including those being regulated, as potentially active
actors in the governance process. Governance is about achieving goals and objectives
through positive and negative control.
To achieve the aim of presenting a comprehensive and systemic approach
to the regulation of health research involving humans in developing countries, I
employed a hybrid framework of governance, which drew from the different
understandings of governance - generic, "good" "sustainable" "traditional," "new" 508

and from regulatory theory. My hybrid framework of governance recognises that the
state is a crucial actor in research governance, being the major source of formal law,
but that other actors, including private actors, are also essential in research
governance. Thus, the framework requires the active involvement of the state and
the complementary in-put from other sectors such as civil society and nongovernmental organizations. In discussing the analytic framework, I described the
main goals of research governance, namely the promotion of socially beneficial
research and the protection of research participants (and by extension communities,
and the public trust). I also established nine criteria by which a research governance
system may be measured. While this framework has its limitations and may not
apply equally in all settings and policy spheres, a hybrid framework that adopts a
generic understanding of governance to which both traditional and new governance
approaches contribute their strengths, harnesses the synergies of different actors and
institutions, and takes into account the political and socioeconomic contexts may be a
strong framework for research governance in developing countries like Nigeria. This
framework, in my opinion, is useful both to understand and to critically grapple with
the governance of health research in developing countries. It is also forward-looking
and helpful for countries seeking to develop and improve systems of governance.
The breadth of the framework offers a macro perspective rather than a detailed
analysis of specific legal or ethical issues, and is suited to the specific purposes of
this thesis.
This framework in mind, I have addressed different components of
research governance, dividing the mechanisms, institutions and processes, into the
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legal, ethical and institutional frameworks.

I have considered national and

international ethics guidelines; professional associations and codes of conduct; ethics
review committees; national regulatory bodies such as the ones which regulate
pharmaceutical production and the use of human participants, departments of health
(of which the drug regulatory agency may be a part); civil society, including nongovernmental organizations which promote patients' rights; the general public,
research participants themselves, and the interactions between these entities. I have
also considered the potentially beneficial role that law can play in research
governance systems, arguing that comprehensive legislation regulating health
research involving humans is essential in developing countries.
To undertake more specific analysis, I focused on Nigeria, a developing
country in Africa, as a case study. Nigeria has taken some positive steps in recent
years towards developing a national system of research governance.

Other

developing countries with the same challenges as Nigeria may examine its emerging
research governance arrangements for useful lessons. I have described the context in
which these emerging governance arrangements will operate. I have also provided a
history of research governance in Nigeria, highlighting specific issues that need to be
addressed as Nigeria moves forward in implementing the emerging governance
arrangements. The history of research governance in Nigeria includes instances of
unethical conduct of research in the country which make effective research
regulation imperative.
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I have engaged in a detailed analysis of current research arrangements in
Nigeria, identifying areas that need to be improved in relation to, inter alia,
comprehensiveness, legitimacy, uniformity, clarity, and adequacy. I have also made
recommendations, arising from the research findings, that may be helpful in ensuring
the effectiveness of the governance arrangements with respect to protecting research
participants, protecting public confidence in the research enterprise and facilitating
research. These recommendations require the active input of all actors in research
governance, including the government, professional associations, research sponsors,
and non-state actors.
Finally, the aim of this thesis was to address health research involving
humans in developing countries from a governance perspective, including the role of
the law in research governance. It is hoped that this thesis will encourage other
efforts to analyse the emerging governance systems in developing countries. More
empirical and qualitative research is needed to identify areas and means of
improvement.

A consideration of the role of law in the emerging governance

arrangements of developing countries is also necessary.

It is hoped that more

research will assist in the development of robust and effective research governance
systems in developing countries, provide information to regulators in various
countries and, most importantly, promote the protection of research participants in
those countries.
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